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Human Immunodeficiency Virus Type 1 (HIV-1) infects approximately two million people 
annually, highlighting the need for a preventative vaccine. An effective HIV-1 vaccine will 
likely need to elicit broadly neutralizing antibodies (bNAbs), which arise naturally in some 
infected individuals and recognize the envelopes (Env) of multiple HIV-1 strains. 
Understanding the molecular events that contribute to bNAb development during infection 
may provide a blueprint for vaccine strategies. Here we investigated the development of a 
V1V2-directed bNAb lineage in the context of viral co-evolution in an HIV-1 superinfected 
participant (CAP256). For this, clonally-related monoclonal antibodies (mAbs), with a range 
of neutralization breadth, were isolated. We determined their developmental pathway from 
strain-specificity towards neutralization breadth and identified viral variants responsible for 
initiating and maturing this bNAb lineage. 
MAbs were isolated by memory B cell culture or trimer-specific single B cell sorting and 
extensively characterized by Env-pseudotyped neutralization, cell surface-expressed Env 
binding, electron microscopy and epitope-predictive algorithms. Antibody next-generation 
sequencing (NGS) at multiple time-points enabled the inference of the unmutated common 
ancestor (UCA) of this lineage. Viral co-evolution was investigated using Env single genome 
amplification and V1V2 NGS. 
A family of 33 clonally-related mAbs, CAP256-VRC26.01-33, was isolated from samples 
spanning four years of infection. The UCA of this lineage possessed an unusually long heavy 
chain complementarity determining region 3 (CDRH3), which resulted from a unique 
recombination event. Surprisingly, this UCA potently neutralized later viral variants that had 
evolved from the superinfecting virus, which we termed bNAb-initiating Envs. Viral 
diversification, which peaked prior to the development of neutralization breadth, created 
multiple immunotypes at key residues in the V1V2 epitope. Exposure to these immunotypes 













Based on these data, we proposed a four-step immunization strategy which includes 
priming with bNAb-initiating Envs to engage rare B cells with a long CDRH3; followed by 
three sequential boosts (including select V1V2 immunotypes) to drive antibody maturation. 
In conclusion, this study has generated a testable HIV-1 vaccine immunization strategy 
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1. The global HIV-1 epidemic 
Thirty three years after the discovery of the Human Immunodeficiency Virus Type-1 (HIV-1) 
as the causative agent for Acquired Immunodeficiency Syndrome (AIDS), and despite 
numerous prevention and awareness campaigns, approximately 2 million new infections 
occur globally every year1.  Of the more than 35 million people infected with HIV-1 
worldwide, two thirds reside in sub-Saharan Africa, where young women are 
disproportionately affected1. In areas such as Vulindlela in KwaZulu Natal, South Africa, the 
HIV-1 prevalence in pregnant women between the ages of 20-24 is strikingly high at 45.5%2, 
leading many young individuals to believe that HIV-1 infection is an unavoidable part of life. 
This resigned mind-set of the most at-risk populations puts into perspective the desperate 
need for an effective and robust HIV-1 prevention intervention, such as an HIV-1 vaccine. 
 
2. HIV-1 prevention 
2.1. Antiretroviral drugs as prevention tools 
Since the discovery in 1983 of HIV-1 as the causal agent of AIDS, numerous prevention 
strategies have been tested. These include male circumcision3,4 and condom use5, but the 
most successful has been the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis 
(PrEP) to prevent both vertical and horizontal transmission of HIV-16. In South Africa, 
mother-to-child transmission has declined from 9.6% in 2008 to ~2.7% in 20117. Studies 
involving discordant couples and homosexual men have shown 67-99% protection through 
the use of PrEP8,9. However while PrEP has been efficacious in clinical trials, its effect at a 
population level is less clear.  Additionally, for HIV-1 infected individuals there is a large 
unmet need for ARV treatment. This is especially true in resource limited areas, such as 
South Africa where despite the largest treatment program in the world, only ~55% of HIV-1 
infected individuals are on treatment (Figure 1)1. In addition, these ARV-based interventions 
rely on adherence in the absence of illness over an extended period of time. Despite the 
possibility of slow-release or long-acting ARVs in pills or vaginal ring formulations, other 
socio-economic barriers may limit the use of these types of strategies in rural communities 























Figure 1. Global distribution of antiretroviral use among HIV-1 infected individuals.  
Circular infographic indicating the proportion of HIV-1 infected individuals receiving antiretroviral 
treatment (ART) in various countries and regions. South Africa has the highest number of individuals 
on ART globally. Source: Global AIDS Update UNAIDS 20161. 
 
2.2. HIV-1 vaccines 
Apart from safe water, vaccines have had the largest effect in reducing pathogen-induced 
mortality10. The recent resurgence of measles in the US, largely due to an increase in vaccine 
hesitancy, highlights the impact of vaccines that rely on the herd effect11. Therefore, while a 
combination of prevention strategies will likely be the most effective solution to limiting the 
spread of HIV-1, a preventative HIV-1 vaccine is urgently needed.  
The first candidate HIV-1 vaccine trial was sanctioned by the US Food and Drug 
Administration in 1987 and since then more than 218 clinical trials have been conducted12. 
However only 5 of these have progressed to phase III efficacy trials (Figure 2), with one 























Figure 2. HIV-1 vaccine phase III efficacy trials.  
Timeline showing start and end dates for the five HIV-1 vaccine efficacy trials, as well as the 
components and efficacy of each. Gray blocks show time frames as well as number of participants 
for each trial. The STEP and Phambili trials (marked by asterisks) tested the same vaccine regimen, 
but in different geographical areas. Adapted from Esparza 201312. 
 
The first trials, VAX003 and VAX004, in North America and Thailand used two distinct gp120 
proteins14 (discussed below in section 3.2) and were conducted amid controversy regarding 
the scientific rationale for testing these vaccine candidates15. While these safe and 
immunogenic candidates had protected chimpanzees from HIV-1 infection, the strains used 
were highly sensitive lab-adapted viruses, which were not representative of primary or 
clinical isolates16,17. Therefore the failure of these vaccines18,19, which aimed to induce 
antibody responses, in large scale efficacy trials in both populations was unsurprising.  
This was followed in 2004 by the STEP trial, which used a recombinant adenovirus serotype 
5 (Ad5) vector encoding the HIV-1 gag, pol and nef genes (described in section 3.2) to elicit 
T-cell responses20. Unfortunately, this trial was stopped after approximately 2 years, 
because an interim analysis showed that vaccinees had an increased rate of HIV-1 infection 
compared to those individuals who received the placebo20. This enhanced risk of infection 
was later attributed to the presence of a prior Ad5 antibody response and/or the 
circumcision status of the vaccinees21. A sister trial conducted in South Africa, called the 
HVTN 503/Phambili  trial, using the same regimen as the STEP trial was stopped early due to 
these results22. 
The fifth efficacy trial, the HVTN 505, which included a DNA prime followed by an Ad5-
vectored boost, was also stopped two years prior to the expected end date, because interim 
analysis showed that the vaccine afforded no protection from HIV-1 infection23-25.  
Trial Components 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Efficacy
VAX004 Recombinant gp120 (B/B) None
VAX003 Recombinant gp120 (B/E) None
STEP* Recombinant Ad5 gag, pol, nef (B)
Enhanced 
infection
Phambili* Recombinant Ad5 gag, pol, nef (B)









DNA gag, pol, nef (B); DNA env (A/B/C); 
Ad5 gag, pol (B) Ad5 env (A/B/C)
None
1998-2003                                              
5,417 participants
1999-2003                                          
2,545 participants
2004-2007           
3,000 participants
2003-2009                                                            
16,402 participants























In contrast, the RV144 Thai trial, a prime-boost regimen (combining a canarypox ALVAC-HIV 
DNA prime, together with the AIDSVAX B/E bivalent gp120 protein boost), showed a modest 
31% efficacy13. A correlates analysis, which compared the immune response in uninfected 
vaccinees, infected vaccinees and infected individuals who received the placebo, showed 
that the presence of V1V2-directed binding antibodies correlated inversely with HIV-1 
infection, while IgA binding antibodies correlated directly with HIV-1 infection26. In addition 
low IgA binding antibody levels in association with high levels of antibody-dependent 
cellular cytotoxicity (ADCC) were inversely correlated with HIV-1 infection. As a result the 
RV144 trial has reinvigorated current vaccine endeavors and focused attention on the 
fragment crystallizable (Fc)-mediated effector functions of antibodies, such as ADCC. 
However a more effective vaccine will likely require the elicitation of broadly cross-
neutralizing antibodies which are capable of tolerating the huge diversity among circulating 
HIV-1 strains.   
 
3. HIV-1  
3.1 The origins of HIV-1 
HIV-1 is a retrovirus that is closely related to the less pathogenic HIV-2, both of which 
originated from zoonotic infections transferred to humans via primates. While Simian 
Immunodeficiency Virus (SIV) that infects sooty mangabeys (Cercocebus atys) is the ancestor 
of HIV-227, HIV-1 is derived from the SIV that infects chimpanzees (Pan troglodytes)28-30. HIV-
1 has been sub-divided into 4 groups, which were each the result of a distinct cross-species 
transmission event, namely M (main), O (outlier), N (non-M, non-O) and P (putative)31. 
Collectively groups N and P infections have been confirmed in less than 20 people, and less 
than 1% of global infections are caused by group O viruses32-34. In contrast HIV-1 group M 
viruses dominate the current pandemic, having infected over 60 million people31. Group M 
has been further divided into 9 subtypes and more than 40 different circulating recombinant 
forms (CRFs), highlighting the enormous level of diversity amongst HIV-1 viral strains31. The 
first reports of AIDS in patients in the United States of America35 and the subsequent 
identification of HIV-1 as the cause36-38 occurred in the 1980’s. However the earliest samples 






















studies have suggested that the time of the most recent common ancestor of pre-pandemic 
HIV-1 group M dates to the 1920s, with the zoonotic transmission from chimpanzees to 
humans occurring even earlier41. This suggests that HIV-1 has been infecting humans for at 
least 100 years. 
 
3.2. HIV-1 genome and virion organization 
HIV-1, a lentivirus of the Retroviridae family, has a ~9.8 kb ribonucleic acid (RNA) genome 
encoding nine open reading frames (ORFs) and a total of 15 viral proteins42. The gag and env 
ORFs are translated into two polyproteins that are subsequently cleaved into the six 
structural components that comprise the virion particle (Figure 3A). The pol gene encodes 
three enzymes, which perform four different catalytic activities required for the various 
stages of the HIV-1 life cycle. In addition the HIV-1 genome codes for six accessory proteins 
which are involved in various functions including the regulation of replication and virion 
assembly.  
The mature HIV-1 particle, which is between 110 and 128 nm in size43, is surrounded by the 
viral membrane (Figure 3B). Embedded within the membrane are the envelope (Env) 
glycoproteins, the functional form of which is composed of three glycoprotein 120-
glycoprotein 41 (gp120-gp41) heterodimers. These functional Env trimers mediate entry 
into the host cell, however non-functional forms of Env44 (discussed in section 5.2) are also 
present in the membrane and act as immunological decoys. Beneath the membrane are the 
matrix (MA) proteins, which are involved in the budding of new viruses from infected cells42. 
Within the MA is the conical core which is composed of capsid (CA) proteins that are 
important for transport of the viral genome into the host cell. The CA surrounds two 
identical viral RNA strands that are closely associated with the nucleocapsid (NC) and three 
viral enzymes, protease (PR), integrase (IN) and reverse transcriptase (RT), required for viral 
replication42. The viral RT, which possesses both polymerase and RNAse H activities, is 
extremely error-prone, with a mutation rate of 1 per 1700 nucleotides incorporated45, 























Figure 3. Genome and particle organization of HIV-1.  
(A) Schematic diagram showing the location of the genetic elements within the HIV-1 genome. Long 
terminal repeat (LTR) segments flank nine open reading frames (gag, pol, vif, vpr, vpu, env, nef, tat 
and rev), two of which are discontinuous (tat in purple and rev in turquoise). The gag and env genes 
encode the structural components of the virion, namely the matrix (MA), capsid (CA), nucleocapsid 
(NC), glycoprotein 120 (gp120) and gp41 proteins. The pol gene codes for three HIV-1 enzymes, 
protease (PR), reverse transcriptase (RT) and integrase (IN). The remaining genes, together with a 
portion of gag encode six accessory proteins. Figure adapted from Frankel et al, 199846. (B) 
Schematic showing the HIV-1 virion. Embedded in the lipid membrane that surrounds the HIV-1 
virion are the envelope (Env) spikes, each of which is composed of three gp120 and three gp41 
proteins. Non-functional Env is also present on the viral surface. The MA proteins surround the CA 
core that encloses two single RNA strands and three enzymes (PR, IN and RT). Figure adapted from 
Levy, 199342. 
 
4. The HIV-1 envelope (Env) 
4.1. HIV-1 Env structure and function 
The HIV-1 Env glycoproteins enable viral infection of host cells through two steps. Firstly, 
gp120 engages the primary host cell receptor cluster of differentiation 4 (CD4)47,48 and the 






















chemokine receptor type 4 (CXCR4)49-51. Secondly, gp41 promotes the fusion of the viral and 
host membranes.  
The cell surface attachment subunit, gp120, which is ~500 amino acids in length, is divided 
into five constant regions (C1-C5) interspersed with five variable regions (V1-V5)52,53, as 
shown in Figure 4. Each variable region, excluding the relatively short V5 region, is 
bracketed by Cys residues, which covalently bind to form disulfide bridges54. The gp120 
subunit is heavily glycosylated, with approximately half its mass attributed to glycan 
residues55. The cleavage and fusion peptides mark the C terminus of gp120 and N terminus 
of gp41 respectively. In contrast to gp120, the ~350 amino acid transmembrane subunit 
(gp41) is less glycosylated and less variable, a probable consequence of its function56. Gp41, 
a type I fusion protein, is divided into three regions, namely the ectodomain, the 
membrane-spanning domain and a long cytoplasmic tail56-58 (Figure 4). Within the 
ectodomain are two helical regions known as the heptad repeats 1 and 2 (HR1 and HR2)59-62 
as well as the membrane proximal external region (MPER), an approximately 24 amino acid, 
tryptophan-rich segment that is highly conserved63,64. The long cytoplasmic tail (~150 amino 
acids in length) has conserved motifs that have been implicated in Env incorporation and 
Gag processing65,66. 
 
Figure 4. Regions of gp120 and gp41.  
Schematic diagram showing that glycoprotein 120 (gp120) is divided into 5 constant regions (C1-C5), 
interspersed with 5 variable regions (V1-V5). The glycoprotein 41 (gp41) contains an ectodomain, 
membrane-spanning domain and cytoplasmic tail. The ectodomain is subdivided into the fusion 
peptide as well as the heptad repeat 1 (HR 1), heptad repeat 2 (HR 2) and the membrane proximal 
external region (MPER). The positions of potential N-linked glycosylation sequons in both gp120 and 























The functional form of Env is a trimer composed of three gp120-gp41 heterodimers or 
protomers, which are held together by non-covalent protomer-protomer interactions within 
a trimer association domain67 and the helical regions of gp4168-71 (Figure 5).  Almost 20 years 
ago, the first atomic details of the gp120 subunit core, which was stabilized through 
deglycosylation, truncation of the termini and deletion of the V1V2 and V3 regions, were 
described72. This recombinant Env fragment was further stabilized through interactions with 
the CD4 receptor and an anti-HIV-1 antibody.  
 
Figure 5. Structure of the pre- and post-fusion HIV-1 Env.   
(A) Ribbon representation of the prefusion trimer, with the approximate division between the gp120 
and gp41 subunits indicated. The outer domain, inner domain, trimer association domain, bridging 
sheet, heptad repeat 1 (HR1) and heptad repeat 2 (HR2) are colored according to the key. (B) Ribbon 
representation of a CD4-bound gp120 monomer, highlighting (in grey shading) the regions of the 
inner domain, bridging sheet and trimer association domain that undergo the largest structural 
rearrangements post-CD4 engagement. (C) Rearrangements in gp41 HR1 and HR2 that occur post-
fusion and result in the formation of the six-helix bundle. Colors represent different regions as 























Since then, numerous crystal structures of recombinant Env (portions of gp120 and gp41) 
have been obtained73-79. In contrast, visualizations of the native trimer were restricted to 
low resolution electron microscopy, until very recently, when the first cleaved prefusion 
BG505 SOSIP.664 Env trimer was structurally characterized to 3.5Å resolution68,69,80. This 
recombinant Env protein is truncated at position 664 (before the transmembrane domain in 
gp41) and deletes most of the MPER, to promote solubility of the protein81. An engineered 
disulfide bond (SOS) between position 501 (in gp120) and 605 (in gp41) covalently links and 
stabilizes the trimer in the prefusion state, following cleavage81-85. An isoleucine mutated to 
a proline at position 559 (IP) in gp41 strengthens gp41-gp41 interactions which also stabilize 
the trimer conformation81. Through the creation of this recombinant HIV-1 Env trimer, we 
now have an almost complete structural view of the native HIV-1 Env before CD4 
engagement and membrane fusion68,69,80.  
Structurally, the gp120 subunit can be divided into the inner, outer and trimer association 
domains67,72 (Figure 5 green, cyan and purple respectively), while the gp41 subunit is divided 
into HR1 and HR259,62 (Figure 5, yellow and grey). The inner domain of gp120 can be further 
sub-divided into the bridging sheet72 (which only fully forms post-CD4 binding), an invariant 
7-stranded beta sandwich (which maintains its structure pre- and post-fusion) and three 
topologically flexible layers74,76. While the outer domain preserves the same relative 
conformation prior to and post CD4 engagement, the trimer association and inner domains 
undergo large structural rearrangements (Figure 5B, grey shading). These include the 
release of the V3 loop, by V1V2 movements, to expose the co-receptor binding site and 
conformational changes in the bridging sheet and the first topological layer of 
gp12068,69,72,73,80. In gp41, a prefusion four-helix collar (Figure 5A), that surrounds the gp120 
N and C termini69, transitions into a post-fusion six-helix bundle, which facilitates membrane 
fusion by releasing energy to overcome this barrier86,87 (Figure 5C). These conformational 
rearrangements are only possible in cleaved Env and thus the reason for the metastable 























4.2. HIV-1 Env biosynthesis 
The HIV-1 Env is initially synthesized and simultaneously glycosylated in the rough 
endoplasmic reticulum as a gp160 polypeptide precursor88. At this stage N-linked glycans, 
transferred onto the free amide of asparagine residues in an N-X-S/T (where X ≠ P) sequon, 
are oligomannose precursors with three glucose, nine mannose and two N-
acetylglucosamine residues (Glc3Man9GlcNAc2)
89 (Figure 6, Step 1). The terminal glucose and 
mannose residues of these oligomannose precursors are then trimmed resulting in high 
mannose, Man5GlcNAc2, glycoforms (Figure 6, Step 2). Upon oligomerization, predominantly 
into immature gp160 trimers, the proteins are trafficked to the trans-Golgi network, where 
N-acetylglucosamine transferase I (GnTI) creates hybrid glycoforms through the transfer of a 
GlcNAc moiety to the D1 arm of accessible high mannose glycans90 (Figure 6, Step 3). 
Further enzymes, such as mannosidase trimming II, GnTII, GnTIV and GnTV, can convert 
hybrid glycans into complex forms through the replacement of the D2 and D3 mannose 
arms with antennae that contain for example galactose and sialic acid residues89-91 (Figure 6, 
Step 4 and 5). Due to the high density of glycans on Env, steric hindrance may limit the 
action of these glycan processing enzymes; therefore three glycoforms (oligomannose, 
hybrid and complex) can exist on Env91-94.  
In addition to post-translation glycan processing, the Env polypeptide can also be tyrosine 
sulfated while passing through the Golgi95. Finally, within the Golgi apparatus, the immature 
gp160 trimers are proteolytically cleaved by furin or furin-like enzymes96 at a highly 
conserved motif K/R-X-K/R-R97,98. The cleaved gp120 and gp41 subunits non-covalently 
associate to form mature trimers and at lipid rafts in the plasma membrane, 8-14 trimers 























Figure 6. Post-translational processing of N-linked glycans.  
Schematic diagram showing the five basic steps of N-linked glycan processing from oligomannose 
precursors to hybrid and complex glycoforms. The terminal mannose residues on the D1, D2 and D3 
arms of oligomannose precursors are trimmed to oligomannose glycoforms (Steps 1 and 2). A 
subsequent transition to the hybrid glycoform occurs via addition of N-acetyl glucosamine (GlcNAc) 
residues to the D1 arm (Step 3). Complex glycans are created through replacement of mannose 
moieties on the D2 and D3 arms with complex antennae that may contain galactose and sialic acid 
residues (Steps 4 and 5). At all stages following hybrid formation, the oligomannose stems may be 
fucosylated. Key indicates shapes for each glycan residue. Adapted from Binley et al, 2010100. 
 
5. B cell responses to the HIV-1 Env 
5.1. B cell diversity 
The year 2015 marked the golden anniversary of the discovery of the B lymphocyte or B cell, 
named so because of its initial identification in the Bursa of birds101. These cells express the 
B cell antigen receptor (BCR) on their surface and the membrane-free, soluble form of BCRs 
are known as antibodies102.  
Each BCR or antibody is composed of four disulfide-linked polypeptide chains, two heavy 
chains and two light chains (Figure 7), which fold into a β-barrel, also known as the 






















forms the Fc region (Figure 7) and determines which of five classes or isotypes (IgM, IgD, 
IgG, IgA and IgE) the antibody belongs to. In humans the IgG and IgA classes can be further 
divided into IgG1-4 and IgA1-2 respectively103. These isotypes determine the type of effector 
functions an antibody can initiate, the localization or compartmentalization and the half-life 
of the antibody. In contrast the more variable portions arrange into two fragment antigen 
binding (Fab) regions per antibody102 (Figure 7). 
B cell genes have a large repertoire of diversity104,105, necessary to combat infection caused 
by a wide spectrum of pathogens. Humans can therefore produce an estimated 109-1013 
unique antibodies106. It would be impossible to encode every antigenic response by a single 
gene; therefore an alternate and efficient way of generating high levels of diversity has 
evolved.  
 
Figure 7. Antibody structure.  
Schematic figure (left) and crystal structure (right) of a human immunoglobulin (Ig) monoclonal 
antibody. Each antibody is composed of two heavy (blue) and two light (grey) chains, which are 
covalently linked through disulfide bonds (yellow). Each antibody has two fragment antigen binding 
(Fab) regions, which are composed of the variable regions of each heavy-light chain pair. The single 
























The heavy and light chain Ig gene loci are located on three different chromosomes107. The 
single heavy chain Ig locus consists of 48 variable (V), 23 diversity (D), 6 joining (J) and 9 
constant (C) functional gene segments 107-109 (Figure 8A). The two light chain loci (kappa and 
lambda) collectively code for 71 variable, 10 joining and 6 constant gene segments107 and 
though they are similar in organization to the heavy chain locus, they do not have D genes. 
Primary diversification occurs in the bone marrow early in B cell development, when 
recombination activating gene (RAG) proteins facilitate the rearrangement of the germline 
Ig genes104,105,110. During this process, single V, (D) and J genes (for both the heavy and light 
chains) are randomly recombined from the germline gene pool, which creates an ancestor B 
cell with a unique gene arrangement (Figure 8B). To enhance this range of diversity, 
insertions between the three gene segments (junctional sites) may also occur, through the 
action of terminal deoxynucleotidyl transferase (TdT)111. 
 
Figure 8. Generation of antibody heavy chain diversity and variable region organization. 
Schematic diagram illustrating how antibody diversity is generated through two steps of 
diversification. (A) Multiple variable (V, purple), diversity (D, blue), joining (J, turquoise) and constant 
(C, grey) gene segments exist in the B cell germline. (B) Primary diversification occurs through a 
unique VDJ recombination event. During this process additional residues (green) can be inserted 
between the V-D and D-J junctions, thereby increasing the diversity. (C) Following antigenic 
exposure, B cells undergo secondary diversification, whereby somatic hypermutation (SHM) enables 






















four relatively conserved framework regions (FR1-4) and three hypervariable complementarity 
determining regions (CDR1-3). The CDR3 contains the entire D gene, as well as portions of the V and 
J gene, which is discussed further in section 8.4. 
 
Following tolerance checks, these mature B cells migrate to the peripheral organs, where 
upon exposure to a cognate antigen, a process of secondary diversification begins (Figure 
8C)102. Somatic hypermutation (SHM) or affinity maturation, one of the mechanisms of 
secondary diversification, is catalyzed by the enzyme activation-induced cytidine deaminase 
(AID). AID introduces point mutations into the single-stranded DNA, by deaminating 
cytosine residues within a W-R-C motif (where W = A/T and R = A/G), thereby producing B 
cell variants or descendants that differ from the original unmutated common ancestor 
(UCA) B cell (Figure 8B).  These B cell variants then compete for binding to follicular 
dendritic cell (FDC)-bound antigen and the entire process is repeated until ultimately the B 
cells with the highest affinity for the antigen are expanded. These two processes alone 
ensure at least a total 5 x 1013 different gene rearrangements102,103. Each heavy and light 
chain variable region is divided into three relatively conserved framework regions (FR1-4), 
interspersed with three hypervariable complementarity determining regions (CDR1-3) 
(Figure 8D). Antigen specificity for the most part is conferred by the sequence of the six 
CDRs, known as CDRH1-3 and CDRL1-3 for those in the heavy and light chains respectively.  
 
5.2. Anti-HIV-1 neutralizing antibodies and HIV-1 Env immune evasion 
Neutralizing antibodies (NAbs) block HIV-1 infection by preventing attachment of the virus 
to the CD4 receptor or by inhibiting the conformational changes required for membrane 
fusion72,112. The native HIV-1 Env is the sole target for NAbs113 and has thus evolved a 
number of strategies to combat immune targeting. The simplest immune evasion tactic is 
the occlusion of the receptor binding sites, through the oligomerization of the trimer114. 
Non-functional or “junk” forms of Env, such as gp41 stumps and gp120-gp41 monomers44, 
are present on every HIV-1 virion at a higher frequency than native Env, providing a highly 
effective way of directing the immune response away from infection-capable Env. Due to 






















target non-neutralizing epitopes that are not accessible in the prefusion native trimer, such 
as the co-receptor binding site in the V3 loop115. The dense glycan cloak of gp120, with host-
derived residues, acts as a further immune constraint112, although multiple studies have 
now shown that glycan interactions are a component of specific anti-HIV-1 responses 
discussed below113,116-119. Finally, the relatively few native Env spikes on the surface of each 
virus exacerbates this problem by limiting bivalent binding and therefore decreasing avidity 
of IgG antibodies120.  
Due to this array of viral immune evasion strategies, the first detectable B cell responses 
against HIV-1 occur eight days after infection, but are in the form of virus-antibody 
complexes121. The first free antibodies are to gp41 and are present a further five days later; 
however these antibodies are often cross-reactive with commensal gut bacteria122,123. The 
first HIV-1 specific responses to gp120 only develop ~27 days post-infection (p.i.), but these 
binding antibodies have no effect on viremia and do not exert selective pressure on the 
virus. Between 12 and 20 weeks p.i., most HIV-1 infected individuals develop strain-specific 
neutralizing responses124-126, which target the more variable regions of the Env trimer, such 
as the C3V4 region, including the α2-helix of gp120127. These responses exert sufficient 
immune pressure on the viral quasispecies to select for rapid and effective viral 
escape124,128-135. 
In contrast to these strain-specific responses, between 10-50% of infected individuals 
develop polyclonal plasma antibodies that are able to neutralize heterologous viruses, 
including those from multiple subtypes and various geographical areas117,119,136-141. These 
types of responses, termed broadly neutralizing antibodies (bNAbs), are however detected 
much later, between one and three years after infection119,139.  
 
5.3. Role of NAb responses in HIV-1 prevention 
The induction of neutralizing antibody responses by vaccination mediates protection from 
multiple human pathogens142-149, therefore the role of bNAbs in mediating protection from 






















HIV-1 Envs expressed in SIV backbones to create simian-human immunodeficiency chimeric 
viruses (SHIVs)150-153, have enabled non-human primate (NHP) protection studies using 
human derived anti-HIV-1 bNAbs. High concentrations of two bNAbs and polyclonal HIV 
immune globulin (HIVIG) administered intravenously offered sterilizing protection following 
intravenous SHIV challenge154. However, HIV-1 infection generally occurs at mucosal 
surfaces, therefore the same intravenous bNAb-HIVIG cocktail was tested in a vaginal 
challenge model and showed protection in 4 of 5 macaques155. Similarly, a topically 
administered vaginal gel or saline solution, containing a single bNAb, protected 9 of 12 
macaques from SHIV infection156. A combination of three bNAbs also prevented infection of 
neonatal macaques via the oral route, which is representative of mother-to-child 
transmission. The protection conferred to neonatal NHPs occurred whether transplacental 
or intravenous bNAbs were administered prior to or after birth respectively157,158. Further 
studies showed that low serum neutralization titers of a single bNAb at the site of infection 
in NHPs could efficiently provide protection159-161. More recently two studies showed 100% 
protection of vaginally challenged NHPs with intravenous administration of single, more 
potent bNAbs at concentrations 20 to 40 fold lower than previous studies162-164, showing 
that bNAb serum concentrations below 10 µg/ml can mediate sterilizing protection. Finally 
specific mutations in the Fc region of bNAbs that enhance binding to the neonatal Fc 
receptor (FcRN) and therefore increased antibody half-life showed improved protection 
from rectal challenge in NHPs165. These proof-of-concept studies have supported the 
development of bNAbs for HIV-1 prevention and clinical trials to test the efficacy of 
passively administered bNAbs in humans are underway166. 
 
6. Anti-HIV-1 broadly neutralizing antibodies (bNAbs) 
6.1. BNAb targets  
There are five targets for bNAbs on the HIV-1 Env trimer and all but one of these epitopes 
can include glycan in addition to peptide contacts113 (Figure 9). The first generation of 
bNAbs, isolated pre-2009, had limited neutralization breadth, especially against non-
subtype B strains167. In contrast second generation bNAbs are extremely broad and potent, 






















possess one or more unusual characteristics, which include exceedingly high levels of SHM, 
exceptionally short or long CDR loops, insertions or deletions (indels) in the Ig variable 
regions and autoreactivity against host antigens169,170. These uncommon characteristics may 
result from the B cell dysfunction that is associated with chronic HIV-1 infection, but 
nonetheless enable bNAbs to neutralize HIV-1 and circumvent viral immune evasion. 
 
 
Figure 9. Broadly neutralizing antibody (bNAb) targets on the prefusion HIV-1 Env trimer.  
Surface representation of the BG505 SOSIP.664 HIV-1 prefusion trimer. Four of the five bNAb targets 
are visible in the BG505 SOSIP.664 and are highlighted in purple (V1V2), green (CD4 binding site), 
cyan (N332 supersite) and yellow (gp120-gp41 interface). The approximate positions of the 
membrane proximal external region (MPER) and the viral membrane are shown in pink and black 
respectively. The gp120 and gp41 subunits are shaded in light grey and dark grey respectively. PDB 
ID: 4TVP. 
 
The first identified171 and most extensively studied bNAb epitope is the CD4 binding site 
(CD4bs), which is present on both trimeric, functional Env and also on gp120 monomers 
(Figure 9, green). Broad antibodies targeting this region can be sub-divided into VH-gene 
restricted or CDRH3-dominated CD4bs subclasses, categorized according to their mode of 
binding172. VH-gene restricted or VRC01-class antibodies mimic CD4 receptor binding 
(through interactions with the conserved D368 residue) and have unusually short CDRL3s 
that avoid steric clashes with the N276 glycan. In contrast, CDRH3-dominated CD4bs bNAbs 






















glycan. While antibodies that target the CD4bs have a range in neutralization breadth and 
potency, the current broadest, VRC07, is able to neutralize 93% of viruses173. Although anti-
HIV-1 bNAbs generally have unusually high levels of SHM, this is especially true for the 
heavy chain variable regions of some CD4bs bNAbs, which are close to 30% mutated 
compared to their germlines174. 
The most recently described bNAb epitope is quaternary (only present on functional Env 
trimers), discontinuous and involves peptide and glycan residues in both gp120 and gp41 
(Figure 9, yellow). These gp120-gp41 interface bNAbs are represented by the antibodies 
8ANC195175, PGT151176,177, 3BC315178 and 35O22179. These highly glycan dependent 
antibodies neutralize between 50-66% of globally circulating viruses, but their neutralizing 
capacity generally does not reach 100% even against viruses that are potently neutralized. 
These neutralization plateaus have been attributed to the glycan heterogeneity of Env, and 
though they have been described in all bNAb classes180, this phenomenon is especially 
striking in gp120-gp41 interface bNAbs. 
The most common bNAb target in chronic HIV-1 infection119,140,181,182, the N332 glycan 
supersite, encompasses the V3, V4 and 2G12 sub-epitopes on gp120183 (Figure 9, cyan). 
Although these sub-epitopes differ significantly, they all converge on the glycan at position 
332 of the C3 region118,184,185. These N332 epitopes are present on the outer domain of Env 
and can therefore be reproduced on monomeric gp120. PGT121 and PGT128, 
representative of V3 targeting bNAbs, have long CDRH3 loops (20-26 amino acids) which 
they use to recognize a short linear peptide in V3 together with the glycans at positions 
N301 and N332/33479,118. The V3 loop is closely associated with the V1V2 region and for this 
reason some V3 targeting bNAbs are also able to interact with the N137 and N156 glycans, 
which are in V1V268,186. However while the N301 and N332/334 glycan interactions are 
critical to neutralization by these bNAbs, removal of the V1V2 glycans does not completely 
abrogate their neutralizing activity118,186. PGT135, a V4 domain bNAb, binds to the base of 
the V4 loop and to glycans at positions N295, N332, N386 and N392118,183. While V4 loop 
bNAbs are also N332 glycan-dependent, they recognize a different face of the glycan 
compared to the V3 loop bNAbs. The final N332 supersite bNAb subclass is typified by the 
antibody 2G12, which possesses a unique heavy chain domain exchange used to create a 






















mode of recognition by 2G12, which does not contact any protein components of gp120. 
2G12 interacts only with terminal glycan moieties at residues N296, N332, N339 and 
N392184,185. The new generation N332 glycan dependent antibodies, isolated after 2G12, are 
extremely potent and neutralize 30-75% of viruses169,170.  
The MPER is the only epitope located solely on the gp41 subunit of Env, however the 
location of this epitope within prefusion Env is still unknown (Figure 9, pink asterisk).  The 
MPER is targeted by the broadest anti-HIV-1 mAbs, such as 10E8 which neutralizes 98% of 
viruses188. The breadth of this class of antibodies is associated with the high sequence 
conservation of the MPER, constrained by its function. This class of bNAbs target 
overlapping, linear sub-epitopes within the MPER, which is formed by two linked helices 
between the transmembrane domain and the gp41 ectodomain. However, these bNAbs 
generally require lipid binding to enhance affinity for the MPER, and are therefore often 
autoreactive189. 
The fifth epitope, created through the interaction of the three gp120 protomers at the 
trimer apex and thus only present on the prefusion Env, is the V1V2 region (Figure 9, 
purple). The quaternary structure-dependent mAbs belonging to this bNAb class are the 
most potent (with IC50 titers in the nanomolar range) and generally depend critically on 
glycan residues at positions 156 and/or 160 and on amino acids at positions 166 and 
169117,118,190-192. BNAbs targeting this site include PG9/16117, the first V1V2 bNAbs isolated, 
as well as the PGT145118 and CAP256-VRC26191,192 antibody families. The V1V2 site and the 
bNAbs that target it are the focus of this thesis and will therefore be discussed in greater 
detail below. 
 
6.2. Broadly neutralizing plasma antibodies in CAPRISA participant, CAP256 
CAP256, an HIV-1 infected participant from the longitudinal CAPRISA 002 acute infection 
cohort in Durban, South Africa, was one of seven individuals who developed broadly 
neutralizing plasma responses (77% of viruses neutralized in a 43 virus panel, Figure 10)119 























Figure 10. Neutralization of autologous and heterologous viruses by CAP256 plasma. 
Longitudinal CAP256 plasma neutralization of the primary infecting (PI, blue) and superinfecting (SU, 
purple) autologous viruses are shown with ID50 titers on the left y-axis and weeks post-infection on 
the x-axis. The number of heterologous viruses neutralized at each time point after the development 
of neutralization breadth is indicated above the dashed lines (black). Figure modified from Gray et al, 
2011119 and Moore et al, 2013193. 
 
CAP256 was infected with a subtype C virus in July 2005 and between 13-15 weeks later was 
superinfected with a second, but distinct subtype C virus194 (Figure 10 and 11). She had a 
median viral load of 105, 000 RNA copies/ml over 219 weeks (~4.5 years) of infection, which 
peaked at 2,390,000 RNA copies/ml when superinfection was detected. At initial infection 
she had a CD4+ T-cell count of 689 cells/µL, which had decreased to 267 cells/µL before she 
initiated ARV treatment in January 2010. Neutralization of heterologous viruses by the 
CAP256 plasma, first detected at 48 weeks, increased incrementally with each year and 
finally peaked by 159 weeks. Despite maintaining this neutralization breadth at 219 weeks, 
the potency of the response began to decrease. Detailed mapping of the CAP256 plasma 
showed that these bNAbs targeted the V1V2 region of Env119,194.  
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Figure 11. CAP256 viral load and CD4+ T cell count data over 259 weeks of HIV-1 infection.  
CAP256 viral loads (RNA copies/ml) in green and CD4+ T cell counts (cells/µL) in blue are shown for 
all time points from 6 to 259 weeks post infection (p.i.). Dotted lines indicate time of superinfection, 
early neutralization breadth, peak in neutralization breadth and antiretroviral (ARV) treatment 
initiation. Viral loads decrease and CD4+ T cell counts increase following ARV initiation. Figure 
adapted from Moore et al, 2011194. 
 
6.3. Anti-HIV-1 bNAb isolation 
Defining and visualizing immune vulnerabilities on the HIV-1 trimer is an important tool to 
aid rational immunogen design, thus the isolation of monoclonal antibodies (mAb) with 
neutralization breadth from infected individuals has been a major focus of the HIV-1 vaccine 
field. Three major strategies have been used to isolate human mAbs against various viral 
and bacterial pathogens, namely the generation of phage display libraries, B cell 
immortalization coupled with functional screening and lastly single B cell sorting followed by 
cloning and expression of the Ig genes. The development of overlapping, multi-primer PCR 
protocols to amplify the Ig variable heavy and light chain genes from single B cells192,195-198 
provided new avenues for mAb isolation, including B cell culture and antigen-specific B cell 
sorting. In addition, the identification of potent, broadly neutralizing plasma from chronic 
HIV-1 infection and the development of high-throughput technologies have greatly aided 
the anti-HIV-1 bNAb isolation effort. 
The first broadly neutralizing anti-HIV-1 antibody, b12171, was isolated using a phage display 
library. However, the random pairing of the Ig variable heavy and light chains in this method 
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may result in antibodies that are not physiologically representative. The next first 
generation bNAbs 2G12116, 2F5199 and 4E10200 were isolated using B cell immortalization 
with Epstein-Barr Virus (EBV), a method described in more detail below.  
 
B cell culture 
B cell immortalization is advantageous as it allows for screening via neutralization and/or 
binding and resulted in the recent isolation of bNAbs CH01-04190 and HJ16201. However this 
method is highly inefficient when using frozen peripheral blood mononuclear cell (PBMC) 
samples from HIV-1 infected individuals. An adaptation of this method, called B cell 
culture117,118,188,201,202, is favored when the antibody response is extremely potent and when 
the epitope is unknown or not defined on recombinant HIV-1 proteins. In this technique 
memory B cells isolated as IgM-/IgD-/IgA-/CD19+ by flow cytometry, are negatively selected 
to limit the activation and subsequent proapoptotic tendencies of the previously frozen B 
cells (Figure 12, top panel). After dilution, these memory B cells are cultured for two weeks 
in the presence of CD40 ligand (to activate the B cells), IL-2 (to promote the proliferation, 
rather than apoptosis of the activated B cells) and IL-21 (to induce expansion of antibody-
secreting cells). After 14 days, the supernatants are screened for neutralization and the Ig 
variable regions of cells with positive neutralization results are PCR amplified. This method 
has been used to isolate multiple second generation bNAbs, including PG9/16117, PGT121-
123, PGT141-145118, 10E8188 and 35O22179. In addition, as part of this thesis, we used B cell 
culture to isolate 25 clonally-related antibodies, named CAP256-VRC26.01-25191,192, which 
were derived from the variable heavy 3-30*18 and variable lambda 1-51*02 germline genes. 
These mAbs targeted the V1V2 epitope and possessed unusually long CDRH3s of between 
























Figure 12. Monoclonal antibody isolation using high-throughput B cell culture and antigen-specific 
B cell sorting.  
During high-throughput B cell culture (top panel), memory B cells are enriched from peripheral 
blood mononuclear cell (PBMC) samples by flow cytometry or using magnetic bead separation. 
Subsequently 2 cells/well are cultured in the presence of CD40 ligand and cytokines for B cell 
activation, proliferation and differentiation. Paired variable heavy and light chain genes from cells 
that are positive on neutralization screens are then PCR amplified, cloned and expressed as 
antibodies. In antigen-specific single B cell sorting (bottom panel), PBMC samples are labelled with 
various cell markers in addition to the engineered antigens. Antigen-specific memory B cells are 
single sorted (one B cell/well) by flow cytometry. Paired variable heavy and light chain genes from all 
cells are then PCR amplified, cloned and expressed as antibodies. 
 
Antigen-specific B cell sorting 
A second mAb isolation approach is flow cytometry-based antigen-specific B cell sorting 
(Figure 12, bottom panel), which relies on the rational design of specific antigenic “baits” to 
select for rare bNAb-producing B cells197,203,204. The first anti-HIV-1 bNAb isolated using this 
method was the CD4bs mAb, VRC01, which bound to a highly specific, rationally engineered 






















with markers that identify each major cell type circulating in the peripheral blood. While 
different staining panels are used, the inclusion of CD19, to identify B cells and IgM/IgD, to 
differentiate naïve B cells, are strict requirements. In terms of antigen-specificity, a 
fluorescent HIV-1 recombinant Env protein or peptide is used as a “bait” (positive selection) 
to label memory B cells that express a BCR capable of binding the specifically designed bait. 
The strategy capitalizes on the high frequency of membrane-bound BCR on the surface of 
memory B cells, which can therefore be relatively well labelled. Often a differential selection 
strategy is applied through the use of a “negative bait”, which except for engineered 
epitope-ablating mutations is identical to the positive bait. Monomeric gp120 proteins or 
MPER peptides have been successfully used to isolate antigen-specific single B cells that 
produce strain-specific133,203,205 and broadly neutralizing antibodies174,197  from HIV-1 
infected individuals. In addition, cells expressing HIV-1 Envs on their surface have also been 
used as antigens and in this way the antibodies 3BC176 and 3BC315 were isolated206,207. 
Until the design and structural characterization of the BG505 SOSIP.664 Env trimer, 
recombinant Env proteins could not be bound by bNAbs targeting quaternary epitopes. The 
use of this antigen for specific single memory B cell sorting was first described through the 
isolation of V1V2 bNAbs belonging to the PGT145 lineage208. Although the BG505 SOSIP.664 
protein is highly representative of prefusion Env, a portion of the V3 loop is partially 
exposed81. For this reason, a small number of non-neutralizing antibodies, in addition to 
most bNAbs, are able to bind to this protein81. The BG505 SOSIP.664 (positive bait) was 
therefore used in conjunction with a gp120 monomer, which exposes non-neutralizing sites 
(negative bait)208. This allowed for distinction of cells that bound neutralizing (BG505 single 
positive cells) and non-neutralizing (gp120/BG505 double positive cells) epitopes.  
The use of the BG505 SOSIP.664 trimer as a viable protein for antigen-specific sorting of 
quaternary dependent V1V2-directed B cells prompted us to adapt the sorting strategy used 
by Sok and colleagues208. We knew from plasma and mAb epitope studies that the bNAb 
response in CAP256 was extremely sensitive to the K169E mutation191,194. We therefore 
created a negative bait, BG505 SOSIP.664 K169E, which we paired with the wild-type BG505 
SOSIP.664192. Using this sorting strategy we were able to isolate 11 CAP256-VRC26 B cells, of 
which 8 had paired heavy-light sequences and were distinct from the 25 B cell culture 






















effective at isolating rare bNAb-producing B cells. This was an improvement over the Sok et 
al strategy where only 48% of isolated B cells belonged to the bNAb lineage. Overall, using 
both binding and neutralization screens, we were able to isolate 33 clonally related 
antibodies belonging to the CAP256-VRC26 lineage. While culture and sorting methods both 
yielded mAbs with high levels of neutralization breadth, members of this lineage showed a 
range of neutralization breadth of between 2 and 63%191,192. This provided us with a unique 
opportunity to investigate the molecular events which shaped the development of breadth 
in this lineage (discussed in section 8.3).  
 
7. V1V2-directed bNAbs 
7.1 The conformational V1V2 Env epitope 
The V1V2 region (50-90 amino acids) is located at the apex of the trimer (Figure 13A) and 
forms part of the trimer association domain67, which holds the native Env in the prefusion, 
closed conformation. In native Env, the V3 loop is closely associated with and protected by 
the V1V2 domain68,69,209,210 (Figure 13A and B). The role of the V1V2 region in immune 
evasion, achieved through high levels of sequence variability and glycosylation, is 
emphasized by the extreme neutralization sensitivity of V1V2-deleted viruses211-215. 
In the prefusion trimer, the most conserved sections of V1V2 fold into five anti-parallel β 
strands (A, B, C and D) (Figure 13C), while the more variable residues form long, flexible 
loops that connect the strands216. In addition to non-covalent hydrogen bonds, inter-strand 
disulfide bridges stabilize this five-stranded β-barrel. The C-strand, which forms the short 
peptide contact zone for most V1V2 bNAbs, is bracketed by the N156 and N160 glycans on 
the edge and central areas of the trimer cap respectively. Additional contacts for V1V2 
bNAbs are located at the highly conserved residues 166 and 169, which are positioned in the 























 Figure 13. Structure of the V1V2 broadly neutralizing antibody epitope.  
(A) Side view ribbon representation of the trimer, highlighting the location of the V1V2 and V3 
regions at the trimer apex. As indicated in the key, the five anti-parallel beta strands (beta-barrel) 
are shown in purple, while stick and surface representations of the N156 and N160 glycans are 
shown in cyan and blue respectively. The key amino acid residues at position 166 and 169 are shown 
as spheres in green and orange respectively. The approximate position of the viral membrane is 
indicated. (B) Ribbon representation of the trimer showing the view from the angle of approach by 
V1V2 bNAbs. Colors and representations are described in A and the key. (C) Schematic diagram 
illustrating the five-stranded beta-barrel of the V1V2 region (residues 129-193), together with the 
connecting loops and positions of glycans and key amino acid residues. Colors are described in A and 
the key. PDB ID: 4TVP. N-linked glycans were modelled using GlyProt217. 
 
The first bNAbs targeting the quaternary V1V2 epitope, PG9 and PG16, are second 
generation bNAbs with excellent breadth (~80%)117. To date, V1V2 class bNAbs have been 
isolated from a total of four HIV-1 individuals, donors IAVI24, IAVI84, CH0219 and CAP256 
yielding antibodies PG9/16117, PGT141-145118/PGDM1400-1412208, CH01-04190 and CAP256-
VRC26.01-33191,192 respectively (Figure 14). While these bNAbs are derived from multiple 






















possess long CDRH3s (24-37 amino acids according to Kabat numbering). These long, 
protruding CDRH3s, the key paratope component of V1V2 bNAbs,  are generally anionic and 
may be sulfated at select tyrosine residues216,218,219.  
 
Figure 14. Broadly neutralizing V1V2-directed antibody characteristics.  
The donor names, genetic characteristics, complementarity determining region 3 in the heavy chain 
(CDRH3) features, N160 glycan dependence and breadth of the PG9/16, CAP256-VRC26.01-33, CH01-
04 and PGT141-145/PGDM1400-1412 V1V2-directed neutralizing antibodies are shown. CDRH3 
structures are shown as surface representations with red and blue shading indicating acidic and 
basic residues respectively. 
 
Low resolution electron microscopy has shown that this class of bNAbs usually bind with a 
stoichiometry of one mAb per trimer83,191,208. Apart from PG9, V1V2-directed bNAbs are 
unable to bind to non-native recombinant forms of Env, including gp120 or monomeric 
V1V2 scaffolds. Although high resolution crystal structures of V1V2 bNAbs bound to the 
trimer have not been published, their crystal structures with scaffolded V1V2 regions78,220 
and a trimer-V1V2 bNAb model216 have provided detailed insights about their modes of 
binding. The long CDRH3s of these bNAbs have been selected because of their ability to 
reach through the extensive V1V2 glycan shield, and contact the conserved peptide residues 
beneath. In this way, antibody binding is stabilized through interactions with the N156 or 
N173 and N160 glycan residues, which can include interactions with sialic acid moieties, 
terminal mannose residues and the N-acetylglucosamine stems. The extensive length of the 
CDRH3s of these bNAbs causes the formation of secondary structural β-sheets, which then 
form strand-strand bonds with the V1V2 C-strand. Lastly, the sulfated tyrosine residues 
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and/or hydrophobic interactions with the positively charged side chains at V1V2 positions 
166 and 169.  In contrast to other V1V2-directed bNAbs, the CAP256-VRC26 lineage is 
affected by N160 glycan mutations in a neutralization potency-dependent manner192. This 
may be dependent on the mode of binding, which is affected by the angle of approach, 
exact contact residues and the types of interactions involved.   
  
7.2. Origin of the long CDRH3 
As previously discussed, all V1V2 class bNAbs possess unusually long CDRH3s, and two 
hypotheses for their development have previously been proposed221,222. Firstly, the 
insertion of amino acids, by TdT, at junctional sites during the initial V, D and J 
recombination event (using a limited subset of germline genes221), could result in formation 
of a long CDRH3. Secondly an accumulation of insertions, created by the action of AID, 
throughout the CDRH3 during affinity maturation could produce a long CDRH3.  
We determined the developmental pathway of the CAP256-VRC26 mAb lineage using Ig 
heavy and light chain variable region next-generation sequencing (NGS) at 9 time points 
between 15 and 206 weeks after HIV-1 infection191. CAP256-VRC26 relatives were detected 
as early as 34 weeks and this data was used to infer the UCA of this lineage. The inferred 
UCA possessed a long CDRH3 of 35 amino acids and comparison with 34 week NGS data 
identified exact sequence matches with this UCA. This study showed that in the CAP256-
VRC26 mAb lineage, the long CDRH3 resulted from a unique recombination event, rather 
than the gradual accumulation of length through SHM. The CAP256-VRC26-UCA was unable 
to neutralize heterologous viruses, but in a relatively short time period (~14 weeks), 
acquired neutralization breadth through subsequent SHM. While the developmental 
pathway for a V1V2 bNAb has only been described in the CAP256-VRC26 lineage, this data is 
considered a model for the development of all mAbs targeting the V1V2 quaternary epitope, 






















8. Virus-antibody co-evolution: a blueprint for vaccine design 
8.1. Viral escape from NAbs  
Most HIV-1 infected individuals develop early strain-specific NAbs against the autologous 
virus after a few months of infection124-126. All NAbs, including strain-specific and broad 
responses, exert sufficient pressure on the virus to select for escape mutations128-
131,134,193,223-229 (Figure 15A).  The high mutation rate of HIV-1 ensures that viral escape 
occurs very rapidly, often via multiple routes or mechanisms, which include amino acid 
mutations, indels and changes in glycosylation. Generation of viral mutants is so efficient, 
that even in individuals with relatively low viral loads, escaped viruses are rapidly 
selected230. As a result, contemporaneous viruses are usually less sensitive or resistant to 
neutralization by autologous NAbs than earlier viruses130,134,193,228. In addition, viruses from 
later in infection are generally resistant to neutralization by early NAb responses. Finally, 
NAb responses that are completely escaped by the viral quasispecies wane in titer as their 
antigenic stimuli decreases130,134 (Figure 15B).  
 
Figure 15. Schematic diagram depicting the anti-HIV-1 neutralizing antibody (NAb) response over 
time.  
(A) “Evolutionary arms race” between the virus and NAb response. Early infection plasma samples 
are unable to neutralize viruses isolated from any time point as the antibody response only develops 
after established viral infection. After the development of the initial NAb response, continual viral 
escape is followed by antibody evolution, with later plasma able to neutralize earlier, but not later or 
contemporaneous viruses. Eventually complete viral escape is selected for, where all subsequent 
viruses are resistant to all later plasma. Red and blue squares indicate viral neutralization sensitivity 
and resistance respectively. (B) NAb response against HIV-1 gradually increases in titer and then 
wanes over the course of infection, due to viral escape. NAb titer is shown on the y-axis and time 






















8.2 Tracking bNAb repertoires 
Antibody isolation, coupled with the recent advances in NGS technologies has provided a 
platform for interrogating B cell repertoires. The use of variable heavy and light chain gene-
specific primers, sequence identifier adapters or indices (to tag individual gene sequences) 
and fragmentation paired with immobilization of sequences allows for the simultaneous 
generation of vast numbers of pooled sequences, which can subsequently be deconstructed 
into individual sequence reads231. NGS has been used extensively to track specific antibody 
repertoires in individuals over time, to compare entire antibody repertoires between 
individuals and to understand the B cell repertoire prior to and after infection and/or 
vaccination231,232. In the HIV-1 field, cross sectional antibody repertoire studies have shown 
how antibody maturation circumvents viral immune evasion mechanisms. The PGT121 
bNAb lineage, for example, matures over time to lose dependence on glycans and trimer 
crosslinking233. Diversity in bNAb lineages, a direct consequence of SHM, is often high234,235 
and in the VRC01 lineage, this mutation rate is comparable with that of HIV-1236, enabling 
this mAb lineage to combat the quickly evolving virus.  
These NGS-aided studies have described how SHM generates multiple versions of clonally-
related NAbs which form lineages descended from a UCA. Therefore a precursor B cell or 
UCA gradually evolves through a series of intermediates, sometimes eventually developing 
the ability to neutralize heterologous viruses. These UCAs and intermediates are inferred, 
because conventional NGS does not biologically pair heavy and light chains or in the case of 
cross-sectional studies, due to sample unavailability, actual sequences of the UCAs cannot 
be acquired. Because the CDR3 of either the heavy or light chain, is created through V(D)J 
recombination, which may include junctional insertions at the recombination sites, inferring 
the sequence of the original CDR3 is impossible with cross-sectional samples. Thus, while 
longitudinal studies can accurately define the UCAs of bNAb lineages, only germline 
revertants, which contain the mature CDR3 within the backbone of a reverted V gene, can 
be derived using cross-sectional samples. Despite the inferred status of germline revertants 
and intermediates on the pathway to the development of neutralization breadth in bNAb 
lineages, these studies have provided valuable insights for vaccine design, particularly when 






















8.3 Virus-antibody co-evolution and the development of neutralization breadth 
Two landmark studies, one of which forms part of this thesis, used NGS to track mAb 
evolution over time to accurately infer the UCAs and intermediates on the pathway to the 
development of a CD4bs237 and a V1V2191 bNAb lineage.  
The UCA of the CH103 mAb lineage237, which targeted the CD4bs, was only capable of 
strain-specific binding to the autologous transmitted/founder virus (Figure 16A). NGS at five 
time points between 6 and 144 weeks p.i. showed that over the course of 27 weeks a 
gradual accumulation of mutations in this mAb lineage led to the development of strain-
specific neutralizing activity and the subsequent acquisition of broad neutralizing 
capabilities (Figure 16A and B). However, coupled with the development of breadth, this 
lineage also developed polyreactive traits. A concomitant accrual of mutations in the viral 
epitope for these mAbs also occurred, suggesting that co-evolution of the virus and mAbs 
led to the development of breadth in this antibody lineage. 
Similarly, we determined the developmental pathway for the CAP256-VRC26 V1V2-directed 
mAb lineage using NGS at nine time points between 15 and 206 weeks after infection191. 
However, unlike the CD4bs CH103 UCA, the CAP256-VRC26 lineage possessed a long CDRH3, 
as a result of a unique recombination event (discussed in section 7.2). A gradual 
accumulation of mutations occurred in both the CAP256-VRC26 lineage and the virus, with 
viral diversity in the V1V2 epitope eventually peaking just prior to the development of 
neutralization breadth (Figure 17). However, while the CH103 UCA was only capable of 
strain-specific binding to autologous Env, the CAP256-VRC26-UCA was able to weakly 
neutralize the autologous superinfecting transmitted/founder virus. In addition, 
development of breadth occurred 14 weeks after the CAP256-VRC26 lineage was first 
























Figure 16. Maturation of the CH103 CD4 binding site mAb lineage towards neutralization breadth.  
(A) Phylogenetic tree displaying the relationship between the unmutated common ancestor (UCA), 
developmental intermediates and broadly neutralizing antibodies (bNAbs) within the CH103 lineage. 
Neutralization of the autologous transmitted/founder virus (CH505) and two heterologous viruses 
(Q842 and BG168) by each antibody is shown in colored blocks with potency indicated by the key. 
Binding of the UCA to the transmitted/founder virus is also shown in a block beneath the 
neutralization data. Intermediate 3 (I3), highlighted in grey, is the first developmental intermediate 
with weak neutralization breadth. CH103, shaded in green, is the mature bNAb. (B) Antibody-Env 
binding models displaying the accumulation of mutations in both the virus and antibody from 14 to 
136 weeks post-infection. Env residues are shown as tubes, with sequence diversity indicated by the 
key. Antibody residues are shown as ribbon representations, with spheres (colored according to the 
key) highlighting mutations. Figure taken from Liao et al 2013237. 
 
CD4bs bNAbs generally arise much later in infection than other bNAb responses and have 
the highest levels of SHM of all bNAb classes. Together with the fact that the CH103 lineage 
took twice as long as the CAP256-VRC26 lineage to develop neutralization breadth, may 
suggest that the V1V2 region may be a more viable vaccine target. In both the CH103 and 
CAP256-VRC26 lineages however, the acquisition of neutralization breadth occurred with 
the gradual and concomitant accumulation of mutations in the mAbs and cognate viral 
























Figure 17. Maturation of the CAP256-VRC26 V1V2-directed mAb lineage towards neutralization 
breadth.  
(A) Maximum likelihood phylogenetic tree showing the pathway of maturation for the heavy (left) 
and light (right) chain of CAP256-VRC26.01, with the branches to the other CAP256-VRC26 
antibodies collapsed. The positions of the inferred intermediates, I1 and I2, are indicated as black 
dots. Branches are colored by time point when next-generation sequences were first detected as 
indicated in the key. Scale shows rate of nucleotide change (per site) between nodes. (B) 
Neutralization of autologous transmitted/founder viruses and V1V2 mutants by the CAP256-VRC26-
UCA, -I1, -I2 and .01. (C) Neutralization of heterologous viruses by the CAP256-VRC26-UCA, -I1, -I2 
and .01. (D) Ribbon representations of the CAP256-VRC26-UCA, -I1, -I2 and .01 Fab regions, with 
accumulating mutations highlighted by spheres. Spheres are colored according to when the 























8.4. Initiation of bNAb precursors 
Identification of viruses or recombinant HIV-1 proteins that are reactive with bNAb 
precursors or UCAs has been challenging and is complicated by the fact that most inferred 
bNAb precursors are germline revertants, which may not recapitulate the paratope of the 
actual antibody correctly. Germline reversions of bNAbs targeting four of the five known 
epitopes on Env (the MPER238,239, the V1V2 region190,240, the N332/V3 region233 and the 
CD4bs197,241-243) show little or no binding to recombinant HIV-1 Env proteins, including those 
derived from viruses that are well neutralized by their mature bNAb counterparts. This is in 
contrast to strain-specific NAb germline revertants, which are more promiscuous in their 
interactions with diverse Envs244. Thus, a major hurdle in the elicitation of bNAbs by 
immunization is the initial interaction between a naïve B cell expressing a bNAb precursor 
and its cognate antigen. 
In addition, longitudinal studies have shown that the epitopes of broadly neutralizing 
plasma responses in many HIV-1 infected individuals are either absent or less than optimal 
on the corresponding transmitted/founder viruses134,227. This, coupled with the delayed 
onset of bNAbs, between one and three years after HIV-1 infection119,139,141 suggests the 
possibility that later viral variants as well as transmitted/founder viruses may engage bNAb 
UCAs.  
The unusual features of bNAbs suggest that their initiation may be further hampered by the 
rarity of their precursors in the naïve B cell pool. For example, VH-restricted CD4bs bNAbs 
generally have an unusually short CDRL3 in the kappa chain, which avoids clashes with the 
V5 and D loops, however only 0.6-1% of naïve B cells possess these short CDRL3 loops245. B 
cells that produce antibodies with long CDRH3 loops, such as those in V1V2- and N332-
directed bNAbs, are generally deleted due to their increased potential for self-reactivity and 
as such are only present in 0.4% of all naïve B cells221. Therefore highly specific immunogens 
will be required to engage and activate these rare bNAb precursors. Two strategies have 
been employed to identify such bNAb-initiating Envs or immunogens, namely the 
identification of naturally occurring viral variants that are engaged by bNAb precursors and 






















The highly conserved CD4bs, for which Env-antibody crystal structures with bNAbs from 14 
different donors172 are available, was used to design79 and optimize241,245 engineered outer 
domain germline targeting (eOD-GT) proteins. To investigate the ability of this immunogen 
to selectively stimulate expansion of CD4bs bNAb precursors, two groups created 
humanized mice, which expressed the germline heavy chain of CD4bs bNAbs, VRC01245 or 
3BNC60246. eOD-GT8, expressed as 60mers on nanoparticles efficiently and preferentially 
activated CD4bs bNAb precursors with the VRC01 or 3BNC60 heavy chains and selected for 
the use of mouse light chains with a short CDRL3. These studies also showed that 
immunization of the engineered mice with the BG505 SOSIP.664 trimer did not prime CD4bs 
bNAb precursors. 
In this thesis, we studied natural infection to identify authentic bNAb-initiating Envs that 
primed the V1V2-directed CAP256-VRC26 response by engaging the rare long CDRH3 of the 
CAP256-VRC26-UCA. While the CAP256-VRC26-UCA was able to weakly neutralize the 
superinfecting virus, this virus was not detected at 34 weeks after infection, when CAP256-
VRC26 sequences were first isolated. However four CAP256 34 week viruses, which were 
closely related to the superinfecting virus, were 5-17-fold more sensitive to neutralization 
by the CAP256-VRC-UCA than the superinfecting virus247. Although the weak neutralization 
of the superinfecting virus may suggest that this Env initiated the response and the 34 week 
Envs boosted the response, the enhanced sensitivity of the 34 week viruses to the CAP256-
VRC bNAb precursor suggested that these Envs (rather than the superinfecting virus Env) 
should be used to create immunogens to prime V1V2-directed responses. 
 
8.5. The role of viral evolution in driving neutralization breadth  
Studies using polyclonal and monoclonal bNAb responses have identified a number of 
factors that are associated with the development of neutralization breadth, including low 
CD4 T cell count119, higher frequency of T follicular helper (Tfh) cells in the periphery248, and 
HLA genotype249. However viral factors, such as high viral loads119,137,139, inter-clade 
superinfection250,251 and higher Env diversity137 have also been linked with the development 






















described an increase in viral diversification within the bNAb epitope prior to the 
development of neutralization breadth191,237.  
We and others have therefore focused on the role of the autologous viral population in 
driving neutralization breadth. Recent studies have highlighted three major mechanisms 
whereby the evolving viral population shapes the development of bNAbs252. Firstly, viral 
escape from other NAb responses can directly create bNAb epitopes by mutating key 
residues within the bNAb sites134,227,253. Secondly, viral escape can induce the exposure of 
bNAb epitopes134 through glycan shifting or changing of variable loop lengths. In addition to 
previous studies which investigated polyclonal plasma responses134, the third mechanism, of 
affinity maturation driven by exposure to multiple viral immunotypes, is described in this 
thesis247 and will therefore be discussed in greater detail below.  
As described in sections 8.3 and 8.4, the CAP256-VRC26-UCA only had the ability to 
neutralize four closely-related autologous viruses and none of a 196 heterologous virus 
panel. The development of breadth in the CAP256 plasma occurred 14 weeks after the first 
detection of the CAP256-VRC26 lineage and just after a peak in viral diversification within 
the V1V2 epitope. This suggested a role for viral evolution in the development of 
neutralization breadth. Therefore, to investigate the specific viral changes that occurred 
during CAP256-VRC26 maturation, we performed viral NGS of the V1V2 region at 28 time 
points between 6 and 206 weeks after infection247. These data showed an accumulation of 
multiple immunotypes (or amino acids) at two key viral residues in the epitope of the 
CAP256-VRC26 mAbs. Indeed, just prior to the development of neutralization breadth in 
CAP256, the autologous viral quasispecies sampled 9 immunotypes at position 169 and 
approximately 17 weeks later amino acid toggling occurred at position 166. This suggested 
that early CAP256-VRC26 lineage members exerted strong selection pressure on the 
autologous virus. Introduction of select immunotypes at positions 169 and 166 into the 
superinfecting virus showed a correlation between neutralization breadth of the CAP256-
VRC26 mAbs and their neutralization of the 169 and 166 mutants (Figure 18). Therefore viral 
escape created multiple immunotypes at key residues in the CAP256-VRC26 V1V2 epitope. 
Exposure to this viral variation drove the evolution of CAP256-VRC26 lineage members with 
the ability to tolerate this diversity and therefore possess neutralization breadth. Thus viral 






















affinity-based mAb selection for escaped viruses, results in mAb evolution towards 
tolerating variability. 
 
Figure 18. Relationship between CAP256-VRC26 antibody neutralization breadth and tolerance of 
multiple immunotypes at positions 169 and 166.  
Thirty monoclonal antibodies (mAbs) in the CAP256-VRC26 lineage are ranked according to 
neutralization breadth in the histogram. Neutralization of the superinfecting virus (SU) and 169 or 
166 mutant viruses by CAP256-VRC26 mAbs are shown as a heat map, with shading showing 
neutralization potency, as indicated in the key. Correlations (r) between neutralization breadth and 
the IC50 titers of each mutant virus are indicated on the right of the heat map. *P < 0.05; **P < 0.005; 
***P < 0.0001, calculated using a two-tailed non-parametric Spearman correlation. Figure taken 
from Bhiman et al 2015247. 
 
8.6 Caveats and implications for vaccine design 
Anti-HIV-1 bNAb evolution has greatly informed immunization strategies to elicit bNAb 
responses. Immunogen engineering and validation, based on these studies, has become the 
new focus of the HIV-1 vaccine field. The use of stabilized trimers as immunogens, including 
the BG505 SOSIP.664245,246,254,255, has already begun, however based on the 
immunodominance of non-bNAb epitopes, it may be necessary to use glycan shielding to 
limit responses to unwanted regions. In addition, scaffolded bNAb epitope proteins may 
provide alternate solutions to avoid stimulation of non-bNAb responses216. Irrespective of 
the type of immunogen, multiple rounds of refinement will likely be required to fine tune 
proposed immunization strategies. These refinements might progress faster through the use 
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of in silico and humanized mice studies. In addition, the concentration of sequential and 
cocktail immunogens may need to be varied to determine the optimal mixture for the 
elicitation of bNAb versus strain-specific NAb responses. 
The inclusion of all Env diversity generated during bNAb development, either as a cocktail of 
multiple immunogens or as sequential series of immunogens, has been proposed237. 
However the identification of viral variants present at distinct steps in bNAb development 
might provide a more rational vaccination strategy. To this end, we have suggested a 
sequential immunization strategy that mimics the virus-antibody co-evolution which 
occurred during the development of the CAP256-VRC26 lineage (Figure 19). This regimen 
begins with a prime, using bNAb-initiating Env derived immunogens, followed by three 
sequential boosts. The initial boost is designed to act as a bridging between the priming 
immunogen and the cocktail of immunogens presented in the second boost. While the first 
two boosts introduce diversity at one site, the final boost generates diversity at a second 
key site in this bNAb epitope. 
 
Figure 19. Recapitulating viral evolution for vaccine design.  
A proposed prime-sequential boost immunization strategy to elicit V1V2-directed bNAbs, based on 
the key viral events that initiated and drove neutralization breadth in the CAP256-VRC26 lineage. A 
CAP256 34-week bNAb-initiating Env (red), which has the 169K and 166R immunotypes, would be 
used as a prime to engage UCAs with long CDRH3s. This would be followed by three sequential 
boosts using immunogens with varying immunotypes to mimic the viral diversification in CAP256 
that drove bNAb development. The 169I boost (orange) would be administered first, followed by a 
cocktail of 169T/Q and R immunogens (blue) and a final boost to expose vaccine-induced mAbs to 























In addition, determining the frequency of bNAb precursors in HIV-1 uninfected, healthy 
individuals will be required to ascertain feasibility of eliciting bNAb responses. Despite a 
recent study, showing that HIV-1 infected individuals who develop neutralization breadth 
and those who do not, have the same Ig germline genetic potential256, the rare 
recombination events that lead to development of bNAbs precursors may suggest that not 
all individuals can make these types of antibodies. NGS screening of the B cell repertoire of 
greater numbers of healthy individuals, from distinct ethnic backgrounds will be necessary 
to determine the frequency of these cells. However if all individuals can produce bNAb 
precursors, this may be a time-dependent occurrence and therefore longitudinal repertoire 
analysis, in adults and children may be necessary. 
 
8.7. Conclusion 
Since the start of this PhD in 2012, the HIV-1 vaccine field has made enormous 
advancements, big innovations and new discoveries to propel research into an exponential 
growth phase. These include the identification of a new bNAb target on the HIV-1 Env, 
elucidation of the developmental pathways of two bNAb lineages and the engineering of an 
HIV-1 immunogen that preferentially activates CD4bs bNAb precursors in humanized mice. 
In addition to this, clinical trial approval to test the efficacy of bNAbs for passive, rather than 
active, vaccination has been granted in countries worst affected by this virus, such as South 
Africa166.  
While the search for an HIV-1 vaccine still continues, almost 30 years after the very first HIV-
1 vaccine trial was performed in 1986257, the isolation and characterization of bNAbs that 
target sites of vulnerability on the HIV-1 Env, coupled with the first structural view of the 
prefusion trimer has moved research towards the rational design of immunogens that can 
elicit these types of responses.  
The findings presented in this thesis show how bNAbs within an HIV-1 infected individual 
gradually mature to acquire neutralization breadth and how this maturation occurs in direct 






















immunization strategy that was identified through the delineation of antibody and virus co-
evolution during the development of neutralization breadth. 
 
9. References 
1 UNAIDS. Global AIDS Update 2016. (Joint United Nations Programme on HIV/AIDS, Geneva, 
Switzerland, 2016). 
 
2 Kharsany, A. B. et al. Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J 
Acquir Immune Defic Syndr 70, 289-295, doi:10.1097/QAI.0000000000000761 (2015). 
 
3 Auvert, B. et al. Randomized, controlled intervention trial of male circumcision for reduction 
of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2, e298, doi:05-PLME-RA-0310R1 
[pii]10.1371/journal.pmed.0020298 (2005). 
4 Gray, R. H. et al. Male circumcision and HIV acquisition and transmission: cohort studies in 
Rakai, Uganda. Rakai Project Team. AIDS 14, 2371-2381 (2000). 
 
5 Pinkerton, S. D. & Abramson, P. R. Effectiveness of condoms in preventing HIV transmission. 
Soc Sci Med 44, 1303-1312 (1997). 
 
6 Hope, T. J. & Marrazzo, J. M. A Shot in the Arm for HIV Prevention? Recent Successes and 
Critical Thresholds. AIDS Res Hum Retroviruses 31, 1055-1059, doi:10.1089/AID.2015.0310 
(2015). 
 
7 Barron, P. et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World 
Health Organ 91, 70-74, doi:10.2471/BLT.12.106807 (2013). 
 
8 Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and 
women. N Engl J Med 367, 399-410, doi:10.1056/NEJMoa1108524 (2012). 
 
9 Grant, R. M. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and 
postexposure prophylaxis. Clin Infect Dis 50 Suppl 3, S96-101, doi:10.1086/651479 (2010). 
 
10 Plotkin, S. T. & Plotkin, S. A. in Vaccines   (eds S. A. Orenstein Plotkin, W. A. & A. A. Offit)  1-
13 (Elsevier/Saunders, 2013). 
11 Prevention, C. f. D. C. a. Measles Cases and Outbreaks, <http://www.cdc.gov/measles/cases-
outbreaks.html> (Accessed 2 June 2016). 
 
12 Esparza, J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 
31, 3502-3518, doi:10.1016/j.vaccine.2013.05.018 (2013). 
 
13 Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in 
Thailand. N Engl J Med 361, 2209-2220, doi:NEJMoa0908492 [pii] 10.1056/NEJMoa0908492 
(2009). 























15 Cohen, J. Planned tests in Thailand spark debate. Science 276, 1197 (1997). 
 
16 Berman, P. W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination 
with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625, 
doi:10.1038/345622a0 (1990). 
 
17 Berman, P. W. et al. Protection of MN-rgp120-immunized chimpanzees from heterologous 
infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 173, 
52-59 (1996). 
 
18 Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 
vaccine to prevent HIV-1 infection. J Infect Dis 191, 654-665, doi:10.1086/428404 (2005). 
 
19 Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a 
bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, 
Thailand. J Infect Dis 194, 1661-1671, doi:10.1086/508748 (2006). 
 
20 Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the 
Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 
372, 1881-1893, doi:10.1016/S0140-6736(08)61591-3 (2008). 
 
21 Duerr, A. et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition 
and demonstrates waning effect over time among participants in a randomized trial of 
recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206, 258-266, 
doi:10.1093/infdis/jis342 (2012). 
 
22 Gray, G. E. et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: 
unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis 
14, 388-396, doi:10.1016/S1473-3099(14)70020-9 (2014). 
 
23 Catanzaro, A. T. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 
candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J 
Infect Dis 194, 1638-1649, doi:10.1086/509258 (2006). 
 
24 Catanzaro, A. T. et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA 
candidate vaccine. Vaccine 25, 4085-4092, doi:10.1016/j.vaccine.2007.02.050 (2007). 
25 Hammer, S. M. et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369, 
2083-2092, doi:10.1056/NEJMoa1310566 (2013). 
 
26 Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J 
Med 366, 1275-1286, doi:10.1056/NEJMoa1113425 (2012). 
 
27 Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H. & Johnson, P. R. An African 
primate lentivirus (SIVsm) closely related to HIV-2. Nature 339, 389-392, 
doi:10.1038/339389a0 (1989). 
 
28 Gao, F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 
436-441, doi:10.1038/17130 (1999). 
 
29 Keele, B. F. et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313, 






















30 Van Heuverswyn, F. et al. Genetic diversity and phylogeographic clustering of SIVcpzPtt in 
wild chimpanzees in Cameroon. Virology 368, 155-171, doi:10.1016/j.virol.2007.06.018 
(2007). 
 
31 Sharp, P. M. & Hahn, B. H. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect 
Med 1, a006841, doi:10.1101/cshperspect.a006841 (2011). 
 
32 Plantier, J. C. et al. A new human immunodeficiency virus derived from gorillas. Nat Med 15, 
871-872, doi:nm.2016 [pii] 10.1038/nm.2016 (2009). 
33 Vallari, A. et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be 
low. AIDS Res Hum Retroviruses 26, 109-115, doi:10.1089/aid.2009.0178 (2010). 
 
34 Vallari, A. et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 85, 1403-1407, 
doi:10.1128/JVI.02005-10 (2011). 
 
35 Gottlieb, M. S. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously 
healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J 
Med 305, 1425-1431, doi:10.1056/NEJM198112103052401 (1981). 
 
36 Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for 
acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983). 
 
37 Gallo, R. C. et al. Isolation of human T-cell leukemia virus in acquired immune deficiency 
syndrome (AIDS). Science 220, 865-867 (1983). 
 
38 Popovic, M., Sarngadharan, M. G., Read, E. & Gallo, R. C. Detection, isolation, and 
continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-
AIDS. Science 224, 497-500 (1984). 
 
39 Zhu, T. et al. An African HIV-1 sequence from 1959 and implications for the origin of the 
epidemic. Nature 391, 594-597, doi:10.1038/35400 (1998). 
 
40 Worobey, M. et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. 
Nature 455, 661-664, doi:10.1038/nature07390 (2008). 
 
41 Faria, N. R. et al. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in 
human populations. Science 346, 56-61, doi:10.1126/science.1256739 (2014). 
 
42 Levy, J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 57, 183-
289 (1993). 
 
43 Gentile, M. et al. Determination of the size of HIV using adenovirus type 2 as an internal 
length marker. J Virol Methods 48, 43-52 (1994). 
 
44 Moore, P. L. et al. Nature of nonfunctional envelope proteins on the surface of human 
immunodeficiency virus type 1. J Virol 80, 2515-2528 (2006). 
 
45 Roberts, J. D., Bebenek, K. & Kunkel, T. A. The accuracy of reverse transcriptase from HIV-1. 























46 Frankel, A. D. & Young, J. A. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67, 1-25, 
doi:10.1146/annurev.biochem.67.1.1 (1998). 
 
47 Klatzmann, D. et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus 
LAV. Nature 312, 767-768 (1984). 
 
48 McDougal, J. S. et al. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral 
protein and the T4 molecule. Science 231, 382-385 (1986). 
 
49 Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. HIV-1 entry cofactor: functional cDNA 
cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 
(1996). 
 
50 Deng, H. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 
661-666, doi:10.1038/381661a0 (1996). 
 
51 Alkhatib, G. et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor 
for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996). 
 
52 Starcich, B. R. et al. Identification and characterization of conserved and variable regions in 
the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45, 637-648 (1986). 
 
53 Willey, R. L. et al. Identification of conserved and divergent domains within the envelope 
gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A 83, 
5038-5042 (1986). 
 
54 Leonard, C. K. et al. Assignment of intrachain disulfide bonds and characterization of 
potential glycosylation sites of the type 1 recombinant human immunodeficiency virus 
envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265, 
10373-10382 (1990). 
 
55 Allan, J. S. et al. Major glycoprotein antigens that induce antibodies in AIDS patients are 
encoded by HTLV-III. Science 228, 1091-1094 (1985). 
 
56 Bosch, M. L. et al. Identification of the fusion peptide of primate immunodeficiency viruses. 
Science 244, 694-697 (1989). 
 
57 Freed, E. O., Myers, D. J. & Risser, R. Characterization of the fusion domain of the human 
immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A 87, 
4650-4654 (1990). 
 
58 Freed, E. O., Delwart, E. L., Buchschacher, G. L., Jr. & Panganiban, A. T. A mutation in the 
human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly 
interferes with fusion and infectivity. Proc Natl Acad Sci U S A 89, 70-74 (1992). 
 
59 Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope 
glycoprotein. Cell 89, 263-273 (1997). 
 
60 Dubay, J. W., Roberts, S. J., Brody, B. & Hunter, E. Mutations in the leucine zipper of the 
human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and 






















61 Lu, M., Blacklow, S. C. & Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane 
glycoprotein. Nat Struct Biol 2, 1075-1082 (1995). 
 
62 Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. Atomic structure of 
the ectodomain from HIV-1 gp41. Nature 387, 426-430 (1997). 
 
63 Munoz-Barroso, I., Salzwedel, K., Hunter, E. & Blumenthal, R. Role of the membrane-
proximal domain in the initial stages of human immunodeficiency virus type 1 envelope 
glycoprotein-mediated membrane fusion. J Virol 73, 6089-6092 (1999). 
 
64 Salzwedel, K., West, J. T. & Hunter, E. A conserved tryptophan-rich motif in the membrane-
proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important 
for Env-mediated fusion and virus infectivity. J Virol 73, 2469-2480 (1999). 
 
65 Haffar, O. K., Dowbenko, D. J. & Berman, P. W. Topogenic analysis of the human 
immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. J 
Cell Biol 107, 1677-1687 (1988). 
 
66 Berman, P. W., Nunes, W. M. & Haffar, O. K. Expression of membrane-associated and 
secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in 
continuous cell lines. J Virol 62, 3135-3142 (1988). 
 
67 Mao, Y. et al. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein 
trimer. Nat Struct Mol Biol 19, 893-899, doi:10.1038/nsmb.2351 (2012). 
 
68 Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 
1477-1483, doi:10.1126/science.1245625 (2013). 
 
69 Pancera, M. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 
514, 455-461, doi:10.1038/nature13808 (2014). 
 
70 Helseth, E., Olshevsky, U., Furman, C. & Sodroski, J. Human immunodeficiency virus type 1 
gp120 envelope glycoprotein regions important for association with the gp41 
transmembrane glycoprotein. J Virol 65, 2119-2123 (1991). 
 
71 Moore, J. P., Willey, R. L., Lewis, G. K., Robinson, J. & Sodroski, J. Immunological evidence for 
interactions between the first, second, and fifth conserved domains of the gp120 surface 
glycoprotein of human immunodeficiency virus type 1. J Virol 68, 6836-6847 (1994). 
 
72 Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 
receptor and a neutralizing human antibody. Nature 393, 648-659 (1998). 
 
73 Huang, C. C. et al. Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025-1028 
(2005). 
 
74 Pancera, M. et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered 
envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A 107, 
1166-1171, doi:0911004107 [pii]10.1073/pnas.0911004107 (2010). 
75 Diskin, R., Marcovecchio, P. M. & Bjorkman, P. J. Structure of a clade C HIV-1 gp120 bound to 
CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol 17, 608-






















76 Finzi, A. et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction 
and CD4-triggered conformational transitions. Mol Cell 37, 656-667, doi:S1097-
2765(10)00154-1 [pii]10.1016/j.molcel.2010.02.012 (2010). 
77 Kwon, Y. D. et al. Crystal structure, conformational fixation and entry-related interactions of 
mature ligand-free HIV-1 Env. Nat Struct Mol Biol 22, 522-531, doi:10.1038/nsmb.3051 
(2015). 
 
78 McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing 
antibody PG9. Nature 480, 336-343, doi:10.1038/nature10696nature10696 [pii] (2011). 
79 Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV 
glycan shield. Science 334, 1097-1103, doi:science.1213256 [pii]10.1126/science.1213256 
(2011). 
80 Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope 
trimer. Science 342, 1484-1490, doi:10.1126/science.1245627 (2013). 
 
81 Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 
gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing 
antibodies. PLoS pathogens 9, e1003618, doi:10.1371/journal.ppat.1003618 (2013). 
 
82 Sanders, R. W. et al. Stabilization of the soluble, cleaved, trimeric form of the envelope 
glycoprotein complex of human immunodeficiency virus type 1. J Virol 76, 8875-8889 (2002). 
 
83 Julien, J. P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing 
antibody PG9. Proc Natl Acad Sci U S A 110, 4351-4356, doi:10.1073/pnas.1217537110 
(2013). 
 
84 Khayat, R. et al. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein 
trimers. J Virol 87, 9865-9872, doi:10.1128/JVI.01222-13 (2013). 
 
85 Klasse, P. J. et al. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP 
envelope glycoprotein. J Virol 87, 9873-9885, doi:10.1128/JVI.01226-13 (2013). 
86 Tan, K., Liu, J., Wang, J., Shen, S. & Lu, M. Atomic structure of a thermostable subdomain of 
HIV-1 gp41. Proc Natl Acad Sci U S A 94, 12303-12308 (1997). 
 
87 Melikyan, G. B. et al. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not 
the bundle configuration, induces membrane fusion. J Cell Biol 151, 413-423 (2000). 
88 Freed, E. O. & Martin, M. A. The role of human immunodeficiency virus type 1 envelope 
glycoproteins in virus infection. J Biol Chem 270, 23883-23886 (1995). 
 
89 Gagneux, P. & Varki, A. Evolutionary considerations in relating oligosaccharide diversity to 
biological function. Glycobiology 9, 747-755, doi:cwc089 [pii] (1999). 
 
90 Choi, B. K. et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in 
the yeast Pichia pastoris. Proc Natl Acad Sci U S A 100, 5022-5027, 
doi:10.1073/pnas.09312631000931263100 [pii] (2003). 
91 Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational 






















92 Zhu, X., Borchers, C., Bienstock, R. J. & Tomer, K. B. Mass spectrometric characterization of 
the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39, 11194-
11204 (2000). 
 
93 Cutalo, J. M., Deterding, L. J. & Tomer, K. B. Characterization of glycopeptides from HIV-
I(SF2) gp120 by liquid chromatography mass spectrometry. Journal of the American Society 
for Mass Spectrometry 15, 1545-1555, doi:10.1016/j.jasms.2004.07.008 (2004). 
 
94 Crispin, M. D. et al. Monoglucosylated glycans in the secreted human complement 
component C3: implications for protein biosynthesis and structure. FEBS Lett 566, 270-274, 
doi:10.1016/j.febslet.2004.04.045S0014579304005125 [pii] (2004). 
95 Cimbro, R. et al. Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes 
V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A 111, 
3152-3157, doi:10.1073/pnas.1314718111 (2014). 
 
96 Hallenberger, S. et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein 
gp160. Nature 360, 358-361, doi:10.1038/360358a0 (1992). 
 
97 McCune, J. M. et al. Endoproteolytic cleavage of gp160 is required for the activation of 
human immunodeficiency virus. Cell 53, 55-67 (1988). 
 
98 Freed, E. O., Myers, D. J. & Risser, R. Mutational analysis of the cleavage sequence of the 
human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol 63, 
4670-4675 (1989). 
 
99 Zhu, P. et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and 
simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100, 15812-15817, 
doi:10.1073/pnas.2634931100 (2003). 
 
100 Binley, J. M. et al. Role of complex carbohydrates in human immunodeficiency virus type 1 
infection and resistance to antibody neutralization. J Virol 84, 5637-5655, 
doi:10.1128/JVI.00105-10 (2010). 
 
101 Cooper, M. D., Peterson, R. D. & Good, R. A. Delineation of the Thymic and Bursal Lymphoid 
Systems in the Chicken. Nature 205, 143-146 (1965). 
 
102 Murphy, K., Travers, P., Walport, M. & Janeway, C. Janeway's immunobiology. 8th edn,  
(Garland Science, 2012). 
 
103 Bellanti, J. A., Escobar-Gutiérrez, A. & Tsokos, G. C. Immunology IV : clinical applications in 
health and disease.  (I Care Press, 2012). 
 
104 Tonegawa, S. Somatic generation of antibody diversity. Nature 302, 575-581 (1983). 
105 Brack, C., Hirama, M., Lenhard-Schuller, R. & Tonegawa, S. A complete immunoglobulin gene 
is created by somatic recombination. Cell 15, 1-14 (1978). 
 
106 Pieper, K., Grimbacher, B. & Eibel, H. B-cell biology and development. J Allergy Clin Immunol 
131, 959-971, doi:10.1016/j.jaci.2013.01.046 (2013). 
 
107 Lefranc, M. P. et al. IMGT, the international ImMunoGeneTics information system. Nucleic 






















108 Siebenlist, U., Ravetch, J. V., Korsmeyer, S., Waldmann, T. & Leder, P. Human 
immunoglobulin D segments encoded in tandem multigenic families. Nature 294, 631-635 
(1981). 
 
109 Corbett, S. J., Tomlinson, I. M., Sonnhammer, E. L., Buck, D. & Winter, G. Sequence of the 
human immunoglobulin diversity (D) segment locus: a systematic analysis provides no 
evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D 
recombination. J Mol Biol 270, 587-597, doi:10.1006/jmbi.1997.1141 (1997). 
 
110 Alt, F. W. & Baltimore, D. Joining of immunoglobulin heavy chain gene segments: 
implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci U S 
A 79, 4118-4122 (1982). 
 
111 Bollum, F. J. Terminal deoxynucleotidyl transferase: biological studies. Adv Enzymol Relat 
Areas Mol Biol 47, 347-374 (1978). 
 
112 Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 
705-711 (1998). 
 
113 Wibmer, C. K., Moore, P. L. & Morris, L. HIV broadly neutralizing antibody targets. Current 
opinion in HIV and AIDS 10, 135-143, doi:10.1097/COH.0000000000000153 (2015). 
 
114 Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J. & Hendrickson, W. A. Oligomeric 
modeling and electrostatic analysis of the gp120 envelope glycoprotein of human 
immunodeficiency virus. J Virol 74, 1961-1972 (2000). 
 
115 Davis, K. L. et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low 
neutralizing potency in acute infection and following vaccination. Virology 387, 414-426, 
doi:10.1016/j.virol.2009.02.022 (2009). 
 
116 Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization 
epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70, 
1100-1108 (1996). 
 
117 Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a 
new HIV-1 vaccine target. Science 326, 285-289 (2009). 
 
118 Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent 
antibodies. Nature 477, 466-470, doi:nature10373 [pii]10.1038/nature10373 (2011). 
119 Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years 
and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 
85, 4828-4840, doi:JVI.00198-11 [pii]10.1128/JVI.00198-11 (2011). 
120 Klein, J. S. & Bjorkman, P. J. Few and far between: how HIV may be evading antibody avidity. 
PLoS pathogens 6, e1000908, doi:10.1371/journal.ppat.1000908 (2010). 
 
121 Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus 
type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-























122 Liao, H. X. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are 
polyreactive and highly mutated. J Exp Med 208, 2237-2249, doi:jem.20110363 
[pii]10.1084/jem.20110363 (2011). 
123 Trama, A. M. et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells 
that share cross-reactivity with commensal bacteria. Cell Host Microbe 16, 215-226, 
doi:10.1016/j.chom.2014.07.003 (2014). 
 
124 Delwart, E. L. et al. Slower evolution of human immunodeficiency virus type 1 quasispecies 
during progression to AIDS. J Virol 71, 7498-7508 (1997). 
 
125 Gray, E. S. et al. Neutralizing antibody responses in acute human immunodeficiency virus 
type 1 subtype C infection. J Virol 81, 6187-6196 (2007). 
 
126 Li, B. et al. Evidence for potent autologous neutralizing antibody titers and compact 
envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80, 
5211-5218, doi:80/11/5211 [pii]10.1128/JVI.00201-06 (2006). 
127 Moore, P. L. et al. The c3-v4 region is a major target of autologous neutralizing antibodies in 
human immunodeficiency virus type 1 subtype C infection. J Virol 82, 1860-1869, 
doi:10.1128/JVI.02187-07 (2008). 
 
128 Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003). 
 
129 Frost, S. D. et al. Neutralizing antibody responses drive the evolution of human 
immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S 
A 102, 18514-18519 (2005). 
 
130 Moore, P. L. et al. Limited neutralizing antibody specificities drive neutralization escape in 
early HIV-1 subtype C infection. PLoS pathogens 5, e1000598 (2009). 
 
131 Rong, R. et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 
infection requires multiple pathways. PLoS pathogens 5, e1000594 (2009). 
 
132 Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing 
antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 4144-4149 (2003). 
 
133 Gray, E. S. et al. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 
and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-
infected individual. J Virol 85, 7719-7729, doi:JVI.00563-11 [pii]10.1128/JVI.00563-11 (2011). 
134 Wibmer, C. K. et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma 
neutralization breadth through sequential recognition of multiple epitopes and 
immunotypes. PLoS pathogens 9, e1003738, doi:10.1371/journal.ppat.1003738 (2013). 
 
135 Murphy, M. K. et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 
infection drives an increase in autologous neutralization breadth. PLoS pathogens 9, 
e1003173, doi:10.1371/journal.ppat.1003173 (2013). 
 
136 Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 






















137 Piantadosi, A. et al. Breadth of neutralizing antibody response to human immunodeficiency 
virus type 1 is affected by factors early in infection but does not influence disease 
progression. J Virol 83, 10269-10274 (2009). 
 
138 Euler, Z. et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 
1 disease progression. J Infect Dis 201, 1045-1053, doi:10.1086/651144 (2010). 
 
139 Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing 
antibodies during human immunodeficiency virus type 1 infection. J Virol 83, 757-769 
(2009). 
 
140 Walker, L. M. et al. A limited number of antibody specificities mediate broad and potent 
serum neutralization in selected HIV-1 infected individuals. PLoS pathogens 6, doi:e1001028 
[pii]10.1371/journal.ppat.1001028 (2010). 
141 Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. 
PLoS pathogens 7, e1001251, doi:10.1371/journal.ppat.1001251 (2011). 
 
142 Bahmanyar, M., Fayaz, A., Nour-Salehi, S., Mohammadi, M. & Koprowski, H. Successful 
protection of humans exposed to rabies infection. Postexposure treatment with the new 
human diploid cell rabies vaccine and antirabies serum. JAMA 236, 2751-2754 (1976). 
 
143 Beasley, R. P. et al. Efficacy of hepatitis B immune globulin for prevention of perinatal 
transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, 
placebo-controlled trial. Hepatology 3, 135-141, doi:S0270913983000166 [pii] (1983). 
 
144 Gellis, S. S., McGuinnes, A. C. & Peters, M. Study of prevention of mumps orchitis by gamma 
globulin. Am. J. Med. Sci. 210, 5 (1945). 
 
145 Groothuis, J. R. et al. Prophylactic administration of respiratory syncytial virus immune 
globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune 
Globulin Study Group. N Engl J Med 329, 1524-1530, doi:10.1056/NEJM199311183292102 
(1993). 
 
146 Janeway, C. A. Use of Concentrated Human Serum gamma-Globulin in the Prevention and 
Attenuation of Measles. Bull N Y Acad Med 21, 202-222 (1945). 
 
147 Korns, R. F. Prophylaxis of German measles with immune serum globulin. J Infect Dis 90, 183-
189 (1952). 
 
148 Ross, A. H. Modification of chicken pox in family contacts by administration of gamma 
globulin. N Engl J Med 267, 369-376, doi:10.1056/NEJM196208232670801 (1962). 
 
149 Snydman, D. R. et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus 
disease in renal-transplant recipients. N Engl J Med 317, 1049-1054, 
doi:10.1056/NEJM198710223171703 (1987). 
 
150 Li, J., Lord, C. I., Haseltine, W., Letvin, N. L. & Sodroski, J. Infection of cynomolgus monkeys 
with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir 






















151 Luciw, P. A., Pratt-Lowe, E., Shaw, K. E., Levy, J. A. & Cheng-Mayer, C. Persistent infection of 
rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human 
immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A 92, 7490-7494 (1995). 
 
152 Sakuragi, S. et al. Infection of macaque monkeys with a chimeric human and simian 
immunodeficiency virus. J Gen Virol 73 ( Pt 11), 2983-2987 (1992). 
 
153 Shibata, R. et al. Generation of a chimeric human and simian immunodeficiency virus 
infectious to monkey peripheral blood mononuclear cells. J Virol 65, 3514-3520 (1991). 
 
154 Mascola, J. R. et al. Protection of Macaques against pathogenic simian/human 
immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73, 
4009-4018 (1999). 
 
155 Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-
1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6, 207-210 
(2000). 
 
156 Veazey, R. S. et al. Prevention of virus transmission to macaque monkeys by a vaginally 
applied monoclonal antibody to HIV-1 gp120. Nat Med 9, 343-346 (2003). 
 
157 Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect 
against mucosal simian-human immunodeficiency virus infection. Nat Med 6, 200-206 
(2000). 
 
158 Hofmann-Lehmann, R. et al. Postnatal passive immunization of neonatal macaques with a 
triple combination of human monoclonal antibodies against oral simian-human 
immunodeficiency virus challenge. J Virol 75, 7470-7480 (2001). 
 
159 Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic 
R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in 
vitro. J Virol 75, 8340-8347 (2001). 
 
160 Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated 
mucosal SHIV challenge in macaques. Nat Med 15, 951-954, doi:nm.1974 
[pii]10.1038/nm.1974 (2009). 
161 Hessell, A. J. et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in 
protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS 
pathogens 5, e1000433, doi:10.1371/journal.ppat.1000433 (2009). 
 
162 Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into 
effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109, 
18921-18925, doi:10.1073/pnas.1214785109 (2012). 
 
163 Pegu, A. et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo 
than those to the CD4 receptor. Sci Transl Med 6, 243ra288, 
doi:10.1126/scitranslmed.3008992 (2014). 
 
164 Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro 























165 Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate 
SHIV infection. Nature 514, 642-645, doi:10.1038/nature13612 (2014). 
 
166 Maynard, J. AMP Study -  Amping up for HIV Prevention, 
              <http://www.hvtn.org/en/science/HVTN-studies/AMPstudy.html> (2 June 2016). 
 
167 Gray, E. S., Meyers, T., Gray, G., Montefiori, D. C. & Morris, L. Insensitivity of paediatric HIV-1 
subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
PLoS Med 3, e255 (2006). 
 
168 Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-
1204, doi:10.1126/science.1241144 (2013). 
 
169 Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31, 
705-742, doi:10.1146/annurev-immunol-032712-095916 (2013). 
 
170 Kwong, P. D., Mascola, J. R. & Nabel, G. J. Broadly neutralizing antibodies and the search for 
an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13, 693-701, 
doi:10.1038/nri3516 (2013). 
 
171 Burton, D. R. et al. A large array of human monoclonal antibodies to type 1 human 
immunodeficiency virus from combinatorial libraries of asymptomatic seropositive 
individuals. Proc Natl Acad Sci U S A 88, 10134-10137 (1991). 
 
172 Zhou, T. et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 
Supersite in 14 Donors. Cell 161, 1280-1292, doi:10.1016/j.cell.2015.05.007 (2015). 
 
173 Yoon, H. et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. 
Nucleic Acids Res 43, W213-219, doi:10.1093/nar/gkv404 (2015). 
 
174 Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal 
antibodies to HIV-1. Science 329, 856-861, doi:science.1187659 
[pii]10.1126/science.1187659 (2010). 
175 Scharf, L. et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope 
spike. Cell Rep 7, 785-795, doi:10.1016/j.celrep.2014.04.001 (2014). 
 
176 Blattner, C. et al. Structural delineation of a quaternary, cleavage-dependent epitope at the 
gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680, 
doi:10.1016/j.immuni.2014.04.008 (2014). 
 
177 Falkowska, E. et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope 
on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657-668, 
doi:10.1016/j.immuni.2014.04.009 (2014). 
 
178 Lee, J. H. et al. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by 
destabilizing the Env spike. Nat Commun 6, 8167, doi:10.1038/ncomms9167 (2015). 
 
179 Huang, J. et al. Broad and potent HIV-1 neutralization by a human antibody that binds the 






















180 McCoy, L. E. et al. Incomplete Neutralization and Deviation from Sigmoidal Neutralization 
Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS pathogens 11, e1005110, 
doi:10.1371/journal.ppat.1005110 (2015). 
 
181 Tomaras, G. D. et al. Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a 
Subset of HIV-1-infected Individuals. J Virol, doi:JVI.05363-11 [pii]10.1128/JVI.05363-11 
(2011). 
182 Walker, L. M. et al. A limited number of antibody specificities mediate broad and potent 
serum neutralization in selected HIV-1 infected individuals. PLoS pathogens 6, e1001028, 
doi:10.1371/journal.ppat.1001028 (2010). 
 
183 Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope 
glycoprotein gp120. Nat Struct Mol Biol 20, 796-803, doi:10.1038/nsmb.2594 (2013). 
 
184 Sanders, R. W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on 
human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76, 7293-7305 (2002). 
 
185 Scanlan, C. N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 
antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of 
gp120. J Virol 76, 7306-7321 (2002). 
 
186 Garces, F. et al. Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused 
on Accommodating or Avoiding Glycans. Immunity 43, 1053-1063, 
doi:10.1016/j.immuni.2015.11.007 (2015). 
 
187 Calarese, D. A. et al. Antibody domain exchange is an immunological solution to 
carbohydrate cluster recognition. Science 300, 2065-2071 (2003). 
 
188 Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. 
Nature 491, 406-412, doi:10.1038/nature11544 (2012). 
 
189 Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 
antibodies. Science 308, 1906-1908 (2005). 
 
190 Bonsignori, M. et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational 
epitope-specific broadly neutralizing antibodies and their inferred unmutated common 
ancestors. J Virol 85, 9998-10009, doi:10.1128/JVI.05045-11 (2011). 
 
191 Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing 
antibodies. Nature 509, 55-62, doi:10.1038/nature13036 (2014). 
 
192 Doria-Rose, N. A. et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That 
Shows Increased Breadth and Exceptional Potency. J Virol 90, 76-91, doi:10.1128/JVI.01791-
15 (2016). 
 
193 Moore, P. L. et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-
dependent antibodies. J Virol 87, 4882-4894, doi:10.1128/JVI.03424-12 (2013). 
 
194 Moore, P. L. et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies 























195 Wardemann, H. et al. Predominant autoantibody production by early human B cell 
precursors. Science 301, 1374-1377 (2003). 
 
196 Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by 
single cell RT-PCR and expression vector cloning. J Immunol Methods 329, 112-124 (2008). 
 
197 Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies 
that mimic CD4 binding. Science 333, 1633-1637, doi:10.1126/science.1207227 (2011). 
 
198 Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against 
influenza virus. Nature 453, 667-671 (2008). 
 
199 Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus 
type 1. J Virol 67, 6642-6647 (1993). 
 
200 Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; 
electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte 
immortalization. AIDS Res Hum Retroviruses 10, 359-369 (1994). 
 
201 Corti, D. et al. Analysis of memory B cell responses and isolation of novel monoclonal 
antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5, e8805, 
doi:10.1371/journal.pone.0008805 (2010). 
 
202 Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat 
Protoc 8, 1907-1915, doi:10.1038/nprot.2013.117 (2013). 
 
203 Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in 
HIV-infected individuals. Nature 458, 636-640 (2009). 
 
204 Doria-Rose, N. A. et al. Frequency and phenotype of human immunodeficiency virus 
envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83, 
188-199 (2009). 
 
205 Morris, L. et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing 
antibody by antigen-specific single B cell sorting. PLoS One 6, e23532, 
doi:10.1371/journal.pone.0023532 (2011). 
 
206 Klein, F. et al. Broad neutralization by a combination of antibodies recognizing the CD4 
binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 
209, 1469-1479, doi:10.1084/jem.20120423 (2012). 
 
207 Gaebler, C. et al. Isolation of HIV-1-reactive antibodies using cell surface-expressed 
gp160Deltac(BaL.). J Immunol Methods 397, 47-54, doi:10.1016/j.jim.2013.09.003 (2013). 
 
208 Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies 
targeting the trimer apex. Proc Natl Acad Sci U S A 111, 17624-17629, 
doi:10.1073/pnas.1415789111 (2014). 
 
209 Pinter, A. et al. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary 
human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly 






















210 Wyatt, R. et al. Involvement of the V1/V2 variable loop structure in the exposure of human 
immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69, 5723-
5733 (1995). 
 
211 Cao, J. et al. Replication and neutralization of human immunodeficiency virus type 1 lacking 
the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71, 9808-9812 
(1997). 
 
212 Johnson, W. E. et al. A replication-competent, neutralization-sensitive variant of simian 
immunodeficiency virus lacking 100 amino acids of envelope. J Virol 76, 2075-2086 (2002). 
 
213 Stamatatos, L. & Cheng-Mayer, C. An envelope modification that renders a primary, 
neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly 
susceptible to neutralization by sera from other clades. J Virol 72, 7840-7845 (1998). 
 
214 Saunders, C. J. et al. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 
envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 79, 
9069-9080 (2005). 
 
215 Sanders, R. W. et al. Variable-loop-deleted variants of the human immunodeficiency virus 
type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between 
the gp120 and gp41 subunits. J Virol 74, 5091-5100 (2000). 
 
216 Gorman, J. et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal 
commonalities that enable vaccine design. Nat Struct Mol Biol 23, 81-90, 
doi:10.1038/nsmb.3144 (2016). 
 
217 GlyProt - In Silico Glycosylation of Proteins,  
              <http://www.glycosciences.de/modeling/glyprot/php/main.php> (2 June 2016). 
 
218 Pancera, M. et al. Crystal structure of PG16 and chimeric dissection with somatically related 
PG9: structure-function analysis of two quaternary-specific antibodies that effectively 
neutralize HIV-1. J Virol 84, 8098-8110, doi:JVI.00966-10 [pii]10.1128/JVI.00966-10 (2010). 
219 Pejchal, R. et al. Structure and function of broadly reactive antibody PG16 reveal an H3 
subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107, 
11483-11488, doi:1004600107 [pii]10.1073/pnas.1004600107 (2010). 
220 Pancera, M. et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-
V2-directed antibody PG16. Nat Struct Mol Biol 20, 804-813, doi:10.1038/nsmb.2600 (2013). 
 
221 Briney, B. S., Willis, J. R. & Crowe, J. E., Jr. Human peripheral blood antibodies with long 
HCDR3s are established primarily at original recombination using a limited subset of 
germline genes. PLoS One 7, e36750, doi:10.1371/journal.pone.0036750 (2012). 
 
222 Gellert, M. V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev 
Biochem 71, 101-132, doi:10.1146/annurev.biochem.71.090501.150203 (2002). 
 
223 Lynch, R. M. et al. The B cell response is redundant and highly focused on V1V2 during early 























224 Sagar, M., Wu, X., Lee, S. & Overbaugh, J. Human immunodeficiency virus type 1 V1-V2 
envelope loop sequences expand and add glycosylation sites over the course of infection, 
and these modifications affect antibody neutralization sensitivity. J Virol 80, 9586-9598 
(2006). 
 
225 Montefiori, D. C. et al. Homotypic antibody responses to fresh clinical isolates of human 
immunodeficiency virus. Virology 182, 635-643 (1991). 
 
226 Wu, X. et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the 
conserved CD4-binding site. J Virol 86, 5844-5856, doi:10.1128/JVI.07139-11 (2012). 
 
227 Moore, P. L. et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody 
epitope through immune escape. Nat Med 18, 1688-1692, doi:10.1038/nm.2985 (2012). 
 
228 Sather, D. N. et al. Broadly neutralizing antibodies developed by an HIV-positive elite 
neutralizer exact a replication fitness cost on the contemporaneous virus. J Virol 86, 12676-
12685, doi:10.1128/JVI.01893-12 (2012). 
 
229 Lynch, R. M. et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 
binding site neutralizing antibodies. J Virol 89, 4201-4213, doi:10.1128/JVI.03608-14 (2015). 
 
230 Mahalanabis, M. et al. Continuous viral escape and selection by autologous neutralizing 
antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83, 662-672 
(2009). 
 
231 Zhu, J. et al. Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation 
sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A 110, 
6470-6475, doi:10.1073/pnas.1219320110 (2013). 
 
232 Kwong, P. D., Mascola, J. R. & Nabel, G. J. Mining the B cell repertoire for broadly 
neutralizing monoclonal antibodies to HIV-1. Cell Host Microbe 6, 292-294, 
doi:10.1016/j.chom.2009.09.008 (2009). 
 
233 Sok, D. et al. The effects of somatic hypermutation on neutralization and binding in the 
PGT121 family of broadly neutralizing HIV antibodies. PLoS pathogens 9, e1003754, 
doi:10.1371/journal.ppat.1003754 (2013). 
 
234 Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and 
deep sequencing. Science 333, 1593-1602, doi:10.1126/science.1207532 (2011). 
 
235 Zhu, J. et al. Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 
454 Pyrosequencing and Bioinformatics. Front Microbiol 3, 315, 
doi:10.3389/fmicb.2012.00315 (2012). 
 
236 Wu, X. et al. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of 
Chronic HIV-1 Infection. Cell 161, 470-485, doi:10.1016/j.cell.2015.03.004 (2015). 
 
237 Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 























238 Xiao, X. et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable 
binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and 
design of vaccine immunogens. Biochem Biophys Res Commun 390, 404-409, doi:S0006-
291X(09)01817-8 [pii]10.1016/j.bbrc.2009.09.029 (2009). 
239 Ma, B. J. et al. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for 
both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS 
pathogens 7, e1002200, doi:10.1371/journal.ppat.1002200 (2011). 
 
240 McGuire, A. T., Glenn, J. A., Lippy, A. & Stamatatos, L. Diverse recombinant HIV-1 Envs fail to 
activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-
1 antibodies PG9 and 447-52D. J Virol 88, 2645-2657, doi:10.1128/JVI.03228-13 (2014). 
 
241 Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. 
Science 340, 711-716, doi:10.1126/science.1234150 (2013). 
 
242 Hoot, S. et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-
CD4bs bNAbs. PLoS pathogens 9, e1003106, doi:10.1371/journal.ppat.1003106 (2013). 
 
243 McGuire, A. T. et al. Engineering HIV envelope protein to activate germline B cell receptors 
of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210, 655-663, 
doi:10.1084/jem.20122824 (2013). 
 
244 McGuire, A. T. et al. HIV antibodies. Antigen modification regulates competition of broad 
and narrow neutralizing HIV antibodies. Science 346, 1380-1383, 
doi:10.1126/science.1259206 (2014). 
 
245 Jardine, J. G. et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-
1 using a germline-targeting immunogen. Science 349, 156-161, 
doi:10.1126/science.aac5894 (2015). 
 
246 Dosenovic, P. et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig 
Knockin Mice. Cell 161, 1505-1515, doi:10.1016/j.cell.2015.06.003 (2015). 
 
247 Bhiman, J. N. et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 
broadly neutralizing antibodies. Nat Med 21, 1332-1336, doi:10.1038/nm.3963 (2015). 
 
248 Locci, M. et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly 
functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39, 
758-769, doi:10.1016/j.immuni.2013.08.031 (2013). 
 
249 Landais, E. et al. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-
Saharan HIV Primary Infection Cohort. PLoS pathogens 12, e1005369, 
doi:10.1371/journal.ppat.1005369 (2016). 
 
250 Cortez, V., Odem-Davis, K., McClelland, R. S., Jaoko, W. & Overbaugh, J. HIV-1 superinfection 
in women broadens and strengthens the neutralizing antibody response. PLoS pathogens 8, 
e1002611, doi:10.1371/journal.ppat.1002611 (2012). 
 
251 Powell, R. L., Kinge, T. & Nyambi, P. N. Infection by discordant strains of HIV-1 markedly 
enhances the neutralizing antibody response against heterologous virus. J Virol 84, 9415-






















252 Moore, P. L., Williamson, C. & Morris, L. Virological features associated with the 
development of broadly neutralizing antibodies to HIV-1. Trends Microbiol 23, 204-211, 
doi:10.1016/j.tim.2014.12.007 (2015). 
 
253 Gao, F. et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing 
antibodies. Cell 158, 481-491, doi:10.1016/j.cell.2014.06.022 (2014). 
 
254 Cheng, C. et al. Immunogenicity of a Prefusion HIV-1-Envelope Trimer in Complex with a 
Quaternary-Specific Antibody. J Virol, doi:10.1128/JVI.02380-15 (2015). 
 
255 Sanders, R. W. et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like 
envelope trimers. Science 349, aac4223, doi:10.1126/science.aac4223 (2015). 
 
256 Scheepers, C. et al. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted 
by the germline Ig gene repertoire. J Immunol 194, 4371-4378, 
doi:10.4049/jimmunol.1500118 (2015). 
 












































































1. Developmental pathway for potent V1V2-directed HIV-neutralizing 
antibodies 
Doria-Rose NA*, Schramm CA*, Gorman J*, Moore PL*, Bhiman JN, DeKosky BJ, Ernandes 
MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, 
Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O’Dell S, 
Roark R, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, NISC 
Comparative Sequencing Program, Mulkin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, 
Ward AB, Georgiou G, Williamson C, Adbool-Karim SS, Morris L, Kwong PD, Shapiro L and 
Mascola JR.  *Joint first authors 
Nature. 2014: 509: 55-62. PMID: 24590074; PMCID: PMC4395007.  
 
This paper described the development of the V1V2-directed CAP256-VRC26 bNAbs, from 





Developmental pathway for potent V1V2-
directed HIV-neutralizing antibodies
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Michael J. Ernandes1, Ivelin S. Georgiev1, Helen J. Kim7,8,9, Marie Pancera1, Ryan P. Staupe1, Han R. Altae-Tran1, Robert T. Bailer1,
Ema T. Crooks10, Albert Cupo11, Aliaksandr Druz1, Nigel J. Garrett5, Kam H. Hoi12, Rui Kong1, Mark K. Louder1, Nancy S. Longo1,
Krisha McKee1, Molati Nonyane3, Sijy O’Dell1, Ryan S. Roark1, Rebecca S. Rudicell1, Stephen D. Schmidt1, Daniel J. Sheward13,
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George Georgiou6,12,18, CarolynWilliamson5,13, Salim S. Abdool Karim5,19, LynnMorris3,4,5, Peter D. Kwong1, Lawrence Shapiro1,2
& John R. Mascola1
Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the
mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such antibodies
are generated and acquire the requisite molecular characteristics for neutralization. Twelve somatically related
neutralizing antibodies (CAP256-VRC26.01–12) were isolated from donor CAP256 (from the Centre for the AIDS
Programme of Research in South Africa (CAPRISA)); each antibody contained the protruding tyrosine-sulphated,
anionic antigen-binding loop (complementarity-determining region (CDR) H3) characteristic of this category of
antibodies. Their unmutated ancestor emerged between weeks 30–38 post-infection with a 35-residue CDR H3, and
neutralized the virus that superinfected this individual 15weeks after initial infection. Improved neutralization breadth
and potency occurred byweek 59withmodest affinitymaturation, andwas preceded by extensive diversification of the
virus population. HIV-1 V1V2-directed neutralizing antibodies can thus develop relatively rapidly through initial
selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation. These data provide
important insights relevant to HIV-1 vaccine development.
Developmental pathways of antibodies that neutralize HIV-1 repres-
ent potential templates to guide vaccine strategies, if their constituent
molecular eventswere understood and could be reproduced1–3. Almost
allHIV-1 infected individualsmount a potent antibody responsewithin
months of infection, but this response preferentially neutralizes auto-
logous virus, which rapidly escapes4,5. Cross-reactive antibodies capable
of neutralizing most HIV-1 strains arise in only,20% of donors after
2–3 years of infection6–9.Anunderstandingof thedevelopment of broadly
neutralizing antibody (NAb) lineages in such donors could provide a
roadmap for vaccine design.
Onemeans to obtain such a roadmap is through isolation of broadly
cross-reactive neutralizing antibodies, characterization of their genetic
sequence andmolecular properties, and examinationof theB cell genetic
recordwithnext-generation sequencing (NGS)10–14. Thegreatest insights
can be gained with longitudinal sampling from early after the time of
HIV-1 infection15. This allows for a genetic delineation of themolecular
evolution leading froman unmutated ancestor antibody, through affin-
ity maturation, to acquisition of neutralization breadth. In principle,
such a roadmap should link antibody molecular characteristics to the
genetic development that a successful vaccine would retrace.
Neutralizing antibodies to the V1V2 region of theHIV-1 viral spike
are among the most prevalent cross-reactive antibodies elicited by nat-
ural infection6,16–18 and have been isolated from several donors19–21.
These antibodies have long heavy-chain complementarity-determining
region 3 loops (CDR H3s) that are protruding, anionic and often tyr-
osine sulphated22,23. These CDRH3s penetrate theHIV-1 glycan shield,
recognizing a quaternary glycopeptide epitope at the apex of theHIV-1
spike that is formed by V1V2s from at least two gp120 protomers22–24.
Here we use antibody isolation, B-cell next-generation sequencing,
structural characterization, and viral single-genome amplification
(SGA) to delineate longitudinal interactions between the developing
antibody and autologous virus within donor CAP256, who showed
evidence of V1V2-mediated neutralization breadth after one year18,25,26.
Our results define the molecular requirements and genetic pathways
that lead to V1V2-directed neutralization, providing a template for
their vaccine elicitation.
*These authors contributed equally to this work.
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Antibody isolation and characterization
DonorCAP256peripheral bloodmononuclear cells (PBMCs) sampled
59, 119 and206weekspost-infectionwereused to isolate 12monoclonal
antibodies by high-throughput B-cell culture, functional screening by
microneutralization, and PCRwith reverse transcription (RT–PCR) of
antibody variable regions27,28 (Fig. 1a). All 12 were somatically related
and distinguished by long CDR H3s of 35–37 amino acids (Kabat29
numbering) (Fig. 1b and Extended Data Fig. 1a). The heavy and light
chains exhibited somatic mutation of 4–15% from their germline-
encoded V-genes, VH3-30 and Vl1-51, respectively (Extended Data Fig
1 and Extended Data Table 1). When these antibodies were reconsti-
tuted as IgG1s, they showed varying degrees of heterologous virus neu-
tralization and were extremely potent against many subtype A and C
strains (Fig. 1b, c, ExtendedData Fig. 2 and Supplementary Fig. 1). The
combination of all 12 antibodies recapitulated plasma neutralization
(Supplementary Fig. 2), indicating the CAP256-VRC26 antibody lin-
eage to be responsible for the neutralization breadth and potency of
donor CAP256.
To map the epitope of the CAP256-VRC26 antibodies, we used
neutralization fingerprints18; binding assays for HIV-1 Envelope (Env)
in soluble, cell surface30, and viral particle31 contexts; and negative stain
electron microscopy (EM) of Fab CAP256-VRC26.09 bound to a sol-
uble cleaved versionof theHIV-1 trimer24,32,33 (Fig. 2a–c, Supplementary
Fig. 3 andExtendedData Figs 3 and4). RecognitionofEnvbyCAP256-
VRC26 antibodies was similar to PG9-class neutralizing antibodies that
recognize the trimericV1V2 cap24,withhigh specificity for theEnvnative
quaternary conformation and one Fab bound per trimer (Fig. 2c, left
and Extended Data Fig. 4). Neutralization activity of CAP256-VRC26
antibodies was reduced or knocked out by Env mutations in V1V2
strands B and C (Fig. 2d), much like the CAP256 plasma25,26 and PG9-
class neutralizing antibodies22,23,34; although unlike PG9, the CAP256-
VRC26 antibodies were only partially and variably sensitive to loss of
glycans at N160 and N156 (Fig. 2d and Extended Data Fig. 5). Overall,
these data indicated the epitope to be at the membrane-distal apex of
theHIV-1 spike close to the trimer axis (Fig. 2e), providing a structural
explanation for the observed quaternary specificity.
Origin and development of the lineage
To obtain a genetic record of theCAP256-VRC26 antibody lineage, we
analysedBcell-immunoglobulin transcripts at eight timepoints between
15 and 206weeks post-infection by 454 pyrosequencing. Although no
CAP256-VRC26 lineage-related transcripts were detected at 15 and
30weeks, related heavy chain and light chain transcripts were found at
all later time points (Fig. 3a). To track longitudinal prevalence, we used
identity-divergenceplots12 of all heavy chain reads assigned to the same
VH3-30germlinegene as the isolatedantibodies.UsingCAP256-VRC26.01
or CAP256-VRC26.08 as the identity referents, segregated islands of
related heavy chain sequences first appeared at week 38 (Fig. 3b). For
all 12antibodies, theprevalence and identity of related sequencespeaked
close to the time of the antibody isolation (Supplementary Fig. 4). To
obtain additional antibody lineage data, we performed linked VH:VL
pairedsequencing35 at five timepoints (Fig. 3aandSupplementaryTable1).
Of 157 unique CAP256-VRC26 pairs, 7 matched either heavy or light
chain sequences present in the 454 pyrosequencing data, including 2
for which both heavy and light chain sequences had previously been
captured (Fig. 3c).
Maximum-likelihood phylogenetic trees were constructed using
the isolated antibodies and the 454data (Fig. 3c). The lineage bifurcates
early, with one branch leading toCAP256-VRC26.01 and a second devel-
oping into CAP256-VRC26.02–12. The unmutated common ancestors
(UCAs) for the heavy and light chain were inferred from the phylogen-
etic trees (Fig. 3c). For the light chain, the UCA had a 12-residue CDR
L3, as inCAP256-VRC26.01, and for the heavy chain, the inferredUCA
had a 35-residue CDR H3 (Extended Data Fig. 6), probably the result
of VDJ recombination with a single D-gene, IgHD3-3*01 and non-
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CAP256-VRC26.0159 8.3% CAKDVGDYKSDEWGT-EYYDISISYPIQDPRAM--VGAFDLW 35 19%
119
CAP256-VRC26.02 8.7% CAKDIREYECEYWTS-DYYDFGRPQPCIDSRGV--VGTFDVW 35 17%
CAP256-VRC26.03 8.7% CAKDLREDECEEWWS-DYYDFGKQLPCRKSRGV--AGIFDGW 35 36%
CAP256-VRC26.04 9.0% CAKDLREDECEEWWS-DYYDFGKQLPCRKSRGV--AGIFDKW 35 30%
CAP256-VRC26.05 10.1% CARDQRYYECEEWAS-DYYDFGREQPCLDPRGV--VGIFDLW 35 21%
CAP256-VRC26.06 10.8% CARDLRELECEEWTLYNYYDFGSRGPCVDPRGV--AGSFDVW 36 17%
CAP256-VRC26.07 11.8% CAKDLREDECEEWWS-DYYDFGKKLPCRKSRGV--AGVFDKW 35 13%
CAP256-VRC26.08 11.8% CVRDQREDECEEWWS-DYYDFGRELPCRKFRGLGLAGIFDIW 37 47%
CAP256-VRC26.09 14.2% CVKDQREDECEEWWS-DYYDFGRELPCRKSRGLGLAGIFDMW 37 47%
206
CAP256-VRC26.10 11.8% CAKDMREYECEYWTS-DYYDFGRPQPCIDRRGV--VGIFDMW 35 23%












































Breadth (194 viruses): 47%

















0 25 50 75 100 125 150 175 200 225
Weeks post-infection
Figure 1 | Development of broad
neutralization by donor CAP256
and isolation of neutralizing
antibodies. a, Timing of antibody
isolation in relation to plasma
neutralization titres against the
primary infecting virus (PI), the
superinfecting virus (SU), and a
panel of 40 heterologous viruses
(geometric mean titre shown).
Percentage breadth (grey area),
percentage of viruses neutralized
with plasma median inhibitory
dilution (ID50) . 45. b, Genetic
characteristics and neutralization
breadth and potency of the 12
isolated antibodies. Week of
antibody isolation and V-gene
mutation rates are indicated.
Residues flanking the Kabat-defined
CDR H3 sequences are shown in
light grey. Neutralization was
assessed against a panel of 47
heterologous viruses. c, Breadth and
potency of antibody CAP256-
VRC26.08 on a panel of 194 Env-
pseudoviruses. Dendrogram shows
phylogenetic relatedness of Env
sequences in the panel.
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junction (Supplementary Fig. 5). This inferred UCA was further sup-
ported by very-low-divergence sequences among the lineagemembers
identified from the week 38 heavy chain data. Five unique sequences
were found, all ofwhichhadCDRH3smatching the inferredUCA in at
least 30 of 35 amino acids while containing three or fewer nucleotide
changes inVHand JH combined (ExtendedData Fig. 6). Thus, the longi-
tudinal NGS analysis established the first appearance of the CAP256-
VRC26 lineage; defined the UCA, the product of gene recombination
in the ancestor B cell of the lineage; and provided a genetic record of the
development of this lineage over four years.
Structures of CAP256-VRC26 antibodies
Todefine the structural characteristicsofCAP256-VRC26 lineagedevelop-
ment, we determined crystal structures for Fabs of the UCA and six
antibodies fromweeks 59, 119 and 206 (Fig. 4, Supplementary Table 2,
and Supplementary Fig. 6a). The mature CDR H3s protruded ,20A˚
above the antigen-combining surface of the heavy chain and contained
a 2-stranded b-sheet, O-sulphated tyrosines, and an intra-CDR H3
disulphide bond (Fig. 4a, b). The CDR H3s of the UCA and CAP256-
VRC26.01 lacked a CDR H3 disulphide bond, exhibited greater dis-
order and were positioned more proximal to the light chain (Fig. 4c);
the appearance of the disulphide bond correlated with adoption of
the mature CDR H3 orientation (Fig. 4c, Supplementary Fig. 6b, and
ExtendedDataFig. 7a).Mutation to remove the relevant cysteine residues
in VRC26.03 resulted in loss of neutralization potency and breadth
(Extended Data Fig. 7b, c). Additionally, the appearance of CDR H3
cysteines coincided with a glycine to arginine mutation at the base
of the CDR H3, possibly limiting flexibility of the mature antibodies
(ExtendedDataFig. 7a, bandSupplementaryFig. 7).Overall, theCAP256-
VRC26 lineage begins with an anionic protruding CDRH3with struc-
tural properties similar topreviously determinedV1V2-directedbroadly
neutralizing antibodies.Development over four years involves the intro-
duction of almost 20 light chain and over 30 heavy chain mutations,
including a disulphide bond. The CDRH3 changes its overall orienta-
tion while losing negative charge and maintaining tyrosine sulphation
(Fig. 4b, c, right).
HIV Env evolution during NAb development
Togain insight into the temporalHIV-1Envchangesdriving thedevelop-
ment of the CAP256-VRC26 lineage, we used SGA to determine viral
sequences over,3 years. CAP256Env sequences showedhigh levels of
diversity driven, in part, by recombination between the superinfecting
virus (SU) that was first detected 15weeks post-infection and the pri-
mary infecting virus (PI)26 (Fig. 5a, Supplementary Figs 8, 9). Differ-
ences between the primary infecting virus and superinfecting virus Env
sequences includedV2 residues 165 and169, and anN160 glycan in the
superinfecting virus that was not present in the primary infecting virus
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Figure 2 | Mapping of CAP256-VRC26 epitope on the HIV-1 Env spike.
a, Correlations between neutralization fingerprints (see Methods) of CAP256-
VRC26 antibodies and CAP256 plasma (left). Darker grey indicates stronger
correlation. Correlations between neutralization fingerprints of CAP256-
VRC26 antibodies and representative antibodies targeting the major HIV-1
neutralization epitopes (right). Correlations are colour-coded by antibody;
darker shades indicate stronger correlations. b, Competition assay. Binding
to ZM53-Env-expressing 293T cells by labelled CAP256-VRC26.08 and
unlabelled competitor antibodies measured by flow cytometry. Assay shown is
representative of three experiments. c, Negative stain electron microscopy
(EM) 3D reconstruction of CAP256-VRC26.09 Fab in complex with soluble
cleaved BG505 SOSIP.664 trimer (left); 2D-class averages of VRC26.09 and
PG9 in complex with BG505 SOSIP.664 trimer (right). d, Neutralization of
Env-pseudoviruses with HIV-ConC and V2 point mutants. Sequence shows
amino acids 160–175. e, LocationofHIV-1 epitopes. EMdensity of viral spike50,
with viral membrane at top and major sites of vulnerability shown as
determined by structural mapping of antibody interactions24 (left). The gp41
membrane proximal external region (MPER) is shown schematically. Model of
V1V2 based on EM structure of BG505 SOSIP.664 trimer24,32, viewed looking
towards the viral membrane along the trimer axis (right). Green ribbon, strand
C. V2 mutations from panel d are shown with surface representation; brighter
green indicates more potent effects on neutralization.
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infecting virus, the superinfecting virus contained V2 residues that are
more commonly found among circulating viruses (Extended Data Fig.
8a). All 12 antibodies neutralized the superinfecting virus, and, with the
exception of CAP256-VRC26.06, failed to neutralize the primary
infecting virus, suggesting the superinfecting virus V1V2 initially
engaged the naive B cell of the CAP256-VRC26 lineage (Fig. 5d,
Extended Data Fig. 8c and Supplementary Fig. 10).
Before theCAP256-VRC26antibodiesdeveloped,mostEnv sequences
had V1V2 regions derived from the primary infecting virus (Fig. 5a–c
and Supplementary Figs 8 and 9) andwere therefore largely neutraliza-
tion resistant (Fig. 5dandSupplementaryFig. 10).Amongsuperinfecting-
virus-like sequences, a rareK169Imutationaroseunder strongdirectional
selection(SupplementaryTable3)as theCAP256-VRC26lineageemerged,
which rendered the superinfecting virus resistant to only the earliest
antibody (ExtendedDataFig. 8d, e), indicating thatCAP256-VRC26.01-
like antibodies drove this viral escape, followed by maturation of the
lineage to tolerate I169. At 48weeks, the viral population underwent
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Total 263,612 248,211 297,401 212,414 278,597 246,413 759,562* 274,168
Unique 108,154 83,375 78,968 95,648 35,568 147,466 173,277* 55,512
CAP256-
VRC26 lineage
Total 0 0 1,113 861 2,229 1,433 7* 554





Total 154,707 114,378 250,437 283,035 228,548 145,072 541,629* 345,823
Unique 50,514 26,491 59,641 108,317 39,583 76,702 151,311* 48,246
CAP256-
VRC26 lineage
Total 0 0 52 1,910 5,486 515 28* 212
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Figure 3 | Maturation of the CAP256-VRC26 lineage revealed by NGS and
VH:VL paired sequencing of B cell transcripts. a, Timeline of longitudinal
peripheral blood samples with quantification of all NGS sequence reads (total
and unique), and CAP256-VRC26 lineage-related reads (total and unique).
Arrows below the line indicate time points of 454pyrosequencing for heavy and
light chain sequences. Circles indicate time points of paired sequencing of
sorted B cells (see Methods). PCR amplifications for pyrosequencing used
primers specific for VH3 family sequences (heavy chain) and V lambda
sequences (light chain), with the exception of the week 176 sample (asterisk),
which was amplified using all-VH gene primers, resulting in fewer CAP256-
VRC26 specific reads. b, Maturation time course for CAP256-VRC26.01 (top)
and CAP256-VRC26.08 (bottom panels). Heat map plots show sequence
identity (vertical axis) versus germline divergence (horizontal axis) for NGS
data. The 12 isolated antibodies are displayed as red ‘x’marks for reference, with
the exception of the CAP256-VRC26.01 and 08 antibodies which are shown as
black dots. Numbers between the top and bottom panels correspond to the
number of raw reads with at least 85% identity to the indicated antibody
(VRC26.01 (top), VRC26.08 (bottom)). c, Phylogenetic trees of the CAP256-
VRC26 clonal lineage for heavy chain (left) and light chain (right) were
constructed by maximum likelihood using the 454 sequences and the isolated
antibodies (black dots, labelled with antibody name). Branches are coloured by
time pointwhenNGS sequenceswere first detected. The orange andblue circles
indicate linked heavy and light chain sequences from the paired sequencing
data. Scale, rate of nucleotide change (per site) between nodes.
RESEARCH ARTICLE
4 | N A T U R E | V O L 0 0 0 | 0 0 M O N T H 2 0 1 4
Macmillan Publishers Limited. All rights reserved©2014
superinfecting-virus-likeV1V2dominating just before thedevelopment
of neutralizationbreadth.NeutralizationofEnv clones by later antibodies
(CAP256-VRC26.02-12) tracked with the presence of superinfecting-
virus-like V1V2 sequences (black bar, Fig. 5c) until escape occurred
through mutations at positions 166 or 169 (Fig. 5c, d and Extended
Data Fig. 8d). These mutations resulted in a net charge change in the
V2 epitope (13 to 0, Fig. 5c, Extended Data Fig. 8b) concomitant with
the antibody CDR H3s becoming less acidic over time (210 to 24,
Fig. 4 and Extended Data Fig. 9) suggesting co-evolution of the viral
epitope and the antibody paratope. Overall, these results highlight the
interplay between virus and antibody, with the superinfecting-virus-
likeV1V2epitope stimulating expansionof theCAP256-VRC26 lineage.
Rapid development of CAP256-VRC26.01
To gain insight into the development of V1V2-directed neutralization,
we focused on the early antibody CAP256-VRC26.01, isolated at week
59, which neutralized 30% of clade C viruses and showed cross-clade
neutralization of nearly 20% (Supplementary Fig. 1). Notably, this week
59 time pointwas 44weeks after superinfection and only 21weeks after
theCAP256-VRC26 lineagewas first detected byNGS.Wealso inferred
heavy and light chains for two developmental intermediates (VRC26-I1
and VRC26-I2) (Fig. 6a and Extended Data Fig. 1) and characterized
their function along with the UCA (Fig. 6b–e). The UCA bound and
neutralized the superinfecting virus weakly, but did not bind or neut-
ralize heterologous viruses.VRC26-I1,VRC26-I2 andCAP256-VRC26.01
demonstrated progressively greater binding and neutralization, with
VRC26-I1 neutralizing 2 of 7 strains and VRC26-I2 neutralizing 6 of 7
strains (Fig. 6e),withdependenceon residues inV2 (Fig. 6c). Interestingly,
the primary infecting virus was neither bound nor neutralized by the
UCA, intermediates, or CAP256-VRC26.01 (Fig. 6c and Supplementary
Fig. 11). These data provide further evidence that the CAP256-VRC26
lineagewas initiatedby interactionwith a superinfecting-virus-likeV1V2.
Subsequent affinity maturation, focused within CDR H3 (Fig. 6f and
Extended Data Table 1), allowed for progressively greater binding and
neutralization with increased viral diversity preceding the emergence
of neutralization breadth. On the basis of the inferred UCA, CAP256-
VRC26.01diverged11%fromgermlineheavychainand7% fromgerm-
line light chain (Fig. 6f). Thus, once an appropriate gene recombination
CDR H3
a CAP256-VRC26.03 (week 119)
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Figure 4 | Structural characteristics
of the developing CAP256-VRC26
lineage. a, Crystal structure of the
antigen-binding fragment (Fab) of
CAP256-VRC26.03 shown in ribbon
diagram representation. b, The intra-
loop disulphide bond and tyrosine
sulphation are shown in stick
representation, and enlarged to show
electron density (bluemesh, 2Fo-Fc at
1s) (left). Molecular surface, with
electrostatic potentials coloured red
for acidic and blue for basic (right).
CDR H3 regions of broadly
neutralizing V1V2-directed
antibodies are shown for
comparison, with the left image in
ribbon representation (tyrosine
sulphates highlighted in red) and the
right image in electrostatic
representation. c, A condensed heavy
chain phylogenetic tree highlights
the isolated antibodies (left). Scale,
rate of nucleotide change between
nodes. The number of amino acid
(aa)mutations to the heavy chain (H)
and light chain (L) relative to the
UCA are shown. Structures of the
variable regions (middle). Mutations
from the UCA are represented as
spheres coloured according to the
week of antibody isolation at which
the mutations first appear. CDR H3
details (right). Residues that are (or
evolve to become) cysteines are
labelled (grey dotted lines indicate
modelled disordered regions). The
position of tyrosines predicted to be
sulphated (scores .1) are noted and
were included in the formal charges
shown for each CDR H3 and the
electrostatic representations (far
right). Asterisk denotes Tyr insertion
in VRC26.06.
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allows for B-cell receptor recognition of the trimeric V1V2 epitope,
development of cross-reactive neutralization can be achieved with
moderate somatic mutation in a matter of months.
Vaccine implications
The V1V2 region of HIV-1 is a common target of serum neutralizing
antibodies6,16–18. In the RV144 Thai vaccine trial, an increased level of
binding antibodies to the V1V2 region was associated with a reduced
risk of infection36 and viral sieve analysis showed immune pressure in
the same region37. Although the vaccine in the RV144 trial did not
elicit broadly neutralizing V1V2-directed antibodies similar to those
describedhere and elsewhere19–21, amore effective vaccinewould ideally
elicit cross-reactive neutralizing antibodies1–3,38. Previously described
V1V2 neutralizing antibodies, and the CAP256-VRC26 lineage, all
have long CDR H3 regions that are necessary to penetrate the glycan
shield and engage a V1V2 epitope (Extended Data Table 1). An im-
portant unanswered question has been whether these long CDR H3s
are fully formed by VDJ recombination, as has been seen in HIV-
uninfected donors39, or emerge by insertions during the process of aff-
inity maturation. We show here that the 35-residue CDR H3 of the
CAP256-VRC26UCAwasproducedduring initial gene rearrangement
and therefore existed at the level of the naive B cell receptor.
A potential rate-limiting developmental step in theCAP256-VRC26
lineage is the gene rearrangement that generated its UCA. By one esti-
mate, human B cells with recombined antibody genes encoding long
($24 amino acids, international immunogenetics database (IMGT)40
definition) or very long ($28 amino acids)CDRH3s constitute,3.5%
and 0.4%, respectively, of naive B cells39. These long B cell receptors
have been associatedwith autoreactivity, and are subject to both central
andperipheral deletion, resulting in an even smaller population of IgG1
memory B cells39,41. We therefore tested the UCA and all 12 CAP256-
VRC26 cloned antibodies for autoreactivity42. The UCA and mature
CAP256-VRC26 antibodies demonstrated little or no reactivity with
Hep2 cells or with cardiolipin (Extended Data Fig. 6b, c). In addition,
NGS of CAP256 peripheral B cells indicated that,0.4% of sequences
had CDRH3s of$ 28 amino acids (Extended Data Fig. 6d) suggesting
that this donor did not have an unusually high frequency of clonal
lineages with long CDR H3 regions.
We also inferred the virological events leading to the stimulation
and evolution of the CAP256-VRC26 lineage by the superinfecting
virus. Similar to the CH103 CD4-binding site lineage in donor CH505
(ref. 15), the autologous virus in CAP256 showed extensive diversifica-
tion before the development of breadth. Subsequent antibody–virus
interactions appeared to drive somatic mutation and development of
cross-reactive neutralization. Finally, the ontogeny of V1V2-directed
neutralizing antibodies revealed by the CAP256-VRC26 lineage indi-
cates that neutralization potency and breadth can be achieved without
extraordinary levels of somatic hypermutation. Although some neutral-
izing antibodies appear to require years of maturation1,3,43,44, we show
that a V1V2-directed B cell lineage can acquire HIV-1 neutralization
breadth within months rather than years. The critical event appears to
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Figure 5 | HIV-1 Env evolution and the development of the CAP256-
VRC26 lineage. a, V1V2 sequences are shown in highlighter format with the
primary infecting virus (PI) designated as master and V2 residues 160 to 171
boxed. Asterisk at week 15 denotes sequences amplified with strain-specific
primers matching the superinfecting virus (SU) virus. b, Logogram of the V2
epitope for all CAP256 sequences, with mutations away from the PI (master
sequence) in colour. c, SU-like V1V2 sequences are indicated by black (present)
and grey (absent) boxes. Escape mutations (K169E or R166S/K) are indicated
by brownboxes. Thenet charge of theV2 epitope (residues 160 to 171) is shown
in purple/white, ranging from 13 to 0. White lines separate clones within a
time point; black lines separate time points. d, Neutralization by the 12
CAP256-VRC26 monoclonal antibodies of representative longitudinal Env
clones isolated between 6 and 176weeks post-infection (weeks shown at far
right). The CAP256 monoclonal antibodies are coloured by time of isolation
(as in Fig. 1). The development of the CAP256-VRC26 antibody lineage,
V1V2-directed plasma neutralizing antibodies and plasma heterologous
neutralization, are indicated on the right.
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with a protruding, tyrosine-sulphated, anionic CDR H3. Identifying
features of antigens able to engage naive B cells with such CDRH3s is a
critical step in design of vaccines targeting V1V2. Such antigens could
be screened for binding to the UCA versions of neutralizing antibodies
as an indicator of the ability to engage an appropriate naive B cell recep-
tor. This work also suggests that although an appropriate trimeric V1V2
construct may elicit neutralizing V1V2 antibodies, sequential immu-
nogens thatmirror viral evolutionmay be needed to drive the develop-
ment of breadth. Overall, the precise delineation of the developmental
pathway for the CAP256-VRC26 lineage should provide a basis for
attempts to elicit broadV1V2-directedHIV-1-neutralizing antibodies.
METHODS SUMMARY
Serial blood samples were collected fromHIV-1-infected subject CAP256 from 6
to 225 weeks after infection. Monoclonal antibodies CAP256-VRC26.01-12 were
generated by single-B cell culture, microneutralization screening, RT–PCR, sub-
cloning, and expression as described in27,28,45. CDR lengths used Kabat notation29
except as indicated. Binding of CAP256-VRC26 antibodies to virus-like particles
was assessed by ELISA31 and binding to cell-surface expressed Env was measured
by flow cytometry30. HIV-1 neutralizing activity of patient plasma and mono-
clonal antibodies was determined with Env-pseudoviruses using the TZM-bl cell
line46,47. Neutralization fingerprints are the rank-order of neutralization potencies
for an antibody against a set of diverse viral strains, calculated as in ref. 18. A 28A˚
reconstruction of the BG505 SOSIP.664 gp140 trimer with a single VRC26.09 Fab
was obtained by negative stain EM using Appion, Xmipp, IMAGIC, and EMAN
software. 454pyrosequencingwasperformed aspreviously described12,14 on samples
from 8 time points after HIV-1 infection. High-throughput VH:VL pairing of peri-
pheral bloodCD271B cellswasperformed in single cell emulsions generatedusing
a flow focusing apparatus35. Phylogenetic analysis, inference of UCA, and iden-
tification, synthesis, and expression of clonememberswere performed as described
in the Methods. Epitope mapping onto the spike trimer was performed with the
software packageUCSFChimera, using experimental data as described inMethods.
Crystallographic analysis of Fab fragments was performed as described in the
Methods. Structure modelling of disordered residues in Fab crystal structures was
performed using Loopy software. Single-genome amplification and expression of
env genes was performed as described in Methods and in refs 48, 49.
Online Content Any additional Methods, ExtendedData display items and Source
Data are available in the online version of the paper; references unique to these
sections appear only in the online paper.
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METHODS
Study subject. CAPRISA participant CAP256 was enrolled into the CAPRISA
acute infection study51 that was established in 2004 in KwaZulu-Natal, South
Africa for follow-up and subsequent identification of HIV seroconversion. CAP256
was one of the 7women in this cohort who developed neutralization breadth6. The
CAPRISA 002 acute infection study was reviewed and approved by the research
ethics committees of theUniversity of KwaZulu-Natal (E013/04), theUniversity of
Cape Town (025/2004), and the University of the Witwatersrand (MM040202).
CAP256 provided written informed consent for study participation. Samples were
drawn between 2005–09.
Isolation and expression of CAP256-VRC26 family genes. PBMC isolated from
CAP256 blood draws at weeks 59, 119 and 206were stained and sorted for IgG1B
cells on a FACS Aria II as described in ref. 18. Cells were plated at two B cells per
well in 384-well plates and cultured for 14 days in the presence of IL-2, IL-21, and
CD40L-expressing irradiated feeder cells, as described in refs 27 and 45. Culture
supernatants were screened by microneutralization as described in ref. 52 against
HIV-1 ZM53.12 and either CAP45.G3 or CAP210.E8 Env-pseudoviruses. Kappa
and lambda light chain gene and IgG heavy chain gene variable regions were
amplified from neutralization-positive wells, subcloned, expressed and purified
as described in ref. 18. Heavy chains were reconstituted as IgG1. The efficiency of
cloning was as follows. For week 59, a total of 15,000 B cells (7,500 wells) were
plated, 8.3%ofwells produced IgG, 4were positive inmicroneutralization, andone
heavy-light chain pair was recovered. For week 119, a total of 45,000 B cells were
plated, 48% of wells produced IgG, 49 wells were positive in microneutralization,
and 8 heavy-light chain pairs were recovered. Forweek 206, a total of 42,000B cells
were plated, 29%of wells produced IgG, 34 wells were positive inmicroneutraliza-
tion and 3 heavy-light chain pairs were recovered.
The antibodies are numberedCAP256-VRC26.01-.12 in order of the time point
of the sample from which they were isolated, and then the degree of heavy-chain
somatic mutation.
Neutralization assays. Single round of replication Env-pseudoviruses were pre-
pared, titred andused to infectTZM-bl target cells as describedpreviously46,47.Neutra-
lization breadth of CAP256-VRC26.01, .03, .06, and .08 were determined using a
previously described18,53 panel of 194 geographically and genetically diverse Env-
pseudoviruses representing themajor subtypes and circulating recombinant forms.
The remaining antibodies were assayed on a subset of this panel. The data were
calculated as a reduction in luminescence units compared with control wells, and
reported as half-maximuminhibitory concentration (IC50) inmicrogramspermicro-
litre for monoclonal antibodies, or reciprocal dilution (ID50) for plasma samples.
Neutralization fingerprints. Owing to the high sequence variability of HIV-1
Env, different viral strains may exhibit different neutralization sensitivities to the
same antibody, and this pattern of neutralization variation can be used to define
the neutralization fingerprint for a given antibody. Namely, the neutralization
fingerprint of an antibody is defined as the rank-order of neutralization potencies
for the antibody against a set of diverse viral strains18.
The correlations between the neutralization fingerprints of the CAP256-VRC26
antibodies and the neutralization patterns of four longitudinal serum time points
(at 59, 106, 159, and 220weeks post-infection) were computed over a set of 29
HIV-1 strains (6535.3, AC10.29, CAAN.A2, CAP210.E8, CAP244.D3, CAP45.G3,
DU156.12,DU172.17,DU422.01, PVO.04,Q168.a2,Q23.17, Q259.d2.17,Q461.e2,
Q769.d22, Q842.d12, QH0692.42, REJO.67, RHPA.7, SC422.8, THRO.18, TRJO.58,
TRO.11, WITO.33, ZM109.4, ZM135.10a, ZM197.7, ZM233.6, ZM53.12)18. The
correlations between the neutralization potencies of the CAP256-VRC26 antibodies
and a reference set of antibodies targeting the fourmajor sites of vulnerability, with
at most two antibodies per unique donor, were computed over a set of 41 HIV-1
strains (6535.3, 0260.v5.c36, 6405.v4.c34,AC10.29,C1080.c3,CAAN.A2,CAP210.E8,
CAP244.D3, CAP45.G3, CNE3, DU156.12, DU172.17, DU422.01, KER2008.12,
KER2018.11,MB201.A1,MB539.2B7, PVO.04,Q168.a2,Q23.17,Q259.17,Q461.e2,
Q769.d22,Q842.d12,QH0692.42,REJO.67,RHPA.7,RW020.2, SC422.8,TH976.17,
THRO.18, TRJO.58, TRO.11, UG037.8,WITO.33, ZM109.4, ZM135.10a, ZM197.7,
ZM214.15, ZM249.1, ZM53.12). The correlations between the neutralization pat-
terns of the four longitudinal serum timepoints and theneutralization fingerprints
of the reference antibodies were computed over a set of 28 HIV-1 strains (6535.3,
AC10.29, CAAN.A2, CAP210.E8, CAP244.D3, CAP45.G3, DU156.12, DU172.17,
DU422.01, PVO.04, Q168.a2, Q23.17, Q259.17, Q461.e2, Q769.d22, Q842.d12,
QH0692.42, REJO.67, RHPA.7, SC422.8, THRO.18, TRJO.58, TRO.11, WITO.33,
ZM109.4, ZM135.10a, ZM197.7, ZM53.12). For the reference antibodies, data from
multiple neutralization experiments were averaged and consolidated. All correla-
tions are based on the Spearman’s rank correlation coefficient.
Virus-like particle ELISA.VLPELISAswere performedasdescribedpreviously31.
Briefly, VLPs were produced by PEI-based cotransfection of 293T cells with a
pCAGGS-based, Env-expressing plasmid and the Env-deficient HIV-1 genomic
backbone plasmid pNL-LucR-E. VLPs were coated on ELISA wells at 203 the
concentration in transfection supernatants. Monoclonal antibody binding was
then assessed by ELISA, omitting detergent in PBS wash buffers and probing with
an anti-human Fc alkaline phosphatase conjugate (Accurate, Westbury, NY) and
SigmaFAST p-nitrophenyl phosphate tablets (Sigma). Plates were read at 405 nm.
Cell-surface Env binding. 293T cells were transiently transfected with plasmids
encoding Env ZM53.12 or CAP256-SU with deletions of the cytoplasmic tail30.
For binding experiments: after 2 days, the cells were stained with ViVid viability
dye (Invitrogen) followed by serial dilutions of antibodies, two washes with PBS/
5% FBS, then R-PE-conjugated F(ab) goat anti-human IgG specific for the Fc
fragment (Jackson ImmunoResearch) at a 1:200 dilution54. For competition assays,
the cells were stained with ViVid viability dye followed by biotinylated CAP256-
VRC26.08 (0.8mgml21) premixed with serially diluted unlabelled competitor
antibodies. After incubation and 2 washes, cells were stained with streptavidin-PE
(Invitrogen) at 1:200dilution.Cellswere analysedonaBDLSRII (BectonDickinson).
Binding wasmeasured as themedian fluorescence intensity (MFI) for each sample
minus the MFI of cells stained with secondary antibody only.
Polyreactivity analysis of antibodies.Antibody binding to cardiolipinwas deter-
mined as in ref. 42. Briefly, using the QUANTALite ACA IgG III ELISA kit (Zeus
Scientific) permanufacturer’s protocol, each antibody was diluted to 100 mgml21
in the kit sample diluent and tested in threefold serial dilutions. Results shown are
representative of at least two independent ELISAs. Positive and negative controls
were included on each plate, and values three times above background were con-
sidered positive. Antibody reactivity to a human epithelial cell line (HEp-2) was
determined with the ANA/HEp-2 Cell Culture IFA Test System (Zeus Scientific)
per manufacturer’s protocol, as described in ref. 42. Antibodies were diluted to
50mgml21 and 25mgml21 in ZOBRA-NS diluent. Positive and negative controls
were included on each slide. Antibodies were scored negative, indeterminate, or
positive (11 to 41) at each dilution. Results are representative of at least two
independent experiments.
Electron microscopy (EM) and image processing. VRC26.09 Fabs in complex
with BG505 SOSIP.664 gp140 trimer produced in HEK 293S cells were analysed
by negative stain EM. A 3 ml aliquot of,8 mgml21 of the complex was applied for
15 s onto a glow discharged, carbon-coated 400 Cu mesh grid and stained with
2% uranyl formate for 20 s. Grids were imaged using a FEI Tecnai T12 electron
microscope operating at 120 kV using a 52,0003magnification and electron dose
of 25 e2 /A˚2, which resulted in a pixel size of 2.05A˚ at the specimen plane. Images
were acquired with a Tietz 4k3 4k CCD camera in 5u tilt increments from 0u to
50u at a defocus of 1,000 nm using LEGINON55.
Particles were picked automatically by usingDoGPicker and put into a particle
stack using theAppion software package56,57. Initial reference free 2D class averages
were calculated using particles binned by 2 via the XmippClustering 2DAlignment
and sorted into128 classes58. Particles corresponding to the complexeswere selected
into a substack and another round of reference free alignment was carried out
with unbinned particles using Xmipp Clustering 2D alignment and IMAGIC
softwares59. To generate an ab initio 3D starting model, a template stack of 44
images of 2D class averages was used without imposing symmetry. The resulting
starting model was refined against 2D class averages for 9 cycles and subsequently
with 6,763 raw particles for 9 cycles using EMAN60. The resolution of the final
reconstruction was calculated to be 28A˚ using an FSC cut-off value of 0.5.
High-throughput sequencing. Amplicon for 454 next-generation sequencing
was prepared as described12,14 with slight modifications as indicated. Briefly, mRNA
was prepared from 10–15million PBMC using an Oligotex kit (Qiagen). cDNA
was synthesized using Superscript II reverse transcriptase (Invitrogen) and oligo-
dT(12–18) primers. Individual PCR reactions were performed with Phusion poly-
merase for 30 cycles. Primers (Supplementary Table 4) consisted of pools of 5–7
oligonucleotides specific for all lambda gene families orVH3 family genes, andhad
adapters for 454 next generation sequencing. For week 176 only, heavy-chain PCR
was performed with primers for all VH families, and mixed lambda and kappa
primers were used for light chain (Supplementary Table 4). PCR products were
gel-purified (Qiagen). Pyrosequencing of the PCR products was performed on a
GSFLX sequencing instrument (Roche-454 Life Sciences, Bradford, CT,USA) on a
half chip per reaction (full chips for week 176). On average, ,250,000 raw reads
were produced.
High-throughput linkage of VH andVL transcripts was performed in single cell
emulsions generated using a flow focusing apparatus35 (B.J.D., manuscript in
preparation). CD271 B cells were isolated from CAP256 PBMCs collected at
34, 48, 59, 69, and 119weeks post-infection by magnetic bead sorting (Miltenyi
Biotec, Auburn, CA). Cells fromweeks 34 and 119were divided in two groups and
half of the cellswere analysedwith FR1primers35, while the other half were analysed
with leader peptide primers41 (Supplementary Table 5). All other time points were
analysed in a single groupusing only FR1primers (SupplementaryTable 1).Overlap
extension RT–PCR was performed as previously reported35, with extension time
increased to 125 s. Nested PCR was performed as described previously with a 23-s
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extension time and PCR products were sequenced using the Illumina 23 250 bp
MiSeq platform. Raw reads were quality-filtered for an Illumina Q-score of 20 in
50%of bases. VRC26-classVH and pairedVL sequences were identified via BLAST
against CDR-H3 nucleotide sequences of the 12 culture-isolated antibodies.
Antibodyomics pipeline.Raw 454 datawas processed using a pipeline implemen-
ted in Python, similar to one we reported previously14. Briefly, reads were filtered
for length, keeping only those between 300 and 600 nucleotides. Germline V genes
were then assigned to each read using BLAST with empirically optimized para-
meters. Reads for which noV genematchwas foundwith an e-value# 10210 were
discarded. For reads assigned to anyVH3-30 orVl1-51 allele, (theCAP256-VRC26
germline genes), ClustalW2 (ref. 61) was used to calculate the sequence identity to
the germline and each isolated antibody. These data were plotted as density heat
maps using ggplot2 in R to produce identity-divergence plots (Fig. 3b and Sup-
plementary Fig. 4).
Finding clonally related sequences.Reads thatwere assigned to the sameV genes
asCAP256-VRC26,VH3-30 andVl1-51,were submitted to IMGTHigh-Vquest62
(http://www.imgt.org/IMGTindex/IMGTHighV-QUEST.html), and the results,
including automated sequence corrections, were used to further sieve for lineage-
related sequences. Reads assigned to J genes matching CAP256-VRC26 (JH3 or
Jl1), and having similar divergence (6 15%) in theV and J genes, similar (6 10%)
nucleotide and amino acid divergences in theV gene, and containing a continuous
open reading frame throughout the entire variable region, were selected for further
processing. Next, reads from all time points were pooled and clustered at 97.25%
sequence identity (twice the standard deviation of expected 454 sequencing error)14
using CDHit63. For each cluster, a representative sequence was chosen from the
earliest possible time point. The choice of cluster representatives from the earliest
time points at which they appeared was critical tomaintaining information on the
chronology of lineage development in subsequent analyses. This procedure yielded
8,485 unique heavy chain and 6,410 unique light chain sequences.
To identify CAP256-VRC26 lineage-member heavy chains, we performed intra-
donor phylogenetic analysis14 on the unique 454 sequence set using the heavy
chain sequences of the 12 isolatedCAP256-VRC26 antibodies. 707 sequenceswere
identified as likely lineage members, of which 27 were discarded after manual
inspection, resulting in a total of 680 unique CAP256-VRC26 lineage heavy chain
sequences.
To identify light chain lineagemembers, a sieve requiring at least 92% sequence
identity in CDR L3 to one of the isolated antibodies resulted in 495 sequences.
Joinsolver64 was used to examine the V-J junctions of these sequences in detail,
to ensure that the recombination points matched those known for the isolated
antibodies (Supplementary Fig. 5). This gave a total of 472 unique CAP256-VRC26
lineage light chain sequences.
Paired reads that were identified as members of the CAP256-VRC26 lineage
were clustered using CDHit63 at 95% sequence identity and consensus VH and VL
sequences were generated for each cluster containing two ormore pairs. Blast was
then used to align the resulting sequences to all clonally related sequences iden-
tified from the 454 sequencing as described above. Gapless alignments covering
at least 190 nucleotides at 97% or greater sequence identity were considered to
be matches. Two of the 157 paired sequences determined to be members of the
CAP256-VRC26 lineage matched known CAP256-VRC26 lineage sequences in
both VH and VL 454 data sets. An additional 4 VH sequences and 1 VL sequence
were found in the 454data, but their light or heavy chain partnerswere not present.
Computation of phylogenetic trees. Phylogenetic trees were constructed from
454 data and the sequences of antibodies isolated fromB cell culture. Raw data are
shown in Nexus format in Supplementary Figs 12 and 13. MEGA5 (ref. 65) was
used to select the general time-reversible model with a gamma-distributed rate
parameter (GTR1G)66 as the best mathematical model for building a maximum-
likelihood tree from the CAP256-VRC26 lineage sequences. FASTML67 was then
used to estimate the gamma parameter and build separate maximum likelihood
trees for heavy and light chain sequences (including the isolated antibodies) and
these were rooted on the germline V gene sequences. Two branches of the light
chain tree were manually moved to match their positioning in the heavy chain
tree based on the evidence from trees constructed solely with the 12 isolated
antibodies. Analysis with DNAML from PHYLIP (Phylogeny Inference Package)
version 3.6 (Felsenstein, J. 2005. PHYLIP (Phylogeny Inference Package) version
3.6. Distributed by the author. Department of Genome Sciences, University of
Washington, Seattle) (http://cmgm.stanford.edu/phylip/dnaml.html) showed that
these rearrangements did not significantly alter the log-likelihood score of the tree.
To create a condensed version of the heavy chain phylogenetic tree (Fig. 4c),
CDR H3 sequences were clustered using a 95% sequence identity threshold and
requiring that all CDR H3s in a cluster have the same length. Isolated antibodies
andmonophyletic clusters with at least fivemembers were represented by a single
leaf, while all other sequences were removed from the tree. In cases where an
internal node was deleted, branch lengths above and below that node were
summed, so that the tree depths of all remaining sequences were maintained.
UCAand inferred intermediates.The phylogenetic trees of all heavy and all light
chain lineage members calculated above (Fig. 3c and Extended Data Fig. 1) were
input into the DNAMLmaximum likelihood software package to infer ancestral
sequences. These are a direct consequence of the input sequences and the math-
ematicalmodel used to build the trees; the gammadistribution found by FASTML
above was used and the topology of the tree was held fixed, so no further informa-
tion was added. The calculated heavy chain UCA was identical to the germline
VH3-30*18 allele. Although theVH3-30*03 allele is only one nucleotide different
from *18, germline sequencing of this donor showed that she carries the *18 allele
and not the *03 allele (Cathrine Mitchell Scheepers, personal communication).
The inferredUCAis very similar to low-divergence sequences found in theweek 38
data set (Extended Data Fig. 6).
To test intermediates in the development of CAP256-VRC26.01, two internal
nodes were chosen from the phylogenetic trees to be approximately equally spaced
in terms of evolutionary distance and the inferred sequences were retrieved using
DNAML. Successful complementation of inferred heavy and light chains for each
intermediate suggests that the lineage is well sampled by the 454 data and that the
calculated phylogenetic trees successfully capture the coupled evolutionary dynamics
of heavy and light chains.
Logograms for CDR H3s were made with Weblogo68.
X-ray crystallography.VRC26.UCA Fab was prepared by digesting purified IgG
with Lys-C at 37uC for 2 h. The reaction was then quenched by the addition of
cOmplete protease inhibitors (Roche). For VRC26.01, VRC26.03, VRC26.04,
VRC26.06, VRC26.07 and VRC26.10 Fab preparation, an HRV3C recognition
site (GLEVLFQGP) was inserted after Lys 235 and purified IgG was incubated
withHRV3Cprotease overnight at 4 uC.For all, the digested antibodies were passed
over Protein A agarose to remove the Fc fragment. The Fab was further purified
over a Superdex 200 gel filtration column and concentrated aliquots were stored at
280 uC. All Fabs were screened against 576 crystallization conditions using a
CartesianHoneybee crystallization robot. Initial crystalswere grownby the vapour
diffusionmethod in sitting drops at 20 uCbymixing 0.2ml of protein complexwith
0.2ml of reservoir solution. Crystals were manually reproduced in hanging drops
by mixing 1.0ml protein complex with 1.0ml reservoir solution. VRC26-UCA was
crystallized with a reservoir solution of 27% PEG 8000 and 0.1M HEPES pH7.5
and was flash frozen in liquid nitrogen with 20% PEG 400 as a cryoprotectant.
VRC26.01was crystallizedwith a reservoir solution of 32%PEG400, 4%PEG3350
and 0.1M sodium acetate pH5.5 and was flash frozen in liquid nitrogen with
20%ethyleneglycol as a cryoprotectant.VRC26.03was crystallizedwith a reservoir
solution of 22% PEG 8000, 5% MPD and 0.1M imidazole pH6.5 and was flash
frozen in liquidnitrogenwith 20%xylitol as a cryoprotectant. VRC26.04was crystal-
lized with a reservoir solution of 14% PEG 3350, 25% ispropanol and 0.1M Tris
pH 8.5 and was flash frozen in liquid nitrogen with 20% ethylene glycol as a
cryoprotectant. VRC26.06was crystallizedwith a reservoir solution of 3M sodium
formate and 0.1M Tris pH7.5 and was flash frozen in liquid nitrogen with 20%
xylitol as a cryoprotectant. VRC26.07 was crystallized with a reservoir solution of
4% PEG 8000, 0.1M zinc acetate and 0.1M MES pH6 and was flash frozen in
liquid nitrogen with 20% glycerol as a cryoprotectant. VRC26.10 was crystallized
with a reservoir solution of 22% PEG 4000, 0.4M sodium acetate and 0.1M Tris
pH7.5 and was flash frozen in liquid nitrogen with no cryoprotectant.
Data for all crystals were collected at a wavelength of 1.00A˚ at SER-CAT beam-
lines ID-22 andBM-22 (AdvancedPhotonSource,ArgonneNational Laboratory).
All diffraction data were processed with the HKL2000 suite69 and model building
and refinement were performed in COOT70 and PHENIX71, respectively. For
VRC26.03 Fab data, amolecular replacement solution consisting of one Fabmole-
cule per asymmetric unit was obtained using PHASER with a search model from
PDB ID 3F12. VRC26.03 then served as a search model for all remaining VRC26
Fabs. Throughout the refinement processes, a cross validation (Rfree) test set con-
sisting of 5% of the data was used and hydrogen atoms were included in the refine-
ment model. Structure validations were performed periodically during the model
building/refinement process with MolProbity72. Ribbon diagram representations
of protein crystal structures were made with PyMOL73 and electrostatics were
calculated and rendered with UCSF Chimera74.
Structure modelling on trimers. Defined locations of the V1V2, V3-glycan and
CD4-binding sites were mapped directly onto EM density of the unliganded
HIV-1 BAL spike (EMD-5019)50 using the software package UCSF Chimera74.
The CD4-binding site was defined by aligning density of the VRC01-bound BAL
spike (EMD-5457)75 with the unliganded map and fitting a crystal structure of
VRC01-bound gp120 (PDB accession number 3NGB)76 to the density. EMdensity
in closeproximity to theFab structurewas colored tohighlight the regionof contact.
The same procedure was used to define the V3-glycan region using a PGT128-
bound trimer (EMD-1970) and crystal structure (PDB id 3TYG)77 and the V1V2
RESEARCH ARTICLE
Macmillan Publishers Limited. All rights reserved©2014
region using the PG9-bound BG505 SOSIP trimer (EMD-2241)24 and a crystal
structure of V1V2-bound PG9 (PDB accession number 3U4E)22. The fit of the
PG9-V1V2 crystal structure to the SOSIP trimer was used to model the trimeric
orientationofV1V2using the threefold symmetry of theHIV-1 spike.TheBG505.664
SOSIP crystal structure33, PDB 4NCO, was presented to highlight the quaternary
location of V1V2 pointmutations. Side chains of residues 166 and 167, not seen in
the crystal structure, weremodelled. TheMan5 glycan atN160, also not seen in the
crystal structure, is represented as in the crystal structure of the PG9-V1V2 com-
plex (PDB accession code 3U4E).
Loop modelling. Two intermediates were calculated at approximately equal
maturation distance along the VRC26-UCA to VRC26.01 pathway. Mutations
associated with the intermediates were mapped directly onto the structure of
VRC26.01. 14 of the 35 residues in the VRC26.01 structure are disordered and
weremodelledwith Loopy78 (http://wiki.c2b2.columbia.edu/honiglab_public/index.
php/Software:Loopy) and represented as grey dots. Mutations of the intermediates
were coloured according to approximate time of occurrence based on the longit-
udinal phylogenetic tree highlighting the timeline of the structural development.
These, and the other antibodies with modelled loops (Fig. 4), were modelled in a
single loop prediction involving four steps. In the first step, Loopy was used to
predict 10 loop conformations. The number of initial loop conformations to be
sampled was set to 50,000 (and the not the default value of 2,000). In the second
step, all 10 loop conformations were refined using the Protein PreparationWizard
inMaestro (http://www.schrodinger.com/). In the third step, sulphate groupswere
added to tyrosine at position 100 of the heavy chain and the entire structure was
then subjected to all-atom energyminimization inMaestro. A fourth and final step
was needed to ensure a reasonable sampling of the rotameric states for the sulphated
tyrosines. The Rapid Torsion Scan module in Maestro was used to sample the chi
angle involving the sulphate moiety in steps of 20 degrees. The model with the
lowest energy after application of the Rapid Torsion Scan module was considered
as the best prediction.
Tyrosine sulphation predictions were carried out in GPS-TPS (Z. Pan et al.,
http://tsp.biocuckoo.org).
Single genome amplification (SGA), sequencing and cloning.HIV-1 RNAwas
isolated from plasma using the Qiagen QIAamp Viral RNA kit, and reverse tran-
scribed to cDNA using SuperScript III Reverse Transcriptase (Invitrogen, CA).
The envelope geneswere amplified from single genome templates49 and amplicons
were directly sequenced using theABI PRISMBigDyeTerminatorCycle Sequencing
Ready Reaction kit (Applied Biosystems, Foster City, CA) and resolved on an ABI
3100 automated genetic analyser. The full-length env sequences were assembled
and edited using Sequencher v.4.5 software (Genecodes, AnnArbor,MI).Multiple
sequence alignments were performed using Clustal X (ver. 1.83) and edited with
BioEdit (ver. 7.0.9) Sequence alignments were visualized using Highlighter for
Amino Acid Sequences v1.1.0 (beta).
For analysis of selection pressure, and to account for recombination between
the SU and PI, sequences were partitioned into two alignments (an SU-related,
and a PI-related alignment) based on the inferred recombination breakpoints
using an in-house script. Breakpoints were identified by a shift in identity from
one reference towards the other, and required at least two sequential polymorph-
isms in common with a corresponding PI/SU-related virus in order to be consid-
ered. Phylogenies for both alignments were then reconstructed using FastTree79
with a GTR1CAT model, and rooted on the PI/SU. Signals of selective pressure
were detectedwithMEME(episodic diversifying selection)80 andDEPS (directional
selection)81 using the FastTree-generated trees, implemented in Hyphy82.
The frequencies of specific amino acids at a site and the distribution of net
charges in the V2 epitope were calculated from the 2012 filtered web alignment
(n5 3,990) from the Los Alamos HIV database (http://www.hiv.lanl.gov/).
Selected envelope ampliconswere cloned into the expression vector pcDNA3.1
(directional) (Invitrogen) by re-amplification of SGA first-round products using
Pfu Ultra II enzyme (Stratagene) with the EnvM primer, 59-TAGCCCTTCCAGT
CCCCCCTTTTCTTTTA-39 (ref. 83) and directional primer, EnvAstop, 59-CAC
CGGCTTAGGCATCTCCTATGGCAGGAAGAA-39 (ref. 48). Cloned env genes
were sequenced to confirm that they exactly matched the sequenced amplicon.
Autologous clones were mutated at key residues within the C-strand using the
Stratagene QuickChange II kit (Stratagene) as described by the manufacturer.
Mutations were confirmed by sequencing. Envelope clones were used to generate
single round of replication Env-pseudoviruses as described above.
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Extended Data Figure 1 | Amino acid sequences of CAP256-VRC26 heavy
and light chains. a, b, Sequences of the 12 B-cell culture derived antibodies,
inferred germlineV and J genes, and inferred intermediates are compared to the
predicted UCA. a, Heavy chain. b, Lambda light chain.
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Extended Data Figure 2 | Neutralization breadth and potency of CAP256-
VRC26 antibodies. a, Neutralization of autologous (CAP256 PI and SU) and
47 heterologous viruses by CAP256-VRC26 antibodies. Neutralization was
measured using a TZM-bl assay with Env-pseudoviruses. Geometric mean was
calculated for values,50mgml21. b, Breadth-potency curves. Neutralization
of a 194-virus panelwasmeasured forVRC26.08, PG9, PGT145 andCH01. The
curves show the percent of viruses neutralized at any given IC50.
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Extended Data Figure 3 | CAP256-VRC26 antibodies recognize a
quaternary epitope. a, All 12 CAP256-VRC26 monoclonal antibodies were
tested by ELISA against gp120 from ZM53 and CAP210. Positive control
antibody PG9 bound to both gp120s (not shown). b, Twenty-three proteins and
scaffolded V1V2 constructs were tested by ELISA for binding of CAP256-
VRC26.03 andCAP256-VRC26.08. PG9 bound to several of these (not shown).
Similar data were observed for CAP256-VRC26.06, .07 and .09. c, Binding of
CAP256-VRC26.03 and CAP256-VRC26.08 to virus-like particles (VLP). VLP
expressing ZM53, ZM53.K169E, CAP210 or no Env were concentrated by
pelleting and used to coat ELISA plates; assays were performed without
detergent to preserve the trimer spikes. Similar datawere observed forCAP256-
VRC26.06, .07 and .09.
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Extended Data Figure 4 | Visualization of CAP256-VRC26.09 bound to
Env trimers by negative-stain electron microscopy. a, Raw micrograph and
corresponding reference free 2D class averages of VRC26.09 in complex with
cleaved soluble BG505 SOSIP.664 gp140 trimers. b, Projection matching of 3D
model refinement and FSC curve used to calculate resolution. Resolution, 28A˚
at FSC5 0.5. c, 3D reconstruction of VRC26.09:BG505 SOSIP.664 complex
(green surface) alone and overlayed with PG9:SOSIP (purple mesh). The
reconstructions are nearly identical in the trimer portionwhile displaying small
differences in the Fab angles.
ARTICLE RESEARCH
Macmillan Publishers Limited. All rights reserved©2014
Extended Data Figure 5 | Effects of V2mutations on neutralization activity
of CAP256-VRC26 antibodies. a, Each panel shows neutralization of wild-
type and N160 glycan mutant CAP210.E8, ConC, KER2018.11 and ZM53.12
viruses. CAP256-VRC26 monoclonal antibodies are partially and variably
affected by loss of N160 glycan, in a virus-strain specific manner. In contrast,
PG9-class antibodies PG9, PGT142, and CH01 are uniformly knocked out by
N160 mutation. b, CAP256-VRC26 monoclonal antibodies are partially and
variably affected by changes inV2 glycans. Neutralization by each antibodywas
measured against wild-type ZM32.12, mutants N156A and N160K, and
ZM53.12 grown in the presence of kifunensine, an inhibitor of glycan
processing. In contrast to CAP256-VRC26 antibodies, PG9 activity is knocked
out by the mutations and by kifunensine. c, HIV-6405 wild type is resistant to
PG9 and CAP256-VRC26 antibodies, and its PG9-sensitive mutant34 is also
sensitive to CAP256-VRC26 antibodies. d, Sequences of wild type and mutant
HIV-6405.
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Extended Data Figure 6 | Origins of long CDR H3s in donor CAP256.
a, Week 38 sequences from 454 that support the calculation of the UCA.
Unique amino acid sequences with 2–5 residue changes in the CDR H3 are
compared to the calculated UCA sequence. Each contained fewer than 3
combined nucleotide mutations in VH and JH. Parentheses, number of
corresponding reads in the raw 454 data. b, c, Lack of autoreactivity. b, ELISA
for binding to cardiolipin. 4E10 was strongly positive, CAP256-VRC26.03 was
weakly positive, and the other 11 CAP256-VRC26 monoclonal antibodies and
the UCA were negative along with control antibody VRC01. c, Staining on
Hep2 cells was assessed at 50 and 25mgml21. Only the positive control, mAb
4E10, showed positive staining. d, Distribution of CDRH3 lengths among 454
sequencing reads of B cell transcripts. The percentage of high-quality NGS
reads that have CDR H3$ 24 or$ 28 are shown for three HIV-1 uninfected
donors (solid circles on both right and left plots) and for donor CAP256 (week
176) amplified with all-VH primers donor, and CAP256 (week 30) amplified
with VH3 primers. High-quality reads are defined as successful V and J
assignments and a continuous open reading frame. CDRH3 lengths use the
IMGT definitions.
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Extended Data Figure 7 | Loss of flexibility at the base of the CDR H3.
a, Top shows logograms of CDR H3 sequences extracted from the heavy chain
phylogenetic tree from weeks 59 and 119. The height of each letter is
proportional its frequency in the population. Sequences that lack a disulphide
bond contain a highly conserved glycine at the third position of the CDR H3
(residue 97, Kabat definition). The appearance of the two cysteines that form
the disulphide bond coincides with a glycine to arginine mutation at this site.
Bottom shows overlay and close-up of crystal structures from Supplementary
Fig. 6A. Loss of the glycine limits flexibility at the base of the CDR H3 and is
shown in the crystal structures to be the initial site of divergence in theCDRH3
loops between the antibodies without the disulphide bond (UCA andCAP256-
VRC26.01) and those with it (CAP256-VRC26.03, .04, .06, .07, .10). This
mutationmay contribute to the conserved trajectory of the CDRH3 protrusion
towards the heavy chain that is seen in the more mature antibody structures.
b, CDRH3 and flanking sequences for VRC26.01, VRC26.03, and a mutant
VRC26.03 in which the conserved cysteines are changed to the corresponding
amino acids found inVRC26.01. c, Neutralization activity of VRC26.03 and the
mutant shown in panel b. The mutant shows reduced activity against CAP256
SU and complete loss of heterologous activity.
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Extended Data Figure 8 | Viral polymorphisms and escape mutations.
a, Frequency of CAP256 PI and SU polymorphisms at positions 160–162
(glycosylation sequon), 165 and 169. Coloured slices on pie charts and
percentages indicate prevalence of these polymorphisms within global
circulating viruses in the Los Alamos Sequence Database (n5 3,990).
b, Distribution of net charge of the V2 epitope, defined as residues 160–171,
within global circulating viruses (n5 3,990). The charge of the PI, SU and
176 week clones are indicated. c, CAP256-VRC26 monoclonal antibody
neutralization of the SU and PI viruses, and of the SU virus mutated to contain
PI polymorphisms 162I, 165V or 169Q. d, CAP256-VRC26 monoclonal
antibody neutralization of the SU virus mutated to contain known CAP256
escape mutations in the V2 epitope. e. CAP256-VRC26 monoclonal antibody
neutralization of 34 week clone (designated wild type, wt) with an SU-like
V1V2, compared to the I169Kbackmutant. c–e,TheV2 epitope sequence, with
mutated residues in red is shown on the left, IC50 values in the middle, and the
time point when mutations were first detected in Env sequences on the right
(weeks post-infection).
ARTICLE RESEARCH
Macmillan Publishers Limited. All rights reserved©2014
Extended Data Figure 9 | Longitudinal changes in CAP256 V1V2.
a, Variation in the V1V2 sequence of six Env clones. Amino acid mutations
from residues 160–171 are highlighted and corresponding changes in
neutralization for the six Env clones by CAP256-VRC26.01-.12 and the UCA
are shown. The charge of the displayed sequences that make up the central
region of the trimer are shown on the right. b, Residue changes highlighted in
a were mapped onto the V1V2 domain in the crystal structure of the HIV-1
BG505.664 SOSIP Env trimer. The structure is viewed looking towards the viral
membrane along the trimer axis. Mutations are coloured as in panel a and
represented as spheres (amino acids) or stick and surface (glycan).
c, Electrostatic surface representations of the full V1V2 region for each Env
clone(top row), Fabs (bottom row). Timeline of infection is shown in the
middle. V1V2 sequences were modelled with SWISS-MODEL using the
BG505.664 SOSIP as a template. Escape mutations R166S, K171N and K169E
resulted in a net charge change in the V2 epitope from 13 (SU) to a rare 0.
Antibody CDR H3s became less negatively charged over time, suggesting co-
evolution of the viral epitope and the antibody paratope.
RESEARCH ARTICLE
Macmillan Publishers Limited. All rights reserved©2014
ExtendedData Table 1 | Genetic characteristics of CAP256-VRC26antibodies andV1V2-directed broadly neutralizing antibodies fromother
donors
a, b, Data are from the present study and from references 19–21. CAP256-VRC26.01-12 are derived fromB cell culture, while CAP256.VRC26-I1 and –I2 (in italics) are inferred intermediates. CDRH3 lengths use
Kabat notation. a, Nucleotides. b, Amino acids.
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Supplementary Figure 1. Neutralization by CAP256-VRC26 antibodies of 194 Env-pseudoviruses.








CAP256-VRC26 CAP256 plasma (ID50)
Clade Virus mAbs (IC50) wk 59 wk106 wk159 wk 220
ZM53.12 0.002 979 14218 13474 15460
ZM233.6 0.0003 238 4360 13476 5261
CAP210.E8 0.002 7091 7830 13580 5250
DU422.01 0.008 <45 346 1907 1968
ZM197.7 0.008 <45 151 1062 1245
DU156.12 0.016 <45 394 1363 1116
CAP45.G3 4.7 287 7898 13402 1006
C ZM214.15 0.33 <45 <45 920 538
ZM109.4 26.5 <45 70 398 156
ZM249.1 0.010 <45 <45 230 119
CAP244.D3 >50 <45 <45 58 62
DU172.17 >50 <45 <45 <45 <45
ZM135.10a >50 <45 68 69 <45
Q842.d12 10.1 <45 47 658 602
A Q23.17 9.5 <45 171 1107 448
Q259.d2.17 0.008 <45 792 114 433
Q168.a2 0.181 <45 70 2349 352
Q461.e2 0.705 <45 <45 422 127
Q769.d22 >50 <45 <45 <45 <45
6535.3 >50 <45 214 788 284
WITO.33 0.003 56 219 293 99
TRO.11 >50 <45 <45 <45 69
AC10.29 0.022 <45 64 48 66
RHPA.7 >50 <45 <45 <45 49
PVO.04 0.308 47 53 86 47
CAAN.A2 >50 <45 <45 <45 <45
B QH0692.42 >50 <45 <45 49 <45
REJO.67 >50 <45 <45 <45 <45
SC422.8 0.178 <45 <45 <45 <45
THRO.18 4.250 <45 <45 <45 <45
TRJO.58 >50 <45 <45 56 <45
Supplementary Figure 2. Neutralization of heterologous viruses by CAP256 plasma and mAbs.  Neutralization of  31 viruses by 
CAP256-VRC26 antibodies and by plasma from CAP256 sampled at 4 timepoints. Plasma data are from ref. 25. Antibody values are 
shown as 50% inhibitory concentration (IC50) of a theoretical combination of all 12 antibodies (calculated as the lowest IC50 for each 
virus). Plasma is shown as 50% inhibitory dilution (ID50) with a starting dilution of 1:45. 
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Supplementary Figure 3. Correlations of  neutralization fingerprints. a,  Correlation of neutralization fingerprints between 
CAP256-VRC26 antibodies and a panel of HIV-1 broadly neutralizing antibodies.  VRC26.01, .07, and .12 were excluded due to low 
















































































6 53 5.3 0.17 0.5 4.9 2.57 0.26 0.46 0.36 0.87 4.67 >50 43.5 0.07 4.18 0.32 0 0.02 >50 >50 >50 1.001 1.88 0.01 >50 8.32
0 2 6 0 .v5.c3 6 7.94 0.32 >50 >50 0.2 31.7 1.18 >50 >50 >50 >50 0.4 2.1 1.65 0.04 0.06 >50 >50 6.97 0.58 0.53 >50 0.13 0.21
6 4 0 5.v4 .c3 4 0.39 1.12 7.51 12.1 0.17 3.92 43.6 >50 >50 >50 >50 0.73 >50 >50 0.02 6.86 >50 >50 37.9 2 2.53 >50 0.2 0.37
A C 10 .2 9 0.23 0.42 0.98 >50 6.05 0.41 >50 1.86 >50 >50 >50 0.36 0.01 0.06 0.03 0.01 0.01 0.006 >50 >50 1.19 0.88 46.1 >50
C 10 8 0 .c3 0.1 0.05 0.06 >50 0.1 0.6 >50 >50 >50 >50 25.4 0.54 0 0 >50 0.12 0.04 0.001 32.4 1.857 1.07 >50 1.27 1.99
C A A N .A 2 1.47 1.2 11.6 >50 0.67 8.49 1.72 >50 >50 11.8 >50 0.21 9.22 9.7 0.01 0.1 >50 5.53 12 1.883 1.17 0.29 >50 0.51
C A P2 10 .E8 0.81 38.2 >50 >50 8.16 4 >50 >50 >50 >50 >50 >50 <0.023 0.13 >50 >50 0.15 >50 >50 >50 >50 >50 >50 >50
C A P2 4 4 .D 3 0.45 0.03 >50 >50 0.07 1.98 0.33 >50 >50 >50 >50 0.28 0.01 0.08 >50 >50 >50 12 >50 0.375 0.64 0.67 0.17 0.1
C A P4 5.G3 0.68 0.03 >50 >50 0.59 2.36 >50 0.11 >50 >50 >50 >50 0.001 0.003 2.08 >50 0.1 0.001 >50 >50 8.9 >50 >50 0.95
C N E3 1.51 0.11 6.79 >50 0.13 2.23 2.75 >50 >50 >50 24.9 1.99 0.12 0.07 >50 >50 0.02 0.252 >50 >50 3.18 >50 >50 0.11
D U 156 .12 0.03 0.03 >50 >50 0.04 <0.023 11.4 1.41 >50 >50 >50 0.03 0.003 0.04 0.01 0.02 0.004 0.001 >50 <0.023 0.09 9.28 3.18 0.02
D U 172 .17 0.05 0.04 >50 >50 0.29 <0.023 >50 0.55 >50 8.32 >50 >50 <0.023 0.23 0.1 0.04 >50 >50 >50 0.223 >50 >50 0.28 >50
D U 4 2 2 .0 1 0.78 >50 >50 >50 >50 1.65 >50 0.4 >50 >50 >50 >50 0.04 0.3 0.16 0.18 >50 >50 >50 >50 >50 >50 >50 >50
KER 2 0 0 8 .12 24 0.27 6.98 6.8 0.25 1.28 >50 >50 >50 >50 >50 0.57 0.004 0.01 2.22 14.7 >50 8.33 3.78 0.301 0.58 >50 0.18 0.4
KER 2 0 18 .11 3.79 0.53 2.01 >50 0.42 8.46 3.28 49.2 40 >50 23.8 0.83 0.001 0.004 >50 >50 0.000 0.003 >50 0.49 0.46 >50 0.51 0.23
M B 2 0 1.A 1 0.28 0.06 0.44 >50 0.46 2.21 27.4 >50 17.7 >50 22.1 0.17 0.01 0.06 0 0.02 0.46 2.49 1.68 0.061 0.17 0.28 0.04 0.07
M B 53 9 .2 B 7 15.1 0.22 2.49 >50 0.09 21.7 3.1 14 3.7 0.04 >50 0.4 0.02 0.06 >50 3.57 0.07 1.19 6.97 0.435 0.43 >50 0.26 0.25
PV O.0 4 3.08 0.35 >50 1.41 0.07 1.99 0.48 >50 >50 >50 >50 0.15 15 6.94 0.13 0.01 0.04 0.143 2.61 0.303 0.55 >50 0.19 2.23
Q16 8 .a2 1.02 0.07 7.83 >50 0.05 18.7 0.3 >50 6.76 0.03 >50 0.14 0.02 0.08 >50 >50 0.49 0.86 5 0.057 0.15 >50 0.04 0.08
Q2 3 .17 1.13 0.05 10.8 >50 0.02 0.13 0.27 >50 10.4 >50 >50 0.11 0 0.01 0 0.01 0 0.002 0.58 0.042 0.09 0.16 <0.023 0.04
Q2 59 .17 4.77 0.02 16.1 >50 0.02 10.2 0.76 >50 10.6 >50 >50 0.05 0.03 0.05 >50 >50 3.95 45 >50 >50 0.06 >50 4.91 0.03
Q4 6 1.e2 1.72 0.16 13.4 >50 0.07 5.53 1.26 >50 >50 0.05 >50 0.21 4.62 2.53 >50 25.6 >50 16 7.93 0.334 0.38 >50 0.16 0.13
Q76 9 .d2 2 0.89 0.01 0.61 >50 0.01 1.73 0.03 >50 1 >50 >50 0.01 0.07 0.01 >50 >50 >50 0.151 0.36 0.046 0.01 >50 0.04 0.01
Q8 4 2 .d12 4.13 0.01 >50 >50 0 8.99 0.01 >50 1.46 >50 >50 0.02 0 0.02 0.02 0.03 0.02 0.067 0.11 0.011 0.01 >50 0.01 0.01
QH0 6 9 2 .4 2 0.69 1.04 2.22 4.99 0.28 1.6 2.63 0.79 25.2 7 >50 0.99 >50 >50 0.94 0.05 >50 >50 9.37 1.392 1.5 >50 0.94 45.3
R EJO.6 7 0.16 0.08 0.3 >50 0.04 0.17 0.05 1.7 2.15 >50 >50 0.01 0.01 0.01 8.87 >50 0.21 0.0003 30 0.0003 0.05 0.13 0.05 0.02
R HPA .7 1.04 0.06 23.2 >50 0.02 13.3 5.1 0.13 8.53 0 >50 0.02 0.89 9.97 0.01 0.03 0.02 0.028 0.33 0.05 0.05 >50 0.13 22.1
R W 0 2 0 .2 1.93 0.03 7.55 >50 0.02 8.21 0.38 10.7 23.6 2.78 >50 0.14 0.16 0.11 0.002 0.01 >50 5.17 0.09 0.088 0.28 6.98 0.02 0.02
SC 4 2 2 .8 0.15 0.11 1.34 5.65 0.05 1.49 0.16 0.2 2.44 >50 17.1 0.03 2.19 0.54 0.1 2.41 1.45 0.027 1.46 0.073 0.12 >50 0.14 0.05
T H9 76 .17 0.3 0.02 0.13 >50 0.03 0.21 11 >50 >50 0.06 28.3 0.12 >50 >50 >50 >50 >50 >50 1.23 0.021 0.13 >50 <0.023 0.03
T HR O.18 0.21 1.6 >50 >50 2.8 1.77 19.7 0.96 >50 >50 >50 1.88 0.89 9.9 >50 >50 0 0.006 >50 >50 5.1 >50 37.9 17.6
T R JO.58 1.21 0.11 >50 >50 0.06 8.75 14.5 >50 >50 >50 >50 0.03 0.58 0.21 4.31 0.01 >50 >50 >50 0.088 0.07 >50 0.22 0.09
TR O.11 0.04 0.12 >50 0.36 0.03 0.6 9.97 >50 5.34 0.06 >50 1.04 4.06 41.5 0.01 0.02 1.86 0.029 17.8 0.2 0.3 0.55 0.04 15.5
U G0 3 7.8 0.13 0.04 0.2 >50 0.02 0.5 0.19 >50 1.76 >50 >50 0.06 0 0.02 0.07 0.02 1.63 2.33 0.78 0.045 0.09 >50 0.05 0.02
W ITO.3 3 0.13 0.04 2.29 0.74 0.03 1.2 12.7 9.67 7.35 >50 18.3 0.04 0 0.01 0.79 >50 0 0 >50 0.631 0.11 >50 0.09 >50
ZM 10 9 .4 0.26 0.01 >50 >50 0.04 0.71 17.1 >50 21.2 8.15 >50 0.05 7.47 0.13 13.7 >50 >50 0.012 30.3 0 0.1 >50 0.03 0.24
ZM 13 5.10 a 0.1 0.48 >50 >50 0.07 0.03 24.5 >50 >50 >50 >50 0.28 >50 >50 1.5 30 >50 >50 12.2 >50 0.98 >50 0.36 >50
ZM 19 7.7 0.07 0.53 35.7 >50 0.4 0.43 >50 >50 35.4 >50 >50 0.31 0.54 0.39 >50 >50 0.12 0.523 3.08 1.55 0.6 >50 0.61 0.18
ZM 2 14 .15 1.41 0.08 >50 >50 0.09 1.45 1.63 4.78 41.4 0.04 >50 0.13 >50 >50 0.68 1.44 >50 >50 11.5 0.701 0.7 >50 0.15 2.86
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0.35 0.35 0.26 -0.08 -0.22 -0.17 -0.22 0.00 -0.31 -0.20 -0.38 -0.43 -0.37 -0.30 -0.20 -0.32 -0.26 -0.53 -0.43 -0.38 0.00 -0.19 -0.33 -0.39 0.01 -0.07 0.00 -0.07
0.34 0.33 0.29 -0.10 -0.28 -0.07 -0.12 0.00 -0.31 -0.14 -0.28 -0.36 -0.37 -0.20 -0.09 -0.21 -0.17 -0.37 -0.31 -0.25 0.08 -0.21 -0.22 -0.25 -0.16 0.08 0.12 0.06
0.18 0.23 0.22 -0.05 -0.36 -0.24 -0.16 0.02 -0.12 -0.33 -0.44 -0.33 -0.20 -0.15 -0.05 0.02 -0.07 -0.20 -0.25 -0.25 0.00 -0.19 -0.18 -0.22 -0.38 0.10 0.12 0.12
0.16 0.08 0.50 0.25 0.02 0.04 0.07 0.31 0.32 0.15 -0.12 -0.01 -0.34 -0.17 -0.22 -0.12 -0.05 -0.17 -0.33 -0.35 -0.34 -0.22 -0.20 -0.20 0.07 -0.17 -0.10 -0.10
0.32 0.32 0.32 -0.12 -0.45 -0.30 -0.21 -0.11 -0.31 -0.24 -0.29 -0.36 -0.22 -0.24 -0.11 -0.14 -0.22 -0.30 -0.25 -0.17 0.16 -0.16 -0.22 -0.17 -0.20 -0.06 -0.04 -0.13
0.40 0.38 0.29 -0.10 -0.38 -0.25 -0.16 -0.10 -0.41 -0.21 -0.29 -0.40 -0.20 -0.17 -0.05 -0.14 -0.17 -0.27 -0.20 -0.13 0.21 -0.10 -0.15 -0.17 -0.18 -0.09 -0.05 -0.18
0.18 0.18 0.34 -0.12 -0.43 -0.14 -0.14 -0.01 -0.12 -0.14 -0.24 -0.26 -0.37 -0.22 -0.18 -0.16 -0.26 -0.27 -0.31 -0.26 -0.05 -0.34 -0.33 -0.20 -0.28 0.16 0.14 0.16
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Supplementary Figure 4A
Supplementary Figure  4A. Longitudinal heavy chain identity-divergence plots for all 12 isolated antibodies, UCA, and inferred 
intermediates I1 and I2. CAP256-VRC26.01 and CAP256-VRC26.08 are shown as black dots; all other isolated antibodies are shown 
as red Xes; UCA, I1, and I2 are shown as open red squares.
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Supplementary Figure 4B
Supplementary Figure  4B. Longitudinal light chain identity-divergence plots for all 12 isolated antibodies, UCA, and inferred 
intermediates I1 and I2. CAP256-VRC26.01 and CAP256-VRC26.08 are shown as black dots; all other isolated antibodies are shown 
as red Xes; UCA, I1, and I2 are shown as open red squares. Unlike the heavy chain plots, most of the light chain plots do not show 
distinct islands, likely because light chains do not have the added junctional diversity of a D gene and thus share greater overall 
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Supplementary Figure  5. VDJ recombination analysis for CAP256-VRC26 lineage. Nucleotide sequence and recombination 
analysis of the calculated unmutated common ancestor (UCA) of the CAP256-VRC26 lineage. a, heavy chain. b, light chain. 
Nucleotides that were excised from the germline genes by recombination are indicated by red italics. Predicted  P-insertions are in 
bold font and N-insertions are underlined. The heavy chain UCA had a complete 35 amino acid CDR H3, formed from a single D 
gene and N-insertions of 34 and 31 nucleotides in length.
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colored by week of 
antibody isolation
Supplementary Figure  6A. Full Fab structures of CAP256-VRC26 antibodies highlighting somatic hypermutation by week of 
appearance. The structures of antigen-binding fragments of CAP256-VRC26 antibodies are depicted in ribbon diagram representation 
with heavy chains in yellow and light chains in blue. Somatic hypermutations are shown in all atom representation, and colored 
according to the week post-infection from which they first appeared in isolated antibodies VRC26.01-12 (week 59, green; week 119, 
cyan; week 206, purple). Grey dashes indicate disordered regions of the CDR H3. The numbers of heavy and light chain mutations 
from the UCA are shown below the structures. See Fig. 4 for phylogenetic placement.
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Supplementary Figure 6B
Supplementary Figure  6B. Crystal packing of CAP256-VRC26 structures. Each of the VRC26 Fab crystal structures are shown 
as ribbon diagrams. Neighboring molecules which pack close to the CDR H3 are displayed as grey ribbon diagrams with transparent 
surface representations. The space group for each structure is noted. Despite the variety of space groups and packing contacts, the five 
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Supplementary Figure 7. Logograms of CDR H3 sequences extracted from the heavy chain phylogenetic tree in Fig. 3c, 
segregated by time point and subfamily. The letters in each stack represent the amino acids observed at that position, and the height 
of each letter is proportional to its frequency in the population. The cysteine residues that are part of a conserved disulfide bond are 
shown in yellow. Grey bars indicate gaps.  a, CDR H3 sequences from the branch of the tree that includes CAP256-VRC26.01. b,
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Supplementary Figure  8. HIV-1 envelope gp160 sequences amplified from CAP256 donor, shown  in highlighter format. The 
primary infecting virus (PI) is designated as master (amino acid colors indicated in key) and the V1V2 region is boxed. The 
development of the CAP256-VRC26 antibody lineage, V1V2 plasma directed neutralizing antibodies, and plasma heterologous 
neutralization, are indicated on the right. Asterisk denotes sequences amplified with strain-specific primers matching the SU virus.
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Supplementary Figure 9
CAP256.1mo.C7J CVKLTPLCVT LNCTTAK-G- -IN------S TDNANAT-KK PNEEIKNCSF NTITEVRDKQ KKEYALFYRL DLVSLNEGDS EGNSSRSGNF STYRLINC
CAP256.1mo.F7J   .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.1mo.1    .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.1mo.F1   .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.3mo.C9 .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.3mo.B3    .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.3mo.C7    .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.3mo.C4   .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.3mo.C1   .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.3mo.A5     .........X ...SD..VN- -..------A .Y.G------ XR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.5mo.14 .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.19     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.17     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP265.5mo.10 .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.23     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.21     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.13 .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.11 .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.7      .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.22     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.24    .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.16 .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.20    .......... .......-.- -..------. .......-.. .........L .......... .......... .......... .......... ........
CAP256.5mo.2      .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.12     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.9     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.6      .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.1      .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.18     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.5mo.4      .......... .......-.- -..------. .......-.. S......... .......... .......... .......... .......... ........
CAP256.5mo.15     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.1      .......... .......-.- -..------. .......-.. .......... .......... .......... .......... ....N..... ........
CAP256.6mo.9      .......... .......-.- -V.------. ......A-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.3      .......... .......-.- -.S------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.2 .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.1.JM   .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.3.JM   .......... .......-.- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.4.JM  .......... .......-D- -..------. .......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.5.JM   .......... .......-.- -..------. .......-.. .......... .......... .......... .......... ......Y... ........
CAP256.6mo.6.JM   .......... .......-.- -..------. I......-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.7.JM  .......... .......-.- -..------. ..K....-.. .......... .......... .......... .......... .......... ........
CAP256.6mo.4 .......... .......-.- -..------. .....T.-.. .......... .......... .......... .I.P..KEG- -------N.N .E......
CAP256.6mo.8      .......... .......-.- -..------. .......-.. .......... .......... .R........ .I.P..KEG- -------N.N .E...T..
CAP256.8mo.4      .......... .......-.- -..------. .....T.-.. .......... .......... .......... .......... ...Y...... ........
CAP256.8mo.5      .......... .......-.- -..------. ....Y..-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.1      .......... .......-.- -..------. I......-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.2      .......... I......-.- -..------. .....V.-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.6      .......... .......-.- -..------. .....D.-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.9      .......... .......-.- -..------. ..K....-.. .......... .......... .......... .......... K......... ........
CAP256.8mo.20    .......... .......-.- -..------. ....K..K.- .......... .......... .......... .........A .......... ........
CAP256.8mo.25    .......... .......-.- -..------. .......K.- .......... .......... .......... .......... .....K.... ........
CAP256.8mo.18 .......... .......-.- -..------. ..K....-.. .......... .......... .......... .......... ....N..... ........
CAP256.8mo.15     .......... .......-.- -..------. .......-.. .......... .......... .......... .......... ...F...... ........
CAP256.8mo.27    .......... .......D-- -..------. .......-.. .......... .......... .......... .......... ...F...... ........
CAP256.8mo.14    .......... .......-.- -..------. A......-.. .......... .......... .......... .......... ...Y...... ........
CAP256.8mo.33   .......... .......-.- -T.------. ..D....-.. .......... .......... .......... ........N. .......... ........
CAP256.8mo.32   .......... .......-.- -..------. ....D..-.. .......... .......... .......... ........N. .......... ........
CAP256.8mo.11    .......... .......-.- -..------. .......-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.13    .......... .......-.- -..------. .......-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.19   .......... .......-.- -..------. ....Y..-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.16    .......... .......-.- -..------. I......-.. .......... .......... .......... .I.P.SGEG- -------N.N .K......
CAP256.8mo.21    .......... .......-.- -..------. I......-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.22 .......... .......-.- -..------. N......-.. .......... .......... .......... .I.P.SGEG- -------N.N .K......
CAP256.8mo.23     .......... .......-.- -..------. N......-.. .......... .......... .......... .I.P.SGEG- -------N.N .K......
CAP256.8mo.29     .......... .......-.- -..------ ......D.-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.30     .......... .......-.- -..------ ........-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.8     .......... .......-.- -..------ ........-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.8mo.26     .......... .......-.- -..------ .....K..K.- .......... .......... .......... .I.P..KEG- -------N.N .E......











Supplementary Figure 9. HIV-1 envelope V1V2 sequences amplified from CAP256 donor, by week, with the primary infecting virus 
(PI) designated as master. Sequences cloned for neutralization assays are underlined. The location of key residues between 160 and 
169 is highlighted.
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CAP256.1mo.C7J CVKLTPLCVT LNCTTAK-G- -IN------S TDNANAT-KK PNEEIKNCSF NTITEVRDKQ KKEYALFYRL DLVSLNEGDS EGNSSRSGNF STYRLINC
CAP256.3mo.C9 .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.9mo.26    .......... .......-.- -..------ ....T.T.K.- .......... .......... .......... .......... ....N..... ........
CAP256.9mo.39     .......... .......-.- -..------ ...K....R.- .......... .......... .......... .......... ....N..... ........
CAP256.9mo.19 .......... .......-.- -..------ R.....V.K.- .......... .......... .......... .......... ....N..... ........
CAP256.9mo.14    .......... .......-.- -..------ .....E..K.- .......... .......... .......... .......... ...F...... ........
CAP256.9mo.6      .......... .......-.- -..------ .....E..K.- .......... .......... .......... .......... ...F...... ........
CAP256.9mo.20     .......... .......-.- -..------ .....E..K.- .......... .......... .......... .......... ...F...... ........
CAP256.9mo.8      .......... .......-.- -..------ ........K.- .......... .......... .......... .......... ...F...... ........
CAP256.9mo.21     .......... .......-.- -..------ .....S..K.- .......... .......... .......... .......... ----...... ........
CAP256.9mo.38 .......... .......-.- -..------ ...T..T.K.- .......... .......... .......... ........E. .......... ........
CAP256.9mo.10     .......... .......-.- -..------ ......T.K.- .......... .......... .......... ........N. .......... ........
CAP256.9mo.34    .......... .......-.- -..------ ......V.K.- .......... .......... .......... ........N. .......... ........
CAP256.9mo.40     .......... .......-.- -..------ ......V.K.- .......... .......... .......... .........Y .......... ........
CAP256.9mo.16 .......... .......-.- -..------ ......V.K.- .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.9mo.17   .......... .......-.- -.D------ ......V.K.- .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.9mo.43    .......... ...SD..VN- -.S------ A.Y.G------ TR........ .AT..L...I .......... .I.P..KEG- -------N.N .E......
CAP256.12mo.17 .......... .....----- -..------ .....E..-.. .......... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.10 .......... .......-.- -.DSTDN-- A.A-----T.. .......... ..T....... .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.13  .....X.... .......-.- -..STDNAN AIY.G------ TR........ .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.12   .......... ...SD..VN- -VT------ A.Y.G------ TR........ .AT..L.... .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.9    .......... ...SD..VN- --------- A.Y.G------ TR........ .AT....... .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.2   .......... ...SD.--N- -..------ A.Y.G------ TR........ .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.14    .......... ...SD..VN- --------- A.Y.G------ TR........ .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.15   .......... ...SD..VN- -.S------ A.Y.G------ TR........ .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.16   .......... ...SD..VN- -.S------ A.Y.G------ TR........ .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.18 .......... ...SD..VN- -.S------ A.Y.G------ TR........ .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.1    .......... ...SD..VN- --------- A.Y.G------ TR........ .AT..L...I R......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.11   .......... ...SD..VN- --------- A.Y.G------ TR........ .AT..L...I R......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.19   .......... ...SD..VN- --------- A.Y.G------ TR........ .AT..L...I R......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.5   .......... ...SD..VN- --------- A.Y.G------ TR........ .AT..L...I R......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.8 .......... ...SD..VN- --------- A.Y.G------ TR........ .AT..L...I R......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.5    .......... ...SD..VN- -.T------ AIH.G------ TR........ .AT....... .R........ .I.P.SGEG- -------N.N .E......
CAP256.12mo.3    .......... ...SD..GNE N-------- V.Y.G------ TR........ .AT......I R......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.4     .......... ...SD..VNE S-------- A.Y.G------ TR........ ...A...... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.10a  ........I. .......-.- -..------ .....T..-.. .......... ..T....... .......... .......... -...N..... ........
CAP256.14mo.4a ........I. ....I..-.- -..------ ..G..T..-.. .......... ..T....... .......... ........N. ....N..... ........
CAP256.14mo.6a   .......... .....IN--- --------- ...T....-.. .......... T......... .......... ........E. ....N..... ........
CAP256.14mo.11a  .......... .....----- -..------ ...T....-.. .......... .......... .......... ........E. ....N..... ........
CAP256.14mo.5a   .......... .....----- -..------ ...T....-.. .......... .......... .......... ........E. ....N..... ........
CAP256.14mo.7a   .......... .....----- -..------ ...T....-.. .......... .......... .......... ........E. ....N..... ........
CAP256.14mo.12a .......... .......-D- -..------ ......V.-.. .......... .......... .......... .I.P.SGEG- -------D.N .E......
CAP256.14mo.9a  .......... .......-D- -..------ ........-I. .T........ ..T....... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.2b   .......... .......-D- -..------ .....S..-.. .......... D......... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.5b   .......... .......-D- -..------ ........-I. .T........ ..T....... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.7b   .......... .......-D- -..------ .....I..-.. .......... ..T..L...I .......... .I.P.SGKG- -------N.N .E......
CAP256.14mo.6b  .......... .......-D- -..------ ........-I. .......... ..T....... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.13B .......... .......-D- -..------ ........-I. .......... ..T....... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.10b .......... ...SD.N--- -..------ A.Y.G------ TR........ .AT......I .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.4b  .......... ...SD.N--- --------- A.Y.G------ TR........ .AT....... .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.2a .......... ...SDVN--- -..------ A.Y.G------ TR........ .ATS.L...E .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.1a  .......... ...SD.N--- -..------ A.Y.G------ TR........ SAT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.8b  .......... ...SD.NV-- --.------ A.Y.G------ TR........ .......... .E........ .I.P.SGEG- -------N.N .E......
15
week









CAP256.1mo.C7J CVKLTPLCVT LNCTTAK-G- -IN------S TDNANAT-KK PNEEIKNCSF NTITEVRDKQ KKEYALFYRL DLVSLNEGDS EGNSSRSGNF STYRLINC
CAP256.3mo.C9 .......... ...SD..VN- -..------A .Y.G------ TR........ .AT..L...K .......... .I.P..KEG- -------N.N .E......
CAP256.21mo.D12   .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.A11b  .......... .....IN-ST T..------ ...T....-I. .......... .IT......I .......... .......... -...N..... .E......
CAP256.21mo.A3 .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .....T.... -...N..... .E......
CAP256.21mo.A6    .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .....T.... -...N..... .E......
CAP256.21mo.A1   .......... .....IN-ST T..------ ........-I. .D........ ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.F1    .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.C4   .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.B2   .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.E12   .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.B10  .......... .....IN-ST T..------ ........-I. .......... ..T..LK..I .......... .......... -...N..... .E......
CAP256.21mo.F4 .......... ...SD.N--- --------- T.Y.G------ TR..T..... .AT...K..I .......... .I.P.SGEG- -------N-N .E......
CAP256.21mo.C1   .......... ...SD.N--- --------- T.Y.G------ TR..T..... .AT...K..I .......... .I.P.SGEG- -------N-N .E......
CAP256.21mo.D6  .......... ...SD.N--- -.T------ VAY.G------ TR........ .AT...K..I .......... .I.P.SGEG- -------N-N .E......
CAP256.21mo.C2   .......... ...SD.N--- --------- T.Y.G------ TR..T..... .AT...K..I .......... .I.P.SGEG- -------N-N .E......
CAP256.21mo.A1  .......... ...SD.N--- --------- T.Y.G------ TR..T..... .AT...K... .......... .I.P.SGEG- -------K.N .E......
CAP256.21mo.A11   .......... .......-D- -..------ ......V.--- T......... .......... .N........ .......... ....---S.. R.......
CAP256.39mo.C2 .......... .......-D- -..------ ....V.V.--- T......... ......S... .N......K. .......... ....---S.. R.......
CAP256.39mo.B1   .......... .......-D- -..------ ....V.V.--- T......... ......S... .N......K. .......... ....---S.. R.......
CAP256.39mo.E1 .......... .......-D- -T.------ ...K..V.--- T......... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.H1 .......... .......-D- -..------ ...HV.V.--- T......... ......S... .N........ .......... D...---S.. .M......
CAP256.39mo.F10 .......... .......-D- -S.------ ...H..V.--- T......... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.6     .......... .......-D- -N.------ ...H..V.--- T......... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.8     .......... .......-D- -T.------ ...H..V.--- T......... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.12   .......... .......-D- -..------ G..H..V.--- T......... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.13   .......... .......-D- -..------ ..G...V.--- T......... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.17   .......... .......-D- -..------ ......V.--- T......... ......S... .N........ .......... D...---S.. .M......
CAP256.39mo.18   .......... .......-D- -..------ ..N...V.--- T......... ......S... .N........ .......... D...---S.. .M......
CAP256.39mo.20  .......... .......-D- --.------ ...H..V.--- TK........ ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.F1 .......... ....HIN-ST T..------ ...TV...YNG AR........ .AT......E .......... .......... -...NS.... ........
CAP256.39mo.4 .......... ....HIN-ST T..------ ...TV...YNG AR........ .AT......E .......... .......... -...N..... .E......
CAP256.39mo.22   .......... ...SDV.--- -..------ V.Y.G------ TK...R.... .AT......E .......... .......... -...NS.... .E......
CAP256.39mo.10 .......... ...SEV.--- -..------ V.Y.G------ TK...R.... .ATS.L...E .......... .......... -...NS.... .E......
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Supplementary Figure 10.  Sequences of individual Env clones tested in Figure 5d. a, HIV-1 envelope clones by week, from 6 to 
176 weeks post infection, with the amino acid sequence of the V1V2 region shown. b, Neutralization (IC50 values) by each of the 12 
CAP256-VRC26 mAbs tested against Env clones. The CAP256 mAbs are colored to indicate the time point when the sequences were 
first detected by next generation sequencing (as in Fig 3).
Weeks p.i. Clone name V2 sequence
6wk (PI)   CAP256.1mo.C7J CSF NTITEVRDKQ KKEYALFYRL DLVSLNEGDS EGNSSRSGNF STYRLINCb
15wk CAP256.3mo.C9 ... .AT..L...K .......... .I.P..KEG- -------N.N .E......b
CAP256.5mo.14 ... .......... .......... .......... .......... ........
CAP265.5mo.10 ... .......... .......... .......... .......... ........
CAP256.5mo.13 ... .......... .......... .......... .......... ........
CAP256.5mo.11 ... .......... .......... .......... .......... ........
CAP256.5mo.16 ... .......... .......... .......... .......... ........b
CAP256.6mo.2 ... .......... .......... .......... .......... ........
CAP256.6mo.4 ... .......... .......... .I.P..KEG- -------N.N .E......b
CAP256.8mo.18 ... .......... .......... .......... ....N..... ........
CAP256.8mo.22 ... .......... .......... .I.P.SGEG- -------N.N .K......
CAP256.8mo.31 ... .AT..L...I .......... .I.P..KEG- -------N.N .E......b
CAP256.9mo.19 ... .......... .......... .......... ....N..... ........
CAP256.9mo.38 ... .......... .......... ........E. .......... ........
CAP256.9mo.16 ... .......... .......... .I.P.SGEG- -------N.N .E......b
CAP256.12mo.17 ... .......... .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.10 ... ..T....... .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.18 ... .AT..L...I .......... .I.P.SGEG- -------N.N .E......
CAP256.12mo.8 ... .AT..L...I R......... .I.P.SGEG- -------N.N .E......b
CAP256.14mo.4a ... ..T....... .......... ........N. ....N..... ........
CAP256.14mo.10b ... .AT......I .......... .I.P.SGEG- -------N.N .E......
CAP256.14mo.2a ... .ATS.L...E .......... .I.P.SGEG- -------N.N .E......b
CAP256.21mo.A3 ... ..T..LK..I .......... .....T.... -...N..... .E......
CAP256.21mo.F4 ... .AT...K..I .......... .I.P.SGEG- -------N-N .E......b
CAP256.39mo.C2 ... ......S... .N......K. .......... ....---S.. R.......
CAP256.39mo.E1 ... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.H1 ... ......S... .N........ .......... D...---S.. .M......
CAP256.39mo.F10  ... ......S... .N........ .......... ....---S.. R.......
CAP256.39mo.F1    ... .AT......E .......... .......... -...NS.... ........
CAP256.39mo.4      ... .AT......E .......... .......... -...N..... .E......
CAP256.39mo.10    ... .ATS.L...E .......... .......... -...NS.... .E......
CAP256.39mo.11    ... .AT......E .......... .......... -...NS.... .E......
94wk     
176wk    
59wk     
23wk     
30wk     
34wk     
38wk     
48wk     
>50 >50 >50 >50 >50 0.030 >50 >50 >50 >50 >50 >50
b b b b b b b b b b b b
0.042 0.008 0.003 0.005 0.009 0.063 0.008 0.004 0.003 0.011 0.014 0.010
b b b b b b b b b b b b
>50 >50 >50 >50 >50 0.11 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 0.094 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 0.086 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 0.059 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 0.12 >50 >50 >50 >50 >50 >50
b b b b b b b b b b b b
>50 >50 >50 >50 >50 0.006 >50 15.1 17.8 >50 11.3 28.1
>50 19.6 8.1 20.9 >50 0.020 8.1 9.1 8.5 >50 >50 6.5
b b b b b b b b b b b b
>50 >50 >50 >50 >50 0.020 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 0.020 >50 >50 >50 0.060 >50 >50
>50 0.049 0.020 0.69 0.10 0.20 1.0 0.050 0.030 0.080 0.040 >50
b b b b b b b b b b b b
>50 >50 >50 >50 >50 0.18 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 0.19 >50 >50 >50 >50 >50 >50
>50 >50 20.3 >50 >50 0.60 >50 >50 >50 >50 24.0 5.1
b b b b b b b b b b b b
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 0.20 0.079 0.38 0.65 >50 12.5 0.04 0.074 0.23 0.27 >50
>50 0.60 0.11 0.52 0.95 1.1 7.0 0.05 0.03 0.38 0.24 >50
>50 0.15 <0.02 0.030 0.18 0.25 0.49 0.040 <0.02 0.14 0.49 >50
b b b b b b b b b b b b
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 0.35 0.19 0.26 0.72 0.20 5.4 0.050 0.039 0.27 0.54 >50
>50 0.32 0.89 1.6 0.31 8.9 >50 0.95 0.72 0.32 1.7 >50
b b b b b b b b b b b b
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
b b b b b b b b b b b b
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
>50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50
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Supplementary Figure 11. CAP256-VRC26 UCA does not bind to PI Env. CAP256-VRC26 UCA and the early antibody CAP256-
VRC26.01 bind to cell-surface expressed Env from the superinfecting virus (SU) but not the primary infecting virus (PI).  Assay 
performed as in Figure 6. Assay shown is representative of 3 independent experiments. MFI, median fluorescence intensity.
Supplementary  Figure 11
μg/mlμg/ml
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Viable CD27+ B 
cells recovered*
Est. CD27+ B 
cells analyzed*
VRC-26 paired    
HC reads
250bp reads post-QF 
(R1+R2)
wk34 FR1** 12 m / 8 m 60% 30k 13 k 0 5,558,841
LP** same as above above above 13 k 0 6,174,263
wk48 FR1 2.9 m / 12.2 m 19% 9 k 8.1 k 17762 2,233,614
wk59 FR1 6.7 m / 5.9 m 53% 4.5 k 4 k 14 5,623,331
wk69 FR1 6.2 m / 5.0 m 55% 31 k 28 k 158 2,486,745
wk119 FR1 5.1 m / 0.5 m 89% 50 k 23 k 735 5,523,921
LP same as above above above 23 k 18 4,259,354
*CD27+ hemocytometer estimates
** Primers shown in Supplementary Table 5
Supplementary Table 1. Statistics for heavy-light chain paired deep sequencing.
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Supplementary Table 2. Crystallographic data collection and refinement statistics
Values in parentheses are for highest-resolution shell
VRC26.UCA VRC26.01 VRC26.03 VRC26.04 VRC26.06 VRC26.07 VRC26.10
Data collection
Space group C2 C2 C2 P1 R32:H I222 P212121
Cell constants  


















90.0, 90.0, 90.0 90,0, 90.0, 90.0
















Rmerge 11 (37) 8 (54) 15(44) 14(39) 13(54) 13(51) 13(46)
I / sI 5.9 (1.8) 16.3 (2.1) 6.9(1.8) 5.8(1.8) 16.6(2.1) 12.5(1.7) 8.4(2.5)
Completeness (%) 85.7 (82.8) 100 (99.8) 88.4 (51.1) 95.9 (79.6) 98.8 (88.5) 93.9 (53.0) 65.2 (50)
Redundancy 2.3 (2.2) 3.7 (3.2) 2.9(1.7) 1.9(1.8) 10.0(5.0) 6.5(3.9) 4.1(3.9)

















Unique reflections 7,500 (660) 48,060 (3,241) 13,071(641) 36,806(2,685) 16,997(1,487) 19,901(1,816) 24,684(2,029)
Rwork / Rfree (%) 21.1/24.6 18/19.9 20.3/24.5 25.6/28.5 19.3/23.3 22.1/24.5 21.0, 24.1
No. atoms
Protein 3249 3324 3447 13,508 3477 3361 3323
Water 17 197 47 0 0 17 267
B-factors (Å2)
Protein 55.0 33.3 47.8 51.3 66.3 36.2 22.2
Water 27.5 43.7 39 na na 33.2 25.1
R.m.s. deviations
Bond lengths (Å) 0.004 0.008 0.003 0.009 0.003 0.005 0.005
Bond angles (°) .885 1.22 0.82 1.15 0.79 1.01 .96
Ramachandran
Most favored regions (%) 90.2 98.2 92.0 91.0 96.0 92.5 96.5
Additional allowed regions (%) 9.4 1.8 7.8 8.4 3.8 7.5 3.3
Disallowed regions (%) 0.6 0.0 0.2 0.6 0.2 0.0 0.2
SUPPLEMENTARY INFORMATION
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Supplementary Table 3.  Signals of selective pressure within in the V2 epitope (residues 160-171) of primary infecting 
(PI)-like and superinfecting (SU)-like viruses. Signals of selective pressure were detected  at each site using MEME ( to 
detect episodic diversifying selection, with p values >0.05 considered significant) and DEPS (directional selection; 
maximum Bayes Factor >20 considered significant, with the preferred amino acid selected for indicated in parentheses).
HXB2 position Analysis* † Output PI SU
160
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
161
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
162
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
163
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
164
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
165
Directional (DEPS) Max BF (Preferred residues) ns 191 (V)
Diversifying (MEME) P value ns ns
166
Directional (DEPS) Max BF (Preferred residues) 3403 (S) ns
Diversifying (MEME) P value ns ns
167
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
168
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
169
Directional (DEPS) Max BF (Preferred residues) ns 77095 (IQ)
Diversifying (MEME) P value ns 0.0001
170
Directional (DEPS) Max BF ns ns
Diversifying (MEME) P value ns ns
171
Directional (DEPS) Max BF (Preferred residues) 290 (K) ns
Diversifying (MEME) P value ns ns
*DEPS ns = <20; †MEME ns = >0.05; BF = Bayes Factor
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For all timepoints except week 176
Heavy Chain: VH3 only 5' pool
XLR-A_VH3 LEADER-A CCATCTCATCCCTGCGTGTCTCCGACTCAG TAAAAGGTGTCCAGTGT
XLR-A_VH3 LEADER-B CCATCTCATCCCTGCGTGTCTCCGACTCAG TAAGAGGTGTCCAGTGT
XLR-A_VH3 LEADER-C CCATCTCATCCCTGCGTGTCTCCGACTCAG TAGAAGGTGTCCAGTGT
XLR-A_VH3 LEADER-D CCATCTCATCCCTGCGTGTCTCCGACTCAG GCTATTTTTAAAGGTGTCCAGTGT
XLR-A_VH3 LEADER-E CCATCTCATCCCTGCGTGTCTCCGACTCAG TACAAGGTGTCCAGTGT
XLR-A_VH3 LEADER-F CCATCTCATCCCTGCGTGTCTCCGACTCAG TTAAAGCTGTCCAGTGT
3' pool
XLR-B_3xwCgammaCH1-2 CCTATCCCCTGTGTGCCTTGGCAGTCTCAG GG GGA AGA CCG ATG GGC CCT TGG T
XLR-B_3CmuCH1 CCTATCCCCTGTGTGCCTTGGCAGTCTCAG GGGAATTCTCACAGGAGACGA













Used for week 176 sample only













XLR-B_3xwCgammaCH1 CCTATCCCCTGTGTGCCTTGGCAGTCTCAG GGGGAAGACCGATGGGCCCTTGGTGG 
XLR-B_3CmuCH1 CCTATCCCCTGTGTGCCTTGGCAGTCTCAG GGGAATTCTCACAGGAGACGA


















Supplementary Table  4. PCR Primers used to prepare amplicon for 454 pyrosequencing.
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ABSTRACT
The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable templates for vaccine design, and
studies of the immunological development of these antibodies are providing insights for vaccination strategies. In addi-
tion, the most potent and broadly reactive of these bNAbs have potential for clinical use. We previously described a family
of 12 V1V2-directed neutralizing antibodies, CAP256-VRC26, isolated from an HIV-1 clade C-infected donor at years 1, 2,
and 4 of infection (N. A. Doria-Rose et al., Nature 509:55–62, 2014, http://dx.doi.org/10.1038/nature13036). Here, we re-
port on the isolation and characterization of new members of the family mostly obtained at time points of peak serum neu-
tralization breadth and potency. Thirteen antibodies were isolated from B cell culture, and eight were isolated using trim-
eric envelope probes for differential single B cell sorting. One of the new antibodies displayed a 10-fold greater
neutralization potency than previously published lineage members. This antibody, CAP256-VRC26.25, neutralized 57% of
diverse clade viral isolates and 70% of clade C isolates with remarkable potency. Among the viruses neutralized, the me-
dian 50% inhibitory concentration was 0.001 g/ml. All 33 lineage members targeted a quaternary epitope focused on V2.
While all known bNAbs targeting the V1V2 region interact with the N160 glycan, the CAP256-VRC26 antibodies showed
an inverse correlation of neutralization potency with dependence on this glycan. Overall, our results highlight the ongoing
evolution within a single antibody lineage and describe more potent and broadly neutralizing members with potential clin-
ical utility, particularly in areas where clade C is prevalent.
IMPORTANCE
Studies of HIV-1 broadly neutralizing antibodies (bNAbs) provide valuable information for vaccine design, and the most potent
and broadly reactive of these bNAbs have potential for clinical use. We previously described a family of V1V2-directed neutraliz-
ing antibodies from an HIV-1 clade C-infected donor. Here, we report on the isolation and characterization of newmembers of
the family mostly obtained at time points of peak serum neutralization breadth and potency. One of the new antibodies,
CAP256-VRC26.25, displayed a 10-fold greater neutralization potency than previously described lineage members. It neutralized
57% of diverse clade viral isolates and 70% of clade C isolates with remarkable potency: the median 50% inhibitory concentra-
tion was 0.001g/ml. Our results highlight the ongoing evolution within a single antibody lineage and describe more potent and
broadly neutralizing members with potential clinical utility, particularly in areas where clade C is prevalent.
Neutralizing antibodies (NAbs) against HIV-1 are likely to be amajor component of an effective vaccine-induced immune
response. Cross-reactive NAbs commonly arise during HIV-1 in-
fection, though only a small subset of infected patients produces
NAbs with a high neutralization breadth and potency (1–4). In
contrast, the HIV-1 envelope glycoprotein (Env) vaccine im-
munogens tested to date have failed to elicit cross-reactive neu-
tralizing antibodies (5, 6). Thus, studying the development of
broadly neutralizing antibodies (bNAbs) in infected individuals
may provide important lessons for vaccine design (5, 7–10). In
addition, the isolation of bNAbs from selected donors has greatly
aided our understanding of the HIV-1 Env structure (11–13) and
vulnerability to neutralizing antibodies (14–16), and such anti-
bodies have the potential to be used for the prevention or treat-
ment of HIV-1 infection (8, 17).
NAbs directed to the V1V2 region of HIV-1 Env are of partic-
ular interest for vaccine design, as this site is antigenic and com-
monly targeted in HIV infection (18, 19). To date, families of
V1V2-directed bNAbs have been isolated from only four different
donors (20–23). These antibodies typically have a long, anionic
heavy chain complementarity-determining region 3 (CDRH3),
which penetrates the glycan shield, and heavy chain variable (VH)
gene mutation levels of 10 to 20%. They bind to the apex region of
the intact trimer and bind poorly or not at all to most monomeric
forms of the protein. Negative-stain electron microscopy studies
show that such antibodies bind with a stoichiometry of one per
trimer and likely interact with more than one protomer (21, 24),
consistent with the location of V1V2 at the apex of the trimer (11,
12). This category of antibodies typically relies on glycan residues,
specifically, N156 and N160 in V2 (23). Glycan dependence some-
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times results in incomplete neutralization, referred to as the pla-
teau effect (23, 25, 26), due in part to the microheterogeneity of
glycoforms at these residues, resulting in a resistant subpopula-
tion within a virus preparation (27).
Our group has extensively studied the antibodies from donor
CAP256, who developed high-titer plasma neutralizing antibodies
to the V1V2 region that first appeared at 1 year and peaked at 3
years of HIV-1 infection (21, 28, 29). This donor was infected with
a clade C virus and 15 weeks later was superinfected with a differ-
ent clade C virus. We isolated 12 V1V2-directed antibodies at
multiple time points over 4 years of infection; all were somatically
related and termed the CAP256-VRC26 lineage, where CAP256
denotes the donor and VRC26 denotes the antibody lineage.
Members of this antibody lineage have a very long CDRH3 of 35 to
37 amino acids and modest levels of V-gene mutation (8 to 15%
sequence divergence compared with that of the germ line). 454
pyrosequencing of virus from early time points showed that the
long CDRH3 was present at the origin of the lineage and allowed
accurate inference of an unmutated common ancestor (UCA) that
was able to bind and neutralize the superinfecting virus (21).
Here, we report on the isolation and characterization of 21 new
members of the CAP256-VRC26 family. These antibodies were
isolated either by B cell culture or by single-cell sorting with trim-
eric Env probes. One of the antibodies, CAP256-VRC26.25
(where the antibody name indicates donor-lineage.clone), neu-
tralizes 57% of HIV-1 isolates, including 70% of clade C isolates,
with an overall 10-fold greater potency than the previously de-
scribed family members. Structure, epitope mapping, and phylo-
genetic analyses provide a deeper understanding of the origin and
evolution of this important lineage.
MATERIALS AND METHODS
Study subject. Centre for the AIDS Programme of Research in South
Africa (CAPRISA) participant CAP256 was enrolled into the CAPRISA
Acute Infection Study (30) that was established in 2004 in KwaZulu-Na-
tal, South Africa, for follow-up and subsequent identification of HIV se-
roconversion. CAP256 was one of the seven women in this cohort who
developed neutralization breadth (31). The CAPRISA 002 Acute Infection
Study was reviewed and approved by the research ethics committees of the
University of KwaZulu-Natal (E013/04), the University of Cape Town
(025/2004), and the University of the Witwatersrand (MM040202).
CAP256 provided written informed consent for study participation. Sam-
ples were drawn between 2005 and 2009.
B cell cultures. Peripheral blood mononuclear cells (PBMCs) isolated
from CAP256 blood draws at week 193 were stained with LIVE/DEAD
Fixable Aqua (Invitrogen), CD19-Cy7-phycoerythrin (PE), IgM-Cy5-PE,
IgD-PE, CD16-Pacific Blue, and CD3-Cy7-allophycocyanin (APC) (BD
Pharmingen). The IgD-negative (IgD) IgM-negative (IgM) B cells
were bulk sorted on a BD FACSAria II flow cytometer as described previ-
ously (19). Cells were plated at 2 B cells per well in 384-well plates and
cultured for 14 days in the presence of CD40L-expressing irradiated
feeder cells, interleukin-2 (IL-2) (Roche), and interleukin-21 (IL-21)
(Gibco), as described previously (32, 33). Culture supernatants were
screened by microneutralization against HIV-1 ZM53.12 and CAP210.E8
Env pseudoviruses as described in reference 34.
Expression and purification of trimeric HIV-1 Env BG505 SOSIP.
664 probes. An Avi tag (GLNDIFEAQKIEWHE) was inserted at the C
terminus of the previously described construct BG505 SOSIP.664.T332N
gp140, referred to here as BG505 SOSIP (35). For BG505 SOSIP.K169E-
Avi, lysine (K) 169 was mutated to a glutamic acid (E) by site-directed
mutagenesis. Both constructs were transfected and purified as described
previously (12). Briefly, HEK 293 cells were cotransfected with BG505
SOSIP and furin plasmid DNAs at a 4:1 ratio. Transfection supernatants
were harvested and purified through either a VRC01 or a 2G12 antibody
affinity column. Proteins were eluted with 3 M MgCl2, 10 mM Tris, pH
8.0. The eluate was concentrated and applied to a Superdex 200 column
equilibrated in 5 mM HEPES, pH 7.5, 150 mM NaCl, 0.02% azide or
phosphate-buffered saline. The fractions corresponding to the trimeric
proteins were pooled, concentrated, flash-frozen in liquid nitrogen, and
stored at 80°C. The proteins were biotinylated at the Avi tag sequence
using BirA ligase and then conjugated to streptavidin-APC or streptavi-
din-PE (Invitrogen) as described previously (36).
The probes were assessed for the correct antigenicity by binding to
antibody-coated beads. Anti-mouse kappa light chain beads (Becton
Dickinson, San Jose, CA) were incubated with anti-human IgG (Becton
Dickinson), washed, incubated with 2 g/ml antibody CAP256-
VRC26.09, PGT128, or F105, and washed again. BG505 SOSIP-streptavi-
din-APC or BG505 SOSIP.K169E-streptavidin-PE (1.5 g) was then in-
cubated with the beads, and the beads were washed and analyzed on an
LSR II flow cytometer (Becton Dickinson).
Cell sorting. PBMCs from week 159 were stained for IgG-positive
(IgG) B cells using LIVE/DEAD Fixable Aqua (Invitrogen), IgG-fluores-
cein isothiocyanate, CD19-Cy7-PE, IgM-Cy5-PE, CD14-PE-Texas Red
(ECD), CD4-ECD, CD3-Cy7-APC, and CD8-Brilliant Violet 711 (BD
Pharmingen). At the same time, they were stained with BG505 SOSIP-
streptavidin-APC and BG505 SOSIP.K169E-streptavidin-PE. Cells that
were BG505 SOSIP-streptavidin-APC positive (APC) IgG CD19
were sorted using a BD FACSAria II flow cytometer into single wells of a
96-well plate containing RNase inhibitor (New England Biolabs), Super-
Script reverse transcriptase buffer (Invitrogen), dithiothreitol, and Igepal
as described previously (36).
Isolation and expression of CAP256-VRC26 family genes. Kappa
and lambda light chain gene and IgG heavy chain gene variable regions
were amplified from neutralization-positive B cell culture wells as de-
scribed in reference 33 or from 96-well sort plates as described in reference
36. Briefly, cells were lysed and subjected to reverse transcription-PCR
(RT-PCR) as described in reference 37 using a modified primer set (see
Table S1 in the supplemental material). These primers were developed by
our group or were described previously (see Table S1 in the supplemental
material) (37–39). Briefly, cells were lysed and subjected to RT-PCR as
described previously (37) using a modified primer and a round of nested
PCR with 3 different multiplex primer pools, which were used to amplify
either the heavy chains or the light chains. The amplicons were subcloned,
expressed, and purified as described in reference 19. For antibodies
CAP256-VRC26.13 to CAP256-VRC26.21, wells that previously yielded
VRC26-lineage lambda chains but no heavy chains were subjected to RT-
PCR using IgA-specific 3= primers. All heavy chains were subcloned and
expressed as IgG1 regardless of the class of the original amplicon.
Neutralization assays. Single-round-of-replication Env pseudovi-
ruses were prepared, titers were determined, and the pseudoviruses were
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used to infect TZM-bl target cells as described previously (40, 41). The
neutralization breadth of CAP256-VRC26.25, CAP256-VRC26.26, and
CAP256-VRC26.27, as well as that of previously described antibodies, was
determined using a previously described panel (19, 36) of up to 200 geo-
graphically and genetically diverse Env pseudoviruses representing the
major subtypes and circulating recombinant forms. The remaining
CAP256-VRC26 antibodies were assayed on a 46-virus subset of this
panel, along with the autologous virus strains CAP256.2.00.C7J (a pri-
mary infecting [PI] strain) and CAP256.206.c9 (a superinfecting [SU]
strain). The data were calculated as a reduction in the number of lumi-
nescence units compared with the number for the control wells and are
reported as the 50% inhibitory concentration (IC50; in micrograms per
microliter) for monoclonal antibodies (MAbs).
N160 glycan mutant Env pseudoviruses were generated by site-di-
rected mutagenesis as described previously (28, 42). All N160 glycan mu-
tants had the N160K mutation, except for ConC, which had the N160A
mutation. The N156 mutants (this study) were generated as N156A mu-
tants by site-directed mutagenesis (GeneImmune, New York, NY). The
BG505 pseudovirus had the wild-type sequence (threonine) at position
332, unlike the BG505 SOSIP probe, which bears a T332N mutation (35).
Neutralization and autoreactivity data for CAP256-VRC26.25 were
generated with a variant that had the amino acid change K126Q in the
light chain, which was inserted during subcloning. We confirmed that this
single amino acid change did not alter the neutralization data.
Autoreactivity. CAP256-VRC26.01 to CAP256-VRC26.32 and UCA
antibodies were assayed at 25 and 50g ml1 for autoreactivity to HEp-2
cells (Inverness Medical Professional Diagnostics) by indirect immuno-
fluorescence and for binding to cardiolipin as described previously using
a Quanta Lite ACA IgG III assay (INOVA Diagnostics Inc., San Diego,
CA) (43). The UCA and seven of the antibodies with the broadest activity
were further evaluated on a panel of autoantigens using an AtheNA Multi-
Lyte ANA-II Plus test system (Alere, Orlando, FL) to detect semiquanti-
tatively IgG antibodies to 9 separate analytes, SSA, SSB, Sm, RNP, Scl-70,
Jo-1, centromere B, double-stranded DNA (dsDNA), and histone, as re-
ported previously (43); values of 120 at 25 g ml1 were considered
positive (43).
Next-generation sequencing analysis. 454 pyrosequencing was per-
formed on PBMCs from week 34, the results for which are reported here,
as well as PBMCs from weeks 38, 49, 59, 119, 176, and 206, the results for
which were described previously (21). mRNA was prepared from 10 mil-
lion to 15 million PBMCs as follows: cells were lysed in 600l buffer RLT
(Qiagen) per 10 million PBMCs and run over a QIAshredder (Qiagen).
The flowthrough was applied to the DNA column from an Allprep kit
(Qiagen), and that flowthrough was used for subsequent purification us-
ing an Oligotex kit (Qiagen). cDNA was synthesized using SuperScript II
reverse transcriptase (Invitrogen) and oligo(dT)12–18 primers with incu-
bation at 70°C for 1 min, chilling on ice, and then synthesis at 42°C for 2 h.
Individual PCRs were performed with Phusion polymerase (Thermo) for
30 cycles. Primers (21) consisted of pools of 5 to 7 oligonucleotides spe-
cific for all lambda chain gene families or for VH3 family genes and had
adapters for 454 next-generation sequencing. For PBMCs from week 176
only, heavy chain PCR was performed with primers for all VH families
and mixed lambda chain and kappa chain primers were used for the light
chain (21). PCR products were gel purified (Qiagen). Pyrosequencing of
the PCR products was performed on a GSFLX sequencing instrument
(Roche-454 Life Sciences, Bradford, CT, USA) on a half chip per reaction
(full chips were used for PBMCs from week 176). On average,250,000
raw reads were produced.
Next-generation sequencing data from each time point were pro-
cessed through an Antibodyomics pipeline (https://github.com/scharch
/SONAR) as previously described (21, 44). Briefly, a series of Python
scripts was used to check transcripts for appropriate length (300 to 600
nucleotides), provide calls for germ line V and J gene assignments by
BLAST analysis, and check for in-frame junctions and open reading
frames. Reads for which the V and J genes were successfully assigned and
that had an in-frame junction and no stop codons were clustered using
the CDHit program (45) at 97.25% identity, and singletons were dis-
carded. In order to better account for possible errors introduced dur-
ing sequencing, we restricted our analysis to sequences appearing at
least twice in any one data set. This resulted in approximately 50%
fewer final heavy chain sequences than we previously reported, but the
phylogenetic structure of the lineage remained the same. In addition,
we used a CDRH3 signature contained in all previously reported se-
quences as a less computationally intensive way of finding related
heavy chain sequences. Thus, heavy chain sequences that matched the
CAP256-VRC26 VH and JH assignments and that had CDRH3s that
were at least 30 amino acids long and that had a YY motif were selected
and combined across all time points. Light chains that matched the
CAP256-VRC26 VL and JL assignments and that had a light chain
complementarity-determining region 3 (CDRL3) with at least 92%
sequence identity to a known CAP256-VRC26 family member were
manually inspected, and those with a recombination pattern matching
that of the known antibodies were combined across all time points.
Selected heavy and light chains from all time points were reclustered so
that sequences observed at multiple time points are represented only
once in the final data set. A final manual inspection was used to remove
sequences with apparent PCR crossover or homopolymer indel errors.
Heavy and light chain trees were built using the FASTML program
(46), and the light chain tree was manually edited to match the heavy
chain arrangement as previously described (21). Ancestral sequences were
inferred from these trees using the DNAML program (47) as previously
described (21).
CAP256-VRC26.25 Fab crystallization and structure determina-
tion. Fab was prepared by inserting an HRV3C recognition site (GLEVL
FQGP) after Lys 235. Purified IgG was incubated with HRV3C protease
overnight at 4°C, and the digested protein was passed over protein A
agarose to remove the Fc fragment and subsequently purified over a Su-
perdex 200 gel filtration column. The Fab preparation was then screened
against 576 crystallization conditions using a Mosquito crystallization ro-
bot. Initial crystals were grown by the vapor diffusion method in sitting
drops at 20°C by mixing 0.1l of protein with 0.1l of reservoir solution.
Crystals were manually reproduced in hanging drops by mixing 1.0 l
protein complex with 1.0 l reservoir solution. Crystals grown in a reser-
voir solution of 23% polyethylene glycol (PEG) 8000 and 0.1 M HEPES,
pH 7.5, were flash frozen in liquid nitrogen with 20% PEG 400 as a cryo-
protectant. Diffraction data were collected at a wavelength of 1.00 Å at the
SER-CAT beamline ID-22 (Advanced Photon Source, Argonne National
Laboratory). All diffraction data were processed with the HKL2000 suite
(48), and model building and refinement were performed in the COOT
(49) and PHENIX (50) programs, respectively. Ribbon diagram represen-
tations of protein crystal structures were made with the PyMOL program
(51), and electrostatics were calculated and rendered with the UCSF Chi-
mera program (52). Data collection and refinement statistics are shown in
Table S2 in the supplemental material.
Amino acid frequency analysis. The resistance score for a given
amino acid (or a gap) was defined as the ratio of its number of occurrences
in sequences from resistant strains to its overall number of occurrences for
the given residue position (53). A higher score indicates that the amino
acid was preferentially found among sequences from resistant strains,
with a score of 1 indicating that the amino acid was found only among
sequences from resistant strains. Associations were analyzed using Fish-
er’s exact test with the Bonferroni correction for multiple comparisons.
Alignments were generated using the MUSCLE algorithm implemented
in Geneious software, version 8.1.7 (54). Logo plots were generated with
the Weblogo application (http://weblogo.berkeley.edu/) (55) and manu-
ally colored by the use of Inkscape software (https://inkscape.org).
Accession numbers. Sequences from this study are available in
GenBank under the following accession numbers: for the heavy and light
chain sequences for CAP256-VRC26.13 to CAP256-VRC26.33, GenBank
accession numbers KT371076 to KT371117; for 454 pyrosequencing data
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sets from CAP256 at week 34, Sequence Read Archive accession numbers
SRR2126754 and SRR2126755; and for pyrosequencing data sets of bioin-
formatically identified lineage members from week 34, GenBank acces-
sion numbers KT371118 to KT371320. Coordinates and structure factors
for CAP256-VRC26.25 have been deposited with the Protein Data Bank
(PDB) under accession number 5DT1.
RESULTS
Isolation of new antibodies. To further understand the
CAP256-VRC26 lineage and in an attempt to find broader and
more potent members, we isolated antibodies from time points
of peak serum neutralization potency and breadth (Fig. 1A).
We used several methods to isolate an additional 21 antibodies.
These included repeated PCR amplifications with cDNA from
wells from the original B cell cultures, using the new primers
described below; a B cell culture of PBMCs from week 193 (Fig.
1B); and single-cell sorting with antigen-specific probes (Fig.
1C), using a PBMC sample from week 159 (at the peak of neu-
tralization breadth in plasma [28, 29]). The recovered antibod-
ies are named as follows: donor-lineage.clone, for example,
CAP256-VRC26.25. For brevity, in some figures we refer to
them as donor.clone, for example, CAP256.25.
(i) B cell cultures.The B cell culture method used here involves
sorting of IgM IgD B cells, followed by culture for 2 weeks and
then microneutralization assays of culture supernatants (32, 34)
(Fig. 1B). Previous B cell cultures from donor CAP256 (21)
yielded multiple wells from which VRC26-lineage lambda chains,
but not IgG heavy chains, were recovered. We used IgA-specific 3=
primers (39) with new sets of multiplex 5= primers (see Materials
and Methods and Table S1 in the supplemental material) and
recovered nine VRC26-lineage heavy chains from these wells.
Some of these may have derived from IgA B cells, as IgA B cells
were not excluded in the sorting. Unexpectedly, two wells yielded
both IgG and IgA amplicons with identical variable regions but
distinct constant regions (Fig. 2A). We concluded that class
switching had occurred in the well during the 2-week culture. The
combination of CD40L and IL-21 was previously shown to sup-
port IgG-to-IgA class switching in human B cells (56–58). We
therefore made the assumption that all such wells originally con-
tained IgG B cells. All antibody sequences were subcloned and
expressed as IgG1. This strategy yielded 9 antibodies (CAP256-
VRC26.13 to CAP256-VRC26.21) derived from the PBMCs from
weeks 119 and 206. We subsequently performed a B cell culture
with B cells derived from week 193 and, using the new primer sets
described in the Materials and Methods and Table S1 in the sup-
plemental material, recovered four additional antibodies
(CAP256-VRC26.22 to CAP256-VRC26.25).
(ii) Single-cell sort with trimer probes. The recent develop-
ment of the trimer mimic BG505 SOSIP (35) provides a probe that
can be used to sort B cells expressing antibodies to quaternary
epitopes (59). The broader antibodies of the CAP256-VRC26 lin-
eage neutralize BG505, and thus, we chose to use this probe with
the goal of isolating lineage members with broader neutralization
capacities (Fig. 1C). To increase the specificity of the probe for the
CAP256-VRC26 lineage, we assessed potential mutations that
FIG 1 Schematics of CAP256-VRC26 antibody isolation. (A) Timeline of antibody isolation. Numbers above the line indicate the week postinfection. The names
of the antibodies isolated at each time point are shown below the line. (B) Schematic of high-throughput B cell culture method. Sorted IgD IgM B cells were
plated at a density of2 cells per well into 384-well plates, followed by assessment by a microneutralization assay (Microneut) on day 14. (C) Schematic of probe
sorting method. IgG B cells bound to APC-labeled BG505 SOSIP were sorted into 96-well plates, followed by reverse transcription-PCR to recover the IgG
genes.
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would knock out V1V2 antibody binding and neutralization: us-
ing an Env pseudovirus of BG505, we made a variant with a dele-
tion of the N160 glycan (the N160K mutant) and a variant with a
mutation in V2 strand C (the K169E mutant). While the N160K
mutation rendered BG505 resistant to PG9-, CH01-, and
PGT145-lineage antibodies, neutralization by CAP256 plasma
and CAP256-VRC26.09 was more affected by the K169E mutation
than by the N160K mutation (Fig. 2B). We therefore made a
K169E mutation in the BG505 SOSIP trimer. Wild-type and mu-
tant molecules were fluorescently labeled, and their antigenicity
was assessed by binding them to beads coated with known anti-
bodies (Fig. 2C). The BG505 SOSIP wild-type probe bound
strongly to PGT128 and CAP256-VRC26.09 and did not bind to
the weakly neutralizing antibody F105. The K169E mutant had
similar binding, but as expected, it did not bind to CAP256-
VRC26.09. As a control, YU2-gp140-foldon, which does not pres-
ent quaternary epitopes (60, 61), was observed to bind PGT128
and F105 but not CAP256-VRC26.09 (Fig. 2C). Using the BG505
SOSIP probe pair, we sorted single IgG B cells from week 159
(Fig. 2D), a time point at which the donor’s plasma showed peak
neutralization breadth and potency (28, 29). We amplified and
subcloned Ig genes from cells that were positive for the wild-type
probe but did not bind the K169E probe. Fourteen wells yielded
heavy chain amplicons, light chain amplicons, or both. In 11 of the
14 wells, the amplicon(s) matched the VRC26 lineage, and 8 such
wells yielded heavy chain-light chain pairs. All eight pairs were
expressed and had neutralizing activity, thus producing lineage
members CAP256-VRC26.26 to CAP256-VRC26.33.
Characteristics of the new CAP256-VRC26 antibodies. The
21 new CAP256-VRC26 antibodies showed a range in the levels of
nucleotide mutations from the sequences of the germ line genes:
mutations in 4.2 to 18% of the nucleotides compared with the
sequences of the VH3-30*18 alleles and 2.5 to 15% of the nucleo-
tides compared with the sequences of the VL1-51*02 alleles
FIG 2 Isolation of CAP256-VRC26 antibodies. (A) Class switch occurs under B cell culture conditions. Identical VDJ regions appear in both IgA and IgG forms
in the same well. The red box highlights sequences that differ between IgG and IgA. (B to D) The BG505 trimer with a mutation in V2 selects for CAP256-
VRC26-lineage B cells. (B) Effect of N160K and K169E mutations on neutralization of HIV BG505 by V1V2-directed antibodies and CAP256 plasma. wt, wild
type; ID50, 50% inhibitory dilution. (C) Quality and specificity of probes. BG505 SOSIP-APC, BG505 SOSIP.K169E-PE, or gp140F-PE probes were used to stain
beads coated with the PGT128, F105, or CAP256-VRC26.09 (CAP256.09) antibody. Histograms of anti-HIV antibodies (red) are overlaid on those for the
anti-influenza virus control (gray). (D) Probe-specific B cell sorting. CAP256 PBMCs were stained with B cell markers and probes. Sorted IgG BG505
SOSIP-APC BG505-SOSIP-K169E-PE B cells (purple) are shown overlaid on all live, IgG B cells (gray).
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(Table 1). Similarly, they varied in the rates of mutations from the
inferred sequence of the UCA: 7 to 23% of the nucleotides com-
pared with the sequence of the UCA heavy chain and 3.6 to 17% of
the nucleotides compared with the sequence of the UCA lambda
chain (see Table S3 in the supplemental material). All had the long
CDRH3s that are characteristic of this lineage (Table 1; see Table
S3 in the supplemental material): 35 or 37 amino acids, as seen
previously (21), or 36 amino acids in the case of CAP256-
VRC26.25. As was observed with the initial set of MAbs, the new
MAbs showed no or marginal autoreactivity when tested in mul-
tiple assays (see Fig. S1 in the supplemental material).
Like the original 12 lineage members, the new CAP256-VRC26
antibodies showed a range of neutralization breadth and potency.
With a 46-virus multiclade panel, their neutralization breadth
varied from 2% to 63% (Table 1; see also Table S4 in the supple-
mental material). The member of the lineage with the broadest
neutralization breadth and the most potency was CAP256-
VRC26.25, which had a median IC50 of 0.003g/ml for this panel,
which makes it 10-fold more potent than the most potent family
members described previously (21). Two others, CAP256-VRC26.26
and CAP256-VRC26.27, also had broader neutralization than previ-
ous relatives but were not as potent as CAP256-VRC26.25. The anti-
bodies CAP256-VRC26.19, CAP256-VRC26.22, and CAP256-
VRC26.29 were similar to CAP256-VRC26.08 in neutralization
breadth, neutralizing 46% of this panel (Table 1).
We also isolated antibodies that showed less neutralization
breadth and potency than previously isolated family members.
The sequence of the antibody with the lowest level of somatic
mutation, CAP256-VRC26.24, showed only 4.2% divergence
from the sequence of the heavy chain germ line and 2.5% from the




% mutation from the
sequence of the following
allele:
CDRH3 length
(no. of amino acids)






Wk 59, culture CAP256-VRC26.01 8.3 3.9 35 20 3.32
Wk 119, culture CAP256-VRC26.02 8.7 4.9 35 17 0.44
CAP256-VRC26.03 8.7 7.4 35 35 0.06
CAP256-VRC26.04 9.0 8.1 35 30 0.27
CAP256-VRC26.05 10 5.6 35 22 0.02
CAP256-VRC26.06 11 7.4 36 17 0.69
CAP256-VRC26.07 12 7.7 35 13 5.00
CAP256-VRC26.08 12 9.8 37 46 0.08
CAP256-VRC26.09 14 9.8 37 46 0.02
Wk 206, culture CAP256-VRC26.10 12 3.9 35 24 0.35
CAP256-VRC26.11 13 14 35 26 1.04
CAP256-VRC26.12 15 8.4 35 7 0.21
CAP256-VRC26.13 15 9.5 35 7 0.09
Wk 119, culture CAP256-VRC26.14 10 7.7 35 24 0.75
CAP256-VRC26.15 10 6.7 35 33 0.34
CAP256-VRC26.16 10 7.7 35 28 0.67
CAP256-VRC26.17 12 8.1 35 28 0.14
CAP256-VRC26.18 12 7.4 35 26 1.66
Wk 206, culture CAP256-VRC26.19 13 10 35 46 0.16
CAP256-VRC26.20 16 13 37 2 1.87
CAP256-VRC26.21 18 14 37 13 0.58
Wk 193, culture CAP256-VRC26.22 16 13 37 46 0.04
CAP256-VRC26.23 9.7 6.3 35 7 0.03
CAP256-VRC26.24 4.2 2.5 35 7 0.46
CAP256-VRC26.25 12 9.8 36 63 0.003
Wk 159, sorting with
new probes
CAP256-VRC26.26 17 9.8 37 59 0.05
CAP256-VRC26.27 16 9.5 37 59 0.05
CAP256-VRC26.28 15 12 37 41 0.08
CAP256-VRC26.29 15 13 37 46 0.09
CAP256-VRC26.30 16 13 37 28 0.76
CAP256-VRC26.31 15 10 37 20 1.66
CAP256-VRC26.32 11 15 35 20 0.10
CAP256-VRC26.33 9.4 6.5 35 22 0.27
a Italics indicate results for antibodies published previously (21); bold font indicates the results for antibodies that are newly reported here.
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sequence of the light chain. Its neutralization capacity was less
broad than that of other early lineage members and it was less
potent than other early lineage members, such as CAP256-
VRC26.01 (Table 1). Other poor neutralizers included CAP256-
VRC26.13; notably, it differed from CAP256-VRC26.12 by only 2
nucleotides or a single amino acid, even though they originated
from different culture wells. An independent well yielded se-
quences that were 100% identical to the sequence of CAP256-
VRC26.13. While these closely related lineage members were not
broadly neutralizing, they did potently neutralize the autologous
CAP256 superinfecting (SU) strain (see Table S4 in the supple-
mental material).
Like the previously identified members of the lineage (21), the
new CAP256-VRC26 antibodies are highly dependent on a qua-
ternary epitope and target V1V2. We assayed for binding to gp120
derived from HIV-1 strain CAP210, which is potently neutralized
by all lineage members except CAP256-VRC26.20. None of the
antibodies bound to this gp120 (see Fig. S2 in the supplemental
material). CAP256-VRC26.25 was further tested on 10 additional
clade C gp120s, with no binding being observed; however, it
bound strongly to the BG505 SOSIP molecule, confirming the
trimer preference of these antibodies. In addition, none of the 33
antibodies were able to neutralize R166A and K169E mutants in
HIV-1 strain ConC (see Fig. S3A in the supplemental material),
BG505.w2, or ZM53.12, and the 33 antibodies showed modest
effects on ConC with mutations at amino acids 167 and 168, sim-
ilar to the donor CAP256 plasma (28). Thus, the epitope recog-
nized by the new CAP256-VRC26 antibodies is similar to that
recognized by the previously described relatives.
Glycan independence of CAP256-VRC26 antibodies. The
PG9-like broadly neutralizing antibodies (PG9/PG16, CH01-04,
and the PGT145/PGDM1400-family antibodies) target a V1V2
epitope with quaternary epitope specificity (20, 22, 23, 59). These
antibodies have been shown to require both glycan and protein
contacts on Env (62, 63), with a strict dependence on the glycan at
N160 (20, 22, 23, 42) and with contacts to other glycans, typically
at N156 (62). We therefore investigated the glycan requirements
of the CAP256-VRC26 antibodies. Removing the glycan at N156
did not abrogate neutralization; it conferred a slight decrease in
potency against HIV-1 strains BG505 and ZM53 and variable ef-
fects against Q461.e2, similar to the effect that we observed with
PG9 (see Fig. S3B in the supplemental material). However, re-
moving the glycan at N160 had more dramatic effects. As ex-
pected, V1V2-directed antibodies PG9, PG16, CH01, and PGT145
were unable to neutralize glycan N160 mutants (Fig. 3A). In con-
trast, CAP256-VRC26 antibodies were affected in a potency-de-
pendent manner. The N160 mutations had little effect on the
susceptibility of viruses that were potently neutralized by
CAP256-VRC26 antibodies but did reduce or abrogate the sensi-
tivity of viruses that were less potently neutralized (Fig. 3B). When
the data for all antibodies were combined, wild-type viruses with
an IC50 of0.1 g/ml were more likely to show a neutralization
reduction of at least 10-fold than the more potently neutralized
viruses (P 0.029, Fisher’s exact test). Thus, the CAP256-VRC26
antibodies can maintain potent neutralization of viruses, despite
the lack of the N160 glycan.
Phylogenetic analysis of the lineage. To deepen our under-
standing of the CAP256-VRC26 lineage, we placed the 12 previ-
ously cloned antibodies, together with the 21 new lineage mem-
bers, within the context of total B cell transcripts. A revised
algorithm (see Materials and Methods) was used to analyze 454
pyrosequencing-derived sequences from week 34 (64) and reana-
lyze all sequences from weeks 38 to 206 (21). Phylogenetic trees
derived from maximum likelihood analysis of the transcripts of all
members of the lineage, along with the 33 cloned antibody se-
quences, are displayed in Fig. 4. As noted previously (21), the tree
for heavy chain sequences bifurcates into an upper branch and a
lower branch. Sequences that map to the upper branch are plen-
FIG 3 CAP256-VRC26 antibodies interact with N160 glycan in a potency-dependent manner. Wild-type Env pseudoviruses and mutants lacking the N160
glycan (dN160) were tested in a TZM-bl neutralization assay. Each pair of dots shows the IC50s for one virus pair, with the results for the wild type being shown
on the left and those for the mutant lacking the N160 glycan being shown on the right. Each graph shows data for one antibody. (A) Results for four representative
PG9-like antibodies; (B) results for the four most potent CAP256-VRC26 antibodies.
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tiful among B cell transcripts from weeks 34 to 59 but are rare
among B cell transcripts obtained at week 119 or later. In contrast,
the lower branch contains sequences from all time points. One
notable feature of the sequences in the lower branch is a Cys-Cys
which may stabilize the CDRH3 structure (21); it appears at week
49 and sequences from all subsequent times of the lower branch.
Week 34 sequences do not contain Cys-Cys and appear in both the
upper and lower branches of the tree.
The placement of the cloned antibodies on these trees led to
several observations. The CAP256-VRC26.24 sequence is 4% mu-
tated from the germ line sequence, clustered with week 59 se-
quences, and is located in the top (CAP256-VRC26.01) branch,
yet it was isolated from week 193 PBMCs; we speculate that it is
derived from a long-lived memory cell. CAP256-VRC26.25, the
antibody with the broadest neutralization and greatest potency,
has a 1-amino-acid insertion in the CDRH3 sequence compared
to the UCA sequence (see Table S3 in the supplemental mate-
rial) and lacks close relatives in the pyrosequencing data set,
and its closest relatives are weakly neutralizing. Six of the eight
antibodies that were derived from the probe sort, including the
CAP256-VRC26.26 and CAP256-VRC26.27 antibodies with
very broad neutralization capacities, cluster with other broad
FIG 4 Development of the CAP256-VRC26 lineage. Maximum likelihood trees of heavy chain (left) and lambda chain (right) sequences. Labeled branches show
heavy chains of antibodies from B cell cultures or probe sorts; unlabeled branches represent sequences from 454 pyrosequencing. The color coding indicates the
time of sampling. The circle indicates the first node in which the signature Cys-Cys motif appears in the CDRH3. Scale, rate of nucleotide change (per site)
between nodes.
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neutralizers, CAP256-VRC26.08, CAP256-VRC26.09, and
CAP256-VRC26.22; all of these bear a 2-amino-acid inser-
tion in the CDRH3 sequence compared to the UCA sequence.
However, weak neutralizers CAP256-VRC26.20, CAP256-
VRC26.30, and CAP256-VRC26.31 also appear in this cluster
and have this insertion. Thus, the antibodies that are the most
closely genetically related do not always display the same level
of neutralizing activity.
CAP256-VRC26.25 structure.To investigate the differences in
neutralization potency and breadth among these antibodies, we
solved the crystal structure of the CAP256-VRC26.25 antigen-
binding fragment (Fab) to 2 Å. The structure was well defined,
including the electron density for the entire CDRH3. Like the
other lineage members, this antibody has a long CDRH3 project-
ing away from the body of the Fab (Fig. 5A). A disulfide bond was
observed near the base of the CDRH3, as expected, and density
confirming the two computationally predicted sulfated tyrosines
was also visible (Fig. 5B). We compared this structure to the struc-
tures solved previously for seven other lineage members; of these,
CAP256-VRC26.03 had a complete CDRH3 structure, while sev-
eral others contained disordered regions of various lengths in the
CDRH3 (21). Notably, the CDRH3 of CAP256-VRC26.25 bends
in a considerably different direction than the others. The angle of
rotation between the CDRH3s of Fabs CAP256-VRC26.03 and
CAP256-VRC26.25, aligned by framework regions, is 79 degrees
(Fig. 5B). When all structures are overlaid (Fig. 5C), we observe
that the UCA and the early antibody CAP256-VRC26.01 bend
in a similar direction, CAP256-VRC26.03, CAP256-VRC26.04,
CAP256-VRC26.06, CAP256-VRC26.07, and CAP256-VRC26.10
bend in nearly the opposite direction, and CAP256-VRC26.25
bends in a direction different from the direction of all of these. The
angle likely depends on the identity of amino acid at position 100V
or 100W. The Gly of CAP256-VRC26.25 inserted at the base of the
CDRH3 allows additional flexibility in the initial projection of the
CDRH3, providing a different range of angles for the antibody to
initially engage the viral spike (Fig. 5D). Thus, stabilization of the
overall CDRH3 structure combined with a local flexibility at the
base may contribute to the improved neutralization breadth and
CAP256.01 CAP256.03 CAP256.25
FIG 5 Structural characteristics of CAP256-VRC26.25. (A) Crystal structure of the antigen-binding fragment (Fab) of CAP256-VRC26.25 shown in ribbon
diagram representation. CDRs are highlighted. (B) The CDRH3 of CAP256-VRC26.25 contains an inserted Gly and is rotated 79 degrees compared to the
orientation of the other lineage members without the insertion. Gray, CAP256-VRC26.03; red, the location of the insertion in the structure and the sequence
alignment. (Bottom left) The electrostatics of the highly anionic CDRH3 (charge, 7) in the same orientation in the image above. The CDRH3 contains two
sulfated tyrosines and a disulfide bond (blue mesh, 2Fo-Fc at 1 sigma). (Bottom right) Electron density of the disulfide bond acquired through affinity maturation.
(C) The CDRH3s bend in different directions. All CAP256-VRC26 structures are shown, with CDRH3s projecting up from the top of the antibody. Loops are
colored by the week of isolation: black, week 34, CAP256-VRC26.UCA; green, week 59, CAP256-VRC26.01; cyan, week 119, CAP256-VRC26.03, CAP256-
VRC26.04, CAP256-VRC26.06, and CAP256-VRC26.07; yellow, week 193, CAP256-VRC26.25; purple, week 206, CAP256-VRC26.10. Disordered residues in
the crystal structures were modeled using the Loopy program. These consist of 19, 14, 3, 11, and 10 residues for CAP256-VRC26.UCA, CAP256-VRC26.01,
CAP256-VRC26.06, CAP256-VRC26.07, and CAP256-VRC26.10, respectively. All CDRH3 residues are well defined for CAP256-VRC26.03, CAP256-
VRC26.04, and CAP256-VRC26.25. (D) The orientation at the base of the protruding CDRH3 loop is partially stabilized through interactions with residues in
the CDRH1. Shown are interactions for CAP256-VRC26.01, CAP256-VRC26.03, and CAP256-VRC26.25. Modeled residues of CAP256-VRC26.01 are
transparent.
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potency of CAP256-VRC26.25 compared to those of the other
lineage members.
CAP256-VRC26.25 has broad neutralization and is highly
potent. CAP256-VRC26.25 is the most potent member of the lin-
eage. On a multiclade panel of 183 Env pseudoviruses, it neutral-
ized 57% of isolates with a median IC50 of 0.001g/ml (Fig. 6; see
also Table S5 in the supplemental material), which makes it 10-
fold more potent than the previously published CAP256-
VRC26.08 variant. We also compared CAP256-VRC26.08 and
CAP256-VRC26.25 to the V1V2-directed antibodies PGDM1400,
PG9, and CH01 (Fig. 6A) and additional antibodies to other neu-
tralization epitopes (Fig. 6B and C; see also Table S5 in the sup-
plemental material). A remarkable characteristic of CAP256-
VRC26.25 is the highly potent neutralization of some viruses. This
can be seen as the leftward shift of the potency-breadth plots com-
pared to the locations of the results for the other antibodies (Fig.
6A) and as dots close to an IC50 of 0.0001g/ml on the scatter plot
(Fig. 6B).
We also examined the completeness of neutralization. Like
other V1V2-directed broadly neutralizing antibodies (23, 65), the
CAP256-VRC26 antibodies neutralize some viruses to a maxi-
mum of less than 90%. About 30% of sensitive viruses were neu-
tralized with this plateau effect. This fraction is very similar to that
for the V1V2-directed bNAb PGDM1400 (see Fig. S4 in the sup-
plemental material).
To further characterize and compare the new CAP256-
VRC26-lineage antibodies, we tested variants CAP256-VRC26.08,
CAP256-VRC26.25, CAP256-VRC26.26, and CAP256-VRC26.27
on a multiclade panel of Env pseudoviruses (see Table S5 in
the supplemental material). CAP256-VRC26.26 and CAP256-
VRC26.27 have neutralization capacities nearly as broad as the
neutralization capacity of CAP256-VRC26.25 at a cutoff of 50
g/ml but less so at an IC50 of0.01 g/ml (Fig. 7A), confirming
the superior potency of CAP256-VRC26.25. We also analyzed the
neutralization breadth within different HIV-1 clades (Fig. 7B).
Against clade C, CAP256-VRC26.25 had a neutralization breadth
of 70% at the IC50 level (Fig. 7B; see also Fig. S5 in the supplemen-
tal material), with even greater coverage of strains from clade G
FIG 6 Neutralization breadth and potency of CAP256-VRC26.08, CAP256-VRC26.25, and selected broadly neutralizing antibodies. The neutralization of a
multiclade virus panel (n 183) was assessed by a TZM-bl pseudovirus assay. (A) Neutralization breadth-potency curves for V1V2-directed bNAbs. Curves show
the percentage of virus neutralized at any given IC50 or IC80. (B, C) Neutralization by bNAbs directed to diverse epitopes. Each dot shows the value for a single
virus. Bars, median value of viruses that are neutralized. (B) IC50s; (C) IC80s.
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and circulating recombinant forms AG and BC. While CAP256-
VRC26.25 neutralized 70% of non-clade B strains overall, it neu-
tralized only 15% of clade B strains. To understand the basis of this
preference, we performed an amino acid frequency analysis (53)
for positions 154 to 184 in V2. Specifically, based on sequence
alignments, we searched for amino acids that were preferen-
tially found among CAP256-VRC26.25-resistant strains versus
CAP256-VRC26.25-sensitive strains for each residue position in
V2 (Fig. 8A). Amino acids that were associated with resistance
were found in at least one position among positions 166, 167, and
169 in 59% of resistant strains. These amino acids were observed
in 71% of clade B strains and in 80% of resistant clade B strains.
Conversely, the amino acid K or R at position 169 occurred in 86%
of sensitive strains but in only 5% of clade B strains, with similar
proportions occurring for D or E at position 164 (Fig. 8B). The
occurrence of resistance-associated amino acids at one or more of
these positions was statistically significant (P  0.001 for each
comparison, Fisher’s exact test), as was the occurrence of the sen-
sitivity-associated amino acids at positions 164 and 169. Thus, the
characteristics of clade B sequences at V2 positions 164, 166, 167,
and 169 may explain much of the resistance found in clade B
strains.
DISCUSSION
The data in this study provide a more comprehensive picture of
the CAP256-VRC26 bNAb lineage. Using modified PCR primers,
B cell culture, and trimeric Env-based probes, we isolated 21 new
members of the CAP256-VRC26 family. Several of these new an-
tibodies showed an increased neutralization breadth and potency
compared to those of previously published antibodies of this lin-
eage, particularly against HIV-1 clade C strains and other subtypes
prevalent in sub-Saharan Africa. CAP256-VRC26.25 in particular
showed exceptional potency, with a median IC50 against neutral-
ized viruses of 0.001 g/ml.
We isolated new clonal relatives of the CAP256-VRC26 lineage
by two methods: B cell culture and antigen-specific B cell sorting.
The differential BG505 SOSIP and BG505 SOSIP.K169E protein
sorting approach proved to be a highly efficient and specific
method for isolating new members of the CAP256-VRC26 lin-
eage. Here, 11/14 sorted cells yielded CAP256-VRC26-lineage
members, and two of the three most broadly neutralizing lineage
members were isolated from the probe sort. The availability of
nearly native trimers has potential for use in sorting for V1V2-
directed and other quaternary epitope-specific antibodies in other
donors (59), while the K169E mutant described here may have
utility for additional donors with serum neutralization depen-
dence on this V2 residue. However, this method has some limita-
tions. Not all Env epitopes are displayed on the BG505 SOSIP
molecule: the MPER region of gp41 is not contained in this con-
struct, and some antibodies may not recognize the BG505 se-
quence. With regard to differential sorting with a knockout mu-
tant, not all donors have neutralization activity that can be
matched to that of a wild-type probe–mutant probe pair. Thus,
the advantage of B cell culture is that it does not require a probe or,
indeed, any a priori knowledge of the antibody specificity. Addi-
tionally, since the wells are screened by neutralization, there may
be selection for the detection of highly potent antibodies. How-
ever, B cell culture is more labor-intensive and time-consuming
than single-cell sorting and is most successful when the donor has
high plasma neutralization titers (N. A. Doria-Rose and N. Longo,
unpublished observations). In addition, culture conditions can

















<50ug/ml 47 58 59 55 <50ug/ml 37 49 49 43
<10ug/ml 43 58 55 53 <10ug/ml 34 48 42 42
<1.0ug/ml 40 57 51 48 <1.0ug/ml 28 42 33 35
<0.1ug/ml 35 53 40 42 <0.1ug/ml 20 33 28 28
















A 26 46 69 58 58 A 26 27 54 38 35
AE 21 43 48 57 57 AE 21 33 48 52 48
AG 16 56 81 69 69 AG 16 50 69 63 56
B 40 3 15 13 10 B 40 0 10 8 3
BC 10 70 100 80 80 BC 10 60 80 60 60
C 57 67 70 72 67 C 57 53 60 63 60
D 8 50 63 75 63 D 8 38 63 50 50
G 7 57 71 71 71 G 7 57 71 71 57
other 13 69 69 69 62 other 13 62 62 46 46
All 198 47 58 59 55 All 198 37 49 49 43
non-B 158 58 70 68 65 non-B 158 46 60 56 52





% of viruses neutralized (IC50<50) % of viruses neutralized (IC80<50)
FIG 7 Neutralization breadth, potency, and clade dependency of CAP256-VRC26 antibodies. The neutralization of large virus panels was assessed by a TZM-bl
pseudovirus assay. (Left) IC50s; (right) IC80s. (A) Values indicate the percentage of viruses (n  198) neutralized at the given cutoff; (B) values indicate the
percentage of viruses neutralized within each virus clade.
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of sequences by PCR, though this can be overcome by using IgA
constant region primers. Of note, the most potent member of
the lineage (CAP256-VRC26.25) was isolated from a B cell cul-
ture, attesting to the advantages of high-throughput functional
screening.
Phylogenetic analysis of the complete CAP256-VRC26 lineage
shows two main branches. The first branch, which included
CAP256-VRC26.01 and CAP256-VRC26.24, may be an evolu-
tionary dead end, in that members of the branch could not be
detected in the B cell transcripts from time points after week 119.
We recently showed that the antibodies in this branch were unable
to tolerate viral escape mutations and were no longer selected for
(64). The Cys-Cys disulfide bond in CDRH3 emerged in the sec-
ond branch, and that sublineage continued to evolve, with se-
quences being observed at all time points. Within this sublineage,
however, antibodies with broad or narrow heterologous neutral-
ization are intermingled. This suggests that individual amino acid
changes, rather than overall sequence relatedness, have greater
effects on the neutralization capacity. Similarly, the levels of mu-
tation compared with the sequence of the germ line V gene or that
of the UCA did not correlate with neutralization. A similar pattern
has been noted for other bNAb lineages (22, 59, 66). These obser-
vations suggest that somatic variant antibodies with a variety of
antiviral capacities frequently evolve side-by-side during chronic
HIV infection. The concurrent diversification of the viral quasi-
species may drive this evolution: while some antibody mutations
may improve the binding to specific autologous viral variants en-
countered in the germinal center, they may not be the same mu-
tations that improve the neutralization breadth against heterolo-
gous viruses.
The CAP256-VRC26 antibodies share many characteristics
with the three other published lineages of V1V2 directed broadly
neutralizing antibodies: the PG9, PGT145, and CH01 lineages (20,
22, 23, 59). These antibodies have long, anionic CDRH3s, exhibit
incomplete neutralization of some viruses (65), and share epitope
requirements: they are highly quaternary epitope specific and pre-
FIG 8 CAP256-VRC26.25 resistance analysis of amino acids in Env V2. (A) (Top) Amino acid frequency analysis. A total of 198 sequences were analyzed (see
Fig. S6 in the supplemental material). The resistance score for each possible amino acid at a given residue position was defined as the ratio of its number of
occurrences in sequences from CAP256-VRC26.25-resistant viruses to its overall number of occurrences. A higher score indicates that the amino acid was
preferentially found among sequences from resistant viruses, with a score of 1 indicating that the amino was found only among sequences from resistant viruses.
Amino acids that occurred at least 3 times at the given position are shown. (Bottom) Logo plot showing the frequency of all amino acids at each position for clade
B (n 40) and non-clade B (n 158) sequences. Red, amino acids associated with resistance; green, amino acids associated with sensitivity. (B) Frequency of
amino acids at positions associated with resistance or sensitivity. Values indicate the percentage of sequences in a given category that bear the indicated amino
acids. For example, 84% of Env sequences from sensitive strains have D or E at position 164. A total of 125 sensitive strains and 73 resistant strains were analyzed.
P was0.001 for each comparison (Fisher’s exact test with the Bonferroni correction).
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fer positive charges in strand C of V2 (53), and their activity is
knocked out by a K169E mutation. However, in contrast to the
three other lineages, which show a strong dependence on the N160
glycan (Fig. 3) (42), the CAP256-VRC26 antibodies showed vari-
able and limited dependence on this glycan. The more potent that
the antibody-mediated neutralization was, the less dependent it
was on the presence of the N160 glycan. We speculate that potent
neutralization is mediated mainly by protein-protein contacts but
that more weakly recognized strains are bound via contacts with
both protein and glycan. It is also possible that alternative glycans
are bound when the N160 glycan is missing. Future structural
studies may provide a better understanding of the mechanism.
Notably, a mutant form of PG9 with increased potency was shown
to neutralize some viruses lacking the N160 glycan (67); this ob-
servation is consistent with the notion that the very high potency
of CAP256-VRC26.25 may relate to the lack of N160 glycan de-
pendency.
CAP256-VRC26.25 neutralized 15% of clade B HIV-1
strains and 70% of non-clade B HIV-1 strains. Amino acids
associated with sensitivity or resistance were noted at positions
164, 166, 167, and 169. The residues associated with sensitivi-
ty—D or E at position 164 and R or K at position 169 —were
rare in clade B; conversely, resistance-associated amino acids
were more common in clade B strains than non-clade B strains.
Of note, several of these preferences mirror the neutralization
activity of the donor’s plasma (28); furthermore, escape muta-
tions that arose in the CAP256 donor virus near the time point
of CAP256-VRC26.25 isolation include S at position 166 and E
at position 169 (21, 64), both of which were associated with
resistance in this virus panel.
In summary, we isolated 21 new members of the CAP256-
VRC26 lineage, including 3 variants that have a broader neutral-
ization capacity than the previously isolated family members. The
best variant, CAP256-VRC26.25, was 10-fold more potent than
the previously published members of this lineage, and its overall
potency (IC50  0.001 g/ml) was comparable to or better than
that of existing bNAbs. In addition, the neutralization capacity of
CAP256-VRC26.25 was quite broad, neutralizing60% of all vi-
ruses and 70% of non-clade B viruses, including clade C viruses.
The mechanism of its outstanding potency may relate to the re-
duced dependence on N160 glycan, the unique CDRH3 confor-
mation, or other structural features that have yet to be elucidated.
The high potency of this antibody may make it an attractive can-
didate for clinical development for prevention of infection or as
part of antiretroviral regimens to treat HIV-1 infection.
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Paper 2: Supplementary Info 
  
Figure S1. Autoreactivity assays. A-C. Thirty-two CAP256-VRC26 antibodies as well as control 
antibodies were assessed for binding to cardiolipin by ELISA, and to Hep2 cells by indirect 
immunofluorescence. 4E10 and VRC07-523-LS, positive controls; VRC01-LS, negative control. A, 
Representative cardiolipin ELISA. B, Representative images from Hep2 staining. C, Summary of 
cardiolipin and Hep2 assays. Scale for cardiolipin: -, <0.12 at 33 ug/ml; +/-, 0.12-0.2; +, 0.2-1.0; ++, 
1.0-2.0 ; +++, >2.0. Hep2 staining was assessed semi-quantitatively as in ref. 44. D, CAP256-VRC26 UCA 
and seven of the broadest antibodies were further tested an autoantigen panel by ATHENA. Values >120 at 






























  Antibody µg/ml SSA SSB Sm RNP Scl 70 Jo 1 dsDNA Cent B Histone 
CAP256-VRC26.UCA - - Synagis 50 3 6 5 1 1 5 6 1 3 
CAP256-VRC26.01 - -   25 5 5 4 2 0 7 3 1 3 
CAP256-VRC26.02 - - 4E10 50 162 242 19 26 6 206 9 14 31 
CAP256-VRC26.03 +/- +/-   25 113 176 9 14 5 161 6 8 17 
CAP256-VRC26.04 - - CAP256-VRC26.UCA 50 2 3 10 2 7 2 8 4 3 
CAP256-VRC26.05 - -   25 2 4 6 2 4 2 5 1 3 
CAP256-VRC26.06 - -   12.5 2 6 2 1 3 2 5 2 3 
CAP256-VRC26.07 - -   6.25 3 5 3 0 2 5 0 2 2 
CAP256-VRC26.08 - - CAP256-VRC26.03 50 3 3 3 3 3 3 10 5 5 
CAP256-VRC26.09 - -   25 3 5 3 2 2 2 9 2 3 
CAP256-VRC26.10 - -   12.5 3 9 4 1 1 3 4 2 1 
CAP256-VRC26.11 - -   6.25 3 3 4 2 2 2 0 2 1 
CAP256-VRC26.12 - - CAP256-VRC26.08 50 3 7 5 3 3 2 17 5 2 
CAP256-VRC26.13 - -   25 1 5 4 2 3 1 9 3 3 
CAP256-VRC26.14 - -   12.5 4 5 1 2 1 2 3 2 2 
CAP256-VRC26.15 - -   6.25 4 8 2 2 1 2 2 2 2 
CAP256-VRC26.16 - - CAP256-VRC26.09 50 4 6 4 1 2 3 7 3 3 
CAP256-VRC26.17 - -   25 4 2 4 2 2 2 6 2 2 
CAP256-VRC26.18 - -   12.5 2 4 3 2 1 3 5 3 2 
CAP256-VRC26.19 - -   6.25 3 3 3 1 1 2 2 2 1 
CAP256-VRC26.20 - - CAP256 VRC26.22 50 6 6 29 7 30 6 90 25 17 
CAP256-VRC26.21 - -   25 4 5 14 4 15 4 44 9 10 
CAP256-VRC26.22 - -   12.5 6 5 8 2 7 3 28 4 6 
CAP256-VRC26.23 - -   6.25 1 7 8 3 6 4 22 3 6 
CAP256-VRC26.24 - - CAP256 VRC26.25 50 3 3 7 2 6 3 4 2 2 
CAP256-VRC26.25 +/- -   25 4 7 6 4 3 3 0 2 2 
CAP256-VRC26.26 - -   12.5 3 5 2 2 3 2 4 1 1 
CAP256-VRC26.27 - -   6.25 3 6 5 3 2 1 4 2 3 
CAP256-VRC26.28 - - CAP256-VRC26.26 50 4 9 6 3 3 4 2 1 2 
CAP256-VRC26.29 - -   25 4 5 4 1 3 2 4 1 1 
CAP256-VRC26.30 - -   12.5 2 6 3 0 3 5 1 2 2 
CAP256-VRC26.31 - -   6.25 2 1 1 1 2 4 1 1 1 
CAP256-VRC26.32 - - CAP256-VRC26.27 50 1 3 2 3 2 2 4 2 2 
  25 4 6 2 2 1 2 1 2 2 
VRC01-LS - -   12.5 4 5 4 1 2 4 7 2 3 
VRC07-523 +/- +   6.25 4 3 2 3 1 4 3 1 2 
VRC07-G54W + +++ 
4E10 ++ + 




































































Figure S2. CAP256-VRC26 antibodies only bind to trimeric HIV-1 Env proteins. Binding was assessed 
by ELISA. A, VRC01 and CAP256-VRC26.25 were assayed for binding to gp120 proteins derived from 11 
clade C isolates or to BG505-SOSIP trimer. B, CAP256-VRC26 antibodies were assayed for binding to 
gp120 from clade C isolate CAP210.2.00. 
A 
B 
Figure S3. Epitope mapping of CAP256-VRC26 antibodies. A, Neutralization of HIV-1 ConC virus (wild 
type) and its V2 mutants by CAP256-VRC26 antibodies. Each pair of dots shows the IC50s for one virus 
pair. Each graph shows data for one virus pair. B, Neutralization of wild type and mutants lacking the N156 
glycan (dN156).  Each pair of dots shows the IC50s for one virus pair. Each graph shows data for antibody. 






























































































































































































max neut 95% 
max neut 12% 
max neut 65% 
Figure S4. Plateau effect and completeness of neutralization. A, Representative curves for 
neutralization by CAP256-VRC26.25, demonstrating complete, plateau, or lack of neutralization. B, 
Maximum neutralization. Selected antibodies were assayed against a multiclade panel (n=183). Top, pie 
charts show the proportion of viruses that are neutralized to a maximum of >90% (red), 50-90% (orange) 
or <50% (white). Viruses that do not reach 50% neutralization at the input concentration of 50 µg/ml are 
considered resistant. Values are the fraction of neutralized viruses with maximum neutralization 50-90% 




































Incomplete neutralization (plateau) 
Resistance 
µg/ml CAP256-VRC26.25  
Figure S5. Breadth and potency of CAP256-VRC26 and selected broadly neutralizing antibodies against clade C 
viruses. Neutralization of a clade C panel (n=54) was assessed by TZM-bl pseudovirus assay. A, IC50s. B, IC80s.  
A 
B 






























Table S1. Primers used for cloning heavy, kappa, and lambda variable genes.
Reference
pool VH1 LEADER-A ATGGACTGGACCTGGAGGAT Scheid2011
VH1 LEADER-B ATGGACTGGACCTGGAGCAT Scheid2011
VH1 LEADER-C ATGGACTGGACCTGGAGAAT Scheid2011
VH1 LEADER-D GGTTCCTCTTTGTGGTGGC Scheid2011
VH1 LEADER-E ATGGACTGGACCTGGAGGGT Scheid2011
VH1-LEADER-F ATGGACTGGATTTGGAGGAT Scheid2011
VH1-LEADER-G AGGTTCCTCTTTGTGGTGGCAG Scheid2011
pool 3'Cg CH1 GGA AGG TGT GCA CGC CGC TGG TC Tiller2008
IgA-ext CGA YGA CCA CGT TCC CAT CT Liao2009
pool VH3 LEADER-A TAAAAGGTGTCCAGTGT Scheid2011
VH3 LEADER-B TAAGAGGTGTCCAGTGT Scheid2011
VH3 LEADER-C TAGAAGGTGTCCAGTGT Scheid2011
VH3 LEADER-E TACAAGGTGTCCAGTGT Scheid2011
VH3 LEADER-F TTAAAGCTGTCCAGTGT Scheid2011
VH4 LEADER-D ATGAAACATCTGTGGTTCTT Scheid2011
VH5 LEADER-A TTCTCCAAGGAGTCTGT Scheid2011
pool 3'Cg CH1 GGA AGG TGT GCA CGC CGC TGG TC Tiller2008
IgA-ext CGA YGA CCA CGT TCC CAT CT Liao2009
pool VH3 LEADER-D GCTATTTTTAAAGGTGTCCAGTGT Scheid2011
VH4 LEADER-A ATGAAACACCTGTGGTTCTTCC Scheid2011
VH4 LEADER-B ATGAAACACCTGTGGTTCTT Scheid2011
VH4 LEADER-C ATGAAGCACCTGTGGTTCTT Scheid2011
VH5 LEADER-B CCTCCACAGTGAGAGTCTG Scheid2011
VH6 LEADER-A ATGTCTGTCTCCTTCCTCATC Scheid2011
VH7 LEADER-A GGCAGCAGCAACAGGTGCCCA Scheid2011
pool 3'Cg CH1 GGA AGG TGT GCA CGC CGC TGG TC Tiller2008
IgA-ext CGA YGA CCA CGT TCC CAT CT Liao2009
pool 5'L-VH 1 ACA GGT GCC CAC TCC CAG GTG CAG Tiller2008
5'L-VH 3 AAG GTG TCC AGT GTG ARG TGC AG Tiller2008
5'L-VH 4/6 CCC AGA TGG GTC CTG TCC CAG GTG CAG Tiller2008
5'L-VH 5 CAA GGA GTC TGT TCC GAG GTG CAG Tiller2008
pool 5xwL-VH1 GCA GCC ACA GGT GCC CAC TCC this study
5xwL-VH1-24 CAG CAG CTA CAG GCA CCC ACG C this study
5xwL-VH1-69 GGC AGC AGC TAC AGG TGT CCA GTC C this study
VH3-L1-MP GCT ATT TTA AAA GGT GTC CAA TGT this study
VH3/4-L1-MP GTG GCA GCT CCC AGA TGG GTC CTG TC this study
VH3/4-L3-MP GTT GCA GTT TTA AAA GGT GTC CAG TG this study
VH5-L1-MP GCT GTT CTC CAA GGA GTC TGT TCC this study
pool 3'IgGint GTT CGG GGA AGT AGT CCT TGA C Tiller2008
IgA1-int GCT GGT GCT GCA GAG GCT CAG Liao2009
IgA2-int GCT GGT GCT GTC GAG GCT CAG Liao2009
Kappa
pool 5'L-VK 1/2 ATG AGG STC CCY GCT CAG CTG CTG G Tiller2008
5'L-VK 3 CTC TTC CTC CTG CTA CTC TGG CTC CCA G Tiller2008
5'L-VK 4 ATT TCT CTG TTG CTC TGG ATC TCT G Tiller2008
single 3'CK 543 GTT TCT CGT AGT CTG CTT TGC TCA Tiller2008
pool 5’ L-Vk1.1-MS TGC TGC TCT GGY TCC CA this study
5’ L-Vk1.2-MS TCT GKY TCY CAG GTG CCA this study
5’ L-Vk1.3-MS CTR CTR CTC TGG STC C this study
5’ L-Vk2-MS TGG GGC TGC TAA TGC TCT this study
5’ L-Vk3-MS CTG GCT CMC AGA TAC CAC this study
5’L Vk4 Tiller ATT TCT CTG TTG CTC TGG ATC TCT G Tiller2008
5’ L-Vk5-MS CCT CCT TTG GAT CTC TGA TAC CA this study
5’L-Vk6-MS TTC TGC TSC TCT GGG TTC C this study
single 3'CK 494 GTG CTG TCC TTG CTG TCC TGC T Tiller2008
Lambda
pool 5'L-VL1/10-RL CCTCCTCACTCACTSTGCAG this study
5'L-VL5/6-RL CTCCTCKCTCACTGCACAG this study
5'L-VL2-RL CCTCCTCACTCAGGGCACAG this study
5'L-VL9-RL CCTCCTCAGTCTCCTCACAG this study
5'L-VL4-RL CTGCCCTTCATTTTCTCCACAG this study
5'L-VL3-RL GCGTCCTTGCTTACTGCACAG this study
5'L-VL8-RL GACTCCTTGCTTATGGATCAG this study
5'L-VL7-RL CCTCCTCACTTGCTGCCCAG this study
single 3'Cl CAC CAG TGT GGC CTT GTT GGC TTG Tiller2008
pool 5'L Vl 1 GGT CCT GGG CCC AGT CTG TGC TG Tiller2008
5'L Vl 2 GGT CCT GGG CCC AGT CTG CCC TG Tiller2008
5'L Vl 3 GCT CTG TGA CCT CCT ATG AGC TG Tiller2008
5'L Vl 4/5 GGT CTC TCT CSC AGC YTG TGC TG Tiller2008
5'L Vl 6 GTT CTT GGG CCA ATT TTA TGC TG Tiller2008
5'L Vl 7 GGT CCA ATT CYC AGG CTG TGG TG Tiller2008
5'L Vl 8 GAG TGG ATT CTC AGA CTG TGG TG Tiller2008
single 3'XhoI Cl CTC CTC ACT CGA GGG YGG GAA CAG AGT G Tiller2008
Heavy Chain Primer mix G3: anneal at 52
Second round, 60 deg
Second Round Heavy chain primers anneal at 58. 
use for G1,G2,G3 first round amplicons
Heavy Chain First Round
Heavy Chain Primer mix G1: anneal at 54
First round: 58 deg
Second round: 52 deg
Heavy Chain Primer mix G2: anneal at 48
First round, 58 deg








Table S1. Primers used for cloning heavy, kappa, and lambda variable genes.
Reference
pool VH1 LEADER-A ATGGACTGGACCTGGAGGAT Scheid2011
VH1 LEADER-B ATGGACTGGACCTGGAGCAT Scheid2011
VH1 LEADER-C ATGGACTGGACCTGGAGAAT Scheid2011
VH1 LEADER-D GGTTCCTCTTTGTGGTGGC Scheid2011
VH1 LEADER-E ATGGACTGGACCTGGAGGGT Scheid2011
VH1-LEADER-F ATGGACTGGATTTGGAGGAT Scheid2011
VH1-LEADER-G AGGTTCCTCTTTGTGGTGGCAG Scheid2011
pool 3'Cg CH1 GGA AGG TGT GCA CGC CGC TGG TC Tiller2008
IgA-ext CGA YGA CCA CGT TCC CAT CT Liao2009
pool VH3 LEADER-A TAAAAGGTGTCCAGTGT Scheid2011
VH3 LEADER-B TAAGAGGTGTCCAGTGT Scheid2011
VH3 LEADER-C TAGAAGGTGTCCAGTGT Scheid2011
VH3 LEADER-E TACAAGGTGTCCAGTGT Scheid2011
VH3 LEADER-F TTAAAGCTGTCCAGTGT Scheid2011
VH4 LEADER-D ATGAAACATCTGTGGTTCTT Scheid2011
VH5 LEADER-A TTCTCCAAGGAGTCTGT Scheid2011
pool 3'Cg CH1 GGA AGG TGT GCA CGC CGC TGG TC Tiller2008
IgA-ext CGA YGA CCA CGT TCC CAT CT Liao2009
pool VH3 LEADER-D GCTATTTTTAAAGGTGTCCAGTGT Scheid2011
VH4 LEADER-A ATGAAACACCTGTGGTTCTTCC Scheid2011
VH4 LEADER-B ATGAAACACCTGTGGTTCTT Scheid2011
VH4 LEADER-C ATGAAGCACCTGTGGTTCTT Scheid2011
VH5 LEADER-B CCTCCACAGTGAGAGTCTG Scheid2011
VH6 LEADER-A ATGTCTGTCTCCTTCCTCATC Scheid2011
VH7 LEADER-A GGCAGCAGCAACAGGTGCCCA Scheid2011
pool 3'Cg CH1 GGA AGG TGT GCA CGC CGC TGG TC Tiller2008
IgA-ext CGA YGA CCA CGT TCC CAT CT Liao2009
pool 5'L-VH 1 ACA GGT GCC CAC TCC CAG GTG CAG Tiller2008
5'L-VH 3 AAG GTG TCC AGT GTG ARG TGC AG Tiller2008
5'L-VH 4/6 CCC AGA TGG GTC CTG TCC CAG GTG CAG Tiller2008
5'L-VH 5 CAA GGA GTC TGT TCC GAG GTG CAG Tiller2008
pool 5xwL-VH1 GCA GCC ACA GGT GCC CAC TCC this study
5xwL-VH1-24 CAG CAG CTA CAG GCA CCC ACG C this study
5xwL-VH1-69 GGC AGC AGC TAC AGG TGT CCA GTC C this study
VH3-L1-MP GCT ATT TTA AAA GGT GTC CAA TGT this study
VH3/4-L1-MP GTG GCA GCT CCC AGA TGG GTC CTG TC this study
VH3/4-L3-MP GTT GCA GTT TTA AAA GGT GTC CAG TG this study
VH5-L1-MP GCT GTT CTC CAA GGA GTC TGT TCC this study
pool 3'IgGint GTT CGG GGA AGT AGT CCT TGA C Tiller2008
IgA1-int GCT GGT GCT GCA GAG GCT CAG Liao2009
IgA2-int GCT GGT GCT GTC GAG GCT CAG Liao2009
Kappa
pool 5'L-VK 1/2 ATG AGG STC CCY GCT CAG CTG CTG G Tiller2008
5'L-VK 3 CTC TTC CTC CTG CTA CTC TGG CTC CCA G Tiller2008
5'L-VK 4 ATT TCT CTG TTG CTC TGG ATC TCT G Tiller2008
single 3'CK 543 GTT TCT CGT AGT CTG CTT TGC TCA Tiller2008
pool 5’ L-Vk1.1-MS TGC TGC TCT GGY TCC CA this study
5’ L-Vk1.2-MS TCT GKY TCY CAG GTG CCA this study
5’ L-Vk1.3-MS CTR CTR CTC TGG STC C this study
5’ L-Vk2-MS TGG GGC TGC TAA TGC TCT this study
5’ L-Vk3-MS CTG GCT CMC AGA TAC CAC this study
5’L Vk4 Tiller ATT TCT CTG TTG CTC TGG ATC TCT G Tiller2008
5’ L-Vk5-MS CCT CCT TTG GAT CTC TGA TAC CA this study
5’L-Vk6-MS TTC TGC TSC TCT GGG TTC C this study
single 3'CK 494 GTG CTG TCC TTG CTG TCC TGC T Tiller2008
Lambda
pool 5'L-VL1/10-RL CCTCCTCACTCACTSTGCAG this study
5'L-VL5/6-RL CTCCTCKCTCACTGCACAG this study
5'L-VL2-RL CCTCCTCACTCAGGGCACAG this study
5'L-VL9-RL CCTCCTCAGTCTCCTCACAG this study
5'L-VL4-RL CTGCCCTTCATTTTCTCCACAG this study
5'L-VL3-RL GCGTCCTTGCTTACTGCACAG this study
5'L-VL8-RL GACTCCTTGCTTATGGATCAG this study
5'L-VL7-RL CCTCCTCACTTGCTGCCCAG this study
single 3'Cl CAC CAG TGT GGC CTT GTT GGC TTG Tiller2008
pool 5'L Vl 1 GGT CCT GGG CCC AGT CTG TGC TG Tiller2008
5'L Vl 2 GGT CCT GGG CCC AGT CTG CCC TG Tiller2008
5'L Vl 3 GCT CTG TGA CCT CCT ATG AGC TG Tiller2008
5'L Vl 4/5 GGT CTC TCT CSC AGC YTG TGC TG Tiller2008
5'L Vl 6 GTT CTT GGG CCA ATT TTA TGC TG Tiller2008
5'L Vl 7 GGT CCA ATT CYC AGG CTG TGG TG Tiller2008
5'L Vl 8 GAG TGG ATT CTC AGA CTG TGG TG Tiller2008
single 3'XhoI Cl CTC CTC ACT CGA GGG YGG GAA CAG AGT G Tiller2008
Heavy Chain Primer mix G3: anneal at 52
Second round, 60 deg
Second Round Heavy chain primers anneal at 58. 
use for G1,G2,G3 first round amplicons
Heavy Chain First Round
Heavy Chain Primer mix G1: anneal at 54
First round: 58 deg
Second round: 52 deg
Heavy Chain Primer mix G2: anneal at 48
First round, 58 deg
Heavy Chain Second Round
 Table S2  Data collection and refinement statistics for crystallography.
Values in parentheses are for highest-resolution shell.
One crystal was used to measure the data.
CAP256-VRC26.25
PDB ID 5DT1 
Data collection
Space group P 21221
Cell dimensions  
    a , b , c  (Å) 77.0, 77.0, 85.2
    a, b, g  ( ) 90.0, 90.0, 90.0
Wavelength (Å) 1
Resolution (Å) 50.00-1.96 (2.04-1.96)
R merge 11.4 (32.9)
I / sI 12.0 (2.0)
Completeness (%) 90.8 (50.4)
Redundancy 5.3 (1.6)
Refinement
Resolution (Å) 42.6-1.96 (2.03-1.96) 
No. reflections 33621 (1632)
R work / R free 16.9/21.5  
No. atoms (total) 3856 
    Protein 3484
    Ligand (glycan) 39 
    Water 333
B -factors
    Protein 33.2 
    Ligand (glycan) 92.8
    Water 37.3
R.m.s. deviations
    Bond lengths (Å) 0.007
    Bond angles ( ) 0.89 
Ramachandran
    Favored (%) 97












Table S3. V-D-J junction sequence (inclusive of CDRH3) and mutation away from UCA.
Antibody nt aa nt aa
CAP256-VRC26.UCA CAKDLGESENEEWA-TDYYDFSIGYPGQDPR--GVVGAFDIW -- -- -- --
CAP256-VRC26.01 CAKDVGDYKSDEWG-TEYYDISISYPIQDPR--AMVGAFDLW 10.2 20.8 3.9 8.1
CAP256-VRC26.02 CAKDIREYECEYWT-SDYYDFGRPQPCIDSR--GVVGTFDVW 12.3 20.1 9.0 14.4
CAP256-VRC26.03 CAKDLREDECEEWW-SDYYDFGKQLPCRKSR--GVAGIFDGW 12.5 20.8 10.2 14.4
CAP256-VRC26.04 CAKDLREDECEEWW-SDYYDFGKQLPCRKSR--GVAGIFDKW 13.0 23.6 9.0 11.7
CAP256-VRC26.05 CARDQRYYECEEWA-SDYYDFGREQPCLDPR--GVVGIFDLW 12.7 23.4 11.7 13.5
CAP256-VRC26.06 CARDLRELECEEWTLYNYYDFGSRGPCVDPR--GVAGSFDVW 15.4 22.9 9.3 15.3
CAP256-VRC26.07 CAKDLREDECEEWW-SDYYDFGKKLPCRKSR--GVAGVFDKW 14.1 25.3 10.5 16.2
CAP256-VRC26.08 CVRDQREDECEEWW-SDYYDFGRELPCRKFRGLGLAGIFDIW 16.9 28.8 10.2 14.4
CAP256-VRC26.09 CVKDQREDECEEWW-SDYYDFGRELPCRKSRGLGLAGIFDMW 18.5 22.9 5.4 9.9
CAP256-VRC26.10 CAKDMREYECEYWT-SDYYDFGRPQPCIDRR--GVVGIFDMW 12.7 27.8 17.4 27.9
CAP256-VRC26.11 CVKDMRELECEEWA-SDYYDFGKPQPCLDRR--GVSGISAWW 12.7 26.4 12.3 20.7
CAP256-VRC26.12 CARDLRESECEEWE-SDYYDFGKKGPCVKPR--GVAGGLDLW 12.7 25.7 13.2 21.6
CAP256-VRC26.13 CARDLRESECEEWE-SDYYDFGKKGPCVKPR--GVAGGLDLW 14.1 22.2 10.2 16.2
CAP256-VRC26.14 CARDVREMECEEWA-SDYYDFGRGGPCRDFR--GVVGILDIW 14.6 17.4 9.0 12.6
CAP256-VRC26.15 CARDLREYECELWA-SDYYDFGKPQPCEDPR--GVVGTSDIW 17.6 22.2 8.7 13.5
CAP256-VRC26.16 CARDVREMECEEWA-SDYYDFGRGGPCRDFR--GVVGILDIW 17.4 22.9 10.8 18.0
CAP256-VRC26.17 CARDMREMECEEWA-SDYYDFGRPGPCRDLR--GVVGTFDIW 16.9 22.9 9.6 15.3
CAP256-VRC26.18 CARDMREMECEEWA-SDYYDFGRSGPCRDFR--GVVGVFDIW 13.4 25.7 10.8 19.8
CAP256-VRC26.19 CARDSREYECELWT-SDYYDFGKPQPCIDTR--DVGGLFDMW 18.1 30.8 13.5 23.4
CAP256-VRC26.20 CVRDQREDECEERW-SDYYHFGRVLPCRKYRGLGLAGVFDIW 20.3 34.2 14.1 20.7
CAP256-VRC26.21 CVRDRQEDECEEWW-SDYYAFGRGGPCRKYHGQGLAGIFDIW 22.8 32.2 13.8 21.6
CAP256-VRC26.22 CVRDRQEDECVEWW-SDYYNFGRELPCSKFRGLGLAGIFDIW 21.2 22.2 7.8 9.9
CAP256-VRC26.23 CAKDLREYECEEWR-SDYYDFGRDQPCIDSQ--GVVGILDIW 12.3 16.7 3.6 6.3
CAP256-VRC26.24 CAKDLGGIKNDEWG-TDYYDISVSYPVQDPR--AVAGIFDVW 7.2 21.5 8.7 15.3
CAP256-VRC26.25 CAKDLREDECEEWW-SDYYDFGKQLPCAKSRG-GLVGIADNW 16.9 22.8 10.5 16.2
CAP256-VRC26.26 CVRDQREDECEEWW-SDYYDFGKELPCRKFRGLGLAGIFDVW 20.8 30.1 10.8 19.8
CAP256-VRC26.27 CVRDQREDECEEWW-SDYYDFGKELPCRKFRGLGLAGIFDIW 19.4 28.8 10.5 19.8
CAP256-VRC26.28 CVRDRQEDECVEWW-SDYYNFGRELPCSKFRGLGLAGIFDIW 21.0 30.8 12.9 18.9
CAP256-VRC26.29 CVRDRQEDECVEWW-SDYYNFGRELPCSKFRGLGLAGIFDIW 20.3 30.8 13.8 21.6
CAP256-VRC26.30 CVRDRQEDECEEWW-SDYYNFGRELPCRKFRGQGLAGIFDIW 21.2 30.1 13.5 20.7
CAP256-VRC26.31 CVRDRQEDECEEWW-SDYYNFGRELPCRKFRGPGLAGIFDIW 20.1 29.5 10.8 18.9
CAP256-VRC26.32 CVKDLRELECEEWT-SDYYDFGRPQPCIDPR--GVSGISAMW 14.6 25.0 18.3 27.0
CAP256-VRC26.33 CARDQRYYECEEWA-SDYYDFGREQPCQDPR--GVVGIFDIW 11.6 20.8 9.3 13.5














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
0260.v5.c36 A >50 3.28 0.003 >50 1.12 >50 0.039 0.020 0.718 17.7
0330.v4.c3 A >50 0.003 0.007 0.697 0.013 0.468 0.041 0.002 0.072 1.27
0439.v5.c1 A >50 >50 25.7 3.78 >50 >50 >50 0.003 0.282 1.44
3365.v2.c20 A 0.100 0.009 0.006 0.339 0.060 1.00 0.059 0.001 0.096 2.30
3415.v1.c1 A >50 0.351 0.031 >50 0.096 5.46 >50 0.001 0.131 5.29
3718.v3.c11 A 0.105 0.016 0.004 0.046 0.038 0.272 1.40 0.009 0.486 2.36
BB201.B42 A 0.001 0.00003 0.001 0.030 0.007 0.126 0.003 0.006 0.366 0.798
BG505.W6M.C2 A 0.173 0.0004 0.001 0.016 0.053 0.633 0.041 0.0003 0.056 0.310
BI369.9A A 0.008 0.0005 0.008 0.018 0.017 0.387 0.008 0.008 0.310 0.231
BS208.B1 A 0.003 0.00004 0.003 0.001 0.008 0.045 >50 0.002 0.011 0.358
KER2008.12 A >50 0.008 0.003 8.33 0.007 0.802 2.22 0.001 0.844 22.0
KER2018.11 A 0.003 0.00008 0.004 0.003 0.008 0.159 >50 0.002 0.881 2.01
KNH1209.18 A >50 0.005 5.13 >50 0.180 38.9 0.002 0.002 0.142 1.44
MB201.A1 A >50 >50 0.278 2.49 0.103 0.243 0.005 0.005 0.286 0.225
MB539.2B7 A 31.9 0.202 0.002 1.19 0.060 >50 >50 0.001 0.685 7.10
MI369.A5 A 0.039 0.001 0.012 0.010 0.050 0.849 0.022 0.004 0.434 0.691
MS208.A1 A 0.0007 0.002 0.002 0.231 0.079 3.05 >50 0.0007 0.335 0.604
Q23.17 A 0.010 0.002 0.0007 0.002 0.003 0.008 0.004 0.003 0.092 0.783
Q259.17 A 0.001 0.00003 0.020 45.0 0.050 >50 >50 >50 0.074 4.52
Q769.d22 A >50 >50 0.002 0.151 0.011 >50 >50 >50 0.038 1.57
Q842.d12 A >50 0.001 0.003 0.067 0.024 0.223 0.016 0.001 0.036 2.31
QH209.14M.A2 A >50 >50 0.031 0.004 >50 >50 >50 0.0009 0.043 1.74
RW020.2 A >50 >50 0.005 5.17 0.124 >50 0.002 0.002 0.393 1.36
UG037.8 A >50 >50 0.056 2.33 0.014 0.287 0.065 >50 0.126 0.095
3301.V1.C24 AC 0.013 0.002 0.009 0.193 0.230 >50 0.009 0.003 0.163 3.96
3589.V1.C4 AC >50 >50 >50 >50 0.027 7.29 >50 0.001 0.162 1.43
6540.v4.c1 AC 0.077 0.003 0.008 0.003 0.030 0.465 >50 0.003 >50 3.01
6545.V4.C1 AC 0.026 0.005 0.009 0.003 0.036 0.171 >50 0.002 >50 2.03
0815.V3.C3 ACD >50 >50 >50 >50 >50 >50 0.020 0.400 0.028 0.461
6095.V1.C10 ACD 0.0007 0.0003 0.024 0.002 0.151 >50 37.3 >50 1.37 0.602
3468.V1.C12 AD >50 >50 >50 >50 1.62 31.5 0.042 0.070 0.055 0.553
Q168.a2 AD 0.148 0.0009 0.005 0.860 0.060 2.26 >50 0.003 0.126 1.93
Q461.e2 AD 0.502 0.001 0.080 16.0 2.05 >50 >50 1.01 0.569 1.53
620345.c1 AE 0.001 0.005 0.300 0.056 1.01 >50 >50 >50 >50 1.50
BJOX009000.02.4 AE >50 >50 0.097 0.099 1.94 10.1 14.7 >50 2.15 0.558
BJOX010000.06.2 AE >50 >50 2.88 >50 0.303 1.57 >50 >50 9.00 0.074
BJOX025000.01.1 AE >50 >50 0.010 1.44 0.096 >50 >50 >50 0.238 0.221
BJOX028000.10.3 AE >50 >50 0.023 4.00 0.690 >50 >50 >50 3.08 0.045
C1080.c3 AE 0.023 0.006 0.0008 0.010 0.002 0.033 >50 >50 0.212 0.099
C2101.c1 AE >50 >50 0.016 0.005 0.031 1.62 >50 >50 0.111 1.17
C3347.c11 AE >50 >50 0.003 0.004 0.030 6.07 >50 >50 0.217 0.006
C4118.09 AE 0.002 0.00004 0.003 0.002 0.038 0.254 >50 0.071 0.100 0.068
CNE3 AE >50 >50 0.020 0.252 0.064 >50 >50 >50 0.358 1.85
CNE5 AE 0.018 0.0003 0.002 0.002 0.008 0.104 >50 >50 0.394 1.31
CNE55 AE 0.026 0.0002 0.008 0.002 0.197 >50 >50 >50 0.564 0.102
CNE56 AE >50 >50 8.16 1.63 >50 >50 >50 >50 1.12 0.070
CNE59 AE >50 >50 0.005 0.018 0.060 2.61 >50 >50 0.422 0.001
R1166.c1 AE >50 >50 0.791 4.44 1.10 13.1 >50 >50 0.172 0.503
R2184.c4 AE 19.8 0.002 0.002 0.050 0.384 >50 >50 >50 0.269 0.686
TH966.8 AE 0.036 0.004 0.006 0.002 0.015 0.049 >50 >50 0.446 0.024
TH976.17 AE >50 0.006 >50 >50 >50 >50 >50 >50 0.456 0.216
235-47.SG3 AG 0.265 0.045 0.013 3.38 0.124 1.14 0.110 1.50 0.015 0.200
242-14 AG 0.0007 0.0001 0.007 0.033 0.048 >50 >50 0.001 >50 0.912
263-8 AG 0.031 0.011 0.020 13.2 0.211 >50 1.23 >50 0.251 0.243
269-12 AG >50 0.005 1.92 4.36 1.42 7.68 0.164 0.001 0.330 0.106
271-11 AG >50 >50 0.021 35.7 0.059 1.44 11.7 >50 0.055 0.587
928-28 AG 0.097 0.002 0.003 >50 0.038 4.51 31.0 >50 0.639 0.128
DJ263.8 AG 0.031 0.001 0.002 0.018 0.091 2.99 0.064 0.001 0.213 0.015
T250-4 AG 0.001 0.0005 0.0006 0.0004 0.004 0.042 0.001 0.0008 >50 0.480
T251-18 AG >50 >50 9.43 0.318 >50 2.23 10.8 0.065 5.38 0.419
T253-11 AG 49.5 0.008 0.003 >50 0.142 3.06 >50 0.003 0.601 0.919
T255-34 AG >50 >50 0.236 >50 0.020 21.1 >50 0.001 0.699 0.289
T257-31 AG 0.009 0.0002 0.005 3.49 0.019 0.768 >50 0.0009 2.14 0.592
T266-60 AG 1.78 0.004 0.510 0.071 0.321 2.49 0.160 0.003 3.69 >50
T33-7 AG >50 0.266 0.001 4.97 0.019 0.323 >50 3.00 0.026 0.806
3988.25 B >50 0.001 0.010 0.007 0.045 >50 0.002 0.003 0.747 0.143
5768.04 B >50 >50 0.003 0.020 0.270 0.825 0.039 0.008 0.639 3.63
6101.10 B >50 >50 >50 >50 >50 >50 0.002 0.013 0.063 0.002
6535.3 B >50 >50 >50 >50 0.166 0.428 0.003 0.002 2.73 0.365
7165.18 B >50 >50 0.918 0.056 >50 2.30 0.019 >50 25.1 0.602
89.6.DG B >50 >50 >50 >50 >50 >50 0.016 >50 1.25 0.290
AC10.29 B >50 0.002 0.010 0.006 0.031 16.3 0.028 0.004 1.60 0.171
ADA.DG B >50 >50 0.028 0.005 0.216 >50 0.002 >50 0.801 0.011
Bal.01 B >50 >50 0.122 >50 0.569 >50 0.011 0.004 0.156 0.638
BaL.26 B >50 >50 0.017 1.41 0.030 >50 0.010 0.004 0.047 0.538
BG1168.01 B >50 >50 >50 >50 >50 >50 >50 0.006 1.07 0.405
BL01.DG B >50 >50 >50 >50 >50 >50 >50 0.003 >50 0.146
BR07.DG B >50 >50 >50 >50 >50 >50 0.064 0.013 2.80 0.025
BX08.16 B >50 0.0006 0.020 0.007 0.017 0.590 0.002 0.003 0.456 0.205
CAAN.A2 B >50 >50 >50 5.53 6.31 >50 0.005 0.001 1.09 1.14
CNE10 B >50 >50 >50 >50 0.222 >50 0.005 >50 0.939 0.0009
CNE12 B >50 >50 >50 >50 >50 >50 0.002 0.004 1.15 0.121
CNE14 B >50 >50 >50 >50 >50 >50 0.002 0.0009 0.507 0.068
CNE4 B >50 >50 >50 >50 >50 >50 11.5 >50 0.971 0.055
CNE57 B >50 >50 >50 >50 >50 >50 0.008 0.003 0.755 0.058
HO86.8 B >50 >50 0.021 0.002 0.051 0.186 >50 5.77 >50 0.549
HT593.1 B >50 >50 0.426 0.058 0.345 >50 >50 0.004 1.07 0.038
HXB2.DG B >50 >50 >50 >50 1.00 >50 >50 0.005 0.071 0.002
JRCSF.JB B >50 >50 0.009 0.001 0.004 0.782 0.061 0.003 0.483 0.523
JRFL.JB B >50 >50 >50 4.90 >50 >50 0.017 0.003 0.034 0.155
MN.3 B >50 >50 >50 >50 17.1 >50 >50 >50 0.018 0.0003
PVO.04 B 11.8 0.016 1.14 0.143 7.63 24.2 0.132 0.015 0.567 2.81
QH0515.01 B >50 >50 >50 >50 >50 >50 8.70 0.002 1.31 1.82
QH0692.42 B >50 >50 >50 >50 >50 >50 0.940 0.085 1.96 0.581
REJO.67 B >50 >50 0.001 0.0004 0.006 0.620 8.87 0.032 0.116 0.234
RHPA.7 B >50 >50 0.345 0.028 9.97 8.33 0.014 0.003 0.066 1.27
SC422.8 B >50 >50 0.777 0.027 0.542 >50 0.098 0.002 0.205 0.232
SF162.LS B >50 >50 >50 >50 >50 >50 0.004 0.005 0.282 0.105
SS1196.01 B >50 >50 0.246 19.4 0.147 >50 0.002 >50 0.359 0.361
THRO.18 B >50 17.7 0.087 0.006 4.87 9.32 >50 >50 7.76 0.100
TRJO.58 B >50 >50 >50 >50 0.173 >50 4.31 0.242 0.177 0.980
TRO.11 B >50 >50 0.632 0.029 >50 >50 0.006 >50 0.730 0.023
WITO.33 B >50 >50 0.001 0.001 0.007 0.013 0.787 0.003 0.157 0.120
YU2.DG B >50 >50 0.304 0.035 2.08 >50 0.068 >50 0.140 2.23
CH038.12 BC 0.072 0.001 >50 46.5 5.53 >50 0.004 >50 0.542 0.583
CH070.1 BC 0.039 0.026 0.002 0.003 0.006 >50 0.003 >50 9.90 4.67
CH117.4 BC 0.003 0.000005 0.002 0.012 0.006 1.16 >50 2.18 0.153 0.203
CH181.12 BC 0.001 0.0000 0.001 0.0003 0.004 0.494 0.007 >50 1.04 0.456
CNE15 BC >50 0.301 0.005 2.60 0.005 0.356 19.0 0.003 0.181 0.703
CNE19 BC 19.7 0.0000 0.003 0.068 0.015 1.90 0.007 0.002 0.269 0.090
CNE20 BC >50 0.0005 0.006 0.042 0.047 1.18 0.002 >50 8.77 0.108
CNE21 BC 0.001 0.0001 0.002 0.002 0.063 >50 0.004 0.0009 0.566 1.14
CNE40 BC >50 0.016 0.483 0.214 0.812 >50 0.224 0.005 0.602 0.0004
CNE7 BC 0.003 0.003 0.007 0.259 1.02 >50 0.032 0.020 0.327 0.184
286.36 C 0.005 0.0003 0.024 0.003 0.185 8.92 0.002 0.005 0.406 0.946
288.38 C >50 >50 1.32 2.61 2.42 8.83 0.006 >50 3.73 0.322
0013095-2.11 C 0.021 0.029 0.007 16.6 0.012 0.981 >50 >50 0.169 0.002
001428-2.42 C 30.9 0.070 0.004 0.0006 0.002 0.074 0.023 0.011 0.020 1.73
0077_V1.C16 C 0.001 0.006 0.002 0.194 0.083 42.9 >50 0.0007 2.09 2.45
00836-2.5 C >50 >50 0.004 0.887 >50 >50 31.8 0.009 0.255 0.797
0921.V2.C14 C 0.036 0.0001 0.005 0.011 0.004 0.382 >50 >50 0.260 1.25
16055-2.3 C 0.004 0.0005 0.002 0.008 0.016 >50 1.02 0.070 0.093 0.605
16845-2.22 C >50 >50 >50 46.7 1.96 5.74 9.41 >50 6.62 0.006
16936-2.21 C 0.250 0.002 1.38 5.14 >50 >50 0.003 0.103 0.301 0.221
25710-2.43 C 0.008 0.0000 0.008 0.002 0.031 2.50 0.014 2.00 0.973 0.040
25711-2.4 C >50 >50 0.763 7.46 0.932 2.78 0.010 0.002 1.18 1.01
25925-2.22 C 0.013 0.0000 0.004 0.003 0.025 2.10 0.024 0.002 0.907 0.491
26191-2.48 C 0.001 0.0001 0.018 0.053 0.132 3.00 0.150 >50 0.325 2.40
3168.V4.C10 C >50 0.109 0.056 0.028 0.092 1.18 0.485 >50 0.215 2.47
3637.V5.C3 C >50 >50 >50 >50 >50 >50 >50 0.055 5.46 2.02
6322.V4.C1 C 0.003 0.0008 0.012 0.073 >50 >50 >50 >50 >50 4.23
6471.V1.C16 C >50 >50 >50 >50 >50 >50 >50 24.4 >50 5.61
6631.V3.C10 C >50 >50 >50 >50 >50 >50 >50 0.002 >50 1.06
6644.V2.C33 C >50 >50 >50 >50 0.025 >50 0.018 >50 0.233 0.007
6785.V5.C14 C 0.005 0.0003 0.010 0.105 0.008 0.879 0.019 >50 0.416 0.550
6838.V1.C35 C 0.001 0.0007 0.001 0.215 0.006 0.137 0.119 0.025 0.338 0.457
96ZM651.02 C 2.63 0.494 0.092 7.33 >50 >50 0.009 0.001 1.01 0.018
BR025.9 C >50 >50 0.004 8.67 0.019 0.224 0.002 0.081 0.437 0.315
CAP210.E8 C 0.003 0.0002 0.001 >50 0.165 15.7 >50 0.002 >50 0.815
CAP244.D3 C 46.0 >50 4.48 12.0 0.067 0.655 >50 0.069 1.01 0.316
CAP256.206.C9 C 0.002 0.0002 0.005 2.20 0.060 2.13 0.009 >50 0.628 0.950
CAP45.G3 C 4.00 0.0000 0.002 0.0008 0.003 0.105 2.08 0.001 5.63 0.919
CNE30 C >50 >50 >50 >50 >50 >50 0.061 0.100 0.954 0.873
CNE31 C >50 >50 0.246 0.068 15.8 >50 0.789 0.002 1.30 0.942
CNE53 C >50 >50 0.017 0.019 0.080 0.236 0.022 >50 0.113 0.425
CNE58 C 0.006 0.0000 0.004 0.062 0.022 0.047 >50 0.0007 0.221 0.501
DU123.06 C 0.015 0.008 0.001 0.024 0.062 0.515 0.033 >50 6.73 0.122
DU151.02 C 0.006 0.0003 0.001 0.006 0.016 0.671 0.005 0.070 11.0 0.588
DU156.12 C 0.006 0.002 0.001 0.008 0.041 0.305 0.005 0.002 0.159 0.004
DU172.17 C >50 >50 2.37 >50 0.190 7.70 0.104 0.0009 >50 0.026
DU422.01 C 1.12 0.053 >50 >50 >50 >50 0.164 0.400 >50 0.189
MW965.26 C 0.003 0.019 0.023 0.147 0.619 >50 0.011 0.038 0.048 0.0005
SO18.18 C 0.002 0.0008 0.003 0.002 0.021 9.73 0.002 0.002 0.066 2.37
TV1.29 C >50 0.339 0.002 3.34 0.005 0.680 0.118 0.0003 >50 0.156
TZA125.17 C 0.018 0.002 0.044 0.115 0.140 >50 9.96 0.056 >50 0.484
TZBD.02 C 0.036 0.003 0.013 0.035 0.170 20.0 0.005 0.001 0.065 1.94
ZA012.29 C >50 >50 2.21 1.26 7.47 >50 0.005 0.054 0.300 3.09
ZM106.9 C 0.010 0.007 0.002 0.016 0.492 >50 0.005 >50 0.256 >50
ZM109.4 C >50 0.003 0.003 0.012 0.154 >50 13.7 0.348 0.150 0.353
ZM135.10a C >50 >50 >50 >50 >50 >50 1.50 >50 1.66 0.180
ZM176.66 C 0.029 0.0001 0.003 0.032 0.010 1.89 13.8 0.0008 0.065 0.246
ZM197.7 C 0.002 0.005 0.024 0.523 0.369 >50 >50 0.002 0.966 0.088
ZM214.15 C 3.23 0.002 >50 >50 >50 >50 0.682 0.012 2.09 2.46
ZM215.8 C >50 >50 0.002 >50 0.073 >50 0.014 0.029 0.442 0.041
ZM233.6 C 0.003 0.0005 0.002 0.008 0.148 0.074 1.14 0.004 2.51 0.110
ZM249.1 C 0.0009 0.0008 0.001 1.99 0.043 >50 >50 0.0009 0.128 0.735
ZM53.12 C 0.003 0.0001 0.007 0.154 0.036 >50 0.002 >50 1.57 2.19
ZM55.28a C 0.005 0.001 0.022 0.687 3.15 >50 0.070 0.0008 0.411 2.85
3326.V4.C3 CD 0.007 0.0000 0.006 0.009 0.030 >50 >50 0.224 0.088 1.25
3337.V2.C6 CD 0.044 0.0002 >50 >50 >50 >50 21.1 0.001 0.100 1.53
3817.v2.c59 CD >50 >50 >50 >50 0.004 0.092 >50 >50 >50 0.354
231965.c1 D >50 >50 0.001 0.122 0.682 >50 >50 0.002 0.278 6.32
247-23 D 0.005 0.0001 0.008 0.017 0.092 >50 >50 >50 3.57 0.659
3016.v5.c45 D 0.005 0.0002 >50 25.4 0.283 >50 >50 0.078 0.172 0.240
57128.vrc15 D >50 0.004 0.003 0.118 0.122 >50 2.16 >50 >50 0.611
6405.v4.c34 D >50 >50 >50 >50 >50 >50 0.019 0.020 2.40 0.674
A03349M1.vrc4a D 2.68 0.004 0.013 4.60 >50 >50 0.013 >50 5.59 0.436
NKU3006.ec1 D >50 >50 >50 >50 >50 >50 >50 >50 0.766 1.06
P1981.C5.3 G 0.008 0.002 0.160 1.08 0.201 >50 0.004 0.001 0.414 0.0005
X1193.c1 G 0.343 0.001 0.162 0.015 0.120 >50 0.028 0.010 0.194 0.724
X1254.c3 G >50 >50 >50 1.27 0.035 18.5 0.024 0.032 0.051 5.85
X1632.S2.B10 G 0.009 0.0004 0.001 0.006 0.087 5.25 >50 0.070 0.133 0.579





PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
# Viruses 183 183 183 183 183 183 183 183 183 183
# Viruses Neutralized
IC50 <50ug/ml 85 104 143 138 146 94 120 124 165 180
IC50 <10ug/ml 78 103 142 128 144 83 109 123 163 178
IC50 <1.0ug/ml 72 102 131 98 125 47 96 117 124 126
IC50 <0.1ug/ml 64 95 113 76 85 10 81 110 28 34
IC50 <0.01ug/ml 41 85 78 38 22 1 42 83 0 13
% VS Neutralized
IC50 <50ug/ml 46 57 78 75 80 51 66 68 90 98
IC50 <10ug/ml 43 56 78 70 79 45 60 67 89 97
IC50 <1.0ug/ml 39 56 72 54 68 26 52 64 68 69
IC50 <0.1ug/ml 35 52 62 42 46 5 44 60 15 19
IC50 <0.01ug/ml 22 46 43 21 12 1 23 45 0 7
Median IC50 0.010 0.001 0.008 0.060 0.064 0.991 0.023 0.003 0.393 0.544
Geometric Mean 0.026 0.002 0.016 0.095 0.085 1.06 0.053 0.007 0.396 0.336







PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
0260.v5.c36 A >50 3.28 0.003 >50 1.12 >50 0.039 0.020 0.718 17.7
0330.v4.c3 A >50 0.003 0.007 0.697 0.013 0.468 0.041 0.002 0.072 1.27
0439.v5.c1 A >50 >50 25.7 3.78 >50 >50 >50 0.003 0.282 1.44
3365.v2.c20 A 0.100 0.009 0.006 0.339 0.060 1.00 0.059 0.001 0.096 2.30
3415.v1.c1 A >50 0.351 0.031 >50 0.096 5.46 >50 0.001 0.131 5.29
3718.v3.c11 A 0.105 0.016 0.004 0.046 0.038 0.272 1.40 0.009 0.486 2.36
BB201.B42 A 0.001 0.00003 0.001 0.030 0.007 0.126 0.003 0.006 0.366 0.798
BG505.W6M.C2 A 0.173 0.0004 0.001 0.016 0.053 0.633 0.041 0.0003 0.056 0.310
BI369.9A A 0.008 0.0005 0.008 0.018 0.017 0.387 0.008 0.008 0.310 0.231
BS208.B1 A 0.003 0.00004 0.003 0.001 0.008 0.045 >50 0.002 0.011 0.358
KER2008.12 A >50 0.008 0.003 8.33 0.007 0.802 2.22 0.001 0.844 22.0
KER2018.11 A 0.003 0.00008 0.004 0.003 0.008 0.159 >50 0.002 0.881 2.01
KNH1209.18 A >50 0.005 5.13 >50 0.180 38.9 0.002 0.002 0.142 1.44
MB201.A1 A >50 >50 0.278 2.49 0.103 0.243 0.005 0.005 0.286 0.225
MB539.2B7 A 31.9 0.202 0.002 1.19 0.060 >50 >50 0.001 0.685 7.10
MI369.A5 A 0.039 0.001 0.012 0.010 0.050 0.849 0.022 0.004 0.434 0.691
MS208.A1 A 0.0007 0.002 0.002 0.231 0.079 3.05 >50 0.0007 0.335 0.604
Q23.17 A 0.010 0.002 0.0007 0.002 0.003 0.008 0.004 0.003 0.092 0.783
Q259.17 A 0.001 0.00003 0.020 45.0 0.050 >50 >50 >50 0.074 4.52
Q769.d22 A >50 >50 0.002 0.151 0.011 >50 >50 >50 0.038 1.57
Q842.d12 A >50 0.001 0.003 0.067 0.024 0.223 0.016 0.001 0.036 2.31
QH209.14M.A2 A >50 >50 0.031 0.004 >50 >50 >50 0.0009 0.043 1.74
RW020.2 A >50 >50 0.005 5.17 0.124 >50 0.002 0.002 0.393 1.36
UG037.8 A >50 >50 0.056 2.33 0.014 0.287 0.065 >50 0.126 0.095
3301.V1.C24 AC 0.013 0.002 0.009 0.193 0.230 >50 0.009 0.003 0.163 3.96
3589.V1.C4 AC >50 >50 >50 >50 0.027 7.29 >50 0.001 0.162 1.43
6540.v4.c1 AC 0.077 0.003 0.008 0.003 0.030 0.465 >50 0.003 >50 3.01
6545.V4.C1 AC 0.026 0.005 0.009 0.003 0.036 0.171 >50 0.002 >50 2.03
0815.V3.C3 ACD >50 >50 >50 >50 >50 >50 0.020 0.400 0.028 0.461
6095.V1.C10 ACD 0.0007 0.0003 0.024 0.002 0.151 >50 37.3 >50 1.37 0.602
3468.V1.C12 AD >50 >50 >50 >50 1.62 31.5 0.042 0.070 0.055 0.553
Q168.a2 AD 0.148 0.0009 0.005 0.860 0.060 2.26 >50 0.003 0.126 1.93
Q461.e2 AD 0.502 0.001 0.080 16.0 2.05 >50 >50 1.01 0.569 1.53
620345.c1 AE 0.001 0.005 0.300 0.056 1.01 >50 >50 >50 >50 1.50
BJOX009000.02.4 AE >50 >50 0.097 0.099 1.94 10.1 14.7 >50 2.15 0.558
BJOX010000.06.2 AE >50 >50 2.88 >50 0.303 1.57 >50 >50 9.00 0.074
BJOX025000.01.1 AE >50 >50 0.010 1.44 0.096 >50 >50 >50 0.238 0.221
BJOX028000.10.3 AE >50 >50 0.023 4.00 0.690 >50 >50 >50 3.08 0.045
C1080.c3 AE 0.023 0.006 0.0008 0.010 0.002 0.033 >50 >50 0.212 0.099
C2101.c1 AE >50 >50 0.016 0.005 0.031 1.62 >50 >50 0.111 1.17
C3347.c11 AE >50 >50 0.003 0.004 0.030 6.07 >50 >50 0.217 0.006
C4118.09 AE 0.002 0.00004 0.003 0.002 0.038 0.254 >50 0.071 0.100 0.068
CNE3 AE >50 >50 0.020 0.252 0.064 >50 >50 >50 0.358 1.85
CNE5 AE 0.018 0.0003 0.002 0.002 0.008 0.104 >50 >50 0.394 1.31
CNE55 AE 0.026 0.0002 0.008 0.002 0.197 >50 >50 >50 0.564 0.102
CNE56 AE >50 >50 8.16 1.63 >50 >50 >50 >50 1.12 0.070
CNE59 AE >50 >50 0.005 0.018 0.060 2.61 >50 >50 0.422 0.001
R1166.c1 AE >50 >50 0.791 4.44 1.10 13.1 >50 >50 0.172 0.503
R2184.c4 AE 19.8 0.002 0.002 0.050 0.384 >50 >50 >50 0.269 0.686
TH966.8 AE 0.036 0.004 0.006 0.002 0.015 0.049 >50 >50 0.446 0.024
TH976.17 AE >50 0.006 >50 >50 >50 >50 >50 >50 0.456 0.216
235-47.SG3 AG 0.265 0.045 0.013 3.38 0.124 1.14 0.110 1.50 0.015 0.200
242-14 AG 0.0007 0.0001 0.007 0.033 0.048 >50 >50 0.001 >50 0.912
263-8 AG 0.031 0.011 0.020 13.2 0.211 >50 1.23 >50 0.251 0.243
269-12 AG >50 0.005 1.92 4.36 1.42 7.68 0.164 0.001 0.330 0.106
271-11 AG >50 >50 0.021 35.7 0.059 1.44 11.7 >50 0.055 0.587
928-28 AG 0.097 0.002 0.003 >50 0.038 4.51 31.0 >50 0.639 0.128
DJ263.8 AG 0.031 0.001 0.002 0.018 0.091 2.99 0.064 0.001 0.213 0.015
T250-4 AG 0.001 0.0005 0.0006 0.0004 0.004 0.042 0.001 0.0008 >50 0.480
T251-18 AG >50 >50 9.43 0.318 >50 2.23 10.8 0.065 5.38 0.419
T253-11 AG 49.5 0.008 0.003 >50 0.142 3.06 >50 0.003 0.601 0.919
T255-34 AG >50 >50 0.236 >50 0.020 21.1 >50 0.001 0.699 0.289
T257-31 AG 0.009 0.0002 0.005 3.49 0.019 0.768 >50 0.0009 2.14 0.592
T266-60 AG 1.78 0.004 0.510 0.071 0.321 2.49 0.160 0.003 3.69 >50
T33-7 AG >50 0.266 0.001 4.97 0.019 0.323 >50 3.00 0.026 0.806
3988.25 B >50 0.001 0.010 0.007 0.045 >50 0.002 0.003 0.747 0.143
5768.04 B >50 >50 0.003 0.020 0.270 0.825 0.039 0.008 0.639 3.63
6101.10 B >50 >50 >50 >50 >50 >50 0.002 0.013 0.063 0.002
6535.3 B >50 >50 >50 >50 0.166 0.428 0.003 0.002 2.73 0.365
7165.18 B >50 >50 0.918 0.056 >50 2.30 0.019 >50 25.1 0.602
89.6.DG B >50 >50 >50 >50 >50 >50 0.016 >50 1.25 0.290
AC10.29 B >50 0.002 0.010 0.006 0.031 16.3 0.028 0.004 1.60 0.171
ADA.DG B >50 >50 0.028 0.005 0.216 >50 0.002 >50 0.801 0.011
Bal.01 B >50 >50 0.122 >50 0.569 >50 0.011 0.004 0.156 0.638
BaL.26 B >50 >50 0.017 1.41 0.030 >50 0.010 0.004 0.047 0.538
BG1168.01 B >50 >50 >50 >50 >50 >50 >50 0.006 1.07 0.405
BL01.DG B >50 >50 >50 >50 >50 >50 >50 0.003 >50 0.146
BR07.DG B >50 >50 >50 >50 >50 >50 0.064 0.013 2.80 0.025
BX08.16 B >50 0.0006 0.020 0.007 0.017 0.590 0.002 0.003 0.456 0.205
CAAN.A2 B >50 >50 >50 5.53 6.31 >50 0.005 0.001 1.09 1.14
CNE10 B >50 >50 >50 >50 0.222 >50 0.005 >50 0.939 0.0009
CNE12 B >50 >50 >50 >50 >50 >50 0.002 0.004 1.15 0.121
CNE14 B >50 >50 >50 >50 >50 >50 0.002 0.0009 0.507 0.068
CNE4 B >50 >50 >50 >50 >50 >50 11.5 >50 0.971 0.055
CNE57 B >50 >50 >50 >50 >50 >50 0.008 0.003 0.755 0.058
HO86.8 B >50 >50 0.021 0.002 0.051 0.186 >50 5.77 >50 0.549
HT593.1 B >50 >50 0.426 0.058 0.345 >50 >50 0.004 1.07 0.038
HXB2.DG B >50 >50 >50 >50 1.00 >50 >50 0.005 0.071 0.002
JRCSF.JB B >50 >50 0.009 0.001 0.004 0.782 0.061 0.003 0.483 0.523
JRFL.JB B >50 >50 >50 4.90 >50 >50 0.017 0.003 0.034 0.155
MN.3 B >50 >50 >50 >50 17.1 >50 >50 >50 0.018 0.0003
PVO.04 B 11.8 0.016 1.14 0.143 7.63 24.2 0.132 0.015 0.567 2.81
QH0515.01 B >50 >50 >50 >50 >50 >50 8.70 0.002 1.31 1.82
QH0692.42 B >50 >50 >50 >50 >50 >50 0.940 0.085 1.96 0.581
REJO.67 B >50 >50 0.001 0.0004 0.006 0.620 8.87 0.032 0.116 0.234
RHPA.7 B >50 >50 0.345 0.028 9.97 8.33 0.014 0.003 0.066 1.27
SC422.8 B >50 >50 0.777 0.027 0.542 >50 0.098 0.002 0.205 0.232
SF162.LS B >50 >50 >50 >50 >50 >50 0.004 0.005 0.282 0.105
SS1196.01 B >50 >50 0.246 19.4 0.147 >50 0.002 >50 0.359 0.361
THRO.18 B >50 17.7 0.087 0.006 4.87 9.32 >50 >50 7.76 0.100
TRJO.58 B >50 >50 >50 >50 0.173 >50 4.31 0.242 0.177 0.980
TRO.11 B >50 >50 0.632 0.029 >50 >50 0.006 >50 0.730 0.023
WITO.33 B >50 >50 0.001 0.001 0.007 0.013 0.787 0.003 0.157 0.120
YU2.DG B >50 >50 0.304 0.035 2.08 >50 0.068 >50 0.140 2.23
CH038.12 BC 0.072 0.001 >50 46.5 5.53 >50 0.004 >50 0.542 0.583
CH070.1 BC 0.039 0.026 0.002 0.003 0.006 >50 0.003 >50 9.90 4.67
CH117.4 BC 0.003 0.000005 0.002 0.012 0.006 1.16 >50 2.18 0.153 0.203
CH181.12 BC 0.001 0.0000 0.001 0.0003 0.004 0.494 0.007 >50 1.04 0.456
CNE15 BC >50 0.301 0.005 2.60 0.005 0.356 19.0 0.003 0.181 0.703
CNE19 BC 19.7 0.0000 0.003 0.068 0.015 1.90 0.007 0.002 0.269 0.090
CNE20 BC >50 0.0005 0.006 0.042 0.047 1.18 0.002 >50 8.77 0.108
CNE21 BC 0.001 0.0001 0.002 0.002 0.063 >50 0.004 0.0009 0.566 1.14
CNE40 BC >50 0.016 0.483 0.214 0.812 >50 0.224 0.005 0.602 0.0004
CNE7 BC 0.003 0.003 0.007 0.259 1.02 >50 0.032 0.020 0.327 0.184
286.36 C 0.005 0.0003 0.024 0.003 0.185 8.92 0.002 0.005 0.406 0.946
288.38 C >50 >50 1.32 2.61 2.42 8.83 0.006 >50 3.73 0.322
0013095-2.11 C 0.021 0.029 0.007 16.6 0.012 0.981 >50 >50 0.169 0.002
001428-2.42 C 30.9 0.070 0.004 0.0006 0.002 0.074 0.023 0.011 0.020 1.73
0077_V1.C16 C 0.001 0.006 0.002 0.194 0.083 42.9 >50 0.0007 2.09 2.45
00836-2.5 C >50 >50 0.004 0.887 >50 >50 31.8 0.009 0.255 0.797
0921.V2.C14 C 0.036 0.0001 0.005 0.011 0.004 0.382 >50 >50 0.260 1.25
16055-2.3 C 0.004 0.0005 0.002 0.008 0.016 >50 1.02 0.070 0.093 0.605
16845-2.22 C >50 >50 >50 46.7 1.96 5.74 9.41 >50 6.62 0.006
16936-2.21 C 0.250 0.002 1.38 5.14 >50 >50 0.003 0.103 0.301 0.221
25710-2.43 C 0.008 0.0000 0.008 0.002 0.031 2.50 0.014 2.00 0.973 0.040
25711-2.4 C >50 >50 0.763 7.46 0.932 2.78 0.010 0.002 1.18 1.01
25925-2.22 C 0.013 0.0000 0.004 0.003 0.025 2.10 0.024 0.002 0.907 0.491
26191-2.48 C 0.001 0.0001 0.018 0.053 0.132 3.00 0.150 >50 0.325 2.40
3168.V4.C10 C >50 0.109 0.056 0.028 0.092 1.18 0.485 >50 0.215 2.47
3637.V5.C3 C >50 >50 >50 >50 >50 >50 >50 0.055 5.46 2.02
6322.V4.C1 C 0.003 0.0008 0.012 0.073 >50 >50 >50 >50 >50 4.23
6471.V1.C16 C >50 >50 >50 >50 >50 >50 >50 24.4 >50 5.61
6631.V3.C10 C >50 >50 >50 >50 >50 >50 >50 0.002 >50 1.06
6644.V2.C33 C >50 >50 >50 >50 0.025 >50 0.018 >50 0.233 0.007
6785.V5.C14 C 0.005 0.0003 0.010 0.105 0.008 0.879 0.019 >50 0.416 0.550
6838.V1.C35 C 0.001 0.0007 0.001 0.215 0.006 0.137 0.119 0.025 0.338 0.457
96ZM651.02 C 2.63 0.494 0.092 7.33 >50 >50 0.009 0.001 1.01 0.018
BR025.9 C >50 >50 0.004 8.67 0.019 0.224 0.002 0.081 0.437 0.315
CAP210.E8 C 0.003 0.0002 0.001 >50 0.165 15.7 >50 0.002 >50 0.815
CAP244.D3 C 46.0 >50 4.48 12.0 0.067 0.655 >50 0.069 1.01 0.316
CAP256.206.C9 C 0.002 0.0002 0.005 2.20 0.060 2.13 0.009 >50 0.628 0.950
CAP45.G3 C 4.00 0.0000 0.002 0.0008 0.003 0.105 2.08 0.001 5.63 0.919
CNE30 C >50 >50 >50 >50 >50 >50 0.061 0.100 0.954 0.873
CNE31 C >50 >50 0.246 0.068 15.8 >50 0.789 0.002 1.30 0.942
CNE53 C >50 >50 0.017 0.019 0.080 0.236 0.022 >50 0.113 0.425
CNE58 C 0.006 0.0000 0.004 0.062 0.022 0.047 >50 0.0007 0.221 0.501
DU123.06 C 0.015 0.008 0.001 0.024 0.062 0.515 0.033 >50 6.73 0.122
DU151.02 C 0.006 0.0003 0.001 0.006 0.016 0.671 0.005 0.070 11.0 0.588
DU156.12 C 0.006 0.002 0.001 0.008 0.041 0.305 0.005 0.002 0.159 0.004
DU172.17 C >50 >50 2.37 >50 0.190 7.70 0.104 0.0009 >50 0.026
DU422.01 C 1.12 0.053 >50 >50 >50 >50 0.164 0.400 >50 0.189
MW965.26 C 0.003 0.019 0.023 0.147 0.619 >50 0.011 0.038 0.048 0.0005
SO18.18 C 0.002 0.0008 0.003 0.002 0.021 9.73 0.002 0.002 0.066 2.37
TV1.29 C >50 0.339 0.002 3.34 0.005 0.680 0.118 0.0003 >50 0.156
TZA125.17 C 0.018 0.002 0.044 0.115 0.140 >50 9.96 0.056 >50 0.484
TZBD.02 C 0.036 0.003 0.013 0.035 0.170 20.0 0.005 0.001 0.065 1.94
ZA012.29 C >50 >50 2.21 1.26 7.47 >50 0.005 0.054 0.300 3.09
ZM106.9 C 0.010 0.007 0.002 0.016 0.492 >50 0.005 >50 0.256 >50
ZM109.4 C >50 0.003 0.003 0.012 0.154 >50 13.7 0.348 0.150 0.353
ZM135.10a C >50 >50 >50 >50 >50 >50 1.50 >50 1.66 0.180
ZM176.66 C 0.029 0.0001 0.003 0.032 0.010 1.89 13.8 0.0008 0.065 0.246
ZM197.7 C 0.002 0.005 0.024 0.523 0.369 >50 >50 0.002 0.966 0.088
ZM214.15 C 3.23 0.002 >50 >50 >50 >50 0.682 0.012 2.09 2.46
ZM215.8 C >50 >50 0.002 >50 0.073 >50 0.014 0.029 0.442 0.041
ZM233.6 C 0.003 0.0005 0.002 0.008 0.148 0.074 1.14 0.004 2.51 0.110
ZM249.1 C 0.0009 0.0008 0.001 1.99 0.043 >50 >50 0.0009 0.128 0.735
ZM53.12 C 0.003 0.0001 0.007 0.154 0.036 >50 0.002 >50 1.57 2.19
ZM55.28a C 0.005 0.001 0.022 0.687 3.15 >50 0.070 0.0008 0.411 2.85
3326.V4.C3 CD 0.007 0.0000 0.006 0.009 0.030 >50 >50 0.224 0.088 1.25
3337.V2.C6 CD 0.044 0.0002 >50 >50 >50 >50 21.1 0.001 0.100 1.53
3817.v2.c59 CD >50 >50 >50 >50 0.004 0.092 >50 >50 >50 0.354
231965.c1 D >50 >50 0.001 0.122 0.682 >50 >50 0.002 0.278 6.32
247-23 D 0.005 0.0001 0.008 0.017 0.092 >50 >50 >50 3.57 0.659
3016.v5.c45 D 0.005 0.0002 >50 25.4 0.283 >50 >50 0.078 0.172 0.240
57128.vrc15 D >50 0.004 0.003 0.118 0.122 >50 2.16 >50 >50 0.611
6405.v4.c34 D >50 >50 >50 >50 >50 >50 0.019 0.020 2.40 0.674
A03349M1.vrc4a D 2.68 0.004 0.013 4.60 >50 >50 0.013 >50 5.59 0.436
NKU3006.ec1 D >50 >50 >50 >50 >50 >50 >50 >50 0.766 1.06
P1981.C5.3 G 0.008 0.002 0.160 1.08 0.201 >50 0.004 0.001 0.414 0.0005
X1193.c1 G 0.343 0.001 0.162 0.015 0.120 >50 0.028 0.010 0.194 0.724
X1254.c3 G >50 >50 >50 1.27 0.035 18.5 0.024 0.032 0.051 5.85
X1632.S2.B10 G 0.009 0.0004 0.001 0.006 0.087 5.25 >50 0.070 0.133 0.579





PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
# Viruses 183 183 183 183 183 183 183 183 183 183
# Viruses Neutralized
IC50 <50ug/ml 85 104 143 138 146 94 120 124 165 180
IC50 <10ug/ml 78 103 142 128 144 83 109 123 163 178
IC50 <1.0ug/ml 72 102 131 98 125 47 96 117 124 126
IC50 <0.1ug/ml 64 95 113 76 85 10 81 110 28 34
IC50 <0.01ug/ml 41 85 78 38 22 1 42 83 0 13
% VS Neutralized
IC50 <50ug/ml 46 57 78 75 80 51 66 68 90 98
IC50 <10ug/ml 43 56 78 70 79 45 60 67 89 97
IC50 <1.0ug/ml 39 56 72 54 68 26 52 64 68 69
IC50 <0.1ug/ml 35 52 62 42 46 5 44 60 15 19
IC50 <0.01ug/ml 22 46 43 21 12 1 23 45 0 7
Median IC50 0.010 0.001 0.008 0.060 0.064 0.991 0.023 0.003 0.393 0.544


















PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
0260.v5.c36 A >50 3.28 0.003 >50 1.12 >50 0.039 0.020 0.718 17.7
0330.v4.c3 A >50 0.003 0.007 0.697 0.013 0.468 0.041 0.002 0.072 1.27
0439.v5.c1 A >50 >50 25.7 3.78 >50 >50 >50 0.003 0.282 1.44
3365.v2.c20 A 0.100 0.009 0.006 0.339 0.060 1.00 0.059 0.001 0.096 2.30
3415.v1.c1 A >50 0.351 0.031 >50 0.096 5.46 >50 0.001 0.131 5.29
3718.v3.c11 A 0.105 0.016 0.004 0.046 0.038 0.272 1.40 0.009 0.486 2.36
BB201.B42 A 0.001 0.00003 0.001 0.030 0.007 0.126 0.003 0.006 0.366 0.798
BG505.W6M.C2 A 0.173 0.0004 0.001 0.016 0.053 0.633 0.041 0.0003 0.056 0.310
BI369.9A A 0.008 0.0005 0.008 0.018 0.017 0.387 0.008 0.008 0.310 0.231
BS208.B1 A 0.003 0.00004 0.003 0.001 0.008 0.045 >50 0.002 0.011 0.358
KER2008.12 A >50 0.008 0.003 8.33 0.007 0.802 2.22 0.001 0.844 22.0
KER2018.11 A 0.003 0.00008 0.004 0.003 0.008 0.159 >50 0.002 0.881 2.01
KNH1209.18 A >50 0.005 5.13 >50 0.180 38.9 0.002 0.002 0.142 1.44
MB201.A1 A >50 >50 0.278 2.49 0.103 0.243 0.005 0.005 0.286 0.225
MB539.2B7 A 31.9 0.202 0.002 1.19 0.060 >50 >50 0.001 0.685 7.10
MI369.A5 A 0.039 0.001 0.012 0.010 0.050 0.849 0.022 0.004 0.434 0.691
MS208.A1 A 0.0007 0.002 0.002 0.231 0.079 3.05 >50 0.0007 0.335 0.604
Q23.17 A 0.010 0.002 0.0007 0.002 0.003 0.008 0.004 0.003 0.092 0.783
Q259.17 A 0.001 0.00003 0.020 45.0 0.050 >50 >50 >50 0.074 4.52
Q769.d22 A >50 >50 0.002 0.151 0.011 >50 >50 >50 0.038 1.57
Q842.d12 A >50 0.001 0.003 0.067 0.024 0.223 0.016 0.001 0.036 2.31
QH209.14M.A2 A >50 >50 0.031 0.004 >50 >50 >50 0.0009 0.043 1.74
RW020.2 A >50 >50 0.005 5.17 0.124 >50 0.002 0.002 0.393 1.36
UG037.8 A >50 >50 0.056 2.33 0.014 0.287 0.065 >50 0.126 0.095
3301.V1.C24 AC 0.013 0.002 0.009 0.193 0.230 >50 0.009 0.003 0.163 3.96
3589.V1.C4 AC >50 >50 >50 >50 0.027 7.29 >50 0.001 0.162 1.43
6540.v4.c1 AC 0.077 0.003 0.008 0.003 0.030 0.465 >50 0.003 >50 3.01
6545.V4.C1 AC 0.026 0.005 0.009 0.003 0.036 0.171 >50 0.002 >50 2.03
0815.V3.C3 ACD >50 >50 >50 >50 >50 >50 0.020 0.400 0.028 0.461
6095.V1.C10 ACD 0.0007 0.0003 0.024 0.002 0.151 >50 37.3 >50 1.37 0.602
3468.V1.C12 AD >50 >50 >50 >50 1.62 31.5 0.042 0.070 0.055 0.553
Q168.a2 AD 0.148 0.0009 0.005 0.860 0.060 2.26 >50 0.003 0.126 1.93
Q461.e2 AD 0.502 0.001 0.080 16.0 2.05 >50 >50 1.01 0.569 1.53
620345.c1 AE 0.001 0.005 0.300 0.056 1.01 >50 >50 >50 >50 1.50
BJOX009000.02.4 AE >50 >50 0.097 0.099 1.94 10.1 14.7 >50 2.15 0.558
BJOX010000.06.2 AE >50 >50 2.88 >50 0.303 1.57 >50 >50 9.00 0.074
BJOX025000.01.1 AE >50 >50 0.010 1.44 0.096 >50 >50 >50 0.238 0.221
BJOX028000.10.3 AE >50 >50 0.023 4.00 0.690 >50 >50 >50 3.08 0.045
C1080.c3 AE 0.023 0.006 0.0008 0.010 0.002 0.033 >50 >50 0.212 0.099
C2101.c1 AE >50 >50 0.016 0.005 0.031 1.62 >50 >50 0.111 1.17
C3347.c11 AE >50 >50 0.003 0.004 0.030 6.07 >50 >50 0.217 0.006
C4118.09 AE 0.002 0.00004 0.003 0.002 0.038 0.254 >50 0.071 0.100 0.068
CNE3 AE >50 >50 0.020 0.252 0.064 >50 >50 >50 0.358 1.85
CNE5 AE 0.018 0.0003 0.002 0.002 0.008 0.104 >50 >50 0.394 1.31
CNE55 AE 0.026 0.0002 0.008 0.002 0.197 >50 >50 >50 0.564 0.102
CNE56 AE >50 >50 8.16 1.63 >50 >50 >50 >50 1.12 0.070
CNE59 AE >50 >50 0.005 0.018 0.060 2.61 >50 >50 0.422 0.001
R1166.c1 AE >50 >50 0.791 4.44 1.10 13.1 >50 >50 0.172 0.503
R2184.c4 AE 19.8 0.002 0.002 0.050 0.384 >50 >50 >50 0.269 0.686
TH966.8 AE 0.036 0.004 0.006 0.002 0.015 0.049 >50 >50 0.446 0.024
TH976.17 AE >50 0.006 >50 >50 >50 >50 >50 >50 0.456 0.216
235-47.SG3 AG 0.265 0.045 0.013 3.38 0.124 1.14 0.110 1.50 0.015 0.200
242-14 AG 0.0007 0.0001 0.007 0.033 0.048 >50 >50 0.001 >50 0.912
263-8 AG 0.031 0.011 0.020 13.2 0.211 >50 1.23 >50 0.251 0.243
269-12 AG >50 0.005 1.92 4.36 1.42 7.68 0.164 0.001 0.330 0.106
271-11 AG >50 >50 0.021 35.7 0.059 1.44 11.7 >50 0.055 0.587
928-28 AG 0.097 0.002 0.003 >50 0.038 4.51 31.0 >50 0.639 0.128
DJ263.8 AG 0.031 0.001 0.002 0.018 0.091 2.99 0.064 0.001 0.213 0.015
T250-4 AG 0.001 0.0005 0.0006 0.0004 0.004 0.042 0.001 0.0008 >50 0.480
T251-18 AG >50 >50 9.43 0.318 >50 2.23 10.8 0.065 5.38 0.419
T253-11 AG 49.5 0.008 0.003 >50 0.142 3.06 >50 0.003 0.601 0.919
T255-34 AG >50 >50 0.236 >50 0.020 21.1 >50 0.001 0.699 0.289
T257-31 AG 0.009 0.0002 0.005 3.49 0.019 0.768 >50 0.0009 2.14 0.592
T266-60 AG 1.78 0.004 0.510 0.071 0.321 2.49 0.160 0.003 3.69 >50
T33-7 AG >50 0.266 0.001 4.97 0.019 0.323 >50 3.00 0.026 0.806
3988.25 B >50 0.001 0.010 0.007 0.045 >50 0.002 0.003 0.747 0.143
5768.04 B >50 >50 0.003 0.020 0.270 0.825 0.039 0.008 0.639 3.63
6101.10 B >50 >50 >50 >50 >50 >50 0.002 0.013 0.063 0.002
6535.3 B >50 >50 >50 >50 0.166 0.428 0.003 0.002 2.73 0.365
7165.18 B >50 >50 0.918 0.056 >50 2.30 0.019 >50 25.1 0.602
89.6.DG B >50 >50 >50 >50 >50 >50 0.016 >50 1.25 0.290
AC10.29 B >50 0.002 0.010 0.006 0.031 16.3 0.028 0.004 1.60 0.171
ADA.DG B >50 >50 0.028 0.005 0.216 >50 0.002 >50 0.801 0.011
Bal.01 B >50 >50 0.122 >50 0.569 >50 0.011 0.004 0.156 0.638
BaL.26 B >50 >50 0.017 1.41 0.030 >50 0.010 0.004 0.047 0.538
BG1168.01 B >50 >50 >50 >50 >50 >50 >50 0.006 1.07 0.405
BL01.DG B >50 >50 >50 >50 >50 >50 >50 0.003 >50 0.146
BR07.DG B >50 >50 >50 >50 >50 >50 0.064 0.013 2.80 0.025
BX08.16 B >50 0.0006 0.020 0.007 0.017 0.590 0.002 0.003 0.456 0.205
CAAN.A2 B >50 >50 >50 5.53 6.31 >50 0.005 0.001 1.09 1.14
CNE10 B >50 >50 >50 >50 0.222 >50 0.005 >50 0.939 0.0009
CNE12 B >50 >50 >50 >50 >50 >50 0.002 0.004 1.15 0.121
CNE14 B >50 >50 >50 >50 >50 >50 0.002 0.0009 0.507 0.068
CNE4 B >50 >50 >50 >50 >50 >50 11.5 >50 0.971 0.055
CNE57 B >50 >50 >50 >50 >50 >50 0.008 0.003 0.755 0.058
HO86.8 B >50 >50 0.021 0.002 0.051 0.186 >50 5.77 >50 0.549
HT593.1 B >50 >50 0.426 0.058 0.345 >50 >50 0.004 1.07 0.038
HXB2.DG B >50 >50 >50 >50 1.00 >50 >50 0.005 0.071 0.002
JRCSF.JB B >50 >50 0.009 0.001 0.004 0.782 0.061 0.003 0.483 0.523
JRFL.JB B >50 >50 >50 4.90 >50 >50 0.017 0.003 0.034 0.155
MN.3 B >50 >50 >50 >50 17.1 >50 >50 >50 0.018 0.0003
PVO.04 B 11.8 0.016 1.14 0.143 7.63 24.2 0.132 0.015 0.567 2.81
QH0515.01 B >50 >50 >50 >50 >50 >50 8.70 0.002 1.31 1.82
QH0692.42 B >50 >50 >50 >50 >50 >50 0.940 0.085 1.96 0.581
REJO.67 B >50 >50 0.001 0.0004 0.006 0.620 8.87 0.032 0.116 0.234
RHPA.7 B >50 >50 0.345 0.028 9.97 8.33 0.014 0.003 0.066 1.27
SC422.8 B >50 >50 0.777 0.027 0.542 >50 0.098 0.002 0.205 0.232
SF162.LS B >50 >50 >50 >50 >50 >50 0.004 0.005 0.282 0.105
SS1196.01 B >50 >50 0.246 19.4 0.147 >50 0.002 >50 0.359 0.361
THRO.18 B >50 17.7 0.087 0.006 4.87 9.32 >50 >50 7.76 0.100
TRJO.58 B >50 >50 >50 >50 0.173 >50 4.31 0.242 0.177 0.980
TRO.11 B >50 >50 0.632 0.029 >50 >50 0.006 >50 0.730 0.023
WITO.33 B >50 >50 0.001 0.001 0.007 0.013 0.787 0.003 0.157 0.120
YU2.DG B >50 >50 0.304 0.035 2.08 >50 0.068 >50 0.140 2.23
CH038.12 BC 0.072 0.001 >50 46.5 5.53 >50 0.004 >50 0.542 0.583
CH070.1 BC 0.039 0.026 0.002 0.003 0.006 >50 0.003 >50 9.90 4.67
CH117.4 BC 0.003 0.000005 0.002 0.012 0.006 1.16 >50 2.18 0.153 0.203
CH181.12 BC 0.001 0.0000 0.001 0.0003 0.004 0.494 0.007 >50 1.04 0.456
CNE15 BC >50 0.301 0.005 2.60 0.005 0.356 19.0 0.003 0.181 0.703
CNE19 BC 19.7 0.0000 0.003 0.068 0.015 1.90 0.007 0.002 0.269 0.090
CNE20 BC >50 0.0005 0.006 0.042 0.047 1.18 0.002 >50 8.77 0.108
CNE21 BC 0.001 0.0001 0.002 0.002 0.063 >50 0.004 0.0009 0.566 1.14
CNE40 BC >50 0.016 0.483 0.214 0.812 >50 0.224 0.005 0.602 0.0004
CNE7 BC 0.003 0.003 0.007 0.259 1.02 >50 0.032 0.020 0.327 0.184
286.36 C 0.005 0.0003 0.024 0.003 0.185 8.92 0.002 0.005 0.406 0.946
288.38 C >50 >50 1.32 2.61 2.42 8.83 0.006 >50 3.73 0.322
0013095-2.11 C 0.021 0.029 0.007 16.6 0.012 0.981 >50 >50 0.169 0.002
001428-2.42 C 30.9 0.070 0.004 0.0006 0.002 0.074 0.023 0.011 0.020 1.73
0077_V1.C16 C 0.001 0.006 0.002 0.194 0.083 42.9 >50 0.0007 2.09 2.45
00836-2.5 C >50 >50 0.004 0.887 >50 >50 31.8 0.009 0.255 0.797
0921.V2.C14 C 0.036 0.0001 0.005 0.011 0.004 0.382 >50 >50 0.260 1.25
16055-2.3 C 0.004 0.0005 0.002 0.008 0.016 >50 1.02 0.070 0.093 0.605
16845-2.22 C >50 >50 >50 46.7 1.96 5.74 9.41 >50 6.62 0.006
16936-2.21 C 0.250 0.002 1.38 5.14 >50 >50 0.003 0.103 0.301 0.221
25710-2.43 C 0.008 0.0000 0.008 0.002 0.031 2.50 0.014 2.00 0.973 0.040
25711-2.4 C >50 >50 0.763 7.46 0.932 2.78 0.010 0.002 1.18 1.01
25925-2.22 C 0.013 0.0000 0.004 0.003 0.025 2.10 0.024 0.002 0.907 0.491
26191-2.48 C 0.001 0.0001 0.018 0.053 0.132 3.00 0.150 >50 0.325 2.40
3168.V4.C10 C >50 0.109 0.056 0.028 0.092 1.18 0.485 >50 0.215 2.47
3637.V5.C3 C >50 >50 >50 >50 >50 >50 >50 0.055 5.46 2.02
6322.V4.C1 C 0.003 0.0008 0.012 0.073 >50 >50 >50 >50 >50 4.23
6471.V1.C16 C >50 >50 >50 >50 >50 >50 >50 24.4 >50 5.61
6631.V3.C10 C >50 >50 >50 >50 >50 >50 >50 0.002 >50 1.06
6644.V2.C33 C >50 >50 >50 >50 0.025 >50 0.018 >50 0.233 0.007
6785.V5.C14 C 0.005 0.0003 0.010 0.105 0.008 0.879 0.019 >50 0.416 0.550
6838.V1.C35 C 0.001 0.0007 0.001 0.215 0.006 0.137 0.119 0.025 0.338 0.457
96ZM651.02 C 2.63 0.494 0.092 7.33 >50 >50 0.009 0.001 1.01 0.018
BR025.9 C >50 >50 0.004 8.67 0.019 0.224 0.002 0.081 0.437 0.315
CAP210.E8 C 0.003 0.0002 0.001 >50 0.165 15.7 >50 0.002 >50 0.815
CAP244.D3 C 46.0 >50 4.48 12.0 0.067 0.655 >50 0.069 1.01 0.316
CAP256.206.C9 C 0.002 0.0002 0.005 2.20 0.060 2.13 0.009 >50 0.628 0.950
CAP45.G3 C 4.00 0.0000 0.002 0.0008 0.003 0.105 2.08 0.001 5.63 0.919
CNE30 C >50 >50 >50 >50 >50 >50 0.061 0.100 0.954 0.873
CNE31 C >50 >50 0.246 0.068 15.8 >50 0.789 0.002 1.30 0.942
CNE53 C >50 >50 0.017 0.019 0.080 0.236 0.022 >50 0.113 0.425
CNE58 C 0.006 0.0000 0.004 0.062 0.022 0.047 >50 0.0007 0.221 0.501
DU123.06 C 0.015 0.008 0.001 0.024 0.062 0.515 0.033 >50 6.73 0.122
DU151.02 C 0.006 0.0003 0.001 0.006 0.016 0.671 0.005 0.070 11.0 0.588
DU156.12 C 0.006 0.002 0.001 0.008 0.041 0.305 0.005 0.002 0.159 0.004
DU172.17 C >50 >50 2.37 >50 0.190 7.70 0.104 0.0009 >50 0.026
DU422.01 C 1.12 0.053 >50 >50 >50 >50 0.164 0.400 >50 0.189
MW965.26 C 0.003 0.019 0.023 0.147 0.619 >50 0.011 0.038 0.048 0.0005
SO18.18 C 0.002 0.0008 0.003 0.002 0.021 9.73 0.002 0.002 0.066 2.37
TV1.29 C >50 0.339 0.002 3.34 0.005 0.680 0.118 0.0003 >50 0.156
TZA125.17 C 0.018 0.002 0.044 0.115 0.140 >50 9.96 0.056 >50 0.484
TZBD.02 C 0.036 0.003 0.013 0.035 0.170 20.0 0.005 0.001 0.065 1.94
ZA012.29 C >50 >50 2.21 1.26 7.47 >50 0.005 0.054 0.300 3.09
ZM106.9 C 0.010 0.007 0.002 0.016 0.492 >50 0.005 >50 0.256 >50
ZM109.4 C >50 0.003 0.003 0.012 0.154 >50 13.7 0.348 0.150 0.353
ZM135.10a C >50 >50 >50 >50 >50 >50 1.50 >50 1.66 0.180
ZM176.66 C 0.029 0.0001 0.003 0.032 0.010 1.89 13.8 0.0008 0.065 0.246
ZM197.7 C 0.002 0.005 0.024 0.523 0.369 >50 >50 0.002 0.966 0.088
ZM214.15 C 3.23 0.002 >50 >50 >50 >50 0.682 0.012 2.09 2.46
ZM215.8 C >50 >50 0.002 >50 0.073 >50 0.014 0.029 0.442 0.041
ZM233.6 C 0.003 0.0005 0.002 0.008 0.148 0.074 1.14 0.004 2.51 0.110
ZM249.1 C 0.0009 0.0008 0.001 1.99 0.043 >50 >50 0.0009 0.128 0.735
ZM53.12 C 0.003 0.0001 0.007 0.154 0.036 >50 0.002 >50 1.57 2.19
ZM55.28a C 0.005 0.001 0.022 0.687 3.15 >50 0.070 0.0008 0.411 2.85
3326.V4.C3 CD 0.007 0.0000 0.006 0.009 0.030 >50 >50 0.224 0.088 1.25
3337.V2.C6 CD 0.044 0.0002 >50 >50 >50 >50 21.1 0.001 0.100 1.53
3817.v2.c59 CD >50 >50 >50 >50 0.004 0.092 >50 >50 >50 0.354
231965.c1 D >50 >50 0.001 0.122 0.682 >50 >50 0.002 0.278 6.32
247-23 D 0.005 0.0001 0.008 0.017 0.092 >50 >50 >50 3.57 0.659
3016.v5.c45 D 0.005 0.0002 >50 25.4 0.283 >50 >50 0.078 0.172 0.240
57128.vrc15 D >50 0.004 0.003 0.118 0.122 >50 2.16 >50 >50 0.611
6405.v4.c34 D >50 >50 >50 >50 >50 >50 0.019 0.020 2.40 0.674
A03349M1.vrc4a D 2.68 0.004 0.013 4.60 >50 >50 0.013 >50 5.59 0.436
NKU3006.ec1 D >50 >50 >50 >50 >50 >50 >50 >50 0.766 1.06
P1981.C5.3 G 0.008 0.002 0.160 1.08 0.201 >50 0.004 0.001 0.414 0.0005
X1193.c1 G 0.343 0.001 0.162 0.015 0.120 >50 0.028 0.010 0.194 0.724
X1254.c3 G >50 >50 >50 1.27 0.035 18.5 0.024 0.032 0.051 5.85
X1632.S2.B10 G 0.009 0.0004 0.001 0.006 0.087 5.25 >50 0.070 0.133 0.579





PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
# Viruses 183 183 183 183 183 183 183 183 183 183
# Viruses Neutralized
IC50 <50ug/ml 85 104 143 138 146 94 120 124 165 180
IC50 <10ug/ml 78 103 142 128 144 83 109 123 163 178
IC50 <1.0ug/ml 72 102 131 98 125 47 96 117 124 126
IC50 <0.1ug/ml 64 95 113 76 85 10 81 110 28 34
IC50 <0.01ug/ml 41 85 78 38 22 1 42 83 0 13
% VS Neutralized
IC50 <50ug/ml 46 57 78 75 80 51 66 68 90 98
IC50 <10ug/ml 43 56 78 70 79 45 60 67 89 97
IC50 <1.0ug/ml 39 56 72 54 68 26 52 64 68 69
IC50 <0.1ug/ml 35 52 62 42 46 5 44 60 15 19
IC50 <0.01ug/ml 22 46 43 21 12 1 23 45 0 7
Median IC50 0.010 0.001 0.008 0.060 0.064 0.991 0.023 0.003 0.393 0.544
Geometric Mean 0.026 0.002 0.016 0.095 0.085 1.06 0.053 0.007 0.396 0.336







PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
0260.v5.c36 A >50 >50 0.014 >50 8.41 >50 0.143 >50 1.50 27.7
0330.v4.c3 A >50 1.04 0.015 18.5 0.038 >50 0.194 0.009 0.188 3.72
0439.v5.c1 A >50 >50 >50 16.1 >50 >50 >50 >50 0.628 4.81
3365.v2.c20 A >50 >50 0.040 34.7 0.233 >50 1.34 0.002 0.181 5.74
3415.v1.c1 A >50 >50 0.395 >50 0.540 >50 >50 0.003 0.297 9.14
3718.v3.c11 A >50 >50 0.014 0.971 0.136 5.33 8.64 0.055 12.1 7.47
BB201.B42 A 0.500 0.001 0.004 2.00 0.026 2.35 0.011 0.115 0.932 2.78
BG505.W6M.C2 A >50 0.012 0.003 0.160 0.141 >50 0.337 0.003 0.153 1.41
BI369.9A A 0.099 0.004 0.023 0.348 0.067 2.16 0.043 0.519 0.925 1.24
BS208.B1 A 0.012 0.0004 0.009 0.008 0.027 0.313 >50 0.070 0.059 2.93
KER2008.12 A >50 0.183 0.012 >50 0.028 >50 >50 0.060 1.76 >50
KER2018.11 A 0.001 0.002 0.012 0.037 0.029 2.02 >50 0.006 1.84 6.38
KNH1209.18 A >50 8.85 >50 >50 >50 >50 0.007 0.007 0.370 5.09
MB201.A1 A >50 >50 0.938 38.1 0.305 >50 0.026 0.211 0.633 1.57
MB539.2B7 A >50 4.00 0.005 >50 0.256 >50 >50 0.010 1.29 >50
MI369.A5 A 2.86 0.019 0.042 0.132 0.226 >50 0.087 0.125 1.15 3.01
MS208.A1 A 1.00 0.232 0.500 30.3 0.609 >50 >50 0.002 1.04 2.54
Q23.17 A >50 1.30 0.004 6.73 0.012 0.028 0.019 0.013 0.252 3.02
Q259.17 A 0.259 0.0003 10.0 >50 0.340 >50 >50 >50 0.251 10.7
Q769.d22 A >50 >50 0.005 4.71 0.038 >50 >50 >50 0.103 4.08
Q842.d12 A >50 0.123 0.007 0.837 0.068 3.75 0.047 0.010 0.089 6.53
QH209.14M.A2 A >50 >50 0.106 0.018 >50 >50 >50 0.003 0.116 4.70
RW020.2 A >50 >50 0.020 >50 0.771 >50 0.009 0.005 0.859 4.10
UG037.8 A >50 >50 0.203 >50 0.080 >50 0.237 >50 0.301 0.661
3301.V1.C24 AC 0.002 0.020 0.075 2.30 1.40 >50 0.030 0.070 0.431 10.2
3589.V1.C4 AC >50 >50 >50 >50 0.098 >50 >50 0.006 0.385 4.32
6540.v4.c1 AC 29.2 0.051 0.022 0.046 0.105 >50 >50 0.020 >50 7.86
6545.V4.C1 AC 27.6 0.096 0.026 0.070 0.144 >50 >50 0.010 >50 6.06
0815.V3.C3 ACD >50 >50 >50 >50 >50 >50 0.072 >50 0.093 1.76
6095.V1.C10 ACD 0.100 0.005 0.062 0.050 1.13 >50 >50 >50 3.81 0.004
3468.V1.C12 AD >50 >50 >50 >50 >50 >50 1.05 >50 0.171 2.75
Q168.a2 AD >50 >50 0.013 25.4 0.179 >50 >50 0.014 0.284 5.23
Q461.e2 AD 19.3 0.080 0.579 >50 15.6 >50 >50 >50 1.54 4.45
620345.c1 AE 0.090 0.051 >50 1.99 >50 >50 >50 >50 >50 4.16
BJOX009000.02.4 AE >50 >50 0.437 0.468 7.73 >50 >50 >50 6.38 3.25
BJOX010000.06.2 AE >50 >50 42.2 >50 1.55 16.7 >50 >50 21.2 0.844
BJOX025000.01.1 AE >50 >50 0.090 10.3 0.826 >50 >50 >50 0.979 1.94
BJOX028000.10.3 AE >50 >50 0.243 >50 3.68 >50 >50 >50 10.3 0.610
C1080.c3 AE 0.046 0.718 0.003 0.247 0.008 >50 >50 >50 0.587 0.683
C2101.c1 AE >50 >50 0.041 0.049 0.139 >50 >50 >50 0.279 4.72
C3347.c11 AE >50 >50 0.015 0.023 0.103 >50 >50 >50 0.706 0.047
C4118.09 AE 0.020 0.001 0.009 0.009 0.093 2.41 >50 >50 0.342 1.03
CNE3 AE >50 >50 >50 21.4 0.598 >50 >50 >50 0.962 4.82
CNE5 AE 0.241 0.024 0.006 0.013 0.027 >50 >50 >50 1.14 3.92
CNE55 AE 5.00 0.006 0.030 0.015 2.08 >50 >50 >50 1.53 1.26
CNE56 AE >50 >50 26.0 5.91 >50 >50 >50 >50 2.93 0.490
CNE59 AE >50 >50 0.019 0.664 0.443 >50 >50 >50 1.13 0.030
R1166.c1 AE >50 >50 2.50 43.6 3.90 >50 >50 >50 0.407 1.75
R2184.c4 AE >50 5.00 0.006 0.482 2.23 >50 >50 >50 1.76 2.23
TH966.8 AE 0.052 0.089 0.016 0.023 0.061 0.098 >50 >50 1.44 0.315
TH976.17 AE >50 8.00 >50 >50 >50 >50 >50 >50 1.23 1.50
235-47.SG3 AG 16.4 2.55 0.043 20.2 0.803 >50 0.842 >50 0.160 0.889
242-14 AG 0.300 0.005 0.033 1.36 0.151 >50 >50 0.020 >50 3.10
263-8 AG 1.88 0.270 0.088 >50 1.27 >50 7.73 >50 0.631 0.996
269-12 AG >50 0.182 4.33 39.4 5.17 >50 1.26 0.005 1.05 0.654
271-11 AG >50 >50 0.081 >50 0.948 >50 >50 >50 0.279 4.21
928-28 AG 4.31 0.041 0.200 >50 0.225 41.3 >50 >50 1.17 0.878
DJ263.8 AG 0.099 0.014 0.009 0.170 0.551 >50 0.202 0.005 3.53 0.176
T250-4 AG 0.007 0.002 0.002 0.030 0.017 0.284 0.012 0.003 >50 2.23
T251-18 AG >50 >50 >50 1.13 >50 >50 >50 >50 10.9 2.09
T253-11 AG >50 32.5 0.016 >50 0.819 >50 >50 0.016 1.29 3.27
T255-34 AG >50 >50 >50 >50 0.126 >50 >50 0.005 1.97 1.83
T257-31 AG 0.118 0.002 0.017 >50 0.059 >50 >50 0.003 6.65 1.94
T266-60 AG 12.0 0.110 1.24 0.276 1.42 >50 0.620 0.023 8.63 >50
T33-7 AG >50 >50 0.008 >50 0.162 3.13 >50 >50 0.060 3.23
3988.25 B >50 0.110 0.100 0.021 0.200 >50 0.008 0.009 1.46 0.651
5768.04 B >50 >50 0.200 0.725 2.54 >50 0.897 0.076 1.54 9.18
6101.10 B >50 >50 >50 >50 >50 >50 0.018 0.366 0.198 0.021
6535.3 B >50 >50 >50 >50 1.22 >50 0.011 0.006 7.90 2.88
7165.18 B >50 >50 4.88 0.217 >50 >50 0.074 >50 >50 2.54
89.6.DG B >50 >50 >50 >50 >50 >50 0.077 >50 3.64 1.14
AC10.29 B >50 1.00 0.090 0.024 0.191 >50 0.118 0.018 3.36 0.947
ADA.DG B >50 >50 0.252 0.047 >50 >50 0.015 >50 1.84 0.127
Bal.01 B >50 >50 >50 >50 >50 >50 0.044 0.029 0.556 2.49
BaL.26 B >50 >50 39.4 >50 0.356 >50 0.050 0.020 0.200 2.24
BG1168.01 B >50 >50 >50 >50 >50 >50 >50 0.046 3.99 1.52
BL01.DG B >50 >50 >50 >50 >50 >50 >50 0.019 >50 1.34
BR07.DG B >50 >50 >50 >50 >50 >50 0.338 >50 7.74 0.304
BX08.16 B >50 >50 0.199 0.100 0.101 >50 0.007 0.060 1.09 1.33
CAAN.A2 B >50 >50 >50 16.5 >50 >50 0.027 0.008 2.85 5.97
CNE10 B >50 >50 >50 >50 1.68 >50 0.027 >50 2.12 0.033
CNE12 B >50 >50 >50 >50 >50 >50 0.014 3.00 2.61 0.875
CNE14 B >50 >50 >50 >50 >50 >50 0.007 0.020 1.25 0.706
CNE4 B >50 >50 >50 >50 >50 >50 >50 >50 2.80 0.707
CNE57 B >50 >50 >50 >50 >50 >50 0.035 0.019 1.62 0.423
HO86.8 B >50 >50 0.104 0.026 0.345 >50 >50 >50 >50 2.59
HT593.1 B >50 >50 1.02 0.154 4.05 >50 >50 0.019 2.58 0.304
HXB2.DG B >50 >50 >50 >50 40.0 >50 >50 0.070 0.178 0.007
JRCSF.JB B >50 >50 0.071 0.007 0.016 >50 0.219 0.030 1.21 2.38
JRFL.JB B >50 >50 >50 48.4 >50 >50 0.071 0.020 0.103 0.824
MN.3 B >50 >50 >50 >50 >50 >50 >50 >50 0.064 0.0003
PVO.04 B >50 0.289 3.17 0.448 20.7 >50 0.436 >50 1.39 8.54
QH0515.01 B >50 >50 >50 >50 >50 >50 >50 0.007 3.56 5.46
QH0692.42 B >50 >50 >50 >50 >50 >50 9.70 >50 5.16 2.84
REJO.67 B >50 >50 0.003 0.002 0.056 >50 >50 0.307 0.291 1.20
RHPA.7 B >50 >50 0.877 0.076 >50 >50 0.046 0.020 0.162 5.05
SC422.8 B >50 >50 3.37 0.076 18.1 >50 0.362 0.010 0.471 1.06
SF162.LS B >50 >50 >50 >50 >50 >50 0.017 0.034 0.770 0.766
SS1196.01 B >50 >50 2.06 >50 1.15 >50 0.011 >50 0.905 1.91
THRO.18 B >50 >50 0.250 0.017 >50 >50 >50 >50 >50 0.715
TRJO.58 B >50 >50 >50 >50 1.81 >50 >50 2.95 0.340 4.33
TRO.11 B >50 >50 1.97 0.092 >50 >50 0.032 >50 1.70 0.398
WITO.33 B >50 >50 0.002 0.004 0.020 0.103 3.25 0.025 0.458 0.943
YU2.DG B >50 >50 0.742 0.091 >50 >50 0.178 >50 0.324 9.46
CH038.12 BC 0.400 0.015 >50 >50 >50 >50 0.020 >50 1.29 2.63
CH070.1 BC 0.500 >50 0.004 0.259 0.018 >50 0.015 >50 >50 14.1
CH117.4 BC 0.042 0.00004 0.004 0.275 0.020 >50 >50 >50 0.352 0.883
CH181.12 BC 0.009 0.00004 0.002 0.0003 0.019 >50 0.039 >50 2.01 2.75
CNE15 BC >50 >50 0.029 >50 0.018 >50 >50 0.088 0.452 2.72
CNE19 BC >50 0.008 0.007 1.32 0.068 >50 0.063 1.00 0.718 0.813
CNE20 BC >50 0.109 0.013 0.917 0.163 >50 0.008 >50 >50 0.650
CNE21 BC 0.023 0.002 0.005 0.014 0.397 >50 0.018 0.003 1.65 4.55
CNE40 BC >50 0.449 1.53 1.41 7.71 >50 1.85 >50 4.43 0.003
CNE7 BC 0.046 0.024 0.032 1.99 4.28 >50 0.096 0.600 1.02 0.958
286.36 C 0.024 0.004 0.046 0.012 0.668 >50 0.009 0.122 1.22 4.41
288.38 C >50 >50 9.87 47.1 >50 >50 0.035 >50 5.95 2.29
0013095-2.11 C >50 >50 0.015 >50 0.074 >50 >50 >50 0.266 0.058
001428-2.42 C >50 >50 0.018 0.020 0.007 >50 0.076 >50 0.059 4.95
0077_V1.C16 C 0.020 0.023 0.007 1.31 0.342 >50 >50 0.002 4.78 12.4
00836-2.5 C >50 >50 0.200 >50 >50 >50 >50 >50 0.799 1.39
0921.V2.C14 C 1.00 0.002 0.014 0.171 0.012 >50 >50 >50 0.794 3.68
16055-2.3 C 0.015 0.005 0.007 0.073 0.037 >50 12.2 >50 0.287 2.84
16845-2.22 C >50 >50 >50 >50 >50 >50 >50 >50 21.5 0.094
16936-2.21 C >50 0.065 >50 >50 >50 >50 0.013 >50 0.825 0.958
25710-2.43 C 0.540 0.004 0.015 0.011 0.139 >50 0.055 >50 2.25 0.282
25711-2.4 C >50 >50 3.31 >50 3.69 >50 0.041 0.019 2.30 2.33
25925-2.22 C 0.078 0.0009 0.011 0.046 0.071 >50 0.072 0.070 2.11 2.01
26191-2.48 C 0.050 0.003 >50 3.17 0.809 >50 0.393 >50 0.900 5.44
3168.V4.C10 C >50 >50 0.502 0.101 0.393 >50 1.94 >50 0.553 7.32
3637.V5.C3 C >50 >50 >50 >50 >50 >50 >50 >50 9.49 7.93
6322.V4.C1 C 0.002 0.012 0.036 1.61 >50 >50 >50 >50 >50 10.2
6471.V1.C16 C >50 >50 >50 >50 >50 >50 >50 >50 >50 21.9
6631.V3.C10 C >50 >50 >50 >50 >50 >50 >50 0.009 >50 3.69
6644.V2.C33 C >50 >50 >50 >50 0.103 >50 0.171 >50 0.659 0.115
6785.V5.C14 C 0.036 0.006 0.059 9.61 0.043 >50 0.072 >50 1.17 2.55
6838.V1.C35 C 0.200 0.042 0.080 14.0 0.032 >50 0.840 >50 0.995 1.55
96ZM651.02 C >50 >50 0.652 >50 >50 >50 0.044 0.070 3.09 0.175
BR025.9 C >50 >50 0.009 >50 0.065 1.37 0.008 >50 2.67 1.27
CAP210.E8 C 0.009 0.004 1.50 >50 0.876 >50 >50 0.037 >50 3.84
CAP244.D3 C >50 >50 >50 >50 0.231 11.8 >50 >50 2.83 1.85
CAP256.206.C9 C 0.006 0.002 0.014 >50 0.142 >50 0.059 >50 1.37 4.28
CAP45.G3 C 0.070 0.001 0.006 0.016 0.010 0.693 19.6 0.012 31.6 3.38
CNE30 C >50 >50 >50 >50 >50 >50 0.249 >50 2.56 4.16
CNE31 C >50 >50 0.898 0.328 >50 >50 2.68 0.006 2.73 2.72
CNE53 C >50 >50 0.089 0.094 0.430 >50 0.054 >50 0.320 1.73
CNE58 C 0.028 0.003 0.011 0.864 0.064 0.776 >50 0.003 0.506 2.52
DU123.06 C 2.29 10.0 0.020 0.355 0.315 4.87 0.101 >50 >50 0.597
DU151.02 C 1.24 0.008 0.004 0.050 0.054 >50 0.021 >50 >50 2.24
DU156.12 C 0.515 0.051 0.003 0.198 0.143 5.46 0.023 0.008 0.403 0.051
DU172.17 C >50 >50 7.10 >50 0.758 >50 0.846 0.010 >50 0.300
DU422.01 C 40.9 0.109 >50 >50 >50 >50 0.365 >50 >50 1.10
MW965.26 C 0.677 0.572 0.317 6.69 26.0 >50 0.051 0.650 0.146 0.007
SO18.18 C 0.013 0.004 0.009 0.200 0.065 >50 0.006 0.007 0.145 5.60
TV1.29 C >50 >50 0.004 >50 0.027 >50 0.318 0.004 >50 0.681
TZA125.17 C 4.40 0.028 0.316 2.50 0.808 >50 >50 1.82 >50 2.17
TZBD.02 C 0.140 0.016 0.042 0.685 0.676 >50 0.060 0.005 0.197 5.39
ZA012.29 C >50 >50 >50 >50 >50 >50 0.021 >50 0.680 6.43
ZM106.9 C 0.500 0.055 0.005 0.203 4.19 >50 0.018 >50 0.535 >50
ZM109.4 C >50 0.253 0.070 0.149 2.44 >50 >50 >50 0.392 2.45
ZM135.10a C >50 >50 >50 >50 >50 >50 9.25 >50 5.72 1.14
ZM176.66 C 10.0 0.001 0.007 1.46 0.033 >50 >50 0.003 0.319 2.16
ZM197.7 C 0.030 0.033 0.170 6.17 2.13 >50 >50 0.015 2.18 0.629
ZM214.15 C >50 0.231 >50 >50 >50 >50 2.37 0.175 5.33 7.10
ZM215.8 C >50 >50 0.011 >50 0.497 >50 0.057 0.149 1.26 0.342
ZM233.6 C 0.022 0.002 0.004 0.396 0.457 0.366 0.296 >50 7.27 0.509
ZM249.1 C 0.128 0.021 2.50 >50 0.267 >50 >50 0.004 0.348 1.62
ZM53.12 C 0.007 0.0009 0.019 6.89 0.129 >50 0.016 >50 3.81 10.4
ZM55.28a C 0.159 0.048 0.106 5.35 >50 >50 0.233 0.003 1.18 11.8
3326.V4.C3 CD 0.044 0.0003 0.012 0.170 0.103 >50 >50 >50 >50 4.51
3337.V2.C6 CD 0.100 0.001 >50 >50 >50 >50 >50 0.002 0.193 5.51
3817.v2.c59 CD >50 >50 >50 >50 0.015 0.734 >50 >50 >50 2.30
231965.c1 D >50 >50 3.00 2.90 >50 >50 >50 0.008 1.26 12.9
247-23 D 1.18 0.005 0.020 0.633 0.422 >50 >50 >50 0.396 1.77
3016.v5.c45 D 2.67 0.005 >50 >50 12.6 >50 >50 9.71 >50 1.42
57128.vrc15 D >50 2.00 0.400 1.48 0.465 >50 >50 >50 5.83 2.46
6405.v4.c34 D >50 >50 >50 >50 >50 >50 0.080 3.00 9.94 3.45
A03349M1.vrc4a D >50 0.120 0.272 >50 >50 >50 0.155 >50 14.8 1.20
NKU3006.ec1 D >50 >50 >50 >50 >50 >50 >50 >50 1.99 3.33
P1981.C5.3 G 0.039 0.022 >50 39.4 2.68 >50 0.013 4.44 1.04 0.020
X1193.c1 G 8.04 0.600 0.517 0.052 0.378 >50 0.091 0.300 0.426 2.47
X1254.c3 G >50 >50 >50 10.1 0.125 >50 0.069 >50 0.147 >50
X1632.S2.B10 G 0.037 0.010 0.005 0.091 0.849 >50 >50 >50 0.597 2.35





PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
# Viruses 183 183 183 183 183 183 183 183 183 183
# Viruses Neutralized
IC80 <50ug/ml 68 89 131 109 129 22 102 90 158 177
IC80 <10ug/ml 61 87 127 92 123 19 100 90 151 167
IC80 <1.0ug/ml 49 78 111 69 98 9 88 83 76 52
IC80 <0.1ug/ml 32 61 83 37 40 2 63 71 6 13
IC80 <0.01ug/ml 8 35 33 6 2 0 10 33 0 5
% VS Neutralized
IC80 <50ug/ml 37 49 72 60 70 12 56 49 86 97
IC80 <10ug/ml 33 48 69 50 67 10 55 49 83 91
IC80 <1.0ug/ml 27 43 61 38 54 5 48 45 42 28
IC80 <0.1ug/ml 17 33 45 20 22 1 34 39 3 7
IC80 <0.01ug/ml 4 19 18 3 1 0 5 18 0 3
Median IC80 0.109 0.022 0.036 0.328 0.233 2.09 0.066 0.019 1.05 2.24
Geometric Mean 0.184 0.026 0.064 0.405 0.280 1.40 0.096 0.027 0.985 1.50
  
 







PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
0260.v5.c36 A >50 >50 0.014 >50 8.41 >50 0.143 >50 1.50 27.7
0330.v4.c3 A >50 1.04 0.015 18.5 0.038 >50 0.194 0.009 0.188 3.72
0439.v5.c1 A >50 >50 >50 16.1 >50 >50 >50 >50 0.628 4.81
3365.v2.c20 A >50 >50 0.040 34.7 0.233 >50 1.34 0.002 0.181 5.74
3415.v1.c1 A >50 >50 0.395 >50 0.540 >50 >50 0.003 0.297 9.14
3718.v3.c11 A >50 >50 0.014 0.971 0.136 5.33 8.64 0.055 12.1 7.47
BB201.B42 A 0.500 0.001 0.004 2.00 0.026 2.35 0.011 0.115 0.932 2.78
BG505.W6M.C2 A >50 0.012 0.003 0.160 0.141 >50 0.337 0.003 0.153 1.41
BI369.9A A 0.099 0.004 0.023 0.348 0.067 2.16 0.043 0.519 0.925 1.24
BS208.B1 A 0.012 0.0004 0.009 0.008 0.027 0.313 >50 0.070 0.059 2.93
KER2008.12 A >50 0.183 0.012 >50 0.028 >50 >50 0.060 1.76 >50
KER2018.11 A 0.001 0.002 0.012 0.037 0.029 2.02 >50 0.006 1.84 6.38
KNH1209.18 A >50 8.85 >50 >50 >50 >50 0.007 0.007 0.370 5.09
MB201.A1 A >50 >50 0.938 38.1 0.305 >50 0.026 0.211 0.633 1.57
MB539.2B7 A >50 4.00 0.005 >50 0.256 >50 >50 0.010 1.29 >50
MI369.A5 A 2.86 0.019 0.042 0.132 0.226 >50 0.087 0.125 1.15 3.01
MS208.A1 A 1.00 0.232 0.500 30.3 0.609 >50 >50 0.002 1.04 2.54
Q23.17 A >50 1.30 0.004 6.73 0.012 0.028 0.019 0.013 0.252 3.02
Q259.17 A 0.259 0.0003 10.0 >50 0.340 >50 >50 >50 0.251 10.7
Q769.d22 A >50 >50 0.005 4.71 0.038 >50 >50 >50 0.103 4.08
Q842.d12 A >50 0.123 0.007 0.837 0.068 3.75 0.047 0.010 0.089 6.53
QH209.14M.A2 A >50 >50 0.106 0.018 >50 >50 >50 0.003 0.116 4.70
RW020.2 A >50 >50 0.020 >50 0.771 >50 0.009 0.005 0.859 4.10
UG037.8 A >50 >50 0.203 >50 0.080 >50 0.237 >50 0.301 0.661
3301.V1.C24 AC 0.002 0.020 0.075 2.30 1.40 >50 0.030 0.070 0.431 10.2
3589.V1.C4 AC >50 >50 >50 >50 0.098 >50 >50 0.006 0.385 4.32
6540.v4.c1 AC 29.2 0.051 0.022 0.046 0.105 >50 >50 0.020 >50 7.86
6545.V4.C1 AC 27.6 0.096 0.026 0.070 0.144 >50 >50 0.010 >50 6.06
0815.V3.C3 ACD >50 >50 >50 >50 >50 >50 0.072 >50 0.093 1.76
6095.V1.C10 ACD 0.100 0.005 0.062 0.050 1.13 >50 >50 >50 3.81 0.004
3468.V1.C12 AD >50 >50 >50 >50 >50 >50 1.05 >50 0.171 2.75
Q168.a2 AD >50 >50 0.013 25.4 0.179 >50 >50 0.014 0.284 5.23
Q461.e2 AD 19.3 0.080 0.579 >50 15.6 >50 >50 >50 1.54 4.45
620345.c1 AE 0.090 0.051 >50 1.99 >50 >50 >50 >50 >50 4.16
BJOX009000.02.4 AE >50 >50 0.437 0.468 7.73 >50 >50 >50 6.38 3.25
BJOX010000.06.2 AE >50 >50 42.2 >50 1.55 16.7 >50 >50 21.2 0.844
BJOX025000.01.1 AE >50 >50 0.090 10.3 0.826 >50 >50 >50 0.979 1.94
BJOX028000.10.3 AE >50 >50 0.243 >50 3.68 >50 >50 >50 10.3 0.610
C1080.c3 AE 0.046 0.718 0.003 0.247 0.008 >50 >50 >50 0.587 0.683
C2101.c1 AE >50 >50 0.041 0.049 0.139 >50 >50 >50 0.279 4.72
C3347.c11 AE >50 >50 0.015 0.023 0.103 >50 >50 >50 0.706 0.047
C4118.09 AE 0.020 0.001 0.009 0.009 0.093 2.41 >50 >50 0.342 1.03
CNE3 AE >50 >50 >50 21.4 0.598 >50 >50 >50 0.962 4.82
CNE5 AE 0.241 0.024 0.006 0.013 0.027 >50 >50 >50 1.14 3.92
CNE55 AE 5.00 0.006 0.030 0.015 2.08 >50 >50 >50 1.53 1.26
CNE56 AE >50 >50 26.0 5.91 >50 >50 >50 >50 2.93 0.490
CNE59 AE >50 >50 0.019 0.664 0.443 >50 >50 >50 1.13 0.030
R1166.c1 AE >50 >50 2.50 43.6 3.90 >50 >50 >50 0.407 1.75
R2184.c4 AE >50 5.00 0.006 0.482 2.23 >50 >50 >50 1.76 2.23
TH966.8 AE 0.052 0.089 0.016 0.023 0.061 0.098 >50 >50 1.44 0.315
TH976.17 AE >50 8.00 >50 >50 >50 >50 >50 >50 1.23 1.50
235-47.SG3 AG 16.4 2.55 0.043 20.2 0.803 >50 0.842 >50 0.160 0.889
242-14 AG 0.300 0.005 0.033 1.36 0.151 >50 >50 0.020 >50 3.10
263-8 AG 1.88 0.270 0.088 >50 1.27 >50 7.73 >50 0.631 0.996
269-12 AG >50 0.182 4.33 39.4 5.17 >50 1.26 0.005 1.05 0.654
271-11 AG >50 >50 0.081 >50 0.948 >50 >50 >50 0.279 4.21
928-28 AG 4.31 0.041 0.200 >50 0.225 41.3 >50 >50 1.17 0.878
DJ263.8 AG 0.099 0.014 0.009 0.170 0.551 >50 0.202 0.005 3.53 0.176
T250-4 AG 0.007 0.002 0.002 0.030 0.017 0.284 0.012 0.003 >50 2.23
T251-18 AG >50 >50 >50 1.13 >50 >50 >50 >50 10.9 2.09
T253-11 AG >50 32.5 0.016 >50 0.819 >50 >50 0.016 1.29 3.27
T255-34 AG >50 >50 >50 >50 0.126 >50 >50 0.005 1.97 1.83
T257-31 AG 0.118 0.002 0.017 >50 0.059 >50 >50 0.003 6.65 1.94
T266-60 AG 12.0 0.110 1.24 0.276 1.42 >50 0.620 0.023 8.63 >50
T33-7 AG >50 >50 0.008 >50 0.162 3.13 >50 >50 0.060 3.23
3988.25 B >50 0.110 0.100 0.021 0.200 >50 0.008 0.009 1.46 0.651
5768.04 B >50 >50 0.200 0.725 2.54 >50 0.897 0.076 1.54 9.18
6101.10 B >50 >50 >50 >50 >50 >50 0.018 0.366 0.198 0.021
6535.3 B >50 >50 >50 >50 1.22 >50 0.011 0.006 7.90 2.88
7165.18 B >50 >50 4.88 0.217 >50 >50 0.074 >50 >50 2.54
89.6.DG B >50 >50 >50 >50 >50 >50 0.077 >50 3.64 1.14
AC10.29 B >50 1.00 0.090 0.024 0.191 >50 0.118 0.018 3.36 0.947
ADA.DG B >50 >50 0.252 0.047 >50 >50 0.015 >50 1.84 0.127
Bal.01 B >50 >50 >50 >50 >50 >50 0.044 0.029 0.556 2.49
BaL.26 B >50 >50 39.4 >50 0.356 >50 0.050 0.020 0.200 2.24
BG1168.01 B >50 >50 >50 >50 >50 >50 >50 0.046 3.99 1.52
BL01.DG B >50 >50 >50 >50 >50 >50 >50 0.019 >50 1.34
BR07.DG B >50 >50 >50 >50 >50 >50 0.338 >50 7.74 0.304
BX08.16 B >50 >50 0.199 0.100 0.101 >50 0.007 0.060 1.09 1.33
CAAN.A2 B >50 >50 >50 16.5 >50 >50 0.027 0.008 2.85 5.97
CNE10 B >50 >50 >50 >50 1.68 >50 0.027 >50 2.12 0.033
CNE12 B >50 >50 >50 >50 >50 >50 0.014 3.00 2.61 0.875
CNE14 B >50 >50 >50 >50 >50 >50 0.007 0.020 1.25 0.706
CNE4 B >50 >50 >50 >50 >50 >50 >50 >50 2.80 0.707
CNE57 B >50 >50 >50 >50 >50 >50 0.035 0.019 1.62 0.423
HO86.8 B >50 >50 0.104 0.026 0.345 >50 >50 >50 >50 2.59
HT593.1 B >50 >50 1.02 0.154 4.05 >50 >50 0.019 2.58 0.304
HXB2.DG B >50 >50 >50 >50 40.0 >50 >50 0.070 0.178 0.007
JRCSF.JB B >50 >50 0.071 0.007 0.016 >50 0.219 0.030 1.21 2.38
JRFL.JB B >50 >50 >50 48.4 >50 >50 0.071 0.020 0.103 0.824
MN.3 B >50 >50 >50 >50 >50 >50 >50 >50 0.064 0.0003
PVO.04 B >50 0.289 3.17 0.448 20.7 >50 0.436 >50 1.39 8.54
QH0515.01 B >50 >50 >50 >50 >50 >50 >50 0.007 3.56 5.46
QH0692.42 B >50 >50 >50 >50 >50 >50 9.70 >50 5.16 2.84
REJO.67 B >50 >50 0.003 0.002 0.056 >50 >50 0.307 0.291 1.20
RHPA.7 B >50 >50 0.877 0.076 >50 >50 0.046 0.020 0.162 5.05
SC422.8 B >50 >50 3.37 0.076 18.1 >50 0.362 0.010 0.471 1.06
SF162.LS B >50 >50 >50 >50 >50 >50 0.017 0.034 0.770 0.766
SS1196.01 B >50 >50 2.06 >50 1.15 >50 0.011 >50 0.905 1.91
THRO.18 B >50 >50 0.250 0.017 >50 >50 >50 >50 >50 0.715
TRJO.58 B >50 >50 >50 >50 1.81 >50 >50 2.95 0.340 4.33
TRO.11 B >50 >50 1.97 0.092 >50 >50 0.032 >50 1.70 0.398
WITO.33 B >50 >50 0.002 0.004 0.020 0.103 3.25 0.025 0.458 0.943
YU2.DG B >50 >50 0.742 0.091 >50 >50 0.178 >50 0.324 9.46
CH038.12 BC 0.400 0.015 >50 >50 >50 >50 0.020 >50 1.29 2.63
CH070.1 BC 0.500 >50 0.004 0.259 0.018 >50 0.015 >50 >50 14.1
CH117.4 BC 0.042 0.00004 0.004 0.275 0.020 >50 >50 >50 0.352 0.883
CH181.12 BC 0.009 0.00004 0.002 0.0003 0.019 >50 0.039 >50 2.01 2.75
CNE15 BC >50 >50 0.029 >50 0.018 >50 >50 0.088 0.452 2.72
CNE19 BC >50 0.008 0.007 1.32 0.068 >50 0.063 1.00 0.718 0.813
CNE20 BC >50 0.109 0.013 0.917 0.163 >50 0.008 >50 >50 0.650
CNE21 BC 0.023 0.002 0.005 0.014 0.397 >50 0.018 0.003 1.65 4.55
CNE40 BC >50 0.449 1.53 1.41 7.71 >50 1.85 >50 4.43 0.003
CNE7 BC 0.046 0.024 0.032 1.99 4.28 >50 0.096 0.600 1.02 0.958
286.36 C 0.024 0.004 0.046 0.012 0.668 >50 0.009 0.122 1.22 4.41
288.38 C >50 >50 9.87 47.1 >50 >50 0.035 >50 5.95 2.29
0013095-2.11 C >50 >50 0.015 >50 0.074 >50 >50 >50 0.266 0.058
001428-2.42 C >50 >50 0.018 0.020 0.007 >50 0.076 >50 0.059 4.95
0077_V1.C16 C 0.020 0.023 0.007 1.31 0.342 >50 >50 0.002 4.78 12.4
00836-2.5 C >50 >50 0.200 >50 >50 >50 >50 >50 0.799 1.39
0921.V2.C14 C 1.00 0.002 0.014 0.171 0.012 >50 >50 >50 0.794 3.68
16055-2.3 C 0.015 0.005 0.007 0.073 0.037 >50 12.2 >50 0.287 2.84
16845-2.22 C >50 >50 >50 >50 >50 >50 >50 >50 21.5 0.094
16936-2.21 C >50 0.065 >50 >50 >50 >50 0.013 >50 0.825 0.958
25710-2.43 C 0.540 0.004 0.015 0.011 0.139 >50 0.055 >50 2.25 0.282
25711-2.4 C >50 >50 3.31 >50 3.69 >50 0.041 0.019 2.30 2.33
25925-2.22 C 0.078 0.0009 0.011 0.046 0.071 >50 0.072 0.070 2.11 2.01
26191-2.48 C 0.050 0.003 >50 3.17 0.809 >50 0.393 >50 0.900 5.44
3168.V4.C10 C >50 >50 0.502 0.101 0.393 >50 1.94 >50 0.553 7.32
3637.V5.C3 C >50 >50 >50 >50 >50 >50 >50 >50 9.49 7.93
6322.V4.C1 C 0.002 0.012 0.036 1.61 >50 >50 >50 >50 >50 10.2
6471.V1.C16 C >50 >50 >50 >50 >50 >50 >50 >50 >50 21.9
6631.V3.C10 C >50 >50 >50 >50 >50 >50 >50 0.009 >50 3.69
6644.V2.C33 C >50 >50 >50 >50 0.103 >50 0.171 >50 0.659 0.115
6785.V5.C14 C 0.036 0.006 0.059 9.61 0.043 >50 0.072 >50 1.17 2.55
6838.V1.C35 C 0.200 0.042 0.080 14.0 0.032 >50 0.840 >50 0.995 1.55
96ZM651.02 C >50 >50 0.652 >50 >50 >50 0.044 0.070 3.09 0.175
BR025.9 C >50 >50 0.009 >50 0.065 1.37 0.008 >50 2.67 1.27
CAP210.E8 C 0.009 0.004 1.50 >50 0.876 >50 >50 0.037 >50 3.84
CAP244.D3 C >50 >50 >50 >50 0.231 11.8 >50 >50 2.83 1.85
CAP256.206.C9 C 0.006 0.002 0.014 >50 0.142 >50 0.059 >50 1.37 4.28
CAP45.G3 C 0.070 0.001 0.006 0.016 0.010 0.693 19.6 0.012 31.6 3.38
CNE30 C >50 >50 >50 >50 >50 >50 0.249 >50 2.56 4.16
CNE31 C >50 >50 0.898 0.328 >50 >50 2.68 0.006 2.73 2.72
CNE53 C >50 >50 0.089 0.094 0.430 >50 0.054 >50 0.320 1.73
CNE58 C 0.028 0.003 0.011 0.864 0.064 0.776 >50 0.003 0.506 2.52
DU123.06 C 2.29 10.0 0.020 0.355 0.315 4.87 0.101 >50 >50 0.597
DU151.02 C 1.24 0.008 0.004 0.050 0.054 >50 0.021 >50 >50 2.24
DU156.12 C 0.515 0.051 0.003 0.198 0.143 5.46 0.023 0.008 0.403 0.051
DU172.17 C >50 >50 7.10 >50 0.758 >50 0.846 0.010 >50 0.300
DU422.01 C 40.9 0.109 >50 >50 >50 >50 0.365 >50 >50 1.10
MW965.26 C 0.677 0.572 0.317 6.69 26.0 >50 0.051 0.650 0.146 0.007
SO18.18 C 0.013 0.004 0.009 0.200 0.065 >50 0.006 0.007 0.145 5.60
TV1.29 C >50 >50 0.004 >50 0.027 >50 0.318 0.004 >50 0.681
TZA125.17 C 4.40 0.028 0.316 2.50 0.808 >50 >50 1.82 >50 2.17
TZBD.02 C 0.140 0.016 0.042 0.685 0.676 >50 0.060 0.005 0.197 5.39
ZA012.29 C >50 >50 >50 >50 >50 >50 0.021 >50 0.680 6.43
ZM106.9 C 0.500 0.055 0.005 0.203 4.19 >50 0.018 >50 0.535 >50
ZM109.4 C >50 0.253 0.070 0.149 2.44 >50 >50 >50 0.392 2.45
ZM135.10a C >50 >50 >50 >50 >50 >50 9.25 >50 5.72 1.14
ZM176.66 C 10.0 0.001 0.007 1.46 0.033 >50 >50 0.003 0.319 2.16
ZM197.7 C 0.030 0.033 0.170 6.17 2.13 >50 >50 0.015 2.18 0.629
ZM214.15 C >50 0.231 >50 >50 >50 >50 2.37 0.175 5.33 7.10
ZM215.8 C >50 >50 0.011 >50 0.497 >50 0.057 0.149 1.26 0.342
ZM233.6 C 0.022 0.002 0.004 0.396 0.457 0.366 0.296 >50 7.27 0.509
ZM249.1 C 0.128 0.021 2.50 >50 0.267 >50 >50 0.004 0.348 1.62
ZM53.12 C 0.007 0.0009 0.019 6.89 0.129 >50 0.016 >50 3.81 10.4
ZM55.28a C 0.159 0.048 0.106 5.35 >50 >50 0.233 0.003 1.18 11.8
3326.V4.C3 CD 0.044 0.0003 0.012 0.170 0.103 >50 >50 >50 >50 4.51
3337.V2.C6 CD 0.100 0.001 >50 >50 >50 >50 >50 0.002 0.193 5.51
3817.v2.c59 CD >50 >50 >50 >50 0.015 0.734 >50 >50 >50 2.30
231965.c1 D >50 >50 3.00 2.90 >50 >50 >50 0.008 1.26 12.9
247-23 D 1.18 0.005 0.020 0.633 0.422 >50 >50 >50 0.396 1.77
3016.v5.c45 D 2.67 0.005 >50 >50 12.6 >50 >50 9.71 >50 1.42
57128.vrc15 D >50 2.00 0.400 1.48 0.465 >50 >50 >50 5.83 2.46
6405.v4.c34 D >50 >50 >50 >50 >50 >50 0.080 3.00 9.94 3.45
A03349M1.vrc4a D >50 0.120 0.272 >50 >50 >50 0.155 >50 14.8 1.20
NKU3006.ec1 D >50 >50 >50 >50 >50 >50 >50 >50 1.99 3.33
P1981.C5.3 G 0.039 0.022 >50 39.4 2.68 >50 0.013 4.44 1.04 0.020
X1193.c1 G 8.04 0.600 0.517 0.052 0.378 >50 0.091 0.300 0.426 2.47
X1254.c3 G >50 >50 >50 10.1 0.125 >50 0.069 >50 0.147 >50
X1632.S2.B10 G 0.037 0.010 0.005 0.091 0.849 >50 >50 >50 0.597 2.35





PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
# Viruses 183 183 183 183 183 183 183 183 183 183
# Viruses Neutralized
IC80 <50ug/ml 68 89 131 109 129 22 102 90 158 177
IC80 <10ug/ml 61 87 127 92 123 19 100 90 151 167
IC80 <1.0ug/ml 49 78 111 69 98 9 88 83 76 52
IC80 <0.1ug/ml 32 61 83 37 40 2 63 71 6 13
IC80 <0.01ug/ml 8 35 33 6 2 0 10 33 0 5
% VS Neutralized
IC80 <50ug/ml 37 49 72 60 70 12 56 49 86 97
IC80 <10ug/ml 33 48 69 50 67 10 55 49 83 91
IC80 <1.0ug/ml 27 43 61 38 54 5 48 45 42 28
IC80 <0.1ug/ml 17 33 45 20 22 1 34 39 3 7
IC80 <0.01ug/ml 4 19 18 3 1 0 5 18 0 3
Median IC80 0.109 0.022 0.036 0.328 0.233 2.09 0.066 0.019 1.05 2.24


















PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
0260.v5.c36 A >50 >50 0.014 >50 8.41 >50 0.143 >50 1.50 27.7
0330.v4.c3 A >50 1.04 0.015 18.5 0.038 >50 0.194 0.009 0.188 3.72
0439.v5.c1 A >50 >50 >50 16.1 >50 >50 >50 >50 0.628 4.81
3365.v2.c20 A >50 >50 0.040 34.7 0.233 >50 1.34 0.002 0.181 5.74
3415.v1.c1 A >50 >50 0.395 >50 0.540 >50 >50 0.003 0.297 9.14
3718.v3.c11 A >50 >50 0.014 0.971 0.136 5.33 8.64 0.055 12.1 7.47
BB201.B42 A 0.500 0.001 0.004 2.00 0.026 2.35 0.011 0.115 0.932 2.78
BG505.W6M.C2 A >50 0.012 0.003 0.160 0.141 >50 0.337 0.003 0.153 1.41
BI369.9A A 0.099 0.004 0.023 0.348 0.067 2.16 0.043 0.519 0.925 1.24
BS208.B1 A 0.012 0.0004 0.009 0.008 0.027 0.313 >50 0.070 0.059 2.93
KER2008.12 A >50 0.183 0.012 >50 0.028 >50 >50 0.060 1.76 >50
KER2018.11 A 0.001 0.002 0.012 0.037 0.029 2.02 >50 0.006 1.84 6.38
KNH1209.18 A >50 8.85 >50 >50 >50 >50 0.007 0.007 0.370 5.09
MB201.A1 A >50 >50 0.938 38.1 0.305 >50 0.026 0.211 0.633 1.57
MB539.2B7 A >50 4.00 0.005 >50 0.256 >50 >50 0.010 1.29 >50
MI369.A5 A 2.86 0.019 0.042 0.132 0.226 >50 0.087 0.125 1.15 3.01
MS208.A1 A 1.00 0.232 0.500 30.3 0.609 >50 >50 0.002 1.04 2.54
Q23.17 A >50 1.30 0.004 6.73 0.012 0.028 0.019 0.013 0.252 3.02
Q259.17 A 0.259 0.0003 10.0 >50 0.340 >50 >50 >50 0.251 10.7
Q769.d22 A >50 >50 0.005 4.71 0.038 >50 >50 >50 0.103 4.08
Q842.d12 A >50 0.123 0.007 0.837 0.068 3.75 0.047 0.010 0.089 6.53
QH209.14M.A2 A >50 >50 0.106 0.018 >50 >50 >50 0.003 0.116 4.70
RW020.2 A >50 >50 0.020 >50 0.771 >50 0.009 0.005 0.859 4.10
UG037.8 A >50 >50 0.203 >50 0.080 >50 0.237 >50 0.301 0.661
3301.V1.C24 AC 0.002 0.020 0.075 2.30 1.40 >50 0.030 0.070 0.431 10.2
3589.V1.C4 AC >50 >50 >50 >50 0.098 >50 >50 0.006 0.385 4.32
6540.v4.c1 AC 29.2 0.051 0.022 0.046 0.105 >50 >50 0.020 >50 7.86
6545.V4.C1 AC 27.6 0.096 0.026 0.070 0.144 >50 >50 0.010 >50 6.06
0815.V3.C3 ACD >50 >50 >50 >50 >50 >50 0.072 >50 0.093 1.76
6095.V1.C10 ACD 0.100 0.005 0.062 0.050 1.13 >50 >50 >50 3.81 0.004
3468.V1.C12 AD >50 >50 >50 >50 >50 >50 1.05 >50 0.171 2.75
Q168.a2 AD >50 >50 0.013 25.4 0.179 >50 >50 0.014 0.284 5.23
Q461.e2 AD 19.3 0.080 0.579 >50 15.6 >50 >50 >50 1.54 4.45
620345.c1 AE 0.090 0.051 >50 1.99 >50 >50 >50 >50 >50 4.16
BJOX009000.02.4 AE >50 >50 0.437 0.468 7.73 >50 >50 >50 6.38 3.25
BJOX010000.06.2 AE >50 >50 42.2 >50 1.55 16.7 >50 >50 21.2 0.844
BJOX025000.01.1 AE >50 >50 0.090 10.3 0.826 >50 >50 >50 0.979 1.94
BJOX028000.10.3 AE >50 >50 0.243 >50 3.68 >50 >50 >50 10.3 0.610
C1080.c3 AE 0.046 0.718 0.003 0.247 0.008 >50 >50 >50 0.587 0.683
C2101.c1 AE >50 >50 0.041 0.049 0.139 >50 >50 >50 0.279 4.72
C3347.c11 AE >50 >50 0.015 0.023 0.103 >50 >50 >50 0.706 0.047
C4118.09 AE 0.020 0.001 0.009 0.009 0.093 2.41 >50 >50 0.342 1.03
CNE3 AE >50 >50 >50 21.4 0.598 >50 >50 >50 0.962 4.82
CNE5 AE 0.241 0.024 0.006 0.013 0.027 >50 >50 >50 1.14 3.92
CNE55 AE 5.00 0.006 0.030 0.015 2.08 >50 >50 >50 1.53 1.26
CNE56 AE >50 >50 26.0 5.91 >50 >50 >50 >50 2.93 0.490
CNE59 AE >50 >50 0.019 0.664 0.443 >50 >50 >50 1.13 0.030
R1166.c1 AE >50 >50 2.50 43.6 3.90 >50 >50 >50 0.407 1.75
R2184.c4 AE >50 5.00 0.006 0.482 2.23 >50 >50 >50 1.76 2.23
TH966.8 AE 0.052 0.089 0.016 0.023 0.061 0.098 >50 >50 1.44 0.315
TH976.17 AE >50 8.00 >50 >50 >50 >50 >50 >50 1.23 1.50
235-47.SG3 AG 16.4 2.55 0.043 20.2 0.803 >50 0.842 >50 0.160 0.889
242-14 AG 0.300 0.005 0.033 1.36 0.151 >50 >50 0.020 >50 3.10
263-8 AG 1.88 0.270 0.088 >50 1.27 >50 7.73 >50 0.631 0.996
269-12 AG >50 0.182 4.33 39.4 5.17 >50 1.26 0.005 1.05 0.654
271-11 AG >50 >50 0.081 >50 0.948 >50 >50 >50 0.279 4.21
928-28 AG 4.31 0.041 0.200 >50 0.225 41.3 >50 >50 1.17 0.878
DJ263.8 AG 0.099 0.014 0.009 0.170 0.551 >50 0.202 0.005 3.53 0.176
T250-4 AG 0.007 0.002 0.002 0.030 0.017 0.284 0.012 0.003 >50 2.23
T251-18 AG >50 >50 >50 1.13 >50 >50 >50 >50 10.9 2.09
T253-11 AG >50 32.5 0.016 >50 0.819 >50 >50 0.016 1.29 3.27
T255-34 AG >50 >50 >50 >50 0.126 >50 >50 0.005 1.97 1.83
T257-31 AG 0.118 0.002 0.017 >50 0.059 >50 >50 0.003 6.65 1.94
T266-60 AG 12.0 0.110 1.24 0.276 1.42 >50 0.620 0.023 8.63 >50
T33-7 AG >50 >50 0.008 >50 0.162 3.13 >50 >50 0.060 3.23
3988.25 B >50 0.110 0.100 0.021 0.200 >50 0.008 0.009 1.46 0.651
5768.04 B >50 >50 0.200 0.725 2.54 >50 0.897 0.076 1.54 9.18
6101.10 B >50 >50 >50 >50 >50 >50 0.018 0.366 0.198 0.021
6535.3 B >50 >50 >50 >50 1.22 >50 0.011 0.006 7.90 2.88
7165.18 B >50 >50 4.88 0.217 >50 >50 0.074 >50 >50 2.54
89.6.DG B >50 >50 >50 >50 >50 >50 0.077 >50 3.64 1.14
AC10.29 B >50 1.00 0.090 0.024 0.191 >50 0.118 0.018 3.36 0.947
ADA.DG B >50 >50 0.252 0.047 >50 >50 0.015 >50 1.84 0.127
Bal.01 B >50 >50 >50 >50 >50 >50 0.044 0.029 0.556 2.49
BaL.26 B >50 >50 39.4 >50 0.356 >50 0.050 0.020 0.200 2.24
BG1168.01 B >50 >50 >50 >50 >50 >50 >50 0.046 3.99 1.52
BL01.DG B >50 >50 >50 >50 >50 >50 >50 0.019 >50 1.34
BR07.DG B >50 >50 >50 >50 >50 >50 0.338 >50 7.74 0.304
BX08.16 B >50 >50 0.199 0.100 0.101 >50 0.007 0.060 1.09 1.33
CAAN.A2 B >50 >50 >50 16.5 >50 >50 0.027 0.008 2.85 5.97
CNE10 B >50 >50 >50 >50 1.68 >50 0.027 >50 2.12 0.033
CNE12 B >50 >50 >50 >50 >50 >50 0.014 3.00 2.61 0.875
CNE14 B >50 >50 >50 >50 >50 >50 0.007 0.020 1.25 0.706
CNE4 B >50 >50 >50 >50 >50 >50 >50 >50 2.80 0.707
CNE57 B >50 >50 >50 >50 >50 >50 0.035 0.019 1.62 0.423
HO86.8 B >50 >50 0.104 0.026 0.345 >50 >50 >50 >50 2.59
HT593.1 B >50 >50 1.02 0.154 4.05 >50 >50 0.019 2.58 0.304
HXB2.DG B >50 >50 >50 >50 40.0 >50 >50 0.070 0.178 0.007
JRCSF.JB B >50 >50 0.071 0.007 0.016 >50 0.219 0.030 1.21 2.38
JRFL.JB B >50 >50 >50 48.4 >50 >50 0.071 0.020 0.103 0.824
MN.3 B >50 >50 >50 >50 >50 >50 >50 >50 0.064 0.0003
PVO.04 B >50 0.289 3.17 0.448 20.7 >50 0.436 >50 1.39 8.54
QH0515.01 B >50 >50 >50 >50 >50 >50 >50 0.007 3.56 5.46
QH0692.42 B >50 >50 >50 >50 >50 >50 9.70 >50 5.16 2.84
REJO.67 B >50 >50 0.003 0.002 0.056 >50 >50 0.307 0.291 1.20
RHPA.7 B >50 >50 0.877 0.076 >50 >50 0.046 0.020 0.162 5.05
SC422.8 B >50 >50 3.37 0.076 18.1 >50 0.362 0.010 0.471 1.06
SF162.LS B >50 >50 >50 >50 >50 >50 0.017 0.034 0.770 0.766
SS1196.01 B >50 >50 2.06 >50 1.15 >50 0.011 >50 0.905 1.91
THRO.18 B >50 >50 0.250 0.017 >50 >50 >50 >50 >50 0.715
TRJO.58 B >50 >50 >50 >50 1.81 >50 >50 2.95 0.340 4.33
TRO.11 B >50 >50 1.97 0.092 >50 >50 0.032 >50 1.70 0.398
WITO.33 B >50 >50 0.002 0.004 0.020 0.103 3.25 0.025 0.458 0.943
YU2.DG B >50 >50 0.742 0.091 >50 >50 0.178 >50 0.324 9.46
CH038.12 BC 0.400 0.015 >50 >50 >50 >50 0.020 >50 1.29 2.63
CH070.1 BC 0.500 >50 0.004 0.259 0.018 >50 0.015 >50 >50 14.1
CH117.4 BC 0.042 0.00004 0.004 0.275 0.020 >50 >50 >50 0.352 0.883
CH181.12 BC 0.009 0.00004 0.002 0.0003 0.019 >50 0.039 >50 2.01 2.75
CNE15 BC >50 >50 0.029 >50 0.018 >50 >50 0.088 0.452 2.72
CNE19 BC >50 0.008 0.007 1.32 0.068 >50 0.063 1.00 0.718 0.813
CNE20 BC >50 0.109 0.013 0.917 0.163 >50 0.008 >50 >50 0.650
CNE21 BC 0.023 0.002 0.005 0.014 0.397 >50 0.018 0.003 1.65 4.55
CNE40 BC >50 0.449 1.53 1.41 7.71 >50 1.85 >50 4.43 0.003
CNE7 BC 0.046 0.024 0.032 1.99 4.28 >50 0.096 0.600 1.02 0.958
286.36 C 0.024 0.004 0.046 0.012 0.668 >50 0.009 0.122 1.22 4.41
288.38 C >50 >50 9.87 47.1 >50 >50 0.035 >50 5.95 2.29
0013095-2.11 C >50 >50 0.015 >50 0.074 >50 >50 >50 0.266 0.058
001428-2.42 C >50 >50 0.018 0.020 0.007 >50 0.076 >50 0.059 4.95
0077_V1.C16 C 0.020 0.023 0.007 1.31 0.342 >50 >50 0.002 4.78 12.4
00836-2.5 C >50 >50 0.200 >50 >50 >50 >50 >50 0.799 1.39
0921.V2.C14 C 1.00 0.002 0.014 0.171 0.012 >50 >50 >50 0.794 3.68
16055-2.3 C 0.015 0.005 0.007 0.073 0.037 >50 12.2 >50 0.287 2.84
16845-2.22 C >50 >50 >50 >50 >50 >50 >50 >50 21.5 0.094
16936-2.21 C >50 0.065 >50 >50 >50 >50 0.013 >50 0.825 0.958
25710-2.43 C 0.540 0.004 0.015 0.011 0.139 >50 0.055 >50 2.25 0.282
25711-2.4 C >50 >50 3.31 >50 3.69 >50 0.041 0.019 2.30 2.33
25925-2.22 C 0.078 0.0009 0.011 0.046 0.071 >50 0.072 0.070 2.11 2.01
26191-2.48 C 0.050 0.003 >50 3.17 0.809 >50 0.393 >50 0.900 5.44
3168.V4.C10 C >50 >50 0.502 0.101 0.393 >50 1.94 >50 0.553 7.32
3637.V5.C3 C >50 >50 >50 >50 >50 >50 >50 >50 9.49 7.93
6322.V4.C1 C 0.002 0.012 0.036 1.61 >50 >50 >50 >50 >50 10.2
6471.V1.C16 C >50 >50 >50 >50 >50 >50 >50 >50 >50 21.9
6631.V3.C10 C >50 >50 >50 >50 >50 >50 >50 0.009 >50 3.69
6644.V2.C33 C >50 >50 >50 >50 0.103 >50 0.171 >50 0.659 0.115
6785.V5.C14 C 0.036 0.006 0.059 9.61 0.043 >50 0.072 >50 1.17 2.55
6838.V1.C35 C 0.200 0.042 0.080 14.0 0.032 >50 0.840 >50 0.995 1.55
96ZM651.02 C >50 >50 0.652 >50 >50 >50 0.044 0.070 3.09 0.175
BR025.9 C >50 >50 0.009 >50 0.065 1.37 0.008 >50 2.67 1.27
CAP210.E8 C 0.009 0.004 1.50 >50 0.876 >50 >50 0.037 >50 3.84
CAP244.D3 C >50 >50 >50 >50 0.231 11.8 >50 >50 2.83 1.85
CAP256.206.C9 C 0.006 0.002 0.014 >50 0.142 >50 0.059 >50 1.37 4.28
CAP45.G3 C 0.070 0.001 0.006 0.016 0.010 0.693 19.6 0.012 31.6 3.38
CNE30 C >50 >50 >50 >50 >50 >50 0.249 >50 2.56 4.16
CNE31 C >50 >50 0.898 0.328 >50 >50 2.68 0.006 2.73 2.72
CNE53 C >50 >50 0.089 0.094 0.430 >50 0.054 >50 0.320 1.73
CNE58 C 0.028 0.003 0.011 0.864 0.064 0.776 >50 0.003 0.506 2.52
DU123.06 C 2.29 10.0 0.020 0.355 0.315 4.87 0.101 >50 >50 0.597
DU151.02 C 1.24 0.008 0.004 0.050 0.054 >50 0.021 >50 >50 2.24
DU156.12 C 0.515 0.051 0.003 0.198 0.143 5.46 0.023 0.008 0.403 0.051
DU172.17 C >50 >50 7.10 >50 0.758 >50 0.846 0.010 >50 0.300
DU422.01 C 40.9 0.109 >50 >50 >50 >50 0.365 >50 >50 1.10
MW965.26 C 0.677 0.572 0.317 6.69 26.0 >50 0.051 0.650 0.146 0.007
SO18.18 C 0.013 0.004 0.009 0.200 0.065 >50 0.006 0.007 0.145 5.60
TV1.29 C >50 >50 0.004 >50 0.027 >50 0.318 0.004 >50 0.681
TZA125.17 C 4.40 0.028 0.316 2.50 0.808 >50 >50 1.82 >50 2.17
TZBD.02 C 0.140 0.016 0.042 0.685 0.676 >50 0.060 0.005 0.197 5.39
ZA012.29 C >50 >50 >50 >50 >50 >50 0.021 >50 0.680 6.43
ZM106.9 C 0.500 0.055 0.005 0.203 4.19 >50 0.018 >50 0.535 >50
ZM109.4 C >50 0.253 0.070 0.149 2.44 >50 >50 >50 0.392 2.45
ZM135.10a C >50 >50 >50 >50 >50 >50 9.25 >50 5.72 1.14
ZM176.66 C 10.0 0.001 0.007 1.46 0.033 >50 >50 0.003 0.319 2.16
ZM197.7 C 0.030 0.033 0.170 6.17 2.13 >50 >50 0.015 2.18 0.629
ZM214.15 C >50 0.231 >50 >50 >50 >50 2.37 0.175 5.33 7.10
ZM215.8 C >50 >50 0.011 >50 0.497 >50 0.057 0.149 1.26 0.342
ZM233.6 C 0.022 0.002 0.004 0.396 0.457 0.366 0.296 >50 7.27 0.509
ZM249.1 C 0.128 0.021 2.50 >50 0.267 >50 >50 0.004 0.348 1.62
ZM53.12 C 0.007 0.0009 0.019 6.89 0.129 >50 0.016 >50 3.81 10.4
ZM55.28a C 0.159 0.048 0.106 5.35 >50 >50 0.233 0.003 1.18 11.8
3326.V4.C3 CD 0.044 0.0003 0.012 0.170 0.103 >50 >50 >50 >50 4.51
3337.V2.C6 CD 0.100 0.001 >50 >50 >50 >50 >50 0.002 0.193 5.51
3817.v2.c59 CD >50 >50 >50 >50 0.015 0.734 >50 >50 >50 2.30
231965.c1 D >50 >50 3.00 2.90 >50 >50 >50 0.008 1.26 12.9
247-23 D 1.18 0.005 0.020 0.633 0.422 >50 >50 >50 0.396 1.77
3016.v5.c45 D 2.67 0.005 >50 >50 12.6 >50 >50 9.71 >50 1.42
57128.vrc15 D >50 2.00 0.400 1.48 0.465 >50 >50 >50 5.83 2.46
6405.v4.c34 D >50 >50 >50 >50 >50 >50 0.080 3.00 9.94 3.45
A03349M1.vrc4a D >50 0.120 0.272 >50 >50 >50 0.155 >50 14.8 1.20
NKU3006.ec1 D >50 >50 >50 >50 >50 >50 >50 >50 1.99 3.33
P1981.C5.3 G 0.039 0.022 >50 39.4 2.68 >50 0.013 4.44 1.04 0.020
X1193.c1 G 8.04 0.600 0.517 0.052 0.378 >50 0.091 0.300 0.426 2.47
X1254.c3 G >50 >50 >50 10.1 0.125 >50 0.069 >50 0.147 >50
X1632.S2.B10 G 0.037 0.010 0.005 0.091 0.849 >50 >50 >50 0.597 2.35





PGDM1400 PGT145 PG9 CH01 PGT121 PGT151 VRC01 10E8
# Viruses 183 183 183 183 183 183 183 183 183 183
# Viruses Neutralized
IC80 <50ug/ml 68 89 131 109 129 22 102 90 158 177
IC80 <10ug/ml 61 87 127 92 123 19 100 90 151 167
IC80 <1.0ug/ml 49 78 111 69 98 9 88 83 76 52
IC80 <0.1ug/ml 32 61 83 37 40 2 63 71 6 13
IC80 <0.01ug/ml 8 35 33 6 2 0 10 33 0 5
% VS Neutralized
IC80 <50ug/ml 37 49 72 60 70 12 56 49 86 97
IC80 <10ug/ml 33 48 69 50 67 10 55 49 83 91
IC80 <1.0ug/ml 27 43 61 38 54 5 48 45 42 28
IC80 <0.1ug/ml 17 33 45 20 22 1 34 39 3 7
IC80 <0.01ug/ml 4 19 18 3 1 0 5 18 0 3
Median IC80 0.109 0.022 0.036 0.328 0.233 2.09 0.066 0.019 1.05 2.24
Geometric Mean 0.184 0.026 0.064 0.405 0.280 1.40 0.096 0.027 0.985 1.50











0260.v5.c36 A >50 3.28 1.12 0.957
0330.v4.c3 A >50 0.003 >50 >50
0439.v5.c1 A >50 >50 1.09 0.381
3365.v2.c20 A 0.100 0.009 0.616 0.116
3415.v1.c1 A >50 0.351 >50 >50
3718.v3.c11 A 0.105 0.016 4.10 6.44
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.001 0.00003 0.189 0.017
BG505.W6M.C2 A 0.173 0.0004 0.015 0.009
BI369.9A A 0.008 0.0005 0.002 0.001
BS208.B1 A 0.003 0.00004 0.005 0.001
KER2008.12 A >50 0.008 10.1 1.02
KER2018.11 A 0.003 0.00008 0.003 0.002
KNH1209.18 A >50 0.005 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A 31.9 0.202 0.651 1.13
MI369.A5 A 0.039 0.001 0.212 0.006
MS208.A1 A 0.0007 0.002 0.540 0.021
Q23.17 A 0.010 0.002 >50 >50
Q259.17 A 0.001 0.00003 0.031 0.008
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.001 22.8 3.08
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.002 0.014 15.4 >50
3301.V1.C24 AC 0.013 0.002 0.012 0.007
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 0.077 0.003 0.057 0.031
6545.V4.C1 AC 0.026 0.005 0.310 0.075
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.0007 0.0003 0.005 0.001
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD 0.148 0.0009 0.017 0.003
Q461.e2 AD 0.502 0.001 0.003 0.006
620345.c1 AE 0.001 0.005 0.006 0.004
BJOX009000.02.4 AE >50 >50 0.264 0.290
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.023 0.006 0.310 0.030
C2101.c1 AE >50 >50 0.683 1.92
C3347.c11 AE >50 >50 0.047 0.041
C4118.09 AE 0.002 0.00004 0.002 0.0004
CM244.ec1 AE 0.556 0.061 0.002 0.007
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.018 0.0003 0.007 0.003
CNE55 AE 0.026 0.0002 0.002 0.0005
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE 2.46 0.001 0.011 0.003
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 0.002 0.005 0.003
R3265.c6 AE 19.8 >50 >50 >50
TH966.8 AE >50 0.004 0.001 0.006
TH976.17 AE 0.036 0.006 >50 >50
235-47.SG3 AG >50 0.045 6.08 1.02
242-14 AG 0.265 0.0001 0.015 0.002
263-8 AG 0.0007 0.011 0.012 0.003
269-12 AG 0.031 0.005 0.592 0.379
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.002 0.856 0.073
DJ263.8 AG 0.097 0.001 0.011 0.008
T250-4 AG 0.031 0.0005 0.002 0.0009
T251-18 AG 0.001 >50 >50 >50
T253-11 AG >50 0.008 0.004 0.024
T255-34 AG 49.5 >50 >50 >50
T257-31 AG >50 0.0002 0.003 0.001
T266-60 AG 0.009 0.004 0.817 0.263
T278-50 AG 1.78 3.67 >50 >50
T280-5 AG >50 0.002 0.265 0.312
T33-7 AG >50 0.266 >50 >50
3988.25 B >50 0.001 0.265 0.277
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.004 3.34 4.77
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 0.002 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 0.0006 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B 11.8 0.016 0.473 0.164
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 5.45 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 17.7 0.726 0.645
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.072 0.001 0.259 0.016
CH070.1 BC 0.039 0.026 0.001 0.001
CH117.4 BC 0.003 0.000 0.0006 0.00001
CH181.12 BC 0.001 0.0000 0.001 0.0000
CNE15 BC >50 0.301 >50 >50
CNE19 BC 19.7 0.0000 1.78 1.17
CNE20 BC >50 0.0005 >50 >50
CNE21 BC 0.001 0.0001 0.007 0.003
CNE40 BC >50 0.016 4.07 2.98
CNE7 BC 0.003 0.003 0.002 0.002
286.36 C 0.004 0.0003 0.004 0.0007
288.38 C >50 >50 >50 >50
0013095-2.11 C 0.021 0.029 0.003 0.001
001428-2.42 C 30.9 0.070 29.7 >50
0077_V1.C16 C 0.001 0.006 0.010 0.002
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 0.036 0.0001 0.001 0.0002
16055-2.3 C 0.004 0.0005 0.008 0.002
16845-2.22 C >50 >50 >50 >50
16936-2.21 C 0.250 0.002 3.46 0.347
25710-2.43 C 0.006 0.0000 0.005 0.001
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.013 0.0000 0.001 0.001
26191-2.48 C 0.001 0.0001 0.001 0.005
3168.V4.C10 C >50 0.109 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.004 0.004 0.006 0.003
6322.V4.C1 C 0.001 0.0008 0.012 0.003
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.005 0.0003 0.005 0.001
6838.V1.C35 C 0.001 0.0007 0.020 0.004
96ZM651.02 C 2.63 0.494 0.037 0.024
BR025.9 C >50 >25 >50 >50
CAP210.E8 C 0.003 0.0002 0.002 0.001
CAP244.D3 C 46.0 >50 36.6 >50
CAP256.206.C9 C 0.002 0.0002 0.003 0.001
CAP45.G3 C 4.00 0.0000 0.004 0.002
Ce1176.A3 C 0.793 0.020 3.78 0.657
CE703010217.B6 C 14.9 0.002 0.062 0.034
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.006 0.0000 0.001 0.002
DU123.06 C 0.015 0.008 0.004 0.005
DU151.02 C 0.006 0.0003 0.001 0.001
DU156.12 C 0.006 0.002 0.011 0.004
DU172.17 C >50 >50 0.788 1.78
DU422.01 C 1.12 0.053 0.080 0.015
MW965.26 C 0.003 0.019 0.016 0.020
SO18.18 C 0.002 0.0008 0.005 0.002
TV1.29 C >50 0.339 0.189 1.26
TZA125.17 C 0.018 0.002 0.008 0.001
TZBD.02 C 0.036 0.003 0.003 0.004
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.010 0.007 0.012 0.005
ZM109.4 C >50 0.003 0.003 0.003
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.029 0.0001 0.001 0.0008
ZM197.7 C 0.002 0.005 0.027 0.001
ZM214.15 C 3.23 0.002 45.7 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.003 0.0005 0.004 0.001
ZM249.1 C 0.0009 0.0008 0.007 0.002
ZM53.12 C 0.004 0.0001 0.003 0.001
ZM55.28a C 0.005 0.001 0.010 0.001
3326.V4.C3 CD 0.007 0.0000 0.001 0.0002
3337.V2.C6 CD 0.044 0.0002 0.175 0.012
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 0.578 >50
247-23 D 0.005 0.0001 0.006 0.002
3016.v5.c45 D 0.005 0.0002 0.022 0.006
57128.vrc15 D >50 0.004 0.003 0.011
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D 2.68 0.004 0.006 0.013
A07412M1.vrc12 D 0.068 0.002 0.0008 0.002
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.006 0.001 0.003 0.003
P1981.C5.3 G 0.008 0.002 0.005 0.002
X1193.c1 G 0.343 0.001 0.302 0.145
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.010 0.0004 0.007 0.002
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC50 <50ug/ml 93 116 112 106
IC50 <10ug/ml 85 115 106 106
IC50 <1.0ug/ml 78 113 96 94
IC50 <0.1ug/ml 68 106 73 81
IC50 <0.01ug/ml 43 93 51 65
% VS Neutralized
IC50 <50ug/ml 47 59 57 54
IC50 <10ug/ml 43 58 54 54
IC50 <1.0ug/ml 39 57 48 47
IC50 <0.1ug/ml 34 54 37 41
IC50 <0.01ug/ml 22 47 26 33
Median IC50 0.013 0.002 0.012 0.005
Geometric Mean 0.029 0.002 0.035 0.011











0260.v5.c36 A >50 3.28 1.12 0.957
0330.v4.c3 A >50 0.003 >50 >50
0439.v5.c1 A >50 >50 1.09 0.381
3365.v2.c20 A 0.100 0.009 0.616 0.116
3415.v1.c1 A >50 0.351 >50 >50
3718.v3.c11 A 0.105 0.016 4.10 6.44
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.001 0.00003 0.189 0.017
BG505.W6M.C2 A 0.173 0.0004 0.015 0.009
BI369.9A A 0.008 0.0005 0.002 0.001
BS208.B1 A 0.003 0.00004 0.005 0.001
KER2008.12 A >50 0.008 10.1 1.02
KER2018.11 A 0.003 0.00008 0.003 0.002
KNH1209.18 A >50 0.005 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A 31.9 0.202 0.651 1.13
MI369.A5 A 0.039 0.001 0.212 0.006
MS208.A1 A 0.0007 0.002 0.540 0.021
Q23.17 A 0.010 0.002 >50 >50
Q259.17 A 0.001 0.00003 0.031 0.008
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.001 22.8 3.08
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.002 0.014 15.4 >50
3301.V1.C24 AC 0.013 0.002 0.012 0.007
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 0.077 0.003 0.057 0.031
6545.V4.C1 AC 0.026 0.005 0.310 0.075
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.0007 0.0003 0.005 0.001
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD 0.148 0.0009 0.017 0.003
Q461.e2 AD 0.502 0.001 0.003 0.006
620345.c1 AE 0.001 0.005 0.006 0.004
BJOX009000.02.4 AE >50 >50 0.264 0.290
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.023 0.006 0.310 0.030
C2101.c1 AE >50 >50 0.683 1.92
C3347.c11 AE >50 >50 0.047 0.041
C4118.09 AE 0.002 0.00004 0.002 0.0004
CM244.ec1 AE 0.556 0.061 0.002 0.007
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.018 0.0003 0.007 0.003
CNE55 AE 0.026 0.0002 0.002 0.0005
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE 2.46 0.001 0.011 0.003
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 0.002 0.005 0.003
R3265.c6 AE 19.8 >50 >50 >50
TH966.8 AE >50 0.004 0.001 0.006
TH976.17 AE 0.036 0.006 >50 >50
235-47.SG3 AG >50 0.045 6.08 1.02
242-14 AG 0.265 0.0001 0.015 0.002
263-8 AG 0.0007 0.011 0.012 0.003
269-12 AG 0.031 0.005 0.592 0.379
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.002 0.856 0.073
DJ263.8 AG 0.097 0.001 0.011 0.008
T250-4 AG 0.031 0.0005 0.002 0.0009
T251-18 AG 0.001 >50 >50 >50
T253-11 AG >50 0.008 0.004 0.024
T255-34 AG 49.5 >50 >50 >50
T257-31 AG >50 0.0002 0.003 0.001
T266-60 AG 0.009 0.004 0.817 0.263
T278-50 AG 1.78 3.67 >50 >50
T280-5 AG >50 0.002 0.265 0.312
T33-7 AG >50 0.266 >50 >50
3988.25 B >50 0.001 0.265 0.277
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.004 3.34 4.77
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 0.002 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 0.0006 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B 11.8 0.016 0.473 0.164
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 5.45 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 17.7 0.726 0.645
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.072 0.001 0.259 0.016
CH070.1 BC 0.039 0.026 0.001 0.001
CH117.4 BC 0.003 0.000 0.0006 0.00001
CH181.12 BC 0.001 0.0000 0.001 0.0000
CNE15 BC >50 0.301 >50 >50
CNE19 BC 19.7 0.0000 1.78 1.17
CNE20 BC >50 0.0005 >50 >50
CNE21 BC 0.001 0.0001 0.007 0.003
CNE40 BC >50 0.016 4.07 2.98
CNE7 BC 0.003 0.003 0.002 0.002
286.36 C 0.004 0.0003 0.004 0.0007
288.38 C >50 >50 >50 >50
0013095-2.11 C 0.021 0.029 0.003 0.001
001428-2.42 C 30.9 0.070 29.7 >50
0077_V1.C16 C 0.001 0.006 0.010 0.002
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 0.036 0.0001 0.001 0.0002
16055-2.3 C 0.004 0.0005 0.008 0.002
16845-2.22 C >50 >50 >50 >50
16936-2.21 C 0.250 0.002 3.46 0.347
25710-2.43 C 0.006 0.0000 0.005 0.001
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.013 0.0000 0.001 0.001
26191-2.48 C 0.001 0.0001 0.001 0.005
3168.V4.C10 C >50 0.109 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.004 0.004 0.006 0.003
6322.V4.C1 C 0.001 0.0008 0.012 0.003
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.005 0.0003 0.005 0.001
6838.V1.C35 C 0.001 0.0007 0.020 0.004
96ZM651.02 C 2.63 0.494 0.037 0.024
BR025.9 C >50 >25 >50 >50
CAP210.E8 C 0.003 0.0002 0.002 0.001
CAP244.D3 C 46.0 >50 36.6 >50
CAP256.206.C9 C 0.002 0.0002 0.003 0.001
CAP45.G3 C 4.00 0.0000 0.004 0.002
Ce1176.A3 C 0.793 0.020 3.78 0.657
CE703010217.B6 C 14.9 0.002 0.062 0.034
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.006 0.0000 0.001 0.002
DU123.06 C 0.015 0.008 0.004 0.005
DU151.02 C 0.006 0.0003 0.001 0.001
DU156.12 C 0.006 0.002 0.011 0.004
DU172.17 C >50 >50 0.788 1.78
DU422.01 C 1.12 0.053 0.080 0.015
MW965.26 C 0.003 0.019 0.016 0.020
SO18.18 C 0.002 0.0008 0.005 0.002
TV1.29 C >50 0.339 0.189 1.26
TZA125.17 C 0.018 0.002 0.008 0.001
TZBD.02 C 0.036 0.003 0.003 0.004
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.010 0.007 0.012 0.005
ZM109.4 C >50 0.003 0.003 0.003
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.029 0.0001 0.001 0.0008
ZM197.7 C 0.002 0.005 0.027 0.001
ZM214.15 C 3.23 0.002 45.7 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.003 0.0005 0.004 0.001
ZM249.1 C 0.0009 0.0008 0.007 0.002
ZM53.12 C 0.004 0.0001 0.003 0.001
ZM55.28a C 0.005 0.001 0.010 0.001
3326.V4.C3 CD 0.007 0.0000 0.001 0.0002
3337.V2.C6 CD 0.044 0.0002 0.175 0.012
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 0.578 >50
247-23 D 0.005 0.0001 0.006 0.002
3016.v5.c45 D 0.005 0.0002 0.022 0.006
57128.vrc15 D >50 0.004 0.003 0.011
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D 2.68 0.004 0.006 0.013
A07412M1.vrc12 D 0.068 0.002 0.0008 0.002
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.006 0.001 0.003 0.003
P1981.C5.3 G 0.008 0.002 0.005 0.002
X1193.c1 G 0.343 0.001 0.302 0.145
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.010 0.0004 0.007 0.002
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC50 <50ug/ml 93 116 112 106
IC50 <10ug/ml 85 115 106 106
IC50 <1.0ug/ml 78 113 96 94
IC50 <0.1ug/ml 68 106 73 81
IC50 <0.01ug/ml 43 93 51 65
% VS Neutralized
IC50 <50ug/ml 47 59 57 54
IC50 <10ug/ml 43 58 54 54
IC50 <1.0ug/ml 39 57 48 47
IC50 <0.1ug/ml 34 54 37 41
IC50 <0.01ug/ml 22 47 26 33
Median IC50 0.013 0.002 0.012 0.005
Geometric Mean 0.029 0.002 0.035 0.011











0260.v5.c36 A >50 3.28 1.12 0.957
0330.v4.c3 A >50 0.003 >50 >50
0439.v5.c1 A >50 >50 1.09 0.381
3365.v2.c20 A 0.100 0.009 0.616 0.116
3415.v1.c1 A >50 0.351 >50 >50
3718.v3.c11 A 0.105 0.016 4.10 6.44
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.001 0.00003 0.189 0.017
BG505.W6M.C2 A 0.173 0.0004 0.015 0.009
BI369.9A A 0.008 0.0005 0.002 0.001
BS208.B1 A 0.003 0.00004 0.005 0.001
KER2008.12 A >50 0.008 10.1 1.02
KER2018.11 A 0.003 0.00008 0.003 0.002
KNH1209.18 A >50 0.005 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A 31.9 0.202 0.651 1.13
MI369.A5 A 0.039 0.001 0.212 0.006
MS208.A1 A 0.0007 0.002 0.540 0.021
Q23.17 A 0.010 0.002 >50 >50
Q259.17 A 0.001 0.00003 0.031 0.008
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.001 22.8 3.08
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.002 0.014 15.4 >50
3301.V1.C24 AC 0.013 0.002 0.012 0.007
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 0.077 0.003 0.057 0.031
6545.V4.C1 AC 0.026 0.005 0.310 0.075
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.0007 0.0003 0.005 0.001
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD 0.148 0.0009 0.017 0.003
Q461.e2 AD 0.502 0.001 0.003 0.006
620345.c1 AE 0.001 0.005 0.006 0.004
BJOX009000.02.4 AE >50 >50 0.264 0.290
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.023 0.006 0.310 0.030
C2101.c1 AE >50 >50 0.683 1.92
C3347.c11 AE >50 >50 0.047 0.041
C4118.09 AE 0.002 0.00004 0.002 0.0004
CM244.ec1 AE 0.556 0.061 0.002 0.007
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.018 0.0003 0.007 0.003
CNE55 AE 0.026 0.0002 0.002 0.0005
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE 2.46 0.001 0.011 0.003
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 0.002 0.005 0.003
R3265.c6 AE 19.8 >50 >50 >50
TH966.8 AE >50 0.004 0.001 0.006
TH976.17 AE 0.036 0.006 >50 >50
235-47.SG3 AG >50 0.045 6.08 1.02
242-14 AG 0.265 0.0001 0.015 0.002
263-8 AG 0.0007 0.011 0.012 0.003
269-12 AG 0.031 0.005 0.592 0.379
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.002 0.856 0.073
DJ263.8 AG 0.097 0.001 0.011 0.008
T250-4 AG 0.031 0.0005 0.002 0.0009
T251-18 AG 0.001 >50 >50 >50
T253-11 AG >50 0.008 0.004 0.024
T255-34 AG 49.5 >50 >50 >50
T257-31 AG >50 0.0002 0.003 0.001
T266-60 AG 0.009 0.004 0.817 0.263
T278-50 AG 1.78 3.67 >50 >50
T280-5 AG >50 0.002 0.265 0.312
T33-7 AG >50 0.266 >50 >50
3988.25 B >50 0.001 0.265 0.277
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.004 3.34 4.77
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 0.002 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 0.0006 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B 11.8 0.016 0.473 0.164
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 5.45 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 17.7 0.726 0.645
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.072 0.001 0.259 0.016
CH070.1 BC 0.039 0.026 0.001 0.001
CH117.4 BC 0.003 0.000 0.0006 0.00001
CH181.12 BC 0.001 0.0000 0.001 0.0000
CNE15 BC >50 0.301 >50 >50
CNE19 BC 19.7 0.0000 1.78 1.17
CNE20 BC >50 0.0005 >50 >50
CNE21 BC 0.001 0.0001 0.007 0.003
CNE40 BC >50 0.016 4.07 2.98
CNE7 BC 0.003 0.003 0.002 0.002
286.36 C 0.004 0.0003 0.004 0.0007
288.38 C >50 >50 >50 >50
0013095-2.11 C 0.021 0.029 0.003 0.001
001428-2.42 C 30.9 0.070 29.7 >50
0077_V1.C16 C 0.001 0.006 0.010 0.002
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 0.036 0.0001 0.001 0.0002
16055-2.3 C 0.004 0.0005 0.008 0.002
16845-2.22 C >50 >50 >50 >50
16936-2.21 C 0.250 0.002 3.46 0.347
25710-2.43 C 0.006 0.0000 0.005 0.001
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.013 0.0000 0.001 0.001
26191-2.48 C 0.001 0.0001 0.001 0.005
3168.V4.C10 C >50 0.109 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.004 0.004 0.006 0.003
6322.V4.C1 C 0.001 0.0008 0.012 0.003
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.005 0.0003 0.005 0.001
6838.V1.C35 C 0.001 0.0007 0.020 0.004
96ZM651.02 C 2.63 0.494 0.037 0.024
BR025.9 C >50 >25 >50 >50
CAP210.E8 C 0.003 0.0002 0.002 0.001
CAP244.D3 C 46.0 >50 36.6 >50
CAP256.206.C9 C 0.002 0.0002 0.003 0.001
CAP45.G3 C 4.00 0.0000 0.004 0.002
Ce1176.A3 C 0.793 0.020 3.78 0.657
CE703010217.B6 C 14.9 0.002 0.062 0.034
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.006 0.0000 0.001 0.002
DU123.06 C 0.015 0.008 0.004 0.005
DU151.02 C 0.006 0.0003 0.001 0.001
DU156.12 C 0.006 0.002 0.011 0.004
DU172.17 C >50 >50 0.788 1.78
DU422.01 C 1.12 0.053 0.080 0.015
MW965.26 C 0.003 0.019 0.016 0.020
SO18.18 C 0.002 0.0008 0.005 0.002
TV1.29 C >50 0.339 0.189 1.26
TZA125.17 C 0.018 0.002 0.008 0.001
TZBD.02 C 0.036 0.003 0.003 0.004
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.010 0.007 0.012 0.005
ZM109.4 C >50 0.003 0.003 0.003
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.029 0.0001 0.001 0.0008
ZM197.7 C 0.002 0.005 0.027 0.001
ZM214.15 C 3.23 0.002 45.7 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.003 0.0005 0.004 0.001
ZM249.1 C 0.0009 0.0008 0.007 0.002
ZM53.12 C 0.004 0.0001 0.003 0.001
ZM55.28a C 0.005 0.001 0.010 0.001
3326.V4.C3 CD 0.007 0.0000 0.001 0.0002
3337.V2.C6 CD 0.044 0.0002 0.175 0.012
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 0.578 >50
247-23 D 0.005 0.0001 0.006 0.002
3016.v5.c45 D 0.005 0.0002 0.022 0.006
57128.vrc15 D >50 0.004 0.003 0.011
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D 2.68 0.004 0.006 0.013
A07412M1.vrc12 D 0.068 0.002 0.0008 0.002
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.006 0.001 0.003 0.003
P1981.C5.3 G 0.008 0.002 0.005 0.002
X1193.c1 G 0.343 0.001 0.302 0.145
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.010 0.0004 0.007 0.002
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC50 <50ug/ml 93 116 112 106
IC50 <10ug/ml 85 115 106 106
IC50 <1.0ug/ml 78 113 96 94
IC50 <0.1ug/ml 68 106 73 81
IC50 <0.01ug/ml 43 93 51 65
% VS Neutralized
IC50 <50ug/ml 47 59 57 54
IC50 <10ug/ml 43 58 54 54
IC50 <1.0ug/ml 39 57 48 47
IC50 <0.1ug/ml 34 54 37 41
IC50 <0.01ug/ml 22 47 26 33
Median IC50 0.013 0.002 0.012 0.005
Geometric Mean 0.029 0.002 0.035 0.011











0260.v5.c36 A >50 3.28 1.12 0.957
0330.v4.c3 A >50 0.003 >50 >50
0439.v5.c1 A >50 >50 1.09 0.381
3365.v2.c20 A 0.100 0.009 0.616 0.116
3415.v1.c1 A >50 0.351 >50 >50
3718.v3.c11 A 0.105 0.016 4.10 6.44
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.001 0.00003 0.189 0.017
BG505.W6M.C2 A 0.173 0.0004 0.015 0.009
BI369.9A A 0.008 0.0005 0.002 0.001
BS208.B1 A 0.003 0.00004 0.005 0.001
KER2008.12 A >50 0.008 10.1 1.02
KER2018.11 A 0.003 0.00008 0.003 0.002
KNH1209.18 A >50 0.005 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A 31.9 0.202 0.651 1.13
MI369.A5 A 0.039 0.001 0.212 0.006
MS208.A1 A 0.0007 0.002 0.540 0.021
Q23.17 A 0.010 0.002 >50 >50
Q259.17 A 0.001 0.00003 0.031 0.008
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.001 22.8 3.08
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.002 0.014 15.4 >50
3301.V1.C24 AC 0.013 0.002 0.012 0.007
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 0.077 0.003 0.057 0.031
6545.V4.C1 AC 0.026 0.005 0.310 0.075
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.0007 0.0003 0.005 0.001
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD 0.148 0.0009 0.017 0.003
Q461.e2 AD 0.502 0.001 0.003 0.006
620345.c1 AE 0.001 0.005 0.006 0.004
BJOX009000.02.4 AE >50 >50 0.264 0.290
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.023 0.006 0.310 0.030
C2101.c1 AE >50 >50 0.683 1.92
C3347.c11 AE >50 >50 0.047 0.041
C4118.09 AE 0.002 0.00004 0.002 0.0004
CM244.ec1 AE 0.556 0.061 0.002 0.007
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.018 0.0003 0.007 0.003
CNE55 AE 0.026 0.0002 0.002 0.0005
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE 2.46 0.001 0.011 0.003
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 0.002 0.005 0.003
R3265.c6 AE 19.8 >50 >50 >50
TH966.8 AE >50 0.004 0.001 0.006
TH976.17 AE 0.036 0.006 >50 >50
235-47.SG3 AG >50 0.045 6.08 1.02
242-14 AG 0.265 0.0001 0.015 0.002
263-8 AG 0.0007 0.011 0.012 0.003
269-12 AG 0.031 0.005 0.592 0.379
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.002 0.856 0.073
DJ263.8 AG 0.097 0.001 0.011 0.008
T250-4 AG 0.031 0.0005 0.002 0.0009
T251-18 AG 0.001 >50 >50 >50
T253-11 AG >50 0.008 0.004 0.024
T255-34 AG 49.5 >50 >50 >50
T257-31 AG >50 0.0002 0.003 0.001
T266-60 AG 0.009 0.004 0.817 0.263
T278-50 AG 1.78 3.67 >50 >50
T280-5 AG >50 0.002 0.265 0.312
T33-7 AG >50 0.266 >50 >50
3988.25 B >50 0.001 0.265 0.277
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.004 3.34 4.77
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 0.002 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 0.0006 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B 11.8 0.016 0.473 0.164
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 5.45 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 17.7 0.726 0.645
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.072 0.001 0.259 0.016
CH070.1 BC 0.039 0.026 0.001 0.001
CH117.4 BC 0.003 0.000 0.0006 0.00001
CH181.12 BC 0.001 0.0000 0.001 0.0000
CNE15 BC >50 0.301 >50 >50
CNE19 BC 19.7 0.0000 1.78 1.17
CNE20 BC >50 0.0005 >50 >50
CNE21 BC 0.001 0.0001 0.007 0.003
CNE40 BC >50 0.016 4.07 2.98
CNE7 BC 0.003 0.003 0.002 0.002
286.36 C 0.004 0.0003 0.004 0.0007
288.38 C >50 >50 >50 >50
0013095-2.11 C 0.021 0.029 0.003 0.001
001428-2.42 C 30.9 0.070 29.7 >50
0077_V1.C16 C 0.001 0.006 0.010 0.002
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 0.036 0.0001 0.001 0.0002
16055-2.3 C 0.004 0.0005 0.008 0.002
16845-2.22 C >50 >50 >50 >50
16936-2.21 C 0.250 0.002 3.46 0.347
25710-2.43 C 0.006 0.0000 0.005 0.001
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.013 0.0000 0.001 0.001
26191-2.48 C 0.001 0.0001 0.001 0.005
3168.V4.C10 C >50 0.109 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.004 0.004 0.006 0.003
6322.V4.C1 C 0.001 0.0008 0.012 0.003
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.005 0.0003 0.005 0.001
6838.V1.C35 C 0.001 0.0007 0.020 0.004
96ZM651.02 C 2.63 0.494 0.037 0.024
BR025.9 C >50 >25 >50 >50
CAP210.E8 C 0.003 0.0002 0.002 0.001
CAP244.D3 C 46.0 >50 36.6 >50
CAP256.206.C9 C 0.002 0.0002 0.003 0.001
CAP45.G3 C 4.00 0.0000 0.004 0.002
Ce1176.A3 C 0.793 0.020 3.78 0.657
CE703010217.B6 C 14.9 0.002 0.062 0.034
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.006 0.0000 0.001 0.002
DU123.06 C 0.015 0.008 0.004 0.005
DU151.02 C 0.006 0.0003 0.001 0.001
DU156.12 C 0.006 0.002 0.011 0.004
DU172.17 C >50 >50 0.788 1.78
DU422.01 C 1.12 0.053 0.080 0.015
MW965.26 C 0.003 0.019 0.016 0.020
SO18.18 C 0.002 0.0008 0.005 0.002
TV1.29 C >50 0.339 0.189 1.26
TZA125.17 C 0.018 0.002 0.008 0.001
TZBD.02 C 0.036 0.003 0.003 0.004
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.010 0.007 0.012 0.005
ZM109.4 C >50 0.003 0.003 0.003
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.029 0.0001 0.001 0.0008
ZM197.7 C 0.002 0.005 0.027 0.001
ZM214.15 C 3.23 0.002 45.7 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.003 0.0005 0.004 0.001
ZM249.1 C 0.0009 0.0008 0.007 0.002
ZM53.12 C 0.004 0.0001 0.003 0.001
ZM55.28a C 0.005 0.001 0.010 0.001
3326.V4.C3 CD 0.007 0.0000 0.001 0.0002
3337.V2.C6 CD 0.044 0.0002 0.175 0.012
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 0.578 >50
247-23 D 0.005 0.0001 0.006 0.002
3016.v5.c45 D 0.005 0.0002 0.022 0.006
57128.vrc15 D >50 0.004 0.003 0.011
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D 2.68 0.004 0.006 0.013
A07412M1.vrc12 D 0.068 0.002 0.0008 0.002
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.006 0.001 0.003 0.003
P1981.C5.3 G 0.008 0.002 0.005 0.002
X1193.c1 G 0.343 0.001 0.302 0.145
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.010 0.0004 0.007 0.002
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC50 <50ug/ml 93 116 112 106
IC50 <10ug/ml 85 115 106 106
IC50 <1.0ug/ml 78 113 96 94
IC50 <0.1ug/ml 68 106 73 81
IC50 <0.01ug/ml 43 93 51 65
% VS Neutralized
IC50 <50ug/ml 47 59 57 54
IC50 <10ug/ml 43 58 54 54
IC50 <1.0ug/ml 39 57 48 47
IC50 <0.1ug/ml 34 54 37 41
IC50 <0.01ug/ml 22 47 26 33
Median IC50 0.013 0.002 0.012 0.005



























0260.v5.c36 A >50 3.28 1.12 0.957
0330.v4.c3 A >50 0.003 >50 >50
0439.v5.c1 A >50 >50 1.09 0.381
3365.v2.c20 A 0.100 0.009 0.616 0.116
3415.v1.c1 A >50 0.351 >50 >50
3718.v3.c11 A 0.105 0.016 4.10 6.44
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.001 0.00003 0.189 0.017
BG505.W6M.C2 A 0.173 0.0004 0.015 0.009
BI369.9A A 0.008 0.0005 0.002 0.001
BS208.B1 A 0.003 0.00004 0.005 0.001
KER2008.12 A >50 0.008 10.1 1.02
KER2018.11 A 0.003 0.00008 0.003 0.002
KNH1209.18 A >50 0.005 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A 31.9 0.202 0.651 1.13
MI369.A5 A 0.039 0.001 0.212 0.006
MS208.A1 A 0.0007 0.002 0.540 0.021
Q23.17 A 0.010 0.002 >50 >50
Q259.17 A 0.001 0.00003 0.031 0.008
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.001 22.8 3.08
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.002 0.014 15.4 >50
3301.V1.C24 AC 0.013 0.002 0.012 0.007
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 0.077 0.003 0.057 0.031
6545.V4.C1 AC 0.026 0.005 0.310 0.075
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.0007 0.0003 0.005 0.001
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD 0.148 0.0009 0.017 0.003
Q461.e2 AD 0.502 0.001 0.003 0.006
620345.c1 AE 0.001 0.005 0.006 0.004
BJOX009000.02.4 AE >50 >50 0.264 0.290
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.023 0.006 0.310 0.030
C2101.c1 AE >50 >50 0.683 1.92
C3347.c11 AE >50 >50 0.047 0.041
C4118.09 AE 0.002 0.00004 0.002 0.0004
CM244.ec1 AE 0.556 0.061 0.002 0.007
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.018 0.0003 0.007 0.003
CNE55 AE 0.026 0.0002 0.002 0.0005
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE 2.46 0.001 0.011 0.003
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 0.002 0.005 0.003
R3265.c6 AE 19.8 >50 >50 >50
TH966.8 AE >50 0.004 0.001 0.006
TH976.17 AE 0.036 0.006 >50 >50
235-47.SG3 AG >50 0.045 6.08 1.02
242-14 AG 0.265 0.0001 0.015 0.002
263-8 AG 0.0007 0.011 0.012 0.003
269-12 AG 0.031 0.005 0.592 0.379
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.002 0.856 0.073
DJ263.8 AG 0.097 0.001 0.011 0.008
T250-4 AG 0.031 0.0005 0.002 0.0009
T251-18 AG 0.001 >50 >50 >50
T253-11 AG >50 0.008 0.004 0.024
T255-34 AG 49.5 >50 >50 >50
T257-31 AG >50 0.0002 0.003 0.001
T266-60 AG 0.009 0.004 0.817 0.263
T278-50 AG 1.78 3.67 >50 >50
T280-5 AG >50 0.002 0.265 0.312
T33-7 AG >50 0.266 >50 >50
3988.25 B >50 0.001 0.265 0.277
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.004 3.34 4.77
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 0.002 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 0.0006 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B 11.8 0.016 0.473 0.164
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 5.45 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 17.7 0.726 0.645
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.072 0.001 0.259 0.016
CH070.1 BC 0.039 0.026 0.001 0.001
CH117.4 BC 0.003 0.000 0.0006 0.00001
CH181.12 BC 0.001 0.0000 0.001 0.0000
CNE15 BC >50 0.301 >50 >50
CNE19 BC 19.7 0.0000 1.78 1.17
CNE20 BC >50 0.0005 >50 >50
CNE21 BC 0.001 0.0001 0.007 0.003
CNE40 BC >50 0.016 4.07 2.98
CNE7 BC 0.003 0.003 0.002 0.002
286.36 C 0.004 0.0003 0.004 0.0007
288.38 C >50 >50 >50 >50
0013095-2.11 C 0.021 0.029 0.003 0.001
001428-2.42 C 30.9 0.070 29.7 >50
0077_V1.C16 C 0.001 0.006 0.010 0.002
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 0.036 0.0001 0.001 0.0002
16055-2.3 C 0.004 0.0005 0.008 0.002
16845-2.22 C >50 >50 >50 >50
16936-2.21 C 0.250 0.002 3.46 0.347
25710-2.43 C 0.006 0.0000 0.005 0.001
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.013 0.0000 0.001 0.001
26191-2.48 C 0.001 0.0001 0.001 0.005
3168.V4.C10 C >50 0.109 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.004 0.004 0.006 0.003
6322.V4.C1 C 0.001 0.0008 0.012 0.003
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.005 0.0003 0.005 0.001
6838.V1.C35 C 0.001 0.0007 0.020 0.004
96ZM651.02 C 2.63 0.494 0.037 0.024
BR025.9 C >50 >25 >50 >50
CAP210.E8 C 0.003 0.0002 0.002 0.001
CAP244.D3 C 46.0 >50 36.6 >50
CAP256.206.C9 C 0.002 0.0002 0.003 0.001
CAP45.G3 C 4.00 0.0000 0.004 0.002
Ce1176.A3 C 0.793 0.020 3.78 0.657
CE703010217.B6 C 14.9 0.002 0.062 0.034
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.006 0.0000 0.001 0.002
DU123.06 C 0.015 0.008 0.004 0.005
DU151.02 C 0.006 0.0003 0.001 0.001
DU156.12 C 0.006 0.002 0.011 0.004
DU172.17 C >50 >50 0.788 1.78
DU422.01 C 1.12 0.053 0.080 0.015
MW965.26 C 0.003 0.019 0.016 0.020
SO18.18 C 0.002 0.0008 0.005 0.002
TV1.29 C >50 0.339 0.189 1.26
TZA125.17 C 0.018 0.002 0.008 0.001
TZBD.02 C 0.036 0.003 0.003 0.004
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.010 0.007 0.012 0.005
ZM109.4 C >50 0.003 0.003 0.003
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.029 0.0001 0.001 0.0008
ZM197.7 C 0.002 0.005 0.027 0.001
ZM214.15 C 3.23 0.002 45.7 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.003 0.0005 0.004 0.001
ZM249.1 C 0.0009 0.0008 0.007 0.002
ZM53.12 C 0.004 0.0001 0.003 0.001
ZM55.28a C 0.005 0.001 0.010 0.001
3326.V4.C3 CD 0.007 0.0000 0.001 0.0002
3337.V2.C6 CD 0.044 0.0002 0.175 0.012
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 0.578 >50
247-23 D 0.005 0.0001 0.006 0.002
3016.v5.c45 D 0.005 0.0002 0.022 0.006
57128.vrc15 D >50 0.004 0.003 0.011
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D 2.68 0.004 0.006 0.013
A07412M1.vrc12 D 0.068 0.002 0.0008 0.002
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.006 0.001 0.003 0.003
P1981.C5.3 G 0.008 0.002 0.005 0.002
X1193.c1 G 0.343 0.001 0.302 0.145
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.010 0.0004 0.007 0.002
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC50 <50ug/ml 93 116 112 106
IC50 <10ug/ml 85 115 106 106
IC50 <1.0ug/ml 78 113 96 94
IC50 <0.1ug/ml 68 106 73 81
IC50 <0.01ug/ml 43 93 51 65
% VS Neutralized
IC50 <50ug/ml 47 59 57 54
IC50 <10ug/ml 43 58 54 54
IC50 <1.0ug/ml 39 57 48 47
IC50 <0.1ug/ml 34 54 37 41
IC50 <0.01ug/ml 22 47 26 33
Median IC50 0.013 0.002 0.012 0.005
Geometric Mean 0.029 0.002 0.035 0.011











0260.v5.c36 A >50 >50 18.6 >50
0330.v4.c3 A >50 1.04 >50 >50
0439.v5.c1 A >50 >50 5.12 3.56
3365.v2.c20 A >50 >50 >50 >50
3415.v1.c1 A >50 >50 >50 >50
3718.v3.c11 A >50 >50 >50 >50
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.500 0.001 7.11 0.816
BG505.W6M.C2 A >50 0.012 0.999 0.050
BI369.9A A 0.001 0.004 0.060 0.011
BS208.B1 A 0.0003 0.0004 0.021 0.008
KER2008.12 A >50 0.183 >50 >50
KER2018.11 A 0.001 0.002 0.022 0.007
KNH1209.18 A >50 8.85 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A >50 4.00 >50 >50
MI369.A5 A 2.86 0.019 4.53 0.572
MS208.A1 A 1.00 0.232 26.8 4.59
Q23.17 A >50 1.30 >50 >50
Q259.17 A 0.259 0.0003 2.65 1.10
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.123 >50 >50
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.119 1.77 >50 >50
3301.V1.C24 AC 0.002 0.020 0.038 0.020
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 29.2 0.051 32.3 >50
6545.V4.C1 AC 27.6 0.096 >50 >50
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.100 0.005 0.023 0.011
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD >50 >25 0.626 5.00
Q461.e2 AD 19.3 0.080 0.048 0.039
620345.c1 AE 0.090 0.051 0.248 0.056
BJOX009000.02.4 AE >50 >50 11.0 >50
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.046 0.718 5.03 0.403
C2101.c1 AE >50 >50 >50 >50
C3347.c11 AE >50 >50 0.773 0.646
C4118.09 AE 0.0003 0.001 0.004 0.002
CM244.ec1 AE 11.1 2.75 0.053 0.236
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.241 0.024 0.068 0.023
CNE55 AE 5.00 0.006 0.008 0.002
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE >50 1.00 0.086 0.035
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 5.00 0.047 0.060
R3265.c6 AE >50 >50 >50 >50
TH966.8 AE >50 0.089 0.042 0.064
TH976.17 AE 0.052 8.00 >50 >50
235-47.SG3 AG >50 2.55 >50 >50
242-14 AG 16.4 0.005 0.731 0.054
263-8 AG 0.300 0.270 0.071 0.018
269-12 AG 1.88 0.182 15.9 >50
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.041 13.3 2.31
DJ263.8 AG 4.31 0.014 0.048 0.024
T250-4 AG 0.005 0.002 0.008 0.003
T251-18 AG 0.0003 >50 >50 >50
T253-11 AG >50 32.5 0.124 0.601
T255-34 AG >50 >50 >50 >50
T257-31 AG >50 0.002 0.010 0.004
T266-60 AG 0.004 0.110 4.71 2.15
T278-50 AG 12.0 >50 >50 >50
T280-5 AG >50 0.008 5.64 17.1
T33-7 AG >50 >50 >50 >50
3988.25 B >50 0.110 19.4 >50
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.272 >50 >50
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 1.00 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 >50 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B >50 0.289 2.33 0.842
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 >50 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 >50 48.8 >50
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.400 0.015 23.6 0.436
CH070.1 BC 0.500 >50 0.177 0.165
CH117.4 BC 0.0008 0.00004 0.004 0.0008
CH181.12 BC 0.0003 0.00004 0.006 0.001
CNE15 BC >50 >50 >50 >50
CNE19 BC >50 0.008 >50 >50
CNE20 BC >50 0.109 >50 >50
CNE21 BC 0.023 0.002 0.057 0.023
CNE40 BC >50 0.449 >50 >50
CNE7 BC 0.046 0.024 0.012 0.010
286.36 C 0.001 0.004 0.016 0.009
288.38 C >50 >50 >50 >50
0013095-2.11 C >50 >50 0.011 0.007
001428-2.42 C >50 >50 >50 >50
0077_V1.C16 C 0.020 0.023 0.026 0.005
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 1.00 0.002 0.004 0.001
16055-2.3 C 0.015 0.005 0.021 0.007
16845-2.22 C >50 >50 >50 >50
16936-2.21 C >50 0.065 >50 >50
25710-2.43 C 0.005 0.004 0.039 0.013
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.007 0.0009 0.053 0.012
26191-2.48 C 0.050 0.003 0.069 0.045
3168.V4.C10 C >50 >50 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.072 0.020 0.017 0.013
6322.V4.C1 C 0.002 0.012 0.053 0.009
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.036 0.006 0.026 0.008
6838.V1.C35 C 0.200 0.042 4.82 0.273
96ZM651.02 C >50 >50 0.408 0.152
BR025.9 C >50 >50 >50 >50
CAP210.E8 C 0.009 0.004 0.008 0.005
CAP244.D3 C >50 >50 >50 >50
CAP256.206.C9 C 0.006 0.002 0.009 0.006
CAP45.G3 C 0.070 0.001 0.111 0.034
Ce1176.A3 C >50 >50 >50 >50
CE703010217.B6 C >50 5.00 4.40 2.19
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.0009 0.003 0.012 0.010
DU123.06 C 2.29 10.0 0.035 0.024
DU151.02 C 1.24 0.008 0.070 0.022
DU156.12 C 0.515 0.051 0.136 0.045
DU172.17 C >50 >50 9.60 >50
DU422.01 C 40.9 0.109 3.37 0.224
MW965.26 C 0.677 0.572 0.661 0.268
SO18.18 C 0.0003 0.004 0.013 0.006
TV1.29 C >50 >50 17.5 >50
TZA125.17 C 4.40 0.028 0.020 0.005
TZBD.02 C 0.140 0.016 0.013 0.017
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.500 0.055 0.245 0.081
ZM109.4 C >50 0.253 0.203 0.600
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.002 0.001 0.009 0.007
ZM197.7 C 0.030 0.033 0.074 0.008
ZM214.15 C >50 0.231 >50 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.022 0.002 0.018 0.011
ZM249.1 C 0.128 0.021 0.524 0.036
ZM53.12 C 0.007 0.0009 0.009 0.005
ZM55.28a C 0.159 0.048 0.033 0.005
3326.V4.C3 CD 0.0008 0.0003 0.005 0.002
3337.V2.C6 CD 0.034 0.001 >50 3.87
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 >50 >50
247-23 D 1.18 0.005 0.022 0.016
3016.v5.c45 D 2.67 0.005 >50 >50
57128.vrc15 D >50 2.00 0.100 0.324
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D >50 0.120 0.182 0.119
A07412M1.vrc12 D 2.63 0.034 0.004 0.009
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.032 0.009 0.009 0.008
P1981.C5.3 G 0.039 0.022 0.013 0.007
X1193.c1 G 8.04 0.600 4.03 4.61
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.037 0.010 0.029 0.011
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC80 <50ug/ml 73 99 91 83
IC80 <10ug/ml 66 97 80 82
IC80 <1.0ug/ml 53 84 67 73
IC80 <0.1ug/ml 38 65 51 57
IC80 <0.01ug/ml 21 37 13 27
% VS Neutralized
IC80 <50ug/ml 37 50 46 42
IC80 <10ug/ml 33 49 40 41
IC80 <1.0ug/ml 27 42 34 37
IC80 <0.1ug/ml 19 33 26 29
IC80 <0.01ug/ml 11 19 7 14
Median IC80 0.072 0.024 0.068 0.023
Geometric Mean 0.085 0.032 0.164 0.043











0260.v5.c36 A >50 >50 18.6 >50
0330.v4.c3 A >50 1.04 >50 >50
0439.v5.c1 A >50 >50 5.12 3.56
3365.v2.c20 A >50 >50 >50 >50
3415.v1.c1 A >50 >50 >50 >50
3718.v3.c11 A >50 >50 >50 >50
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.500 0.001 7.11 0.816
BG505.W6M.C2 A >50 0.012 0.999 0.050
BI369.9A A 0.001 0.004 0.060 0.011
BS208.B1 A 0.0003 0.0004 0.021 0.008
KER2008.12 A >50 0.183 >50 >50
KER2018.11 A 0.001 0.002 0.022 0.007
KNH1209.18 A >50 8.85 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A >50 4.00 >50 >50
MI369.A5 A 2.86 0.019 4.53 0.572
MS208.A1 A 1.00 0.232 26.8 4.59
Q23.17 A >50 1.30 >50 >50
Q259.17 A 0.259 0.0003 2.65 1.10
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.123 >50 >50
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.119 1.77 >50 >50
3301.V1.C24 AC 0.002 0.020 0.038 0.020
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 29.2 0.051 32.3 >50
6545.V4.C1 AC 27.6 0.096 >50 >50
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.100 0.005 0.023 0.011
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD >50 >25 0.626 5.00
Q461.e2 AD 19.3 0.080 0.048 0.039
620345.c1 AE 0.090 0.051 0.248 0.056
BJOX009000.02.4 AE >50 >50 11.0 >50
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.046 0.718 5.03 0.403
C2101.c1 AE >50 >50 >50 >50
C3347.c11 AE >50 >50 0.773 0.646
C4118.09 AE 0.0003 0.001 0.004 0.002
CM244.ec1 AE 11.1 2.75 0.053 0.236
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.241 0.024 0.068 0.023
CNE55 AE 5.00 0.006 0.008 0.002
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE >50 1.00 0.086 0.035
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 5.00 0.047 0.060
R3265.c6 AE >50 >50 >50 >50
TH966.8 AE >50 0.089 0.042 0.064
TH976.17 AE 0.052 8.00 >50 >50
235-47.SG3 AG >50 2.55 >50 >50
242-14 AG 16.4 0.005 0.731 0.054
263-8 AG 0.300 0.270 0.071 0.018
269-12 AG 1.88 0.182 15.9 >50
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.041 13.3 2.31
DJ263.8 AG 4.31 0.014 0.048 0.024
T250-4 AG 0.005 0.002 0.008 0.003
T251-18 AG 0.0003 >50 >50 >50
T253-11 AG >50 32.5 0.124 0.601
T255-34 AG >50 >50 >50 >50
T257-31 AG >50 0.002 0.010 0.004
T266-60 AG 0.004 0.110 4.71 2.15
T278-50 AG 12.0 >50 >50 >50
T280-5 AG >50 0.008 5.64 17.1
T33-7 AG >50 >50 >50 >50
3988.25 B >50 0.110 19.4 >50
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.272 >50 >50
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 1.00 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 >50 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B >50 0.289 2.33 0.842
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 >50 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 >50 48.8 >50
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.400 0.015 23.6 0.436
CH070.1 BC 0.500 >50 0.177 0.165
CH117.4 BC 0.0008 0.00004 0.004 0.0008
CH181.12 BC 0.0003 0.00004 0.006 0.001
CNE15 BC >50 >50 >50 >50
CNE19 BC >50 0.008 >50 >50
CNE20 BC >50 0.109 >50 >50
CNE21 BC 0.023 0.002 0.057 0.023
CNE40 BC >50 0.449 >50 >50
CNE7 BC 0.046 0.024 0.012 0.010
286.36 C 0.001 0.004 0.016 0.009
288.38 C >50 >50 >50 >50
0013095-2.11 C >50 >50 0.011 0.007
001428-2.42 C >50 >50 >50 >50
0077_V1.C16 C 0.020 0.023 0.026 0.005
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 1.00 0.002 0.004 0.001
16055-2.3 C 0.015 0.005 0.021 0.007
16845-2.22 C >50 >50 >50 >50
16936-2.21 C >50 0.065 >50 >50
25710-2.43 C 0.005 0.004 0.039 0.013
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.007 0.0009 0.053 0.012
26191-2.48 C 0.050 0.003 0.069 0.045
3168.V4.C10 C >50 >50 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.072 0.020 0.017 0.013
6322.V4.C1 C 0.002 0.012 0.053 0.009
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.036 0.006 0.026 0.008
6838.V1.C35 C 0.200 0.042 4.82 0.273
96ZM651.02 C >50 >50 0.408 0.152
BR025.9 C >50 >50 >50 >50
CAP210.E8 C 0.009 0.004 0.008 0.005
CAP244.D3 C >50 >50 >50 >50
CAP256.206.C9 C 0.006 0.002 0.009 0.006
CAP45.G3 C 0.070 0.001 0.111 0.034
Ce1176.A3 C >50 >50 >50 >50
CE703010217.B6 C >50 5.00 4.40 2.19
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.0009 0.003 0.012 0.010
DU123.06 C 2.29 10.0 0.035 0.024
DU151.02 C 1.24 0.008 0.070 0.022
DU156.12 C 0.515 0.051 0.136 0.045
DU172.17 C >50 >50 9.60 >50
DU422.01 C 40.9 0.109 3.37 0.224
MW965.26 C 0.677 0.572 0.661 0.268
SO18.18 C 0.0003 0.004 0.013 0.006
TV1.29 C >50 >50 17.5 >50
TZA125.17 C 4.40 0.028 0.020 0.005
TZBD.02 C 0.140 0.016 0.013 0.017
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.500 0.055 0.245 0.081
ZM109.4 C >50 0.253 0.203 0.600
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.002 0.001 0.009 0.007
ZM197.7 C 0.030 0.033 0.074 0.008
ZM214.15 C >50 0.231 >50 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.022 0.002 0.018 0.011
ZM249.1 C 0.128 0.021 0.524 0.036
ZM53.12 C 0.007 0.0009 0.009 0.005
ZM55.28a C 0.159 0.048 0.033 0.005
3326.V4.C3 CD 0.0008 0.0003 0.005 0.002
3337.V2.C6 CD 0.034 0.001 >50 3.87
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 >50 >50
247-23 D 1.18 0.005 0.022 0.016
3016.v5.c45 D 2.67 0.005 >50 >50
57128.vrc15 D >50 2.00 0.100 0.324
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D >50 0.120 0.182 0.119
A07412M1.vrc12 D 2.63 0.034 0.004 0.009
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.032 0.009 0.009 0.008
P1981.C5.3 G 0.039 0.022 0.013 0.007
X1193.c1 G 8.04 0.600 4.03 4.61
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.037 0.010 0.029 0.011
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC80 <50ug/ml 73 99 91 83
IC80 <10ug/ml 66 97 80 82
IC80 <1.0ug/ml 53 84 67 73
IC80 <0.1ug/ml 38 65 51 57
IC80 <0.01ug/ml 21 37 13 27
% VS Neutralized
IC80 <50ug/ml 37 50 46 42
IC80 <10ug/ml 33 49 40 41
IC80 <1.0ug/ml 27 42 34 37
IC80 <0.1ug/ml 19 33 26 29
IC80 <0.01ug/ml 11 19 7 14
Median IC80 0.072 0.024 0.068 0.023
Geometric Mean 0.085 0.032 0.164 0.043











0260.v5.c36 A >50 >50 18.6 >50
0330.v4.c3 A >50 1.04 >50 >50
0439.v5.c1 A >50 >50 5.12 3.56
3365.v2.c20 A >50 >50 >50 >50
3415.v1.c1 A >50 >50 >50 >50
3718.v3.c11 A >50 >50 >50 >50
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.500 0.001 7.11 0.816
BG505.W6M.C2 A >50 0.012 0.999 0.050
BI369.9A A 0.001 0.004 0.060 0.011
BS208.B1 A 0.0003 0.0004 0.021 0.008
KER2008.12 A >50 0.183 >50 >50
KER2018.11 A 0.001 0.002 0.022 0.007
KNH1209.18 A >50 8.85 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A >50 4.00 >50 >50
MI369.A5 A 2.86 0.019 4.53 0.572
MS208.A1 A 1.00 0.232 26.8 4.59
Q23.17 A >50 1.30 >50 >50
Q259.17 A 0.259 0.0003 2.65 1.10
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.123 >50 >50
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.119 1.77 >50 >50
3301.V1.C24 AC 0.002 0.020 0.038 0.020
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 29.2 0.051 32.3 >50
6545.V4.C1 AC 27.6 0.096 >50 >50
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.100 0.005 0.023 0.011
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD >50 >25 0.626 5.00
Q461.e2 AD 19.3 0.080 0.048 0.039
620345.c1 AE 0.090 0.051 0.248 0.056
BJOX009000.02.4 AE >50 >50 11.0 >50
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.046 0.718 5.03 0.403
C2101.c1 AE >50 >50 >50 >50
C3347.c11 AE >50 >50 0.773 0.646
C4118.09 AE 0.0003 0.001 0.004 0.002
CM244.ec1 AE 11.1 2.75 0.053 0.236
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.241 0.024 0.068 0.023
CNE55 AE 5.00 0.006 0.008 0.002
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE >50 1.00 0.086 0.035
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 5.00 0.047 0.060
R3265.c6 AE >50 >50 >50 >50
TH966.8 AE >50 0.089 0.042 0.064
TH976.17 AE 0.052 8.00 >50 >50
235-47.SG3 AG >50 2.55 >50 >50
242-14 AG 16.4 0.005 0.731 0.054
263-8 AG 0.300 0.270 0.071 0.018
269-12 AG 1.88 0.182 15.9 >50
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.041 13.3 2.31
DJ263.8 AG 4.31 0.014 0.048 0.024
T250-4 AG 0.005 0.002 0.008 0.003
T251-18 AG 0.0003 >50 >50 >50
T253-11 AG >50 32.5 0.124 0.601
T255-34 AG >50 >50 >50 >50
T257-31 AG >50 0.002 0.010 0.004
T266-60 AG 0.004 0.110 4.71 2.15
T278-50 AG 12.0 >50 >50 >50
T280-5 AG >50 0.008 5.64 17.1
T33-7 AG >50 >50 >50 >50
3988.25 B >50 0.110 19.4 >50
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.272 >50 >50
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 1.00 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 >50 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B >50 0.289 2.33 0.842
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 >50 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 >50 48.8 >50
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.400 0.015 23.6 0.436
CH070.1 BC 0.500 >50 0.177 0.165
CH117.4 BC 0.0008 0.00004 0.004 0.0008
CH181.12 BC 0.0003 0.00004 0.006 0.001
CNE15 BC >50 >50 >50 >50
CNE19 BC >50 0.008 >50 >50
CNE20 BC >50 0.109 >50 >50
CNE21 BC 0.023 0.002 0.057 0.023
CNE40 BC >50 0.449 >50 >50
CNE7 BC 0.046 0.024 0.012 0.010
286.36 C 0.001 0.004 0.016 0.009
288.38 C >50 >50 >50 >50
0013095-2.11 C >50 >50 0.011 0.007
001428-2.42 C >50 >50 >50 >50
0077_V1.C16 C 0.020 0.023 0.026 0.005
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 1.00 0.002 0.004 0.001
16055-2.3 C 0.015 0.005 0.021 0.007
16845-2.22 C >50 >50 >50 >50
16936-2.21 C >50 0.065 >50 >50
25710-2.43 C 0.005 0.004 0.039 0.013
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.007 0.0009 0.053 0.012
26191-2.48 C 0.050 0.003 0.069 0.045
3168.V4.C10 C >50 >50 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.072 0.020 0.017 0.013
6322.V4.C1 C 0.002 0.012 0.053 0.009
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.036 0.006 0.026 0.008
6838.V1.C35 C 0.200 0.042 4.82 0.273
96ZM651.02 C >50 >50 0.408 0.152
BR025.9 C >50 >50 >50 >50
CAP210.E8 C 0.009 0.004 0.008 0.005
CAP244.D3 C >50 >50 >50 >50
CAP256.206.C9 C 0.006 0.002 0.009 0.006
CAP45.G3 C 0.070 0.001 0.111 0.034
Ce1176.A3 C >50 >50 >50 >50
CE703010217.B6 C >50 5.00 4.40 2.19
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.0009 0.003 0.012 0.010
DU123.06 C 2.29 10.0 0.035 0.024
DU151.02 C 1.24 0.008 0.070 0.022
DU156.12 C 0.515 0.051 0.136 0.045
DU172.17 C >50 >50 9.60 >50
DU422.01 C 40.9 0.109 3.37 0.224
MW965.26 C 0.677 0.572 0.661 0.268
SO18.18 C 0.0003 0.004 0.013 0.006
TV1.29 C >50 >50 17.5 >50
TZA125.17 C 4.40 0.028 0.020 0.005
TZBD.02 C 0.140 0.016 0.013 0.017
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.500 0.055 0.245 0.081
ZM109.4 C >50 0.253 0.203 0.600
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.002 0.001 0.009 0.007
ZM197.7 C 0.030 0.033 0.074 0.008
ZM214.15 C >50 0.231 >50 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.022 0.002 0.018 0.011
ZM249.1 C 0.128 0.021 0.524 0.036
ZM53.12 C 0.007 0.0009 0.009 0.005
ZM55.28a C 0.159 0.048 0.033 0.005
3326.V4.C3 CD 0.0008 0.0003 0.005 0.002
3337.V2.C6 CD 0.034 0.001 >50 3.87
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 >50 >50
247-23 D 1.18 0.005 0.022 0.016
3016.v5.c45 D 2.67 0.005 >50 >50
57128.vrc15 D >50 2.00 0.100 0.324
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D >50 0.120 0.182 0.119
A07412M1.vrc12 D 2.63 0.034 0.004 0.009
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.032 0.009 0.009 0.008
P1981.C5.3 G 0.039 0.022 0.013 0.007
X1193.c1 G 8.04 0.600 4.03 4.61
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.037 0.010 0.029 0.011
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC80 <50ug/ml 73 99 91 83
IC80 <10ug/ml 66 97 80 82
IC80 <1.0ug/ml 53 84 67 73
IC80 <0.1ug/ml 38 65 51 57
IC80 <0.01ug/ml 21 37 13 27
% VS Neutralized
IC80 <50ug/ml 37 50 46 42
IC80 <10ug/ml 33 49 40 41
IC80 <1.0ug/ml 27 42 34 37
IC80 <0.1ug/ml 19 33 26 29
IC80 <0.01ug/ml 11 19 7 14
Median IC80 0.072 0.024 0.068 0.023
Geometric Mean 0.085 0.032 0.164 0.043











0260.v5.c36 A >50 >50 18.6 >50
0330.v4.c3 A >50 1.04 >50 >50
0439.v5.c1 A >50 >50 5.12 3.56
3365.v2.c20 A >50 >50 >50 >50
3415.v1.c1 A >50 >50 >50 >50
3718.v3.c11 A >50 >50 >50 >50
398-F1_F6_20 A >50 >50 >50 >50
BB201.B42 A 0.500 0.001 7.11 0.816
BG505.W6M.C2 A >50 0.012 0.999 0.050
BI369.9A A 0.001 0.004 0.060 0.011
BS208.B1 A 0.0003 0.0004 0.021 0.008
KER2008.12 A >50 0.183 >50 >50
KER2018.11 A 0.001 0.002 0.022 0.007
KNH1209.18 A >50 8.85 >50 >50
MB201.A1 A >50 >50 >50 >50
MB539.2B7 A >50 4.00 >50 >50
MI369.A5 A 2.86 0.019 4.53 0.572
MS208.A1 A 1.00 0.232 26.8 4.59
Q23.17 A >50 1.30 >50 >50
Q259.17 A 0.259 0.0003 2.65 1.10
Q769.d22 A >50 >50 >50 >50
Q769.h5 A >50 >50 >50 >50
Q842.d12 A >50 0.123 >50 >50
QH209.14M.A2 A >50 >50 >50 >50
RW020.2 A >50 >50 >50 >50
UG037.8 A >50 >50 >50 >50
246-F3.C10.2 AC 0.119 1.77 >50 >50
3301.V1.C24 AC 0.002 0.020 0.038 0.020
3589.V1.C4 AC >50 >50 >50 >50
6540.v4.c1 AC 29.2 0.051 32.3 >50
6545.V4.C1 AC 27.6 0.096 >50 >50
0815.V3.C3 ACD >50 >50 >50 >50
6095.V1.C10 ACD 0.100 0.005 0.023 0.011
3468.V1.C12 AD >50 >50 >50 >50
Q168.a2 AD >50 >25 0.626 5.00
Q461.e2 AD 19.3 0.080 0.048 0.039
620345.c1 AE 0.090 0.051 0.248 0.056
BJOX009000.02.4 AE >50 >50 11.0 >50
BJOX010000.06.2 AE >50 >50 >50 >50
BJOX025000.01.1 AE >50 >50 >50 >50
BJOX028000.10.3 AE >50 >50 >50 >50
C1080.c3 AE 0.046 0.718 5.03 0.403
C2101.c1 AE >50 >50 >50 >50
C3347.c11 AE >50 >50 0.773 0.646
C4118.09 AE 0.0003 0.001 0.004 0.002
CM244.ec1 AE 11.1 2.75 0.053 0.236
CNE3 AE >50 >50 >50 >50
CNE5 AE 0.241 0.024 0.068 0.023
CNE55 AE 5.00 0.006 0.008 0.002
CNE56 AE >50 >50 >50 >50
CNE59 AE >50 >50 >50 >50
CNE8 AE >50 1.00 0.086 0.035
R1166.c1 AE >50 >50 >50 >50
R2184.c4 AE >50 5.00 0.047 0.060
R3265.c6 AE >50 >50 >50 >50
TH966.8 AE >50 0.089 0.042 0.064
TH976.17 AE 0.052 8.00 >50 >50
235-47.SG3 AG >50 2.55 >50 >50
242-14 AG 16.4 0.005 0.731 0.054
263-8 AG 0.300 0.270 0.071 0.018
269-12 AG 1.88 0.182 15.9 >50
271-11 AG >50 >50 >50 >50
928-28 AG >50 0.041 13.3 2.31
DJ263.8 AG 4.31 0.014 0.048 0.024
T250-4 AG 0.005 0.002 0.008 0.003
T251-18 AG 0.0003 >50 >50 >50
T253-11 AG >50 32.5 0.124 0.601
T255-34 AG >50 >50 >50 >50
T257-31 AG >50 0.002 0.010 0.004
T266-60 AG 0.004 0.110 4.71 2.15
T278-50 AG 12.0 >50 >50 >50
T280-5 AG >50 0.008 5.64 17.1
T33-7 AG >50 >50 >50 >50
3988.25 B >50 0.110 19.4 >50
5768.04 B >50 >50 >50 >50
6101.10 B >50 >50 >50 >50
6535.3 B >50 >50 >50 >50
7165.18 B >50 >50 >50 >50
45_01dG5 B >50 0.272 >50 >50
89.6.DG B >50 >50 >50 >50
AC10.29 B >50 1.00 >50 >50
ADA.DG B >50 >50 >50 >50
Bal.01 B >50 >50 >50 >50
BaL.26 B >50 >50 >50 >50
BG1168.01 B >50 >50 >50 >50
BL01.DG B >50 >50 >50 >50
BR07.DG B >50 >50 >50 >50
BX08.16 B >50 >50 >50 >50
CAAN.A2 B >50 >50 >50 >50
CNE10 B >50 >50 >50 >50
CNE12 B >50 >50 >50 >50
CNE14 B >50 >50 >50 >50
CNE4 B >50 >50 >50 >50
CNE57 B >50 >50 >50 >50
HO86.8 B >50 >50 >50 >50
HT593.1 B >50 >50 >50 >50
HXB2.DG B >50 >50 >50 >50
JRCSF.JB B >50 >50 >50 >50
JRFL.JB B >50 >50 >50 >50
MN.3 B >50 >50 >50 >50
PVO.04 B >50 0.289 2.33 0.842
QH0515.01 B >50 >50 >50 >50
QH0692.42 B >50 >50 >50 >50
REJO.67 B >50 >50 >50 >50
RHPA.7 B >50 >50 >50 >50
SC422.8 B >50 >50 >50 >50
SF162.LS B >50 >50 >50 >50
SS1196.01 B >50 >50 >50 >50
THRO.18 B >50 >50 48.8 >50
TRJO.58 B >50 >50 >50 >50
TRO.11 B >50 >50 >50 >50
WITO.33 B >50 >50 >50 >50
YU2.DG B >50 >50 >50 >50
CH038.12 BC 0.400 0.015 23.6 0.436
CH070.1 BC 0.500 >50 0.177 0.165
CH117.4 BC 0.0008 0.00004 0.004 0.0008
CH181.12 BC 0.0003 0.00004 0.006 0.001
CNE15 BC >50 >50 >50 >50
CNE19 BC >50 0.008 >50 >50
CNE20 BC >50 0.109 >50 >50
CNE21 BC 0.023 0.002 0.057 0.023
CNE40 BC >50 0.449 >50 >50
CNE7 BC 0.046 0.024 0.012 0.010
286.36 C 0.001 0.004 0.016 0.009
288.38 C >50 >50 >50 >50
0013095-2.11 C >50 >50 0.011 0.007
001428-2.42 C >50 >50 >50 >50
0077_V1.C16 C 0.020 0.023 0.026 0.005
00836-2.5 C >50 >50 >50 >50
0921.V2.C14 C 1.00 0.002 0.004 0.001
16055-2.3 C 0.015 0.005 0.021 0.007
16845-2.22 C >50 >50 >50 >50
16936-2.21 C >50 0.065 >50 >50
25710-2.43 C 0.005 0.004 0.039 0.013
25711-2.4 C >50 >50 >50 >50
25925-2.22 C 0.007 0.0009 0.053 0.012
26191-2.48 C 0.050 0.003 0.069 0.045
3168.V4.C10 C >50 >50 >50 >50
3637.V5.C3 C >50 >50 >50 >50
3873.V1.C24 C 0.072 0.020 0.017 0.013
6322.V4.C1 C 0.002 0.012 0.053 0.009
6471.V1.C16 C >50 >50 >50 >50
6631.V3.C10 C >50 >50 >50 >50
6644.V2.C33 C >50 >50 >50 >50
6785.V5.C14 C 0.036 0.006 0.026 0.008
6838.V1.C35 C 0.200 0.042 4.82 0.273
96ZM651.02 C >50 >50 0.408 0.152
BR025.9 C >50 >50 >50 >50
CAP210.E8 C 0.009 0.004 0.008 0.005
CAP244.D3 C >50 >50 >50 >50
CAP256.206.C9 C 0.006 0.002 0.009 0.006
CAP45.G3 C 0.070 0.001 0.111 0.034
Ce1176.A3 C >50 >50 >50 >50
CE703010217.B6 C >50 5.00 4.40 2.19
CNE30 C >50 >50 >50 >50
CNE31 C >50 >50 >50 >50
CNE53 C >50 >50 >50 >50
CNE58 C 0.0009 0.003 0.012 0.010
DU123.06 C 2.29 10.0 0.035 0.024
DU151.02 C 1.24 0.008 0.070 0.022
DU156.12 C 0.515 0.051 0.136 0.045
DU172.17 C >50 >50 9.60 >50
DU422.01 C 40.9 0.109 3.37 0.224
MW965.26 C 0.677 0.572 0.661 0.268
SO18.18 C 0.0003 0.004 0.013 0.006
TV1.29 C >50 >50 17.5 >50
TZA125.17 C 4.40 0.028 0.020 0.005
TZBD.02 C 0.140 0.016 0.013 0.017
ZA012.29 C >50 >50 >50 >50
ZM106.9 C 0.500 0.055 0.245 0.081
ZM109.4 C >50 0.253 0.203 0.600
ZM135.10a C >50 >50 >50 >50
ZM176.66 C 0.002 0.001 0.009 0.007
ZM197.7 C 0.030 0.033 0.074 0.008
ZM214.15 C >50 0.231 >50 >50
ZM215.8 C >50 >50 >50 >50
ZM233.6 C 0.022 0.002 0.018 0.011
ZM249.1 C 0.128 0.021 0.524 0.036
ZM53.12 C 0.007 0.0009 0.009 0.005
ZM55.28a C 0.159 0.048 0.033 0.005
3326.V4.C3 CD 0.0008 0.0003 0.005 0.002
3337.V2.C6 CD 0.034 0.001 >50 3.87
3817.v2.c59 CD >50 >50 >50 >50
231965.c1 D >50 >50 >50 >50
247-23 D 1.18 0.005 0.022 0.016
3016.v5.c45 D 2.67 0.005 >50 >50
57128.vrc15 D >50 2.00 0.100 0.324
6405.v4.c34 D >50 >50 >50 >50
A03349M1.vrc4a D >50 0.120 0.182 0.119
A07412M1.vrc12 D 2.63 0.034 0.004 0.009
NKU3006.ec1 D >50 >50 >50 >50
P0402.c2.11 G 0.032 0.009 0.009 0.008
P1981.C5.3 G 0.039 0.022 0.013 0.007
X1193.c1 G 8.04 0.600 4.03 4.61
X1254.c3 G >50 >50 >50 >50
X1632.S2.B10 G 0.037 0.010 0.029 0.011
X2088.c9 G >50 >50 >50 >50









# Viruses 198 198 198 198
Total VS Neutralized
IC80 <50ug/ml 73 99 91 83
IC80 <10ug/ml 66 97 80 82
IC80 <1.0ug/ml 53 84 67 73
IC80 <0.1ug/ml 38 65 51 57
IC80 <0.01ug/ml 21 37 13 27
% VS Neutralized
IC80 <50ug/ml 37 50 46 42
IC80 <10ug/ml 33 49 40 41
IC80 <1.0ug/ml 27 42 34 37
IC80 <0.1ug/ml 19 33 26 29
IC80 <0.01ug/ml 11 19 7 14
Median IC80 0.072 0.024 0.068 0.023

















































3. Viral variants that initiate and drive maturation of V1V2-directed 
HIV-1 broadly neutralizing antibodies 
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This publication identified the viral variants that initially engaged the rare CAP256-VRC25-
UCA and showed how creation of multiple viral immunotypes drove maturation of this mAb 
lineage towards neutralization breadth. 
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The elicitation of broadly neutralizing antibodies (bNAbs) is 
likely to be essential for a preventative HIV-1 vaccine, but this 
has not yet been achieved by immunization. In contrast, some 
HIV-1-infected individuals naturally mount bNAb responses 
during chronic infection, suggesting that years of maturation 
may be required for neutralization breadth1–6. Recent studies 
have shown that viral diversification precedes the emergence of 
bNAbs, but the significance of this observation is unknown7,8. 
Here we delineate the key viral events that drove neutralization 
breadth within the CAP256-VRC26 family of 33 monoclonal 
antibodies (mAbs) isolated from a superinfected individual. 
First, we identified minority viral variants, termed bNAb-
initiating envelopes, that were distinct from both of the 
transmitted/founder (T/F) viruses and that efficiently engaged 
the bNAb precursor. Second, deep sequencing revealed a 
pool of diverse epitope variants (immunotypes) that were 
preferentially neutralized by broader members of the antibody 
lineage. In contrast, a ‘dead-end’ antibody sublineage unable to 
neutralize these immunotypes showed limited evolution and failed 
to develop breadth. Thus, early viral escape at key antibody-virus 
contact sites selects for antibody sublineages that can tolerate 
these changes, thereby providing a mechanism for the generation 
of neutralization breadth within a developing antibody lineage.
The identification of bNAbs against genetically diverse viruses such 
as HIV-1 (ref. 9), together with in-depth longitudinal evolutionary 
studies are providing key insights for vaccine design7,8,10–12. BNAbs to 
the variable regions 1 and 2 (V1V2) of the HIV-1 envelope (Env) are 
among the most prevalent and potent cross-reactive antibodies, but the 
virological events that allow for their elicitation and maturation remain 
unclear. We have previously described the CAP256-VRC26 mAb 
lineage, isolated from an HIV-1 subtype C–superinfected individ-
ual, which targets the V1V2 C-strand at the apex of the viral enve-
lope glycoprotein (Fig. 1a)7. This lineage developed from a bNAb 
precursor or unmutated common ancestor (UCA) with a 35–amino 
acid heavy chain complementarity determining region 3 (CDRH3), 
and it acquired breadth through moderate levels of somatic hyper-
mutation (SHM)7. To better define the complex viral populations 
responsible for eliciting these antibodies and driving their matura-
tion, we performed next-generation sequencing (NGS) at 28 different 
time points over 4 years (with an average of 85,000 reads and 788 
consensus sequences per time point). From 6–13 weeks, all sequences 
were closely related to the primary infecting virus (PI) (Fig. 1b 
and Supplementary Fig. 1), but at 15 weeks, when superinfection 
(SU) occurred, there was a dramatic shift in viral populations, with 
SU-like viruses accounting for 99.8% of 3,228 consensus sequences 
(Supplementary Fig. 2). From 17 weeks, V1V2 sequences from 
the PI and SU viruses persisted, rapidly forming a PI-SU recom-
binant population, although PI-like viruses dominated briefly at 
23 weeks, perhaps as a result of immune escape from earlier non- 
V1V2-directed neutralizing antibodies that preferentially neutralized 
SU-like viruses13. Notably, diversification in all three viral popula-
tions (PI, SU and recombinants) increased after the CAP256-VRC26 
lineage was first detected in blood by NGS at 34 weeks (Fig. 1b and 
Supplementary Fig. 3).
As residues 169 and 166 in the V1V2 C-strand form a crucial 
part of the CAP256-VRC26 bNAb epitope and are likely to be 
important in virus-mAb co-evolution, we focused on defining escape 
mutations at these positions. Residue 169 differed between the 
PI (169Q) and SU viruses (169K), with the majority of viral variants 
circulating after 23 weeks possessing a PI-derived 169Q mutation 
(Fig. 1c and Supplementary Fig. 2). From 27 weeks onwards, the 
virus sampled 11 different amino acids at position 169, and varia-
tion was most pronounced at 42 weeks (Fig. 1c), shortly before the 
development of neutralization breadth. The major escape path-
way from 42–119 weeks was a 169I mutation, and thereafter 169E 
dominated. Toggling was also observed at position 166 (Fig. 1d), 
although this occurred later, with the wild-type 166R immunotype 
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(present in both the PI and SU viruses) occurring in more than 
98% of sequences until 53 weeks. At 59 weeks, the virus sampled 
four amino acids (166R, T, K or S), and thereafter 166K, followed 
by 166S, became prevalent. By 159 weeks, all viral sequences 
contained the mutually exclusive K169E or R166S mutations. 
As both the K169E and R166S mutations abrogate neutralization 
by the CAP256-VRC26 mAbs7,13 it is unclear why it took two 
years for these escape pathways to dominate despite their low-level 
presence early in the development of the CAP256-VRC26 family 
(Supplementary Fig. 2).
The CAP256-VRC26 UCA was unable to neutralize any of 196 
HIV-1 isolates (Supplementary Fig. 4), suggesting that Env variants 
able to engage this UCA may be rare. Because CAP256-VRC26 NGS 
transcripts were first detected in blood 19 weeks after superinfection 
(Supplementary Fig. 3), we analyzed contemporaneous (34-week) 
viral sequences to identify a bNAb-initiating Env. Neutralization 
of the SU virus, but not the PI virus, by the CAP256-VRC26 UCA 
indicated that an SU-like variant elicited this lineage7. Although 8% 
(75/937) of V1V2 next-generation sequences at the 34-week time 
point were SU-like, none were identical to the SU virus (Fig. 2a and 
Supplementary Fig. 5). Single-genome amplification was therefore 
used to isolate six functional 34-week Env clones, which differed from 
the SU virus by 2–8 amino acids in V1V2 and by up to 26 changes 
across the entire Env (Fig. 2b). We observed evidence of early immune 
pressure, with three of six clones containing K169I or K169E muta-
tions, and four of six clones deleting or shifting the glycan at residue 
139 (Fig. 2c). As expected, the clones with 169I or 169E mutations 
were resistant to neutralization by the UCA; however, the three clones 
containing a wild-type 169K were 5–17-fold better neutralized than 
the SU virus (Fig. 2d). Thus, the 34-week viral variants that evolved 
from the CAP256 SU T/F virus (but differed from the T/F virus by at 
least 12 amino acids) provided a stronger stimulus for the CAP256-
VRC26 lineage.
We next sought to define how this lineage matured to acquire 
neutralization breadth in the context of CAP256 viral diversifica-
tion. A heavy chain phylogenetic tree of 33 isolated CAP256-VRC26 
mAbs (12 previously described7 and 21 recently isolated mAbs14) 
and CAP256-VRC26 NGS transcripts from 34 to 206 weeks showed 
an early bifurcation7 (Fig. 3a). A small sublineage of 34–59-week 
sequences, including the CAP256-VRC26.01 and 0.24 mAbs, 
exhibited restricted evolution. A second larger sublineage, contain-
ing transcripts from all time points as well as most of the mAbs 
(Fig. 3a), displayed extensive evolution, suggesting adaption in 
response to emerging viral escape mutations, such as K169T/I/Q/R 
and R166K (Fig. 1c,d). To test this hypothesis, we introduced these 
immunotypes into the SU virus and assayed them against 32 mAbs 
(CAP256-VRC26.20 does not neutralize SU and was excluded). 
The CAP256-VRC26.01 and 24 mAbs, from the smaller sublineage 
with limited breadth, both neutralized the SU virus at 0.04 µg/ml 
(Fig. 3b). However, SU viruses containing the 166 or 169 immu-
notypes were either neutralization resistant or showed a >670-fold 
reduction in neutralization sensitivity (Fig. 3b). Thus, the inability of 
mAbs in this dead-end sublineage to tolerate viral escape mutations 
was likely to be responsible for limiting their evolution and capacity 
to become broadly neutralizing.
Among the 30 CAP256-VRC26 mAbs from the evolving subline-
age that showed a range of neutralization breadth (2–63%), the 169T, 
169I or 169Q mutations abolished or reduced the activity of mAbs 
with limited breadth (Fig. 3c). In contrast, the neutralizing activity of 
broader family members was largely unaffected. This observation was 
SU
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Figure 1 Viral diversification over time in CAP256 HIV-1 Env V1V2. (a) BG505 SOSIP.664 trimer structure (PDB: 4TVP) fitted into a 3D reconstruction 
of the CAP256-VRC26.09 fragment antigen-binding (Fab)-trimer complex (EMD-5856, left). BG505 V1V2 cap with residues 166 and 169 shown as 
spheres and the C-strand highlighted in green (right). (b) Hamming distance from the PI sequence (y axis) versus weeks after infection (x axis) for all 
next-generation V1V2 consensus sequences. Values <0.03 and >0.23 were used to distinguish PI-like (blue) and SU-like (black) viruses respectively, 
whereas those sequences with an intermediate distance (0.03–0.23) were classified as PI-SU recombinant viruses (purple, REC). Hamming distances 
were normalized for sequence length, and the relative frequency of sequences with a given distance are indicated by the size of the circle (normalized 
for depth of sequencing, but not for viral load; see Supplementary Fig. 1). CAP256-VRC26 next-generation transcript detection in the blood is shown 
by gray shading. (c,d) The frequency of amino acids (y axis) at positions 169 (c) and 166 (d) are shown as stacked bars, with each bar representing a 
single time point from 6 to 206 weeks after infection (x axis). Amino acids are colored as indicated, with Del representing a deletion. The inset (*) in c 
expands the 42-week time point (when nine immunotypes are present), to highlight the minority immunotypes present at frequencies of <5%. The time 
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more pronounced for the R166K mutant, which was resistant to 16 out 
of 30 mAbs (Fig. 3c), consistent with the selection of this immunotype 
during later stages of bNAb development (Fig. 1d). However, six of 
the nine broadest mAbs were still able to neutralize this mutant at 
titers <1 µg/ml. With the exception of the K169R mutation, breadth 
was correlated with the ability to neutralize the 169 or 166 mutants 
(Fig. 3c and Supplementary Fig. 6). Overall mAbs with limited 
neutralization breadth were most severely affected by variation at 
positions 169 and 166, whereas the broadest mAbs were able to toler-
ate these early viral escape mutations, thus providing a mechanism for 
the evolution of neutralization breadth within this lineage.
Because high levels of SHM are often required for HIV-1 broad 
neutralization15,16, we investigated the relationship between SHM 
and neutralization breadth in the CAP256-VRC26 family (Fig. 4a). 
As expected, the nine mAbs with >40% breadth were 17–22% mutated 
from the UCA; however, three ‘off-track’ mAbs with a similar level of 
Figure 2 Characterization of the CAP256 
34-week Envs. (a) Frequency of 34-week 
next-generation V1V2 consensus sequences 
possessing a C-strand derived from the PI  
(blue, n = 862) or SU (black, n = 75) viruses.  
(b) Amino acid highlighter plot of single-genome 
amplification (SGA)-derived Env, comparing 
six SU-like 34-week clones (77, 80, 81, 31, 
55 and 68) to the SU virus (designated as the 
master). Mismatches from the SU are shown as 
colored ticks and the V1V2 region is boxed.  
(c) Amino acid sequence alignment of the V1V2 
region (HXB2 residues 126–196) comparing the 
SU and the six SGA-derived SU-like 34 week  
sequences. Red font denotes clones with a 
wild-type K169, whereas gray font indicates 
sequences with 169I or 169E mutations. Amino 
acid identity to the SU virus is represented 
by dots, deletions are shown as dashes and 
glycosylation sequons are shaded in gray.  
(d) CAP256-VRC26 UCA neutralization (y axis) 
of the SU virus (black) and the 34-week clones 
with 169K (red) and 169I or 169E (gray).  
UCA mAb concentration is shown on the x axis. 

























































































Figure 3 Relationship between bNAb phylogeny, 
neutralization breadth and tolerance of multiple 
immunotypes at positions 169 and 166.  
(a) A condensed heavy chain phylogenetic tree, 
rooted on the VH3-30*18 germline gene and 
displaying the positions of the 33 CAP256-
VRC26 mAbs. Antibody and mAbs are colored 
according to whether they were isolated from 
34–59 weeks (gray) or 119–206 weeks (black). 
The tree bifurcates into two sublineages 
(separated by a dashed line); one showing 
restricted evolution (left) contains only antibody 
transcripts from early time-points, whereas a 
continually evolving sublineage (right) contains 
transcripts from all time points. Scale shows  
the rate of nucleotide change between nodes.  
(b) Dead-end mAbs in the sublineage with 
restricted evolution are ranked according 
to percentage neutralization breadth in the 
histogram. Neutralization of the SU virus and 
169- and 166-mutant viruses by CAP256-
VRC26.01 and 24 are shown as a heat map, 
with shading showing neutralization potency, 
as indicated in the key. (c) Thirty mAbs in the 
continually evolving sublineage are ranked 
according to neutralization breadth in the 
histogram. Neutralization of the SU virus and 169- and 166-mutant viruses by CAP256-VRC26 mAbs are shown as a heat map, with shading showing 
neutralization potency, as indicated in the key. Correlations (r) between neutralization breadth and the IC50 titers of each mutant virus are indicated on 
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SHM (17–21%) had only 2–6% breadth (Fig. 4a). Therefore, as observed 
in several families of HIV-specific antibodies17–20 and influenza- 
specific antibodies21, high levels of SHM in the CAP256-VRC26 lin-
eage were not sufficient to confer breadth. To determine whether 
different viral variants drove the evolution of broad versus off-track 
mAbs, we tested both groups of mAbs against longitudinal CAP256 
viruses (Fig. 4b). Hierarchical clustering analysis of mAbs and viruses 
on the basis of their neutralization profiles showed a clear pheno-
typic separation between broad and off-track mAbs, with the latter 
neutralizing substantially fewer autologous viruses, but we could not 
attribute this to any genetic features of the mAbs. Both groups neutral-
ized viruses with an SU-like C-strand, including the bNAb-initiating 
34-week clones. All viruses neutralized by off-track antibodies were 
also sensitive to at least one broad mAb, suggesting that viral vari-
ants associated with the development of neutralization breadth also 
selected off-track mAbs. Indeed, clustering of broad and off-track 
mAbs within a single phylogenetic branch highlights the stochastic 
nature of mAb maturation toward breadth (Fig. 4c).
In conclusion, we identified 34-week viral variants, which we have 
termed bNAb-initiating Envs, that effectively engaged the UCA of the 
CAP256-VRC26 V1V2 lineage. Although low-frequency viral escape 
mutations at 27–30 weeks may suggest that CAP256-VRC26 antibodies 
were present earlier, the 34-week Envs nonetheless represent optimal 
priming immunogens for this lineage. Identification of rare bNAb- 
initiating Envs is likely to be of particular importance for V1V2 bNAb 
precursors, which are derived from a pool of rare B cells with long 
CDRH3 regions8,18,22–26. Second, we have defined a new mechanism 
for how accumulating viral variants contribute to bNAb development. 
Thus, viral escape creates multiple immunotypes, and in parallel SHM 
generates antibodies with differential abilities to engage these epitope 
variants. Those antibody sublineages that are able to tolerate variabil-
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Figure 4 Viral variants that shaped the maturation of broad and off-track antibodies. (a) Relationship between neutralization breadth of CAP256-VRC26 mAbs 
(%, y axis) and mutations away from the UCA (%, x axis). Broad mAbs with >40% neutralization breadth, off-track mAbs with limited neutralization breadth 
(<6%) and dead-end mAbs are shown in red, turquoise and gray respectively. The remaining 19 mAbs are shown in black. (b) CAP256-VRC26 mAbs and 
longitudinal CAP256 viruses isolated between 6–59 weeks are hierarchically clustered by their neutralization profiles. Neutralization sensitivity is shown 
as a heat map with potency indicated in the key. The sequence alignment shows viral C-strand amino acid residues between positions 160–172 (HXB2 
numbering), shaded to designate sequences that are PI derived (blue shading), PI-SU recombinants (purple shading) or SU derived (no shading). Off-track 
(turquoise) and broad (red) mAbs are clustered separately, whereas longitudinal viral variants are clustered by neutralization sensitivity, largely segregated on 
the basis of an SU-derived V1V2 C-strand. (c) A condensed heavy chain phylogenetic tree (Fig. 3) with a single clade expanded to illustrate the phylogenetic 
relatedness of an off-track mAb (turquoise) to seven broad mAbs (red). (d) Schematic depicting how CAP256 viral evolution results in the engagement of the 
CAP256-VRC26 UCA (light gray) and the subsequent development of two distinct mAb sublineages. The sublineage with restricted evolution contains dead-
end mAbs (dark gray), which cannot tolerate viral escape mutations. The continually evolving sublineage contains bNAbs (red) and off-track mAbs (turquoise). 
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however, that viral diversity may also limit the evolution of less-toler-
ant mAbs (dead-end sublineages), or it may divert maturation of mAbs 
toward strain specificity (off-track mAbs) (Fig. 4d). This process, which 
provides a framework for vaccine design (Supplementary Fig. 7), is 
distinct from the multi-lineage cooperative pathway described for a 
CD4–binding site bNAb lineage10, highlighting the complex and varied 
pathways to breadth. Future immunization strategies should therefore 
aim to include bNAb-initiating Envs to prime bNAb precursor B cells, 
as well as rationally verified Env variants as sequential boosts to mature 
the response to neutralization breadth.
MeTHodS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Antibody 454 sequencing reads have been depos-
ited in the National Center for Biotechnology Information (NCBI) 
Sequence Read Archive (SRA) under the accession numbers 
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accession numbers KT698223–KT698227.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Study participant. CAP256 was part of the CAPRISA 002 Acute Infection 
study, a cohort of 245 high-risk, HIV-negative women that was established 
in 2004 in Durban, South Africa, for follow-up and subsequent identification 
of HIV seroconversion27. This HIV-infected individual was among the seven 
women in this cohort who developed neutralization breadth1. The CAPRISA 002 
Acute Infection study was reviewed and approved by the research ethics com-
mittees of the University of KwaZulu-Natal (E013/04), the University of Cape 
Town (025/2004) and the University of the Witwatersrand (MM040202). 
CAP256 provided written informed consent. Randomization and blinding 
were not performed in this study.
V1V2 next-generation sequence library preparation. RNA extraction, 
cDNA synthesis and subsequent amplification were carried out as described 
previously28, with the following modifications: A minimum of 5,000 
HIV-1 RNA copies were isolated from longitudinal plasma, spanning 4 years of 
infection, using the QIAamp Viral RNA kit (Qiagen, Germany). The cDNA syn-
thesis primer was designed to bind to the C3 region of the envelope (HXB2  gp160 
position 1,094–1,118) and included a randomly assigned 9-mer tag (Primer 
ID method) to uniquely label each cDNA molecule, followed by a universal 
primer binding site to allow out-nested PCR amplification of cDNA templates 
(primers listed in Supplementary Table 1). First-round amplification primers 
were designed to amplify the V1 to V3 region of the envelope (HXB2 gp160 
positions 332–358) and contained a template-specific binding region, followed 
by a variable-length spacer of 0–3 randomly assigned bases to increase sam-
ple complexity. In addition, PCR primers contained 5′ overhangs, intro-
ducing binding sites for the Nextera XT indexing primers (Illumina, CA) 
(Supplementary Table 1). The nested PCRs were carried out using the Nextera 
XT indexing kit. After indexing, samples were purified using the MinElute 
PCR Purification Kit (Qiagen, Germany), quantified using the Quant-iT 
PicoGreen dsDNA assay (Life Technologies, NY) and pooled in equimolar 
concentrations. The pooled amplicons were gel extracted using the QIAquick 
gel purification kit (Qiagen, Germany) to ensure primer removal and the final 
library submitted for sequencing on an Illumina MiSeq (San Diego, CA), using 
2 × 300 paired-end chemistry.
V1V2 next-generation sequence analysis. Raw reads were processed using 
a local instance of Galaxy29–31, housed within the University of Cape Town 
High-Performance Computing core. Read quality was assessed using fastqc 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Short reads 
(<150 bp) and low-quality data were filtered out using the Filter FASTQ 
(version 1.0.0) tool32 with a minimum quality of Q35 for 3′ base trimming. 
Forward and reverse reads were joined using FASTQ joiner (version 2.0.0)32. 
A custom python script was used to bin all reads containing an identical Primer 
ID tag, to align the reads within each bin using MAFFT33 and to produce a 
consensus sequence based on a majority rule. Sequences with just one Primer 
ID representative, as well as consensus sequences derived from less than three 
reads and those containing degenerate bases, were excluded and the remain-
ing sequences from each time point were aligned with MAFFT, Muscle34 
or RAMICS35. The calculation of amino acid frequencies and Hamming 
distances (for each sequence relative to the consensus sequence from the 
first time point–inferred PI virus), were performed using custom python 
scripts. Amino acid frequency distributions were plotted using Prism 6 
(GraphPad), whereas Hamming distances were plotted using the python 
library Matplotlib36. All custom scripts used in these analyses, including the 
Primer ID binning script, are available upon request from Gordon Botha 
(gbot300@gmail.com).
Single-genome amplification and sequencing. HIV-1 RNA was isolated from 
plasma using the Qiagen QIAamp Viral RNA kit and reverse transcribed to 
cDNA using SuperScript III Reverse Transcriptase (Invitrogen, CA). The enve-
lope genes were amplified from single-genome templates37, and amplicons were 
directly sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing 
Ready Reaction kit (Applied Biosystems, Foster City, CA) and resolved on an 
ABI 3100 automated genetic analyzer. The full-length env sequences were 
assembled and edited using Sequencher version 4.5 software (Genecodes, Ann 
Arbor, MI). Multiple sequence alignments were performed using Clustal X 
(version 1.83) and edited with BioEdit (version 7.0.9.0) Sequence alignments 
were visualized using Highlighter for Amino Acid Sequences version 1.1.0 
(beta). Selected amplicons were cloned into the expression vector pcDNA 
3.1 (directional) (Life Technologies) by reamplification of SGA first-round 
products using Fusion enzyme (Stratagene) with the EnvM primer38 and the 
directional primer EnvAStop39. Cloned env genes were sequenced to confirm 
that they exactly matched the sequenced amplicon, and assayed for function 
by transfection in 293T cells, as described below.
Site-directed mutagenesis. CAP256 15-wk SU was mutated at positions 
169 and 166 by site-directed mutagenesis using the Stratagene QuikChange II 
kit (Stratagene) as described by the manufacturer. Mutations were confirmed 
by sequencing.
Antibody next-generation sequence analysis. NGS reads from each time 
point were processed with an antibodyomics approach described previously7. 
Reads with successfully assigned V and J genes, an in-frame junction and 
no stop codons were clustered at 97.25% nucleotide sequence identity with 
CD-HIT to account for possible sequencing error and singletons were dis-
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kde2d function in R. A maximum likelihood tree was built using FastML as 
described7. The tree was collapsed for display by clustering CDRH3 sequences 
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to define a major branch.
Antibody expression. Equal quantities of antibody heavy and light 
chain plasmids were co-transfected into FreeStyle 293F cells (Life 
Technologies) using the PEIMAX transfection reagent (Polysciences). 
Monoclonal antibodies were purified from cell-free supernatants after 
6 d using protein A affinity chromatography.
Neutralization assays. The JC53bl-13 (TZM-bl) and 293T cell lines, con-
firmed to be free of Mycoplasma, were cultured in DMEM (Gibco BRL 
Life Technologies) containing 10% heat-inactivated FBS and 50 µg/ml 
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with 0.25% trypsin in 1 mM EDTA (Gibco BRL Life Technologies). 
Env-pseudotyped viruses were obtained by co-transfecting the Env plas-
mid with pSG3∆Env40, using the FuGENE transfection reagent (Roche) as 
previously described1. Neutralization was measured as described by a 
reduction in luciferase gene expression after single-round infection of 
JC53bl-13 cells with Env-pseudotyped viruses1. Titers were calculated as the 
reciprocal plasma dilution (ID50) causing 50% reduction of relative light units 
(RLU). Viral and antibody hierarchical clustering based on neutralization 
profiles was performed using the Heatmap Hierachical Clustering tool on 
the LANL HIV sequence database http://www.hiv.lanl.gov/content/sequence/
HEATMAP/heatmap.html.
Images. Electron microscopy and protein structure representations were 
created with Chimera 1.5.3rc and The PyMOL Molecular Graphics System, 
Version 1.3r1edu, Schrödinger LLC. Neutralization images were created 
in GraphPad Prism6, sequence alignments were made with BioEdit41 and 
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Supplementary Table 1 PCR primers used to prepare V1V2 amplicons for MiSeq next-generation 
sequencing. 
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 1 Change in viral load over time in CAP256. Sequences were classified as PI-
like (black), SU-like (blue) or REC (purple) based on their relative Hamming distance away from PI, as 
described in Fig 1a. The number of viral copies for each population was derived from its relative 
proportion of the total viral load per time point (y-axis) and is shown versus weeks after infection (x-axis).	  
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 2 Frequency of amino acids or immunotypes (%) at positions (a) 169 and (b)  
166 in V1V2 next-generation consensus sequences between 6 and 206 weeks after infection. Read 
depth after quality filtering is shown for each time-point. Green, blue, or purple shading indicates ranges 
of amino acid frequencies, as shown in the key. 	  
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 3 Detection of the CAP256-VRC26 lineage in the periphery. Heat map plots 
show sequence identity to the UCA (y-axis) versus germline divergence (x-axis) for all VH3-30*18 
sequences identified in antibody next-generation sequences (NGS) from 15 to 206 weeks. The time of 
superinfection (SU), the emergence of the CAP256-VRC26 NGS transcripts and onset of plasma 
breadth are shown. Frequency of sequences is coloured as indicated by the key. Previously published 
data7 did not include this 34-week time-point. 
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 4 CAP256-VRC26 
UCA neutralization of a panel of 196 
heterologous HIV-1 viruses from multiple 
subtypes. Values shown are IC50 values 
with a starting concentration of 50 µg/ml, 
and >50 indicating no neutralization, as 
indicated in the key. 	  
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 5 Amino acid 
alignment of the 34-week V1V2 next-
generation consensus sequences (HXB2 
positions 120-197). Amino acid identity to 
the superinfecting virus (15-wk SU) is shown 
as dots, while deletions are shown as 
dashes. The primary infecting virus (6-wk 
PI) is also included in the alignment. 
Residues are coloured according to BioEdit 
amino acid assignments. 
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 6 CAP256-VRC26 mAb neutralization of 169/166 mutants and correlation with  
neutralization breadth. A two-tailed Spearman rank test was used to calculate the r and P values 
between IC50 neutralization titers of K169T/Q/I/R or R166K mutants (IC50 titres on the y-axis) and 
heterologous neutralization breadth (percentage on the x-axis).  
Nature Medicine: doi:10.1038/nm.3963
Supplementary Figure 7 Recapitulating viral evolution for vaccine design. (a) A proposed prime-sequential boost immunization 
strategy to elicit V1V2-directed bNAbs, based on the key viral events that initiated and drove neutralization breadth in the CAP256-
VRC26 lineage. A CAP256 34-week bNAb-initiating Env (red), which has the 169K and 166R immunotypes, would be used as a 
prime to engage UCAs with long CDRH3s. This would be followed by three sequential boosts using immunogens with varying 
immunotypes to mimic the viral diversification in CAP256 that drove bNAb development. The 169I boost (orange) would be 
administered first, followed by a cocktail of 169T/Q and R immunogens (blue) and a final boost to expose vaccine-induced mAbs to 
the 166K immunotype (purple).  (b) Prevalence of major immunotypes among subtype C and all global viruses are shown in pie 
charts, with those included in the proposed immunization schedule shaded black. The proposed schedule is tailored towards 
subtype C viruses using experimentally validated immunotypes. However, vaccine coverage may potentially be enhanced for 
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